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Abstract 
 
Antibiotics are some of the most effective drugs saving uncountable lives since their 
introduction more than 70 years ago. However, drug-resistant bacteria are rapidly 
spreading and posing one of the gravest threats to human health. Furthermore, the 
evolution of resistance is outpacing the discovery and development of new antibiotics. 
Therefore, stewardship of our existing and precious antibiotics is urgently needed. 
The objective of this thesis is to develop point-of-care sensors for therapeutic antibiotic 
monitoring, particularly for vancomycin, which not only allow prudent antibiotic use, but 
very importantly lead to better health outcomes associated with lower healthcare costs.  
The sensor development is approached with two different detection techniques: 
I) colourimetric detection via visible spectroscopy, and II) nanomechanical detection via 
cantilever array sensors.  
I) The thesis’ main focus was to develop a colourimetric vancomycin assay that builds on 
the point-of-care bench top device ‘Pelorus’ of our industrial partner – Sphere Medical 
Ltd. in Cambridge, UK. The assay could be successfully developed and benchmarked to 
UCLH’s gold standard. It includes extraction from whole serum prior to a labelling 
reaction that permits subsequent quantification via visible spectroscopy. Free and 
bound drug concentrations can be quantified within minutes, which is crucial for the 
determination of antibacterial activity and an advantage over current routine assays. 
Furthermore, the labelling reaction produced a novel molecule, which was structurally 
characterised. The developed assay could be patented with recent PCT entry.  
II) Nanomechanical detection of active free antibiotic concentration in human serum via 
cantilever arrays could be demonstrated. Combined with equilibrium theory, it led to 
better understanding of the biophysical mode of action improving treatment, dosage 
and drug discovery. It could be published in an article in Nature Nanotechnology.  
This project has been early stage proof-of-concept work. The next step towards 
commercialisation should involve clinical evaluation from whole blood and may further 
extend to multi-analyte and hand-held sensors for therapeutic monitoring. 
OUTCOMES OF MY DOCTORAL STUDY 
  
 
 
6 
 
Outcomes of My Doctoral Study 
 
PATENT 
Title of Invention: Analyte Extraction Apparatus and Method. Inventors:  
Natascha Kappeler, Rachel A. McKendry, Daren J. Caruana, Russell Keay, David M. 
Pettigrew. Applicants: Sphere Medical Ltd, Cambridge, UK & UCL Business PLC, 
London, UK. Application Number: 1302774.3, Reference Number: RZ/P43636GB, 
Pages: 1-31, Filing Date: 18th February 2013, PCT Date: 18th February 2014.  
 
 
PUBLICATIONS 
Rachel A. McKendry & Natascha Kappeler: Sensors: Good vibrations for bad bacteria. 
Nature Nanotechnology, 8(7), 483–484, 2013. doi:10.1038/nnano.2013.127. 
 
Natascha Kappeler: Thoughts on an education. Nature Nanotechnology, 8(11), 794–796, 
2013. doi:10.1038/nnano.2013.239.   
 
Joseph W. Ndieyira, Natascha Kappeler, Stephen Logan, Matthew A. Cooper,  
Chris Abell, Rachel A. McKendry & Gabriel Aeppli: Surface-stress sensors for  
rapid and ultrasensitive detection of active free drugs in human serum.  
Nature Nanotechnology, 9(3), 225-232, 2014. doi: 10.1038/nnano.2014.33.  
 
Natascha Kappeler: Review: Cantilevers for Biological Monitoring. Contemporary 
Physics. In preparation - deadline: 1st May 2014.  
 
 
GRANT 
Principle Investigator: Rachel A. McKendry, Co Investigator: Natascha Kappeler. 
Title: Early-Stage Development of Novel Glycopeptide Antibiotics against 
Multidrug-Resistant Superbug Infections. UCL Therapeutic Innovation Fund. 
Underpinning Funding: NHS, National Institute for Health Research, NIHR University 
College London Hospitals Biomedical Research Centre, NIHR Biomedical Research 
Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and 
University College London, and Wellcome Trust. Funding: £ 50,000.  
 
 
IMAGE DESIGN 
François Huber, Hans Peter Lang & Christoph Gerber: Nanomechanical Sensors: 
Measuring a response in blood. Nature Nanotechnology, 9(3), 165-167, 2014. 
doi:10.1038/nnano.2014.42. 
ACKNOWLEDGMENTS 
  
 
 
7 
 
Acknowledgments 
 
A tremendously large and very special thank you goes to Prof. Rachel McKendry for 
being simply the perfect supervisor to me, as well as for her inspiration, her guidance, 
her support on all kinds of issues and, of course, for giving me the opportunity to do my 
PhD in her group. Furthermore I am very thankful that she has enabled me to develop 
and improve my professional and personal skills in various different ways. For example 
by strengthening my network of important contacts, supporting my attendance at 
different management courses, strongly encouraging my interest in public engagement, 
providing the environment to mature and grow into an independent scientist and 
constantly supporting the progression of my scientific career with publications and being 
co-investigator on a grant application. Many thanks go to Dr. Daren Caruana, my 
subsidiary supervisor, for all his support, for his great enthusiasm and for providing the 
essential additive point of view on my PhD project. I would like to express my gratitude 
to my industrial supervisors - Dr. Steve Fowler and Dr. Russell Keay and to my two 
former industrial supervisors - Dr. David Pettigrew and Dr. Peter Laitenberger from 
Sphere Medical Ltd. in Cambridge for giving me a very interesting industrial insight and 
for their assistance and ideas. It is great to be part of such an excellent team, to get 
inputs from different environments and to work at this interdisciplinary interface.  
 
Furthermore I would like to thank Dr. Joseph Ndieyira from the LCN, who also played an 
important role in my PhD. A special thank goes to Dr. Antonio Jesús Ruiz Sánchez for his 
support and his assistance especially in the field of organic and analytical chemistry. 
Another very special thank goes to Alexander Wright, who has been my first student and 
a great pleasure to work with, for doing a perfect job in proof reading my whole thesis. 
Many thanks go to Dr. Abil Aliev and Dr. Stephen Hilton for their assistance with the 
nuclear magnetic resonance (NMR) measurements and purification, all the very 
interesting discussions and their enthusiasm, to Dr. Carolyn Hyde for her help with the 
mass spectrometry experiments, and to Dr. Anne Dawnay for performing the 
comparison with the gold standard assay at the University College London Hospital 
(UCLH).  
ACKNOWLEDGMENTS 
  
 
 
8 
 
A great thanks goes to all other present and former members of Rachel McKendry’s 
group, especially to Dr. Eleanor Gray for all her support, the great explanations 
especially in the field of genetics and virology, and all the very productive discussions. To 
Valérian Turbé for the great atmosphere in the office and in the lab, and for being my 
rock. To Kristina Schlegel for her friendship and for being part of the famous team 
Venice along with Val. To Dr. Tania Saxla and Kailey Nolan for their friendship, all their 
help and the great atmosphere in the office. To Benjamin Miller for the great 
atmosphere in the lab and for very last proof readings. To Dr. Rodolfo Hermans for being 
extremely helpful in various issues, for the legendary ladies nights and for being a great 
friend. To Joe Bailey for his friendship, introduction to the British way of life and for 
being a brilliant honour lady. To Dr. Manuel Vögtli and Dr. Daniel Engstrom, who I sadly 
miss at the LCN, for still being very supportive and becoming good friends. And to Dr. 
Richard Thorogate for managing the laboratories and the consumables.  
 
Many thanks go to Prof. Gabriel Aeppli, the co-Director of the LCN, for his support and 
the enjoyable short conversations in Swiss German; to Dr. Frederique Guesdon for 
dealing with the health and safety issues; and to Nipa Patel, Rosie Baverstock-West, 
Gosia Janczak, Joanna Rooke and Denise Ottley for their help with any kind of 
administrative issues.  
 
Furthermore I would like to extend my acknowledgments to all the co-workers in Sphere 
Medical Ltd. and the LCN for the wonderful working atmosphere and all the very 
pleasant conversations during and after work. Many thanks go to the other members of 
our INASCON 2013 organising committee, who are, asides from Val and Kristina, 
Thuong-Thuong Nguyen, Michael Gerspach, Tim Wootton and Samir Aoudjane, for 
sharing such a great experience and becoming friends through thick and thin. I would 
also like to thank Dr. Dessislava Nikolova, Angie Ma, Jenny Oberg and Dr. Maurice 
Mourad, who I sadly miss at the LCN, for all the fruitful discussions, their support, 
friendship and the continuing visits in London.   
ACKNOWLEDGMENTS 
  
 
 
9 
 
A very special thank goes to Prof. Christoph Gerber for being my personal mentor, for all 
his inspiration and patronage; and together with Dr. Hans Peter Lang, Dr. Natalija 
Backmann, and Dr. François Huber all from the University of Basel, for supporting my 
work with cantilever arrays and for always welcoming me back in Switzerland. 
 
Many thanks go to the University College London (UCL), Sphere Medical Ltd., The 
Engineering and Physical Sciences Research Council (EPSRC), and Health Tech and 
Medicines Knowledge Transfer Network (KTN) for providing the essential financial 
support. An additional thank goes to UCL’s Graduate School for supporting my 
attendance inclusive talk at the Antimicrobials 2013 conference in Sydney, Australia; and 
moreover for reviving my public engagement activities by awarding me with a bursary to 
attend the Science Festival 2012 in Cheltenham, UK. In the same context, I would like to 
thank Dr. Steve Cross, the head of UCL public engagement, for offering me the 
opportunity to perform my very first stand-up comedy routine as therapeutic window 
leading to my stage name “Swiss Nano”. Many thanks go to Daniel Friesner from the 
Science Museum for his unbreakable enthusiasm and support for the still ongoing 
organisation of an antibiotic awareness day.   
 
Then a very personal thank you to my friends from the continent, particularly Angie, 
Simone, Thomas, Audrey, Anita, Beth, Corina, Saadet, and Adi, for their friendship, 
support and understanding; and of course my “NANOs”, namely Meli, Nele, Susanne, 
Sonja, Lucas, This, Dario, Andy, Luki, Tinu, and Petz, for all their visits, brilliant and 
supportive discussions, and the great annual short trips colloquially know as 
“Nanoreisli”.  
 
Then I owe a huge thank you to my London family, Chloe, Hannah, Hilary, and Tony, for 
introducing me into the life of the British and the English language, for receiving me in 
their family, their support and the many enjoyable years. Last but not least, I would like 
to thank my parents, to whom I dedicate my thesis, for their love and immensely strong 
support.  
CONTENTS 
  
 
 
10 
 
Contents  
 
Abstract ________________________________________________________________ 5 
Outcomes of My Doctoral Study _____________________________________________ 6 
Acknowledgments ________________________________________________________ 7 
Contents ______________________________________________________________ 10 
List of Figures __________________________________________________________ 15 
List of Tables ___________________________________________________________ 19 
Abbreviations __________________________________________________________ 20 
1 Introduction _____________________________________________________ 24 
1.1 Objectives of the Thesis ___________________________________________ 25 
1.2 Requirements for PoC Therapeutic Drug Monitoring Sensors ______________ 29 
1.3 Thesis Outline ___________________________________________________ 31 
2 Antibiotics, Resistance, Stewardship and Drug Discovery __________________ 33 
2.1 Definition of Antibiotics, Antimicrobials and Antibacterials _______________ 35 
2.2 The History of Antibiotics, Resistance and Drug Discovery ________________ 38 
2.2.1 Antibiotic and Antibiotic Resistance Timeline _______________________ 38 
2.2.2 Golden Era of Antibiotic Drug Discovery ___________________________ 40 
2.3 Lack of Antibiotics and Rise in Resistance our Global Challenges ___________ 43 
3 The Glycopeptide Antibiotic – Vancomycin _____________________________ 46 
3.1 History of Vancomycin – the Glycopeptide Antibiotic ____________________ 46 
3.2 Vancomycin’s Structure, Mode of Action and Resistance _________________ 47 
3.3 Vancomycin’s Pharmacology _______________________________________ 52 
3.3.1 Current Vancomycin Dosing Strategy _____________________________ 52 
3.3.2 General Definition of Pharmacokinetics and Pharmacodynamics _______ 53 
3.3.3 Pharmacokinetics of Vancomycin ________________________________ 54 
3.3.4 Pharmacodynamics of Vancomycin _______________________________ 56 
4 Therapeutic Drug and Vancomycin Monitoring __________________________ 60 
4.1 Current Gold Standards in Therapeutic Vancomycin Monitoring ___________ 60 
4.2 Health Economic Importance of Therapeutic Vancomycin Monitoring ______ 64 
4.3 Summary of Needs for Therapeutic Vancomycin Monitoring ______________ 65 
4.4 Industrial Partner – Sphere Medical Ltd., Cambridge, UK _________________ 68 
  
CONTENTS 
  
 
 
11 
 
 
 
5 Proof-of-Principle and Benchmarking of Colourimetric Detection ___________ 71 
5.1 Introduction ____________________________________________________ 72 
5.1.1 Spectroscopy ________________________________________________ 72 
5.1.1.1 Ultra-Violet and Visible Spectroscopy _________________________ 74 
5.1.1.2 The Beer-Lambert-Bouguer Law ______________________________ 79 
5.1.1.3 Colourimetry _____________________________________________ 83 
5.1.2 The Gibbs Reagent and its Reaction ______________________________ 89 
5.1.2.1 History of the Gibbs Reagent ________________________________ 90 
5.1.2.2 The Gibbs Reagent Reactions and their Applications _____________ 91 
5.1.3 The Anaesthetic Propofol ______________________________________ 95 
5.1.3.1 Concise History of General Anaesthesia and Anaesthetics _________ 95 
5.1.3.2 Propofol _________________________________________________ 96 
5.1.3.3 Therapeutic Propofol Monitoring using Gibbs reagent ___________ 100 
5.1.4 Objectives for Proof-of-Principle & Colourimetric Benchmarking ______ 104 
5.2 Materials and Methods ___________________________________________ 106 
5.2.1 Chemicals __________________________________________________ 106 
5.2.1.1 Buffer Solutions and Solvents _______________________________ 106 
5.2.1.2 Gibbs Reagent and Phenolic Compounds______________________ 106 
5.2.1.3 Blood Components _______________________________________ 107 
5.2.2 Experimental Set-up__________________________________________ 108 
5.2.2.1 UV/vis Spectrometer ______________________________________ 108 
5.2.2.2 Cuvettes _______________________________________________ 108 
5.2.3 Measurement Procedure, Data Capturing and Analysis ______________ 108 
5.3 Results and Discussions __________________________________________ 109 
5.3.1 Proof-of-Principle Experiments _________________________________ 110 
5.3.2 Benchmarking Experiments with Gibbs Reagent and Propofol ________ 115 
5.4 Conclusion and Outlook __________________________________________ 119 
  
CONTENTS 
  
 
 
12 
 
 
 
6 Colourimetric Detection of Vancomycin ______________________________ 120 
6.1 Introduction ___________________________________________________ 121 
6.2 Materials and Methods ___________________________________________ 127 
6.2.1 Chemicals __________________________________________________ 127 
6.2.1.1 Buffer Solutions, Solvents and Antibiotic ______________________ 127 
6.2.1.2 Blood Components _______________________________________ 128 
6.2.1.3 Interferents _____________________________________________ 128 
6.2.2 Experimental Instrumentation _________________________________ 129 
6.2.2.1 UV/vis Spectrometer ______________________________________ 129 
6.2.2.2 Cuvettes _______________________________________________ 130 
6.2.2.3 Solid Phase Extraction _____________________________________ 130 
6.2.2.4 Homogenous enzyme immunoassay _________________________ 130 
6.2.3 Measurement Procedure, Data Capturing and Analysis ______________ 131 
6.2.3.1 Measurement Procedure and Data Capturing __________________ 131 
6.2.3.2 Data Processing, Analysis and Statistics _______________________ 133 
6.3 Results and Discussion ___________________________________________ 136 
6.3.1 Labelling of Vancomycin at High Concentrations ___________________ 136 
6.3.2 Detection in Clinical Range and Preliminary Serum Studies ___________ 143 
6.3.3 Extraction Protocol Development from Foetal Bovine Serum _________ 149 
6.3.4 Optimisation of the Gibbs Reagent Concentration __________________ 165 
6.3.5 Change from Foetal Bovine to Whole Human Serum ________________ 174 
6.3.6 Effect of Serum Protein Binding on Vancomycin Detection ___________ 178 
6.3.7 Selectivity Evaluation with a Subset of Interferents _________________ 184 
6.3.8 Direct Comparison with a Gold Standard Technique ________________ 189 
6.4 Discussion and Conclusion ________________________________________ 194 
  
CONTENTS 
  
 
 
13 
 
 
 
7 Study of Labelling Reaction and Coloured Product ______________________ 198 
7.1 Introduction ___________________________________________________ 199 
7.2 Materials and Methods ___________________________________________ 201 
7.2.1 Chemicals __________________________________________________ 201 
7.2.1.1 Coupling Reagent and Antibiotic ____________________________ 201 
7.2.1.2 Solvents ________________________________________________ 201 
7.2.2 Instrumentation _____________________________________________ 201 
7.2.2.1 Mass Spectrometer _______________________________________ 201 
7.2.2.2 NMR instrumentation _____________________________________ 202 
7.2.3 Measurement Procedure, Data Capturing and Analysis ______________ 202 
7.3 Results and Discussion ___________________________________________ 205 
7.3.1 Mass Spectrometry Studies ____________________________________ 205 
7.3.2 1H-NMR Analysis _____________________________________________ 209 
7.4 Conclusion and Outlook __________________________________________ 225 
8 Nanomechanical Detection of Vancomycin ____________________________ 229 
8.1 Introduction ___________________________________________________ 231 
8.1.1 History of Cantilever and Cantilever Array Sensors _________________ 231 
8.1.2 The Core and Mode of Operations for Cantilever Array Sensors _______ 237 
8.1.3 Applications of Cantilever (Array) Sensors ________________________ 243 
8.1.4 Surface Stress and Optical Beam Deflection Readout ________________ 244 
8.1.5 Principle of Nanomechanical Detection of Drug-Target Binding _______ 249 
8.1.6 Binding Investigation via Langmuir Adsorption Isotherm _____________ 252 
8.1.7 The Percolation Model on Cantilevers and Bacteria _________________ 254 
8.1.8 Objectives for Nanomechanical Detection of Vancomycin ____________ 257 
8.2 Materials and Methods ___________________________________________ 257 
8.2.1 Chemicals __________________________________________________ 257 
8.2.1.1 Buffer Solution and Antibiotic ______________________________ 258 
8.2.1.2 Mucopeptides Analogues, Internal Reference and SAM __________ 259 
  
CONTENTS 
  
 
 
14 
 
 
 
8.2.2 Cantilever Arrays ____________________________________________ 262 
8.2.2.1 Metal Coating ___________________________________________ 262 
8.2.2.2 Functionalization _________________________________________ 262 
8.2.3 Experimental Set-ups _________________________________________ 265 
8.2.3.1 The “Basel Nose” System __________________________________ 265 
8.2.4 Measurement Procedure, Data Processing and Analysis _____________ 267 
8.3 Result and Discussions ___________________________________________ 271 
8.3.1 Benchmarking Experiment _____________________________________ 272 
8.3.1.1 Benchmarking Specificity __________________________________ 272 
8.3.1.2 Benchmarking Sensitivity and Detection in Pseudo-Serum ________ 273 
8.3.2 Requirements Study for Nanomechanical Antibiotic Monitoring _______ 276 
8.3.2.1 Specificity and Discussion of Reference _______________________ 276 
8.3.2.2 Sensitivity in Vancomycin’s Clinical Range _____________________ 277 
8.4 Conclusion and Outlook __________________________________________ 281 
9 Conclusion and Outlook ___________________________________________ 285 
9.1 Conclusion _____________________________________________________ 286 
9.1.1 Colourimetric Detection ______________________________________ 286 
9.1.2 Nanomechanical Detection ____________________________________ 290 
9.2 Future Work ___________________________________________________ 294 
9.2.1 Multi-analyte Sensor for Therapeutic Drug Monitoring ______________ 294 
9.2.2 Hand-held Device ____________________________________________ 295 
9.2.3 Antibiotic Drug Discovery on the Basis of the novel VanGibbs _________ 297 
9.3 Closing Remarks ________________________________________________ 297 
Bibliography __________________________________________________________ 298 
Appendix _____________________________________________________________ 346 
 
LIST OF FIGURES 
  
 
 
15 
 
List of Figures 
1.01: Overarching miniaturisation development process investigated in this thesis. ___ 28 
2.01: A timeline for antibiotic research. ______________________________________ 45 
3.01: Vancomycin’s structure, its mode of action and one example for a resistance 
mechanism. _____________________________________________________ 50 
3.02: Peptidoglycan biosynthesis as an antibiotic target. ________________________ 51 
3.03: Pharmacodynamics of antibiotics. ______________________________________ 59 
4.01: Schematic illustration of the working principles of the TVM gold standard assays. 63 
4.02: Point-of-care sensors developed by our Industrial Partner – Sphere Medical Ltd., 
Cambridge. ______________________________________________________ 70 
5.01: Electromagnetic spectrum including visible spectrum. _____________________ 78 
5.02: Prediction of the absorbed wavelength according to observed colours by the use of 
the colour wheel. _________________________________________________ 87 
5.03: Three compounds as examples for colourimetric studies. ___________________ 88 
5.04: The Gibbs reagent and its reactions. ____________________________________ 94 
5.05: Propofol and the crystallographic structure of its binding sites on human serum 
albumin (HSA). ___________________________________________________ 99 
5.06: Sphere Medical’s Pelorus bench top device and its correlation with a reference 
method. _______________________________________________________ 103 
5.07: A schematic of the colourmetric detection of vancomycin via visible spectroscopy.
 ______________________________________________________________ 105 
5.08: Proof-of-principle experiments with the commercially available product of the 
Gibbs-phenol reaction. ____________________________________________ 114 
5.09: Benchmarking experiments of the colourimetric detection of propofol via Gibbs 
reagent coupling reaction. _________________________________________ 118 
6.01: Hypothesis of Gibbs reagent coupling reaction to vancomycin resulting in a novel 
vanGibbs molecule. ______________________________________________ 126 
6.02: Chosen interferents with phenolic motifs, which could couple to Gibbs reagent and 
affect the vancomycin quantification. ________________________________ 134 
6.03: Solid phase extraction (SPE). _________________________________________ 134 
6.04: UV/vis spectra of borate buffer and various solvents. _____________________ 135 
LIST OF FIGURES 
  
 
 
16 
 
6.05: First vancomycin labelling with Gibbs reagent. ___________________________ 141 
6.06: Vancomycin monitoring at high concentration and stoichiometric analysis. ____ 142 
6.07: Therapeutic vancomycin monitoring at clinical concentrations. _____________ 147 
6.08: Time dependency studies of the Gibbs reagent coupling reaction and first serum 
trials. __________________________________________________________ 148 
6.09: Test of a suitable solvent to elute vancomycin from the SPE cartridge. _______ 159 
6.10: Test of potential eluent for the ability to optically detect therapeutic vancomycin 
concentrations via Gibbs reagent coupling. ___________________________ 160 
6.11: Assessment of pure vancomycin absorbencies in the solvent mixture planned to be 
the eluent for the SPE. ____________________________________________ 161 
6.12: Feasibility test for the reduction of the eluent volume aiming to increase the 
sensitivity. ______________________________________________________ 162 
6.13: Developed extraction protocol of vancomycin from foetal bovine serum. _____ 163 
6.14: Two types of serum albumins reacting with Gibbs reagent. ________________ 164 
6.15: Optimisation of the Gibbs reagent concentration in relation to the vancomycin 
concentration. __________________________________________________ 171 
6.16: Comparison between previously used Gibbs reagent concentration to optimised 
concentration in reaction with 29 µM vancomycin. _____________________ 172 
6.17: Test of expected sensitivity increase due to the optimised Gibbs reagent 
concentration. __________________________________________________ 173 
6.18: Comparison of elute compositions between foetal bovine serum (FBS) and whole 
human (serum). _________________________________________________ 177 
6.19: Effect of serum protein binding on vancomycin detection. _________________ 182 
6.20: Developed extraction protocol of vancomycin from foetal bovine serum. _____ 183 
6.21: SPE stages spectra of three possible interferents for selectivity evaluation. ____ 187 
6.22: Absorbencies at 589 nm for each interferent and in direct comparison to 
vancomycin. ____________________________________________________ 188 
6.23: Direct comparison of the herein developed colourimetric assay with the gold 
standard VANC2 from Roche COBAS®. _______________________________ 192 
6.24: Colourimetric assay for therapeutic monitoring of free and bound vancomycin 
concentration. __________________________________________________ 193 
LIST OF FIGURES 
  
 
 
17 
 
7.01: Hypothesis of Gibbs reagent coupling reaction to vancomycin resulting in a novel 
vanGibbs molecule. ______________________________________________ 200 
7.02: Theoretical and experimental mass spectra of pure vancomycin. ____________ 207 
7.03: Theoretical and experimental mass spectra of the novel reaction product 
vanGibbs. ______________________________________________________ 208 
7.04: 1H-NMR analysis of vancomycin and comparison with the literature. _________ 217 
7.05: Labelled structure of vancomycin for 1H-NMR assignments and comparison with 
literature. ______________________________________________________ 218 
7.06: 1H-NMR study of vancomycin in reaction conditions and comparison with 
literature. ______________________________________________________ 219 
7.07: Proton coded vancomycin structure for the 1H-NMR assignments and comparison 
with literature. __________________________________________________ 220 
7.08: Overlay 1H-NMR spectra of the starting materials and the novel product vanGibbs 
obtained with different molar ratios of the two starting materials. _________ 221 
7.09: Proton coded vancomycin structure for the 1H-NMR assignments of vancomycin 
and vanGibbs. ___________________________________________________ 222 
7.10: Detailed 1H-NMR comparison of vancomycin and the novel product obtained with 
two different molar ratios in the region of 8.0 – 4.2 ppm. ________________ 223 
7.11: 1H-NMR NOESY analysis of vancomycin and vanGibbs. ____________________ 224 
7.12: Proposed reaction scheme of the vancomycin Gibbs reaction under alkaline 
conditions as it is presented in our patent (Kappeler et al. 2013). __________ 227 
7.13: Structural comparison of different glycopeptide antibiotic derivatives obtained by 
Mannich reactions with our vanGibbs molecule. _______________________ 228 
8.01: Photographs of STM and AFM replicas. ________________________________ 235 
8.02: Publications per year incorporating specified search terms related to cantilever 
sensors. ________________________________________________________ 236 
8.03: Core of a cantilever array sensor and its mode of operations. _______________ 242 
8.04: Schematic of set-up to measure adsorbate induced surface stress with the bending 
cantilever method. _______________________________________________ 248 
8.05: Nanomechanical detection of drug-target interactions via cantilever array sensors.
 ______________________________________________________________ 251 
LIST OF FIGURES 
  
 
 
18 
 
8.06: Nanomechanical drug-target percolation model on cantilever arrays and bacteria.
 ______________________________________________________________ 256 
8.07: Mucopeptides analogues, internal reference and self-assembled monolayer. __ 261 
8.08: Cantilever array functionalization stage. ________________________________ 264 
8.09: Schematic and picture of the “Basel Nose” instrumental set-up. ____________ 266 
8.10: Cantilever Arrays as Nanomechanical Sensors. ___________________________ 270 
8.11: Benchmarking experiments. _________________________________________ 275 
8.12: Requirements study for a nanomechanical therapeutic vancomycin monitoring 
sensor. ________________________________________________________ 280 
8.13: Influence of the underlying DAla self-assembled monolayer (SAM) film on surface 
stress and equilibrium dissociation constant   . ______________________ 283 
9.01: Therapeutic vancomycin concentrations for a future handheld device. _______ 296 
LIST OF TABLES 
  
 
 
19 
 
List of Tables 
5.01: Visible spectrum’s colour regions with approximate wavelengths. ____________ 87 
6.01: Developed solid phase extraction protocol. _____________________________ 154 
6.02: Estimated free and bound fractions from the different elution stages. ________ 183 
6.03: Results obtained from the VANC2 Roche COBAS® assay. ___________________ 192 
6.04: Results obtained from the developed colourimetric assay. _________________ 193 
6.05: Characteristics of colourimetric detection for TDM. _______________________ 197 
7.01: 1H-NMR comparison of vancomycin with literature. ______________________ 218 
7.02: 1H-NMR comparison of vancomycin at high pD with literature. ______________ 220 
7.03: 1H-NMR comparison of vancomycin with vanGibbs 1:2. ___________________ 222 
8.01: Nanomechanical detection of vancomycin in buffer. ______________________ 280 
8.02: Nanomechanical detection of vancomycin in pseudo-serum. _______________ 280 
8.03: Characteristics of nanomechanical detection for TDM. ____________________ 284 
9.01: Characteristics of the two investigated detection techniques for TDM. _______ 292 
I: One-way ANOVA from chapter 6.3.3. _____________________________________ 351 
II: Fisher’s LSD from chapter 6.3.3. _________________________________________ 351 
III: One-way ANOVA of FBS from chapter 6.3.5. _______________________________ 353 
IV: Fisher’s LSD of FBS from chapter 6.3.5. ___________________________________ 353 
V: One-way ANOVA of WHS from chapter 6.3.5. ______________________________ 354 
VI: Fisher’s LSD of WHS from chapter 6.3.5. __________________________________ 354 
 
 
ABBREVIATIONS 
  
 
 
20 
 
Abbreviations 
ac    alkaline conditions 
AFM    atomic force microscope 
AM   amplitude modulation 
AU   absorbance unit  
AUC   area under the curve 
BASF Badische Anilin- und Soda-Fabrik (Baden Aniline and Soda 
Factory) 
BSA   bovine serum albumin 
C. difficile   Clostridium difficile 
CE    “Conformité Européenne” 
cfu   colony-forming units 
COSY   correlated spectroscopy  
CPE   carbapenemase-producing Enterobacteriaceae 
CSV   comma-separated values 
DAla   L-Lysine-(ε-Ac)-D-Alanyl-D-Alanine 
DCPIP   2,6-dichlorophenolindophenol 
ddH2O   distilled and deionised water  
DI   distilled 
Diprivan  diisopropyl intravenous anaesthetic 
DLac   L-Lysine-(ε-Ac)-D-Alanyl-D-Lactate 
DNA   deoxyribonucleic acid 
e-beam   electron beam 
EMIT   enzyme multipled immunoassay techniques 
E. coli   Escherichia coli 
EPSRC   Engineering and Physical Sciences Research Council 
ESI   electrospray ionisation 
FBS   foetal bovine serum  
FDA    Food and Drug Administration 
FM   frequency modulation  
FPIA   fluorescence polarisation immunoassay 
ABBREVIATIONS 
  
 
 
21 
 
G6PDH   glucose-6-phosphate dehydrogenase 
GISA    glycopeptide-intermediate Staphylococcus aureus 
GlcNAc    N-acetylglucosamine  
HCAI   healthcare associated infections 
HOMO   highest occupied molecular orbital 
HPLC   high-performance liquid chromatography 
HSA   human serum albumin 
I   interesting spin 
ICI    Imperial Chemical Industries  
ICU   intensive care unit 
IR   infra-red 
ISFET   ion-sensitive field effect transistor 
IUPAC    International Union of Pure and Applied Chemistry 
IV   intravenous 
KTN   Knowledge Transfer Network 
LCN   London Centre for Nanotechnology 
Ltd.   Limited 
LUMO   lowest unoccupied molecular orbital  
MEMS   micro-electro-mechanical system 
MHRA   Medicines and Healthcare Products Regulatory Agency 
MIC   minimal inhibitory concentration  
MPC   mutant prevent concentration 
MRSA   methicillin-resistant Staphylococcus aureus  
MSW   mutant selection window  
MurNAc  N-acetylmuramic acid  
NAD   nicotinamide adenine dinucleotide 
NDM-1   New Delhi metallo-beta-lactamase-1 
NEMS   nano-electro-mechanical system 
NHS   National Health Service 
NMR   nuclear magnetic resonance  
NOE   nuclear Overhauser effect 
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NOESY    nuclear Overhauser effect spectroscopy 
OR   operation room  
PEEK   polyetheretherketone 
PEG   polyethylene glycol (in our case: tri-ethylene glycol) 
PG   peptidoglycan 
PoC   point-of-care 
ppm   parts-per-million 
PSD   position sensitive detector 
RNA   ribonucleic acid 
ROESY    rotating frame nuclear Overhauser effect spectroscopy  
S   source spin 
S. aureus   Staphylococcus aureus 
SAM   self-assembled monolayer 
SEAr   electrophilic aromatic substitution  
SFM   scanning force microscope 
SI International System of Units (abbreviated from French: 
Système international d'unités) 
SNI   Swiss Nanoscience Institute  
SOI silicon-on-insulator 
SPR   surface plasmon resonance  
STM   scanning tunnelling microscope 
TDM   therapeutic drug monitoring 
TLC   thin layer chromatography 
TOCSY   total correlation spectroscopy 
TVM   therapeutic vancomycin monitoring  
UCL   University College London/London’s Global University 
UCLH   University College London Hospital 
UV   ultraviolet 
VCSELs   vertical cavity surface emitting lasers 
VIS   visible 
VISA   vancomycin-intermediate Staphylococcus aureus 
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VRE vancomycin-resistant Enterococcus or    
vancomycin-resistant Enterococci  
VRSA   vancomycin-resistant Staphylococcus aureus  
VSE   vancomycin-sensitive (susceptible) Enterococcus or 
   vancomycin-sensitive (susceptible) Enterococci 
VSSA   vancomycin-susceptible Staphylococcus aureus 
WEF   World Economic Forum 
WHO   World Health Organization 
WHS   whole human serum  
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CHAPTER 1: Introduction 
1 Introduction 
Antibiotics are some of the most effective drugs, saving uncountable lives since their 
introduction more than 70 years ago. Former deadly diseases such as syphilis, 
gonorrhoea and bacterial pneumonia have become curable. One could argue that their 
widespread use has contributed to the dramatic rise of average life expectancy. 
However, resistant bacteria are naturally evolving and by administering antibiotics we 
increase the evolutionary pressure fuelling their Darwinian selection. Consequently, as 
the use of antibiotics has increased, numerous drug resistant bacterial infections have 
emerged and continue to spread. In the last couple of years, it has become obvious that 
the evolution of resistant bacteria is outpacing the discovery and development of 
replacement drugs. Furthermore, with high global mobility, resistant strains of bacteria 
can spread very rapidly. This is one of the gravest threats to human health and has 
recently been classified alongside dangers such as terrorism and global warming (Davies 
2011). 
 
The objective of this thesis is to develop point-of-care sensors for therapeutic antibiotic 
monitoring, which not only allow the prudent use of our existing antibiotics whilst 
ensuring that their concentrations stay above the mutant prevention concentration, but 
also lead to better health outcomes associated with lower healthcare costs (Imamovic 
and Sommer 2013). Such a sensor will be a key tool for antibiotic stewardship and for 
personalised medicine. It will reduce the therapeutic decision time and enable the drug 
dose to be titrated to the desired active target concentration according to the patient’s 
individual drug adsorption, distribution, metabolism and excretion characteristics. 
Furthermore, it will detect accumulation or changes in the drug clearance rate and 
provide early detection of faults in the drug delivery system.  
 
The development of these sensors focuses particularly on the antibiotic vancomycin and 
is approached with two different detection techniques: I) colourimetric detection via 
visible spectroscopy, and II) nanomechanical detection via cantilever array sensors. This 
thesis is an ‘industrial CASE studentship’ between University College London, UK as an 
academic partner and Sphere Medical Ltd. in Cambridge, UK as an industrial partner. 
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1.1 Objectives of the Thesis 
The funding scheme ‘industrial CASE studentship’ by the Engineering and Physical 
Sciences Research Council (EPSRC) provides a first-rate, challenging research training 
experience, within the context of a mutually beneficial research collaboration between 
academic and industrial partners. In the present case, the unique research collaboration 
is based on the active integration of Sphere Medical’s expertise in highly innovative 
medical monitoring devices especially for the critical care environment and London 
Centre of Nanotechnology’s breakthrough in specific surface chemistry for antibiotic 
capturing. Hence this project, which has been originally entitled “Nanomechanical Point-
of-Care Devices for Antibiotic Monitoring” (Laitenberger, McKendry, and Ndieyira 2010), 
gives the unique opportunity to merge the interests of industry with the aims of the 
university. Moreover it provides a multidisciplinary training at the interface of biology, 
chemistry, physics, engineering and medicine whilst involving interactions with 
researchers from universities, companies and clinics.  
 
The main objective of this PhD thesis is the development of the next generation of 
point-of-care (PoC) sensors for therapeutic antibiotic monitoring, particularly for the 
glycopeptide antibiotic vancomycin. In order to achieve this challenging goal, two 
detection technologies are investigated: 
 
I) Colourimetric detection of vancomycin measured with visible spectroscopy 
builds on Sphere Medical’s Pelorus bench top device. The goal is to 
specifically elute vancomycin out of the biological matrix and then to label it 
with Gibbs reagent to induce a detectable colour change. This approach of 
labelling phenol moieties with Gibbs reagent and measuring it 
spectroscopically builds on Sphere Medical’s work with the anaesthetic 
propofol in the Pelorus bench top device (Pettigrew, Laitenberger, and Liu 
2012; Liu et al. 2012). The main focus of this thesis has been laid on to the 
development of this first detection technique. Therefore its experimental 
study spans over three consecutive chapters. The benchmarking 
experiments according to Sphere Medical’s Pelorus device are presented in 
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chapter 5 on page 71 et seqq. The development of the colourimetric 
detection of vancomycin, including the labelling reaction, extraction 
protocol and subsequent patent filing, are discussed in chapter 6 starting on 
page 120. Further characterisation of the ‘vanGibbs’ molecule especially 
important for patent validation can be found in chapter 7 from page 198 
onwards.    
 
II) Nanomechanical detection of vancomycin binding to a mimetic bacterial 
cell wall layer on cantilever array sensors. This approach, builds on previous 
work by Prof. Rachel McKendry and colleagues, has shown that cantilever 
array sensors offer a unique tool to study surface-active drugs and the 
nanomechanical consequences of drug-target binding interactions. 
Therefore cantilever array sensors paired with specific surface chemistry for 
antibiotic capturing establish an ideal basis for a nanomechanical sensor for 
therapeutic vancomycin monitoring (Watari, Ndieyira, and McKendry 2010; 
Ndieyira et al. 2008; McKendry et al. 2002; Sushko et al. 2008; J. Zhang et al. 
2006; Shu et al. 2005; McKendry 2012; Watari et al. 2007). This approach is 
described in chapter 8 starting on page 229.  
 
 
Along with developing each technique for therapeutic antibiotic monitoring at the point-
of-care, the overarching aim is to evaluate the feasibility of miniaturising the different 
detection techniques for patient attached real-time monitoring devices. Therefore, the 
two techniques were deliberately chosen as an overall miniaturisation development 
process. As schematically illustrated in figure 1.01, this development includes the 
progression from the current gold standard with a laboratory-based device, over a 
bench top device with intermittent near-patient monitoring capabilities, to a future 
patient attached sensor chip with the ability to monitor in real-time.  
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Therefore, the first technique (I) is a simple, robust and low cost bench top device. Due 
to its similarities with the Pelorus system, this technique also benefits from a close 
proximity to the market. The second technique (II) is the development towards a future 
sensor chip, which aims to be incorporated into the patient’s intravenous lines for real-
time continuous monitoring. However with the current read-out system, cantilever array 
sensors, as the second technique (II), are still closer to be applicable in a bench top 
device than in an intravenous sensor chip. Therefore it represents the transition from a 
bench top device to a future patient attached sensor.  
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Figure 1.01: Overarching miniaturisation development process investigated in this thesis.  
This development includes the progression from the current gold standards with a laboratory-
based device, over a bench top device with intermittent near-patient monitoring capabilities, to a 
future patient attached sensor chip with the ability to monitor in real-time. From the left to the 
right not only are the dimensions of the devices scaling down, but also the requirements in time, 
staff, transportation distance and administration are diminishing resulting in minimal associated 
costs. The two schematics at the bottom depict the different detection techniques used to 
approach the different stages in the miniaturisation development process: I) colourimetric 
detection via visible spectroscopy, and II) nanomechanical detection via cantilever array sensors.  
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min. several 
floors
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1.2 Requirements for PoC Therapeutic Drug Monitoring Sensors   
In order to study and examine these two techniques, sensors, biosensors and their 
characteristics have to be first defined in general terms. Furthermore, if sensors are 
used at the PoC, requirements of PoC tests have to be described.   
 
Sensors are devices that measure an input signal and convert it, often several times, into 
an electrical signal which can then be read out by an instrument or an observer. Ideally 
sensor technologies should be an optimal compromise between specificity, sensitivity, 
simplicity, speed and costs. (Scheller et al. 2001; Thévenot et al. 2001; D’Orazio 2003) 
 
The Medicines and Healthcare Products Regulatory Agency (MHRA), which is a UK 
government agency responsible for ensuring medicines and medical devices, defines a 
PoC test as follows: ‘Any analytical test performed for a patient by a healthcare 
professional outside of the conventional laboratory’ (MHRA 2010). This definition 
includes rapid tests for monitoring and/or diagnostic purposes at or near the site of 
patient care. PoC tests are often transportable, portable and handheld instruments, 
which enable patient, physician and the care team to receive a quicker result that allows 
immediate clinical management (Luppa et al. 2011).  
 
Consequently, a PoC therapeutic drug monitoring sensor, which monitors an analyte, 
the drug, and generates a concentration dependent signal, needs to fulfil the following 
requirements:  
 
 Sensitive to clinically relevant drug concentrations. 
 High specific for the required drug with very low interference or cross-reactivity 
with other drugs or blood components (e.g. serum proteins, antibodies, 
antigens, hormones). 
 Rapid. 
 Simple, not require specialist equipment and staff.   
 Cost effective. 
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 Robust and stable in the application and storage environment. 
 Safe in case of any malfunction. 
 Sterile, nontoxic and preferably the part in direct contact with sample should be 
disposable.  
 Quantify free and bound drug fraction: An additional benefit for a therapeutic 
antibiotic monitoring sensor, particularly for vancomycin, would be the option 
to monitor free and active drug concentration. Since it is commonly accepted 
that a drug bound to blood serum proteins, will have a reduced biological 
activity, this in turn affects the distribution in the body, elimination rates, tissue 
penetration and presence at the site of infection. Hence it is mainly the 
unbound fraction of the antibiotic which is active against the infecting organisms 
(Shin et al. 1991; Butterfield et al. 2011; Sun, Maderazo, and Krusell 1993; 
Zeitlinger et al. 2011; Stein and Wells 2010). Serum binding and its effect are 
further discussed in chapter 3.3.3. 
 
Moreover according to PoC sensors for therapeutic antibiotic monitoring, the recent 
published “UK Five Year Antimicrobial Resistance Strategy 2013 to 2018” by the 
Department of Health and the Department for Environment Food & Rural Affairs listed 
PoC sensors as urgent requirement for new or improved rapid diagnostic ‘as well as to 
reassess the appropriateness of the diagnosis and treatment’ (Department of Health 
2013). Furthermore, they list the use of PoC sensor for improvement in knowledge of 
antibiotics and antibiotic resistance, and as a key tool for antibiotic stewardship 
(Department of Health 2013). 
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1.3 Thesis Outline 
The objective of this thesis is to develop point-of-care sensors for therapeutic antibiotic 
monitoring. Due to the multidisciplinary approach of this development with two 
different detection assays, it has been decided that the investigation of each technique 
is separated into different chapters. Each chapter consists of a first subsection covering 
the technique specific introduction, followed by a subsection listing the corresponding 
materials and methods, a third subsection presenting and discussing the results, and a 
fourth and last section drawing the conclusions. Moreover, since the main focus of the 
thesis is the development of the colourimetric technique, its experimental study spans 
over three consecutive chapters. Consequently, the thesis is organised as follows: 
 
 Chapter 1 gave a concise introduction and describes the thesis’ objectives as well 
as the requirements seeking to be fulfilled by the different techniques.  
 
 Chapter 2 provides a general overview of antibiotics and antimicrobial resistance, 
which is a major threat to human health and a global challenge that urgently 
needs to be tackled. Furthermore, it discusses antibiotic stewardship and drug 
discovery.  
 
 Chapter 3 describes the antibiotic vancomycin including pharmacological 
characteristics with special focus on serum binding and its effect on antibacterial 
activity. It also lists the so far unmet clinical needs seeking to be addressed in this 
thesis.  
 
 Chapter 4 reviews the need for the therapeutic drug monitoring technologies 
whilst emphasising its health economic importance with special focus on 
antibiotic monitoring. Additionally, it presents the current gold standards for 
therapeutic vancomycin monitoring and a profile of our industrial partner, Sphere 
Medical Ltd., Cambridge, UK.  
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 Chapter 5 is the first of three consecutive chapters describing the investigation of 
colourimetric detection via visible spectroscopy. This part contains proof-of-
principle and benchmarking experiments with reference to Sphere Medical’s 
Pelorus device, which colourimetrically quantifies the anaesthetic propofol. 
 
 Chapter 6 is the largest chapter in the thesis. It presents the development of the 
colourimetric detection of vancomycin, including the labelling reaction, extraction 
protocol from serum, free and bound drug quantification, comparison to a gold 
standard technique and subsequent patent filing.   
 
 Chapter 7 is the last chapter related to the colourimetric detection of vancomycin. 
It discusses the characterisation of the vanGibbs molecule and the labelling 
reaction mechanism by NMR and mass spectrometry studies.   
 
 Chapter 8 describes the nanomechanical detection of vancomycin by cantilever 
array sensors, which is the second detection technique investigated in this thesis.  
 
 Chapter 9 is the final chapter and summarises the key findings and conclusions. 
Furthermore, it outlines ideas for future work.  
 
 The appendix includes the statistical analysis from chapter 6.    
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CHAPTER 2:  
Antibiotics, Resistance,  
Stewardship and Drug Discovery 
2 Antibiotics, Resistance, Stewardship and Drug Discovery 
One of medicine’s greatest success stories in the 20th century was the discovery and 
development of antibiotics and antibacterial agents for the treatment of bacterial 
infections. Countless lives were saved and previous lethal illnesses such as syphilis, 
gonorrhoea and bacterial pneumonia, that were predominately incurable, could 
suddenly be cured. In more recent times, some antibiotics have even shown to be 
effective as antiviral or anticancer drugs (Demain and Sanchez 2009; Davies and Davies 
2010).  
 
However, the implementation and reliance of antibiotic therapy has led to a significant 
problem. Bacteria are acquiring mutations which can make them resistant to antibiotics, 
due to a variety of factors. The resistant bacterium may then be selected by further use 
of antibacterial drugs according to Darwin’s theory of ‘survival of the fittest’ and ‘natural 
selection’ (Darwin 1859). The resistance acquiring factors include the naturally 
stochastic appearance of genetic variations paired with short generation times, the 
ability to pass genetic information such as genes encoding resistance and multi-
resistance between individuals from the same or different genera, and the increased 
mutagenesis of ‘hypermutable’ strains found in natural bacterial populations (Walsh and 
Wright 2005; Williams and Bardsley 1999; Livermore 2007; Blázquez 2003).  
 
Recent discoveries of mutation mechanisms, induced by growth-limiting stress, add an 
additional perspective to the evolution of resistance. Stressors include hypoxia, 
starvation, oxidative stress and antibiotics (Shee, Hastings, and Rosenberg 2013; 
MacLean, Torres-Barceló, and Moxon 2013). In the last ten years, work has shown that 
some antibiotics, including β-lactams, quinolones and aminoglycosides, can induce 
mutagenesis (Davies and Davies 2010; Kohanski et al. 2007; Miller et al. 2004). The 
resulting mutations may give resistance to the same antibiotic (Cirz et al. 2005), to 
CHAPTER 2: ANTIBIOTICS, RESISTANCE, STEWARDSHIP AND DRUG DISCOVERY  
  
 
 
34 
 
different or even a wide range of antibiotics (Kohanski, DePristo, and Collins 2010; 
Pérez-Capilla et al. 2005). 
 
Hence, the widespread use of antibiotics amongst humans and animals has created a 
global problem in spreading resistance acquisition. Unfinished treatments, overuse in 
agriculture and farming, misuse against viral infections and usage for prophylaxis has 
accelerated the pace at which bacteria are able to overcome the bacteriostatic and 
bactericidal mechanism implemented by many types of antibiotic agents. The typical 
antibiotic-resistance mechanisms include efflux pumps, target gene-product 
modifications, and inactivation of the antibiotic compound by enzymes. (Dantas et al. 
2008; Spellberg, Bartlett, and Gilbert 2013) 
 
Consequently, a combination of multi-resistant bacterial strains and a lack of new 
potent antibacterial drugs is a global healthcare problem (Butler and Cooper 2011; 
Cooper and Shlaes 2011; Ledford 2012; Howell 2013; Davies 2011; Chan 2013; 
McKendry and Kappeler 2013).  
 
Additionally, very recent studies have confirmed that bacteria are not only acquiring 
resistance against antibiotics, but also against broad-spectrum antimicrobial agents such 
as triclosan (Drury et al. 2013). Due to its antibacterial and antifungal activity, triclosan is 
a commonly used additive in various consumer products such as antibacterial soaps, 
shampoos and toothpastes (Thompson et al. 2005). Moreover, it has become a 
recommended treatment in surgical units for the decolonisation of patients, whose skin 
is carrying methicillin-resistant Staphylococcus aureus (MRSA) (Coia et al. 2006a; Coia et 
al. 2006b).  
 
These alarming developments show beyond dispute that the responsibility of protecting 
antibiotic efficacy lies in our hands. There can be no doubt that we urgently need to 
tackle the global challenge of antimicrobial resistance.  
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In simple terms, there are three areas of focus underpin the fight against developing 
antibacterial resistance. The first is traditional practices in infection prevention and 
control, the second is improved antibiotic stewardship, while the third is the 
development of new antibacterial drugs (Spellberg, Bartlett, and Gilbert 2013).  
 
This chapter provides a general overview of antibiotics and antibiotic resistance 
including terminology (2.1), history (2.2), the lack of antibiotics and the rise in resistance 
as our global challenges (2.3).  
2.1 Definition of Antibiotics, Antimicrobials and Antibacterials 
The word “antibiotic” is derived from “antibiosis”, which originated from the Ancient 
Greek and means ‘against life’. It is believed that this term was introduced by the French 
mycologist Jean Paul Vuillemin (1861 – 1932) in 1889 when he described the 
characteristic of a group of drugs, which showed activity against microorganisms 
(Calderón and Sabundayo 2007).  
 
In 1947, Selman A. Waksman (1888 – 1973), a Ukrainian-born American inventor, 
biochemist and microbiologist, published one of the first definitions for the term 
“antibiotic”. He concluded that “An antibiotic is a chemical substance, produced by 
microorganisms, which has the capacity to inhibit the growth of and even to destroy 
bacteria and other microorganisms. The action of an antibiotic against microorganisms is 
selective in nature, some organisms being affected and others not at all or only to a 
limited degree; each antibiotic is thus characterised by a specific antimicrobial spectrum. 
The selective action of an antibiotic is also manifested against microbial versus host 
cells. Antibiotics vary greatly in their physical and chemical properties and in their 
toxicity to animals. Because of these characteristics, some antibiotics have remarkable 
chemotherapeutic potentialities and can be used for the control of various microbial 
infections in man and in animals.” (Waksman 1947).  
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Historically, Waksman’s definition did not include semi- and fully synthetic antibiotic 
agents, however, this was later extended to include synthetic agents (von Nussbaum et 
al. 2006).  
 
In conclusion, ‘antibiotic(s)’ is an umbrella term for a whole range of compounds with 
antimicrobial activity. However, it is important to distinguish between antimicrobial 
medicines/medication/drugs/agents1, which include antifungal, antiparasitic and 
antibacterial agents, and a wide range of less specific or non-specific chemicals, metals, 
plants or natural compounds with antimicrobial activity (von Nussbaum et al. 2006). 
They span from disinfectants such as iodine (Coia et al. 2006a; Coia et al. 2006b), 
alcohols (Coia et al. 2006a; Coia et al. 2006b; Marshall et al. 2004), and detergents with 
additives like triclosan (Drury et al. 2013; Thompson et al. 2005). Further, they include, 
for instance, the metals copper (Casey et al. 2010; O’Gorman and Humphreys 2012) and 
silver (Percival, Bowler, and Russell 2005), which are broadly applied in healthcare 
facilities (Ojeil et al. 2013). Moreover, organic acids including citric and lactic acids 
(Eswaranandam, Hettiarachchy, and Johnson 2006), and plant extracts including 
essential oils such as garlic, tea tree oil and thymol2 (Smith-Palmer, Stewart, and Fyfe 
1998; Selim 2011; Kollanoor Johny et al. 2010; Ogata et al. 2005; Nostro et al. 2007), are 
known to have antibacterial activity (Windler, Height, and Nowack 2013). However, 
                                                            
1 For simplicity, these four terms are treated as synonyms within this thesis.  
2 Thymol is the colloquial name of 2-isopropyl-5-methylphenol and it serves as structural basis for 
bromothymol blue (BTB). BTB is a pH indicator changing its colour from yellow to blue above a pH 
of 7.6. It is typically one compound of the universal pH indicator paper (Scudi 1941; Mertens et 
al. 2004; Foster and Gruntfest 1937). Coloured compounds serving as pH indicators are further 
discussed in chapter 5.1.1.3. Due to its phenolic moiety, thymol was described by Harry D. Gibbs 
to react with 2,6-dibromoquinonechoroimide in a similar manner to phenol resulting in a blue 
coloured indophenolic compound (Gibbs 1926b; Gibbs 1926a; Adam et al. 1981). The Gibbs 
reagent and its mechanism plays an important role in the first detection technique investigated 
in this thesis and will be discussed in chapter 5.1.2. Furthermore, it resembles the anaesthetic 
propofol structurally, which will be further discussed in this thesis (see chapter 5.1.3 and 5.3.2). 
Therefore, it is often used as internal standard in different propofol monitoring experiments 
(Cussonneau et al. 2007; Dawidowicz and Fornal 2000; Liu et al. 2012; Dawidowicz et al. 2006; 
Dawidowicz and Kalitynski 2005; Hornuss et al. 2007; Miekisch et al. 2008; Adam et al. 1981; 
Dawidowicz, Kobielski, and Pieniadz 2008a). And to close the circle, phenolic compounds 
including propofol and especially dipropofol, which on the first glance resembles the structure of 
triclosan, were reported to have antimicrobial activity (Ogata et al. 2005). 
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most of them are applied locally to disinfect surfaces or on wounds and are not 
administered in patients.  
 
To determine whether a compound is a therapeutic agent, or more specifically an 
antimicrobial agent, the following two definitions provided by the German physician and 
scientist Paul Ehrlich (1854 – 1915), need to be considered. For the international medical 
congress in 1913, Paul Ehrlich wrote an “Address in Pathology on Chemiotherapy” 
(Ehrlich 1913) and he defined “The only substances, therefore, that can be used as 
therapeutic agents are those in which the ratio between organotropic effect and 
parasitotropic effect is a favourable one, and that can be easily ascertained by 
experimental comparison of the dosis toxica with the dosis tolerata. The only substance 
that can be considered therapeutic agents are those of which is a fraction of the dosis 
tolerata is sufficient to bring about therapeutic effects.” (Ehrlich 1913, p. 355) Ehrlich’s 
second definition is “Corpora non agunt nisi fixata. When applied to the special case in 
point this means that parasites are only killed by those materials to which they have a 
certain relationship, by means of which they are fixed by them. I call such substances 
‘parasitotropic’.” (Ehrlich 1913, p. 353) In other words, this suggest that “A drug will not 
work unless it is bound” (Rang et al. 2007, p. 8). 
 
Nowadays, the term ‘antibiotic(s)’ is widespread and used synonymously with 
antibacterials. Therefore, in the context of this thesis, it was decided that the word 
‘antibiotic(s)’ will be synonymous with antibacterials, unless otherwise declared, even 
though it is not entirely correct.  
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2.2 The History of Antibiotics, Resistance and Drug Discovery 
The history of antibiotics and antibiotic resistance are closely linked. The starting point 
for such a topic is also particularly tricky to specify.  
2.2.1 Antibiotic and Antibiotic Resistance Timeline 
For example, one could argue that the history of antibiotics and antibiotic resistance 
began almost four billion years ago when the first bacteria and other microorganisms 
began to populate the world (Wright 2010; Fernandes 2006). It is likely that the 
competition between bacteria, for limited resources began at the same time and has not 
stopped since (DeLong and Pace 2001; Fernandes 2006). Bacteria compete by producing 
chemical that kill or inhibit the growth of competitor organisms. The development of 
resistance was the process by which microorganisms evolved in order to overcome the 
effects of these chemicals.  
 
Resistance mainly develops via a process of random genetic mutations that are changes 
of the microorganism’s genetic material. Certain mutations in the genome will confer a 
specific phenotype to the organism, which in some cases is favourable in protection 
against harmful toxins and chemicals. Should a mutation arise that limits the effect of an 
antibiotic agent, the surviving microorganism is described as “antibiotic resistant”.  
In Darwinian terms referring to ‘natural selection’ and ‘survival of the fittest’ (Darwin 
1859), the mutated and selected microorganism is the fittest in this specific 
environment and subsequently survives and proliferates. The same applies to a 
bacterium or microorganism that randomly evolved a more potent chemical and is able 
to obtain more resources and will thrive (Sommer, Dantas, and Church 2009; Dantas et 
al. 2008; Walsh and Wright 2005).  
 
Consequently, in the face of this exposure to chemicals over a long time, it is not too 
surprising that microbes have evolved complex machinery for sensing, responding to 
and metabolising chemicals harmful to them (Wright 2010). In conclusion, one could 
argue that antibiotics on planet earth have been “invented” by microorganisms 
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including bacteria and the simultaneous development of antibiotic resistance has 
evolved as a natural by-product of the process (Spellberg, Bartlett, and Gilbert 2013). 
 
In more practical terms, the history of antibiotics begins when humans first developed 
substances to treat bacterial diseases. However, it is hard to specifically date when 
humans first used substances against bacterial growth. There is evidence that several 
natural substances with known antibacterial effect, such as various roots, honey and 
moulds, were used in ancient Egypt and China (Wainwright 1989).  
 
On the other hand, it seems fairly straightforward to put a start date to antibiotic 
resistance history as it basically is the same as the first application of an antibacterial 
substance. Since in simple terms, one can say that with every single use of an 
antibacterial chemical the evolutionary pressure on bacteria rises. Antibiotics increase 
the selective pressure on bacterial populations, allowing the resistant bacteria to thrive 
whilst the susceptible bacteria die off. In some cases, antibiotics even induce 
mutagenesis, for example, by stimulating the production of reactive oxygen species 
(Dwyer, Kohanski, and Collins 2009; Kohanski, DePristo, and Collins 2010) or induction of 
DNA damage that activates error-prone polymerases (Miller et al. 2004; Cirz et al. 2005; 
Pérez-Capilla et al. 2005). Moreover, bacteria have the ability to pass their resistance to 
other bacteria via conjugation. This can occur between bacteria from different genera 
(Theuretzbacher 2013; Davies and Davies 2010; von Nussbaum et al. 2006; Fernandes 
2006; Alekshun and Levy 2007; Gould 2011). 
 
The beginning of the antibiotic era could alternatively be defined by Waksman’s 
definition (see chapter 2.1). This would require us to look for the first use of a “chemical 
substance, produced by microorganisms, which had the capacity to inhibit the growth 
of, or even to destroy bacteria and other microorganisms” (Waksman 1947). However, 
providing a conclusive answer for the very first use of an antibiotic in modern ages 
would be particularly difficult (Foster and Raoult 1974).  
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2.2.2 Golden Era of Antibiotic Drug Discovery  
Undoubtedly amongst the most famous people associated with antibiotic’s history is 
Sir Alexander Fleming (1881 – 1955), a Scottish biologist and pharmacologist. By 1928, 
Fleming was already a well-known researcher for his work on Staphylococcus and the 
antibacterial property of lysozyme (Fleming 1922). His laboratory was often untidy with 
bacterial cultures left out on the benches. Upon his departure for a holiday, his 
laboratory was left in a similar state, with culture plates stacked one on top of the other. 
On his return, six weeks later, he found his culture contaminated with mould. 
Furthermore, the colonies of Staphylococci, which had surrounded the mould, had 
undergone lysis. He interpreted this observation as the activity of an anti-bacterial 
substance produced by the fungus. He identified this fungus as Penicillium rubrum. Thus 
Fleming named this substance penicillin (Fleming 1929). In further experiments he found 
that this substance prevented growth of Staphylococci and other bacteria even when it 
was diluted several hundred times. This natural antibacterial drug gave humanity the 
first effective treatment against several diseases such as diphtheria, gonorrhoea, 
pneumonia, scarlet fever and syphilis. During the Second World War, penicillin saved 
countless lives by helping treat bacterial infections contracted by war-wounded soldiers. 
In 1945 Fleming, Howard Flory (1898 – 1968), an Australian pathologist, and Ernst Chain 
(1906 – 1979), a German biochemist, were awarded the Nobel Prize for Medicine for 
their discovery of the first natural antibiotic, penicillin (Fleming 1929; Fernandes 2006; 
Ligon 2004). 
 
However, already before Alexander Fleming’s discovery, several scientists associated a 
connection between the appearance of mould and the disappearance of bacteria. For 
the sake of brevity, only two of them are subsequently presented. In 1871, Sir John Scott 
Burdon-Sanderson (1828 – 1905), a British physiologist, reported that culture liquid, 
which was covered with the mould Penicillium rubrum, lacks bacteria (Burdon-
Sanderson 1871). Four years later, John Tyndall (1820 – 1893), an Irish physicist 
demonstrated in several studies the previous observed antibacterial activity of 
Penicillium. However, he concluded that the bacteria in the liquid, covered by the 
CHAPTER 2: ANTIBIOTICS, RESISTANCE, STEWARDSHIP AND DRUG DISCOVERY  
  
 
 
41 
 
mould, died due to the lack of oxygen and consequently did not deem these findings 
relevant (Tyndall 1881; Landsberg 1949; Foster and Raoult 1974).  
 
A couple of years after Burdon-Sanderson and Tyndall, a fairly different approach was 
undertaken by Paul Ehrlich, who has previously been introduced in subsection (2.1). 
Ehrlich had worked extensively on immunology, antiserum to combat diphtheria, 
standardising therapeutic serums and on a new technology for in vivo staining. In the 
course of the latter, he came across methylene blue, which was later taken on by his 
friend Robert Koch (1843 – 1910), a German physician and pioneering microbiologist, for 
his research on pathogens causing tuberculosis (Gensini, Conti, and Lippi 2007). In 1908 
Paul Ehrlich was awarded the Nobel Prize for Physiology or Medicine for providing a 
theoretical basis for immunology as well as for his work on serum (Raju 1998). Based on 
these previous studies, Ehrlich theorised that a drug with antimicrobial activity could be 
discovered which does not kill the human host. He called it a “bewitched bullet” (Ehrlich 
1913). To find such a “magic bullet”, Ehrlich’s team conducted a survey of hundreds of 
systematically modified chemical compounds (Schwartz 2004; Foster and Raoult 1974). 
In 1909 they discovered ‘Salvarsan’ (3-amino-4-hydroxyphenylarsenic, arsphenamine, or 
compound 606), which only one year later got introduced as the first effective organic 
compound against syphilis (Lloyd et al. 2005; von Nussbaum et al. 2006; Schwartz 2004). 
His methodical search for a specific cure for an identified disease can be seen as the 
introduction of targeted chemotherapy. He is therefore considered as the creator of the 
field of chemotherapy (Schwartz 2004). Ehrlich also described the process of the 
development of drug resistance and the therapeutic index of a drug as the ratio 
between the average minimum effective dose and the average maximum tolerated dose 
in a group of subjects, which is still in use today (Ehrlich 1913; Rang et al. 2007).  
 
Following Ehrlich’s Salvarsan, the next synthetic antibiotic Prontosil, a sulfonamid, was 
discovered many years later in 1932 (Schwartz 2004; Otten 1986). After five years of 
testing thousands of various azo dyes compounds, Gerhard Domagk (1895 – 1964), a 
German pathologist and bacteriologist, discovered that one compound is remarkably 
effective against streptococcal sepsis in mice. In 1939, Gerhard Domagk was awarded 
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the Nobel Prize in Physiology or Medicine “for his discovery of the antibacterial effects 
of Prontosil” (Raju 1999).  
 
The successful development of penicillin in 1928 showed that many antibiotics could be 
awaiting discovery. Therefore, the golden era of antibiotic drug discovery began in the 
1940s by screening of natural products and systematic search of antibacterial producing 
microorganisms (von Nussbaum et al. 2006; Lewis 2012; Fernandes 2006; Walsh and 
Wright 2005; Singh and Barrett 2006). One of the pioneers of this time was Selman A. 
Waksman, who was previously introduced in subsection 2.1. He exploited bacteria’s 
ability to produce their own antibiotics and systematically tested them. His main interest 
was for Streptomyces, which are the largest genus of Gram-positive actinobacteria. In 
1943, this testing led to the discovery of streptomycin, the first antibiotic used to treat 
tuberculosis. In 1952 Waksman received the Nobel Prize in Physiology or Medicine for 
his “ingenious, systematic and successful studies of the soil microbes that have led to 
the discovery of streptomycin.” (Ginbserg 2005; Lewis 2012)  
 
As already highlighted at the beginning, it is impossible to tell the history of antibiotics 
without resistance. This applies to penicillin as well. By the late 1950s, up to 85% of 
clinical isolates of Staphylococci were found to be resistant against penicillin (Williams 
and Bardsley 1999). Consequently from the 1960s to the 70s, the development of 
antibiotic resistant bacteria added urgency to the search for new antibiotic compounds. 
However, with screening of natural products nearly no new antibacterial substances 
were found anymore. Therefore, semi-synthetic modifications of existing antibiotics 
seemed to be very promising. This approach was less risky and deemed successful due 
to the known toxicity and selectivity of the parent antibiotic. (Fernandes 2006; Kappeler 
2010) 
 
However, by the early 1980s after two decades of deriving analogues, this method 
seemed to be exhausted whilst bacteria resistance continuously thrived, fuelled by the 
extensive and uncontrolled use of antibiotics, especially in hospitals and agriculture 
(Levy and Marshall 2004; Sommer, Dantas, and Church 2009). 
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In the late 80s and 90s researchers started to screen small drug libraries and re-tried the 
synthetic chemistry approach. However, the yield has been very poor, so that many 
companies returned to known natural compounds. Figure 2.01 presents a timeline for 
antibiotic research. (Fernandes 2006; Lewis 2012; Wright 2010; Gwynn et al. 2010)  
2.3 Lack of Antibiotics and Rise in Resistance our Global Challenges 
Today the most up-to-date methods, such as microbial gene cloning, genome 
sequencing, protein expressions, high-throughput screening and combinatorial libraries, 
have not led to an improved yield of new antibiotics. In the past 40 years, less than a 
handful of new antibiotic classes have been launched (Cooper and Shlaes 2011). 
Furthermore after decades of little success, pharmaceutical companies are ‘pulling the 
plug’ on antibiotic discovery. Most of them have either left the field, such as Merck 
(New Jersey, U.S.A.) and Eli Lilli (Indiana, U.S.A.), or have hugely downsized their effort 
(Lewis 2012). Hence as Dr Margaret Chan, Director-General of the World Health 
Organization (WHO), recently announced “In terms of new replacement antibiotics, the 
pipeline is virtually dry” (Chan 2013). Therefore, it is beyond dispute that the rise in 
antimicrobial resistance and the lack of new antibiotics in the antimicrobial drug 
discovery pipeline are two interlocking global challenges, which urgently have to be 
tackled (Butler and Cooper 2011; Cooper and Shlaes 2011; Ledford 2012).  
 
Metaphorically, it can be seen as a constant ‘arms race’ of bacteria against humans and 
vice versa. This is as a very good example of the “Red Queen Hypothesis” proposed by 
Leigh Van Valen (1935 – 2010), an American evolutionary biologist, in 1973 (Van Valen 
1973). The hypothesis describes how any evolutionary system must develop 
continuously to maintain its fitness relative to coevolving and competing systems 
(Woodford and Livermore 2009; Woodford 2003). The ‘Red Queen’ refers to the 
character in Lewis Carroll’s novel “Alice Through the Looking Glass”, who told Alice 
“Now, here you see, it takes all the running you can do, to keep in the same place” 
(Carroll 1871). Similarly, we have to do all the ‘running’ we can do in order to keep up 
with the evolution of antimicrobial resistance.  
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However, the emergence of new highly-resistant bacteria, such as carbapenemase-
producing Enterobacteriaceae3 (CPE) and New Delhi metallo-beta-lactamase-1 (NDM-1) 
producing bacteria (Kumarasamy et al. 2010), as well as the re-emergence of old 
enemies, such as the well-known hospital ‘superbug’ MRSA, are clear evidence that we 
are limping behind. 
 
Dr. Margaret Chan emphasised at several occasions, including last year’s conference on 
“Combating Antimicrobial Resistance: Time for Action” in Copenhagen, that antibiotic 
resistance could bring “the end of modern medicine as we know it. Things as common as 
‘strep throat’ or a child’s scratched knee could once again kill”(Chan 2013). Furthermore, 
there is a greater risk “that hospitalization kills instead of cures” (Chan 2013). Supporting 
this, the Chief Medical Officer for England, Professor Dame Sally Davies, recently 
announced the “antibiotic apocalypse” and said “that we might not see global warming” 
since “the apocalyptic scenario is that when I need a new hip in 20 years I’ll die from a 
routine infection because we’ve run out of antibiotics” (Davies 2011). Moreover, she 
rated antibiotic resistance as one of the gravest threats to human health alongside 
dangers such as global warming and terrorism (Davies 2011). Supporting this, the recent 
annual report on global risks from the World Economic Forum (WEF) stated “the 
greatest risk [...] to human health comes in the form of antibiotic-resistant bacteria” 
(Howell 2013). 
  
                                                            
3 Enterobacteriaceae is a family of Gram-negative bacteria including the genera Salmonella, 
Klebsiella, Shigella, Yersinia with the species Yersinia pestis, and Escherichia with the species 
Escherichia coli (E. coli).  
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Figure 2.01: A timeline for antibiotic research. New antibiotic classes are highlighted in bold 
letters. Antibiotics originated from natural product are shown in black and those that are 
synthetic are written in green letters. Technologies used in antibacterial drug discovery are 
shown in red letters. Gram-positive bacteria are drawn in purple and Gram-negative bacteria are 
in pink. Clostridium difficile (C. difficile) is shown in black. The almost closed loop indicates the 
current risk of returning to the pre-antibiotic era. Schematic adopted from Fernandes 2006. 
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CHAPTER 3:  
The Glycopeptide Antibiotic – Vancomycin 
3 The Glycopeptide Antibiotic – Vancomycin 
Antibiotics are subdivided into several different classes. One class is the glycopeptide 
antibiotics. Glycopeptide antibiotics are originally natural compounds active against 
Gram-positive bacteria and produced by several genera of actinomycetales, which are 
an order of the actinobacteria. Actinomycetales form branching filaments, which appear 
like the mycelia of a fungus and therefore were initially classified as actinomycetes. 
Actinobacteria are Gram-positive bacteria, which can be terrestrial or aquatic and they 
play a vital role in turnover of organic matter (Malabarba, Nicas, and Thompson 1997; 
Servin et al. 2008). 
 
This chapter is divided into three subsections. The first subsection (3.1) presents a 
concise history of vancomycin. The second subsection (3.2) shows vancomycin’s 
structure, explains its mode of action and discusses a mechanism of resistance. The third 
and last subsection (3.3) discusses vancomycin’s pharmacology with focus on 
pharmacokinetics and pharmacodynamics.   
3.1 History of Vancomycin – the Glycopeptide Antibiotic 
Vancomycin is the archetype of the glycopeptide antibiotics and was first described in 
1956 (McCormick et al. 1956; McCormick, McGuire, and McGuire 1962). Three years 
earlier, in a natural products screening program by the pharmaceutical company Eli Lilly 
(Indianapolis, USA), Dr. Edmund Carl Kornfeld (1919 – 2012), an American organic 
chemist, and his team collected a soil sample in Borneo. In this soil sample they found an 
unknown microbe and they were able to isolated a new antibacterial substance out of it 
(Moellering 2006; Griffith 1981). This substance was produced by Amycolatopsis 
orientalis (formerly designated as Streptomyces orientalis). It became the name 
“vancomycin” after the word “vanquish” (Levine 2006). 
 
 
CHAPTER 3: THE GLYCOPEPTIDE ANTIBIOTIC - VANCOMYCIN 
  
 
 
47 
 
Already two years after its isolation, vancomycin got approved by the US Food and Drug 
Administration (FDA) for treatment of Gram-positive infections in hospitals. However, 
due to its toxicity it was used only for infections where other antibiotics, like β-lactam, 
failed. Therefore the introduction of semi-synthetic penicillins overshadowed 
vancomycin. However with rise of MRSA infection in hospitals, vancomycin has become 
one of the drugs of last resort worldwide. MRSA is one of many examples demonstrating 
that human induced evolutionary pressure causes bacteria resistance. Staphylococcus 
aureus mutated from a harmless methicillin-susceptible skin bacterium, with which 
typically everyone is colonised, to a multi-resistant highly infectious ‘superbug’ (Marshall 
et al. 2004; Chen 2013). 
 
Due to the widespread and often indiscriminate use of vancomycin, the first resistant 
bacteria to glycopeptides antibiotics were observed in 1987 as vancomycin-resistant 
Enterococci (VRE) emerged (Johnson et al. 1990). Approximately ten years later, further 
vancomycin resistant bacteria developed, such as vancomycin-intermediate 
Staphylococcus aureus (VISA) (also termed GISA for glycopeptide-intermediate 
Staphylococcus aureus) and afterwards vancomycin-resistant Staphylococcus aureus 
(VRSA) (Hiramatsu 2001; Hopewood et al. 2007; Kahne et al. 2005; Gould 2010).  
3.2 Vancomycin’s Structure, Mode of Action and Resistance  
The structure elucidation of vancomycin took many years to solve (Marshall 1965; 
Perkins 1969; Williams and Kalman 1977; Sheldrick et al. 1978) and its final structure 
was not found until 1981 (Harris and Harris 1982). Since then vancomycin’s structure 
and its non-covalent binding interactions have been extensively studied by X-ray 
crystallography (Schäfer, Schneider, and Sheldrick 1996; Loll et al. 1998; Nitanai et al. 
2009) and nuclear magnetic resonance (NMR) methods (Williams et al. 1983; Williams 
1984; Pearcea and Williams 1995).  
 
The core structural element of vancomycin and all glycopeptide antibiotics is a linear 
heptapeptide backbone consisting of seven amino acid residues. Five aromatic amino 
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acids are invariant and their residues are cross-linked together to build the characteristic 
rigid concave shape (figure 3.01 A). This backbone structure provides a further name for 
this antibiotic class – dalbaheptides (Hubbard and Walsh 2003).  
 
The activity of the glycopeptide antibiotics results from their ability to inhibit bacterial 
cell wall biosynthesis. Their mode of action targets peptidoglycan, a conserved structural 
feature of bacteria, which is vital for their mechanical integrity. The peptidoglycan cell 
wall is an excellent antibiotic target because it occurs exclusively in bacteria and has no 
counterpart in mammalian cells, which is a very crucial for an effective antibiotic as 
described by Ehrlich (Ehrlich 1913). The peptidoglycan is a robust mesh-like 
carbohydrate polymer, which is made of alternating units of N-acetylglucosamine 
(GlcNAc) and N-actylmuramic acid (MurNAc). Each MurNAc is attached to a 
pentapeptide, which terminates in L-Lysine-((Glycine)5)-D-Alanyl-D-Alanine (DAla-DAla) 
(figure 3.02 A and B). Attached to the inner membrane in the cytoplasm, these two units 
become cross-linked to GlcNAc-MurNAc-pentapeptide. Afterwards all these cross-linked 
units get exported to the outer membrane where transglycosylase enzymes polymerise 
them to long chains. This transfer to the outer membrane takes place via lipid carriers, 
undecaprenyl phosphates (C55H91O4P), which are embedded in the membrane. Lastly 
these units get cross-linked via transpeptidase enzymes to the existing cell wall 
(Schouten et al. 2006; Schneider and Sahl 2010).  
 
Glycopeptide antibiotics recognise and bind strongly to the pentapeptide terminating in 
DAla-DAla and thus inhibit release of the building block unit from the lipid carrier 
(figure 3.01 A and 3.02 A). Consequently transglycoslation and transpeptidation (cross-
linking) cannot be carried out, which prevents the essential cell wall formation and 
turnover. This causes a loss in mechanical integrity, leading to lysis of the bacterium due 
to the high osmotic pressure inside the bacterial cell. In contrast to glycopeptide 
antibiotics, β-lactam antibiotics, such as penicillin, inactivate several proteins involved in 
the transglycoslation and transpeptidation. This inactivation also causes lysis of the 
bacterial cell due to loss of mechanical integrity. The proteins to which the β-lactam 
antibiotics are binding to are summarised as penicillin-binding proteins (PBPs). Both 
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antibiotic target sides are indicated in figure 3.02 A. (Ndieyira et al. 2008; Kahne et al. 
2005; Nagarajan 1994; Allen and Nicas 2003; Rang et al. 2007; Kappeler 2010; Hiramatsu 
2001; McKendry 2012)  
 
The binding interaction between vancomycin and the DAla-DAla dipeptide is 
characterised by five hydrogen bonds (figure 3.01 A). Due to these interactions the 
antibiotic is forming a groove with its binding pocket along the peptide (figure 3.01 B 
and C). (Williams 1996; Williams 1984; Kannan et al. 1988; Nagarajan 1994; Kahne et al. 
2005) 
 
There are different mechanisms causing resistance against vancomycin. Two examples 
are briefly presented below.  
 
i) One example of a resistance mechanism is the subtle change from an amide to an 
ester in peptidoglycan’s precursor occurring in VRE. This change from D-Alanyl-D-
Alanine to D-Alanyl-D-Lactate (from DAla to DLac) results in the deletion of a single 
hydrogen bond from the binding pocket and the subsequent creation of destabilising 
lone pair-lone pair interactions between the peptide and the antibiotic. These 
changes in interaction render the antibiotic therapeutically ineffective (figure 3.01 D). 
(Arthur et al. 1996; Arthur et al. 1992; Nagarajan 1994; Cooper and Williams 1999)  
 
ii) Another example is the mechanism employed by the different clinical strains of 
VRSA. All of them feature a significant thickened cell wall in comparison to 
vancomycin-susceptible Staphylococcus aureus (VSSA). This thickened cell wall 
impairs the penetration of vancomycin molecules and consequently prevents them 
from reaching the peptidoglycan precursor. (French 2006; Hiramatsu 2001; Holmes, 
Johnson, and Howden 2012; Calfee 2012; Gould 2011; Chen 2013; Woodford and 
Livermore 2009)  
 
The firstly presented resistant mechanism will be further exploited for the 
nanomechanical detection of vancomycin described in chapter 8.  
CHAPTER 3: THE GLYCOPEPTIDE ANTIBIOTIC - VANCOMYCIN 
  
 
 
50 
 
 Figure 3.01: Vancomycin’s 
structure, its mode of 
action and one example 
for a resistance 
mechanism. 
 
A) Lewis’ structure of 
vancomycin binding to 
DAla-DAla. The dotted blue 
lines indicate five hydrogen 
bonds.  
 
B) Three- dimensional 
model of vancomycin 
binding to the dipeptide of 
the peptidoglycan 
precursor. For improved 
visibility of the groove, an 
artificial surface in yellow is 
drawn around the 
vancomycin molecule.  
 
C) A cross section through 
(B) shows the interaction 
of the vancomycin binding 
pocket with the dipeptide. 
The five hydrogen bonds 
are shown with turquoise 
lines.  
 
Schematics B and C 
courtesy of Dr. Manuel 
Vögtli.   
 
D) Resistance mechanism 
occurring in vancomycin-
resistant Enterococci 
(VRE). The exchange of the 
dipeptides’s terminal from 
a DAla to a DLac replaces an 
amide with an ester. This 
subtle change results in a 
deletion of one hydrogen 
bond (indicated by the red 
line) and adds destabilising 
lone pair-lone pair 
interactions, which renders 
the antibiotic ineffective.  
 
i 
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Figure 3.02: Peptidoglycan biosynthesis as an antibiotic target. A) Schematic representation of 
cell wall biosynthesis of S. aureus. The synthesis starts in the cytoplasm with the conversion of 
UDP-N-acetylglucosamine (UDP-GlcNAC) (i) to the soluble precursor UDP-MurNAc-penta-
peptide (ii). The conversion is sequentially catalysed by the enzymes MurA to MurF. Then, (ii) 
gets linked via another phosphate to the membrane embedded lipid carrier, undecaprenyl 
phosphate (C55-P), by MraY. The whole complex, C55-P-MurNAc-pentapeptide (iii), is also called 
lipid I. The translocase, MurG, subsequently cross-links UDP-GlcNAc to the muramoyl moiety of 
lipid I, producing a precursor of lipid II (C55-P-GlcNAc-pentapeptid) (iv). In S. aureus, 5 glycines are 
added to this precursor catalysed by FemXAB enzymes leading to the final structure of lipid II (v) 
which is further detailed in schematic B. Afterwards, lipid II is translocated across the membrane 
by a mechanism which is still the subject of scientific debate. On the membrane outside, the 
peptidoglycan unit is incorporated into the growing network through the activity of penicillin-
binding proteins (PBPs) by transglycosylation (TG) and transpeptidation (TP) reactions. The red 
boxes indicate the antibiotic target sites of β-lactam and glycopeptide antibiotics. It has to be 
emphasised that other classes of antibiotics also target the peptidoglycan biosynthesis. 
B) Chemical structure of lipid II produced by S. aureus. The colour coding refers to schematic A. 
Both schematics adapted from Schneider & Sahl 2010.   
(i) 
(ii) 
(iii) (iv) 
β-lactam 
antibiotics 
glycopeptide 
antibiotics 
(v) 
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3.3 Vancomycin’s Pharmacology 
This chapter gives a concise overview of vancomycin’s pharmacology to provide the 
required background for the assessment of the clinical needs for a PoC sensor for 
therapeutic antibiotic monitoring, which is summarised in chapter 4.3. This chapter 
consists of four subsections. The first subsection (3.3.1) describes the current dosing 
strategy of vancomycin and its administration. The second subsection (3.3.2) defines 
pharmacokinetics and pharmacodynamics. The third (3.3.3) and the fourth subsection 
(3.3.4) discuss vancomycin’s pharmacokinetics and pharmacodynamics respectively.  
3.3.1 Current Vancomycin Dosing Strategy 
Vancomycin has been used clinically for more than 50 years and is one of the antibiotics 
of last resort. It is effective against serious Gram-positive bacterial infection, such as 
MRSA and Clostridium difficile (C. difficile). Traditionally vancomycin has been 
considered bactericidal (kills bacteria) against most of the Gram-positive bacteria, such 
as S. aureus and Pneumococci, but bacteriostatic (stops bacteria from reproducing) 
against Enterococci (Roberts, Lipman, et al. 2008; Saribas and Bagdatli 2004; French 
2006). Vancomycin is generally used to treat septicaemia, endocarditis, 
pseudomembranous colitis, catheter-related blood stream infections, skin and soft 
tissue infections and as prophylaxis for certain procedures and implants. It is also 
valuable in treatment of severe staphylococcal infection in patients allergic both to 
penicillins and cephalosporins.  
 
The normal route of vancomycin administration is intravenous as opposed to oral, since 
the drug is not able to cross the gastrointestinal mucosa due to its size and its 
hydrophobicity. For treatment of C. difficile and associated pseudomembranous colitis, 
vancomycin must be given orally as intravenous administration will not achieve the 
minimum therapeutic concentration in the gut lumen (Rang et al. 2007).   
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The British National Formulary (BNF) recommends peak serum values for vancomycin to 
be in the range of 25 to 40 μg/ml which corresponds to 17.3 to 27.6 μM of vancomycin, 
and trough values should be in the range of 10 to 15 μg/ml and 15 to 20 μg/ml for 
complicated infections, which corresponds to 6.9 to 10.4 μM and 10.4 to 13.8 μM 
vancomycin respectively. For paediatrics, the peak serum values can reach 60 μg/ml 
which corresponds to 41.4 μM of vancomycin, and trough values are typically measured 
in the range of 5 to 10 μg/ml which corresponds to 3.5 to 6.9 μM vancomycin (Eiland, 
English, and Eiland 2011; Miles et al. 1997; Gordon et al. 2012; Nandí-Lozano, Ramírez-
López, and Avila-Figueroa 2003).  
 
Vancomycin is typically administered in two daily dose of 1 g or sometimes in smaller 
doses more frequently, such as four times 500 mg (Tobin 2002; Thomson et al. 2009; 
Kitzis and Goldstein 2006). However, some studies suggest that continuous infusion may 
be more favourable than the formerly used single dosage or intermitted regimes, 
especially for infections with S. aureus, which show an elevated vancomycin minimal 
inhibitory concentration (MIC) (Roberts, Kirkpatrick, and Lipman 2011; Roberts, Lipman, 
et al. 2008; Rello et al. 2005). A lower pharmacokinetic (see subsection 3.3.2 and 3.3.3) 
variability and better cost-efficiency was observed (Jelassi et al. 2011). Nevertheless this 
is still a controversial topic and other studies did not see a significant improvement in 
the pharmacodynamics of vancomycin with continuous infusion (Rybak et al. 2009a; 
Wysocki et al. 2001). Consequently, further studies can be expected (Roberts and 
Lipman 2009).  
3.3.2 General Definition of Pharmacokinetics and Pharmacodynamics 
A very simplified definition is “what the body does to the drug” is termed 
pharmacokinetics and “what the drug does to the body” is termed pharmacodynamics 
(Rang et al. 2007).  
 
The following two bullet points provide a more extended description:  
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- The word pharmacokinetics has its origin in Ancient Greek and is derived from the 
two terms pharmakon “drug” and kinetikos “to do with motion”. It describes the 
relationship of drug concentrations over the course of time attained in different body 
regions during and after dosing. This includes absorption, distribution and 
metabolism and excretion, which is often abbreviated as ADME or LADME if 
liberation is taken into account. Hence it describes how the body affects a drug from 
administration until elimination. (Rang et al. 2007; Craig 2003) 
 
- Pharmacodynamics, on the other hand, is derived from Greek word dynamikos 
“powerful” and describes the effect of the drug on the human body itself, on 
microorganism or on parasites within or on the human body. This includes the mode 
of action of the drug as well as the relationship between the concentration and 
effect. It can be concluded that pharmacokinetic parameters are related via 
pharmacodynamics to the pharmacologic effect. (Rang et al. 2007; Craig 2003) 
3.3.3 Pharmacokinetics of Vancomycin  
Despite more than half a century of clinical experience and many studies, there are large 
differences in the published vancomycin model parameters leading to great variance 
and intense debate with regards to the pharmacokinetics values. This is especially the 
case for several patient populations, such as children, immuno-compromised, intensive 
care and dialysis patients, for whom the pharmacokinetic parameters can be 
significantly different (Helgason, Thomson, and Ferguson 2008; Lomaestro 2011; Rybak 
et al. 2009b; Eiland, English, and Eiland 2011; Miles et al. 1997; Gordon et al. 2012).  
 
Similar accounts for protein binding, which is observed and reported for antibiotics over 
many years and still remains a very contradictory topic. There are still no standardised 
pharmacodynamic models that take protein binding into account, even though there are 
many studies proving its importance to the efficacy of the antibiotic and consequently to 
the health outcome and for the prevention of antimicrobial resistance. In this context, 
Zeitlinger and colleague’s paper bears the provoking title “Protein Binding: do we ever 
learn?” (Zeitlinger et al. 2011). It reports that literature suggest that the proportion of 
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vancomycin bound to proteins can vary between 10 – 82% with 55 % often quoted as 
the mean fraction bound. It is believed that vancomycin is predominately binding to 
serum albumin which is the most abundant plasma protein in mammals. However, it is 
also known to bind to other proteins including alpha-1-acid glycoprotein. (Bohnert and 
Gan 2013; Butterfield et al. 2011; Cantú et al. 1990; Ackerman et al. 1988; Zokufa et al. 
1989; Rodvold et al. 1988; Kitzis and Goldstein 2006; Shin et al. 1992; Shin et al. 1991; 
Zeitlinger et al. 2011; Dawidowicz, Kobielski, and Pieniadz 2008a; Fournier, Medjoubi-N, 
and Porquet 2000).  
 
The volume difference in serum between various patient groups such as children, the 
elderly, obese or dialysis patients is expected to be significant. Additionally, critical ill 
patients may suffer from physiological changes that alter the pharmacokinetics of drugs 
including antibiotics, which may lead to sub-therapeutic concentrations or changes in 
drug clearance especially in dialysis patients (Roberts et al. 2011; Roberts and Lipman 
2009; Udy et al. 2010; Roberts, Kirkpatrick, and Lipman 2011). Furthermore especially in 
paediatric care, there is little data guiding the dosing and monitoring of vancomycin 
leading to a wide variety of doses and dosing frequencies resulting in reduced success in 
achieving the recommended plasma concentrations (Miles et al. 1997; Eiland, English, 
and Eiland 2011; Gordon et al. 2012; Kitzis and Goldstein 2006). Nandí-Lozano and 
colleagues reported that from 70 paediatric patient treated with vancomycin less than 
20% were in the therapeutic range (Nandí-Lozano, Ramírez-López, and Avila-Figueroa 
2003).  
 
Additionally, most, if not all, gold standard drug monitoring methods only measure the 
total antibiotic concentration and do not distinguish between bound and free fractions, 
even though studies have suggested that the correlation between free and total fraction 
is poor (Zeitlinger et al. 2011; Estes and Derendorf 2010; Butterfield et al. 2011).  
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3.3.4 Pharmacodynamics of Vancomycin 
Pharmacodynamics of antibacterials deals with the relationship between drug exposure 
and antimicrobial effect (Craig 2003). Pharmacodynamically, the antibiotic activity is 
dependent on the interaction between drug concentrations at the site of infection, 
bacterial load, phase of bacterial growth and the MIC of the pathogen. A change in any 
of these factors will affect the pharmacodynamics of the antibiotic against the particular 
pathogen and therefore may not only affect the therapy outcome but also predispose 
development of antibiotic resistance. (Roberts, Kruger, et al. 2008; Levison 2004) 
 
Various different studies show that vancomycin’s pharmacodynamic characteristics, 
despite the similarity in mechanism, are not fully comparable to the pharmacodynamics 
profile of the β-lactam antibiotics, such as penicillin. Hence vancomycin is neither a 
solely time-dependent killer nor a solely concentration-dependent killer. Instead its 
clinical effectiveness is related to both the time above the MIC and the total amount of 
antibiotic, which is best described with the pharmacodynamics parameter: AUC over 
MIC, which is typically abbreviated as AUC/MIC (figure 3.03 A). AUC stands for the area 
under the curve and is a measure for the total exposure of an antibiotic to an organism 
(Rybak et al. 2009b; Muppidi et al. 2012; Stein and Wells 2010; Avent et al. 2013; Dhand 
and Sakoulas 2012; Udy et al. 2010; Roberts and Lipman 2009; Rybak 2006; Holmes, 
Johnson, and Howden 2012; Estes and Derendorf 2010; Gould 2011; Butterfield et al. 
2011; Thomson et al. 2009). In theory, to accurately determine the AUC, multiple serum 
concentration measures are needed. However, in practice with the current gold 
standards of therapeutic antibiotic monitoring, this is nearly impossible. The current 
gold standards of therapeutic antibiotic monitoring are further discussed in chapter 4.1. 
 
Two other aspects play an important role in the pharmacodynamics of vancomycin. 
These are (i) the so called ‘MIC creep’ and (ii) the mutant selection window (MSW) in 
combination with the mutant prevention concentration (MPC). 
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i) MIC creep: The increasing use of vancomycin since the mid 1980s is associated with a 
decreasing bacterial susceptibility (Dhand and Sakoulas 2012). The MICs of 
vancomycin VSSA, which previously have been characterised with a vancomycin MIC 
of below 1.5 mg/l, are now quite often observed creeping into the range of 1.5 to 
2 mg/l. These elevated MICs of VSSA are referred to as the ‘vancomycin MIC creep’. 
Such less susceptible VSSA are currently much more frequent in various healthcare 
settings around the globe than vancomycin non-susceptible strains such as VISA, 
which has a vancomycin MIC ranging from 4 to 8 mg/l, and VRSA with a vancomycin 
MIC of > 16 mg/l (Dhand and Sakoulas 2012; Estes and Derendorf 2010; Wang et al. 
2013). These less susceptible bacteria are the cause for prolonged bacteremia, 
treatment failures, increased mortality and higher relapse possibilities, which poses 
strong evidence for the urgent need for therapeutic vancomycin monitoring (Kitzis 
and Goldstein 2006; Rybak et al. 2009a; Holmes, Johnson, and Howden 2012; 
Pumerantz et al. 2011; Estes and Derendorf 2010; Chen 2013; Calfee 2012; van Hal, 
Lodise, and Paterson 2012; Muppidi et al. 2012; Dhand and Sakoulas 2012). 
 
ii) Mutant selection window (MSW) and mutant prevention concentration (MPC): 
Various studies suggested that inappropriately low antibiotic dosing is contributing to 
the increasing rate of antibiotic resistance. Consequently for many antibiotics a MSW 
could be identified, within which it is proposed that resistant mutants are selected 
(Firsov et al. 2006; Roberts, Kruger, et al. 2008; Imamovic and Sommer 2013). Since 
this MSW is typically in the concentration range from between MIC and MPC, 
attention should be paid to the antibiotic dosing strategy. The MPC is defined as the 
concentration required to prevent emergence of bacteria with single step mutations 
in a population of at least 1010 cells (figure 3.03 B). Not only should the blood 
concentration of the antibiotic kept above the MIC of the bacteria in question, it 
should also be able to deal with the most resistant subpopulation in this colony. 
Therefore the concentration should be above the MPC, which may be achieved by 
maximising antibiotic exposure by administering the highest recommended dose to 
the patient. In taking this approach into account, the selection of resistant mutants 
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will be prevented and further development or resistance will be limited. (Roberts, 
Kruger, et al. 2008; French 2006) 
 
Following on this, the next chapter (4) describes therapeutic drug and vancomycin 
monitoring and its health economic importance. Furthermore, it also summarises the 
assessment of the clinical needs for a PoC sensor for therapeutic antibiotic monitoring.   
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Figure 3.03: Pharmacodynamics of antibiotics. A) Schematic of fundamental pharmacodynamic 
parameters on a concentration vs. time diagram. Typically three models are differentiated which 
describe the clinical efficacy of the various antibiotic classes best: i) concentration-dependent 
killing is defined via the ratio of maximum serum antibiotic concentration (Cmax) to MIC: Cmax/MIC; 
which is for example exhibited by aminoglycosides, ii) time-dependent killing is expressed by the 
time (T) for which the antibiotic concentration exceeds the MIC: T>MIC; which is associated with 
β-lactam antibiotics, and iii) area of the concentration time curve during 24 hours illustrated by 
AUC0-24 divided by the MIC: AUC0-24/MIC; which for example is largely displayed by 
fluoroquinolones and glycopeptides, as both antibiotics show concentration- and time-
dependent killing. Cmin depicts the minimum serum antibiotic concentration. B) Mutant selection 
window (MSW) and mutant prevention concentration (MPC) depicted against the logarithmic 
change of the colony-forming units (cfu) and the antibiotic concentration. This graph represents 
the reduction of bacterial colonies with increased antibiotic exposure. For bacteria to survive the 
first ‘drop’ (MIC), a first mutation is required. Then to survive the second ‘drop’ (MPC), they have 
to acquire a second mutation, which is less likely. If the antibiotic concentration is between the 
two ‘drops’ in the MSW, selection of the resistant bacteria may occur. Both schematics adapted 
from Roberts, Kruger, et al. 2008. 
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CHAPTER 4: 
Therapeutic Drug and Vancomycin Monitoring 
4 Therapeutic Drug and Vancomycin Monitoring 
Therapeutic drug monitoring (TDM) is a model example of the multidisciplinary 
approach to patient care defining modern healthcare practices and personalised 
medicine. Nursing staff, clinicians, pharmacist and scientist are all involved in the 
adjustment and optimisation to tailor the treatment to individual patient’s needs. TDM 
enables the drug dose to be titrated to the desired target concentration within the 
therapeutic range according to patient’s individual drug adsorption, distribution, 
metabolism and excretion. Repeated measurements allow the detection of 
accumulation or changes in the drug clearance rate and additionally may provide early 
detection of faults in the drug delivery system. As a result, TDM is often implemented 
for drugs with a narrow therapeutic range, pharmacokinetic variability and target 
concentrations that are difficult to monitor. Moreover, it is also of great benefit where 
special care is requires, such as paediatrics or intensive care settings. (Gross 2002; Kang 
and Lee 2009) 
 
This chapter is divided in four subsections. The first subsection (4.1) describes the 
current gold standards in therapeutic vancomycin monitoring (TVM). The second 
subsection (4.2) discusses the health economic importance of TVM. The third subsection 
(4.3) summarises the assessment of the clinical needs for a PoC sensor for therapeutic 
antibiotic monitoring. The fourth and the last subsection (4.4) presents a profile of our 
industrial partner, Sphere Medical Ltd., Cambridge, UK.   
4.1 Current Gold Standards in Therapeutic Vancomycin Monitoring  
The administration of many therapeutic drugs, including vancomycin, is routinely guided 
by therapeutic drug monitoring (TDM). The current gold standards for therapeutic 
vancomycin monitoring are immunoassays, such as the enzyme multiple immunoassay 
technique (EMIT) and the fluorescence polarisation immunoassay (FPIA). According to 
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the literature, the latter seems to be one of the most popular assays in clinics (Tobin 
2002; Wilson, Davis, and Tobin 2003; Yu, Zhong, and Wei 2010; White 2000).  
 
The mode of operation of these two immunoassays, EMIT and FPIA, is described below:  
 
- The working principle of an EMIT is based on competition between vancomycin 
in the samples, which can be either serum or plasma, and the vancomycin 
labelled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) 
provided within the assay for the antibody binding sites (figure 4.01 A). The 
enzyme is from the bacteria Leuconostoc mesenteroides and therefore requires 
a bacterial coenzyme, which is employed in the assay. This bacterial origin 
assures that endogenous serum G6PDH is not interfering. The antibodies are 
monoclonal mouse anti-vancomycin antibodies and the enzyme activity of the 
labelled vancomycin decreases upon binding to them. Active enzyme converts 
oxidised nicotinamide adenine dinucleotide (NAD) to NADH resulting in an 
absorbance change at 340 nm, which can be measured spectrophotometrically. 
Consequently, the vancomycin in the sample and the unbound enzyme labelled 
vancomycin included in the assay are directly proportional. (“Package Insert: 
VANC2 COBAS® from Roche Diagnostics” 2012; Wild 2013) 
 
- The change of tumbling rates for free and bound molecules is exploited for FPIA. 
The absorbance of light is depending on the orientation of the molecule relative 
to the direction and polarization of the exciting light. The subsequent emission 
as fluorescence by electronically excited molecule is typically polarised. 
However, if tumbling molecules rotate during the excitation period the 
orientation of the fluorescence polarisation may be randomised. Consequently, 
the faster the tumbling, the less polarisation is measured. FPIA makes use of 
competitive-binding assay principle. In a vancomycin focused device, 
fluorescein-labelled vancomycin, which is generically called ‘tracer’, competes 
with added sample vancomycin for the antibody-binding sites (figure 4.01 B). 
Again the sample can be either serum or plasma and the used antibodies are 
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mouse anti-vancomycin antibodies. The complex of a tracer bound to an 
antibody rotates slower than the free tracer. Further, if their rotation rate is low 
relative to the rate of the emission of fluorescence than a polarised emission 
occurs. Contrarily, free tracer, that rotates rapidly, results in unpolarised 
emission. Consequently, the vancomycin in the sample is proportional to the 
free tracer and can be determined via measuring the degree of polarisation of 
the fluorescence emission. (“Package Insert: AXSYM® SYSTEM Vancomycin II 
from Abbott” 2005; Dandliker et al. 1973; Jolley et al. 1981; Schwenzer, Wang, 
and Anhalt 1983; Wild 2013) 
 
Conclusively, all of these currently used techniques require a sample collection into 
specialised container and transport to a specialised laboratory with trained staff, which 
is either located within or outside the hospital. This process is expensive, laborious, 
time-consuming and requires a lot of administrative work (see subsection 4.2). 
Moreover, the inevitable delays between tests and results means that important 
therapeutic decisions are delayed and patient pathways can become slow and 
cumbersome (Cooper and Shlaes 2011; Tobin 2002; Wilson, Davis, and Tobin 2003; 
Begg, Barclay, and Kirkpatrick 1999; Yu, Zhong, and Wei 2010; Jesús Valle, López, and 
Navarro 2008). Additionally, as previously mentioned, routine drug monitoring only 
measures the total antibiotic concentration even though protein binding varies. This 
could be problematic as it is generally accepted that only the free drug fraction is 
pharmacologically active. Moreover, studies have suggested that the correlation 
between free and total fraction is poor. Therefore, one might conclude that the total 
vancomycin concentration is not predictive for the free amount of the antibiotic and as a 
result it is recommended to routinely monitor the free drug concentrations (Berthoin et 
al. 2009; Estes and Derendorf 2010; Butterfield et al. 2011).  
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Figure 4.01: Schematic illustration of the working principles of TVM gold standard assays.  
A) EMIT. The assay provides monoclonal mouse anti-vancomycin antibodies shown in grey and 
vancomycin molecules labelled with the enzyme G6PDH shown as dark blue crescent shape with 
either a green or a red dot. If the labelled vancomycin is free, the enzyme is active, which is 
illustrated with the colour green as opposed to red, and oxidises NAD to NADH. NADH can be 
spectrophotometrically detected at 340 nm depicted as a yellow star in the background. Upon 
sample injection, the vancomycin molecules in the sample, shown as dark blue crescent shape, 
compete with the labelled vancomycin for the antibody binding sites. Consequently, the amount 
of vancomycin in the sample is directly proportional to the amount of unbound labelled 
vancomycin, which can be spectrophotometrically quantified. B) FPIA. Comparable to the EMIT, 
the assay provides monoclonal mouse anti-vancomycin antibodies shown in grey and vancomycin 
molecules labelled with fluorescein shown as dark blue crescent shape with an orange triangle. 
Upon light absorbance the fluorescein-labelled vancomycin molecules get excited and 
consequently emit fluorescence. If fluorescein-labelled vancomycin is bound to the antibody, the 
emitted fluorescence is polarised because the tumbling rate of this larger complex, illustrated as 
orange arrows, is low relative to the emission rate. Contrarily, the free vancomycin rotates 
rapidly and results in unpolarised emission. If vancomycin containing sample is added, those 
vancomycins compete together with the labelled molecules for the antibody binding sites. 
Therefore, vancomycin in the sample is directly proportional to free fluorescein-labelled 
vancomycin, which can be quantified by the degree of polarisation of the emitted fluorescence.  
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4.2 Health Economic Importance of Therapeutic Vancomycin 
Monitoring 
The health economic case for therapeutic vancomycin monitoring has been analysed in 
different countries. In 2002, NHS Bristol launched a survey to study vancomycin TDM in 
different institutions (Tobin 2002). They questioned 310 participants from UK NHS 
hospitals, UK public health laboratories, UK private hospitals and other European and 
non-European hospitals. According to this survey, the cost of a vancomycin assay itself is 
only £4, but increases to £35 if the costs associated with taking blood, the transport to 
the microbiology laboratory within or outside the institution, time for paperwork, 
running the assay, result reporting and interpretation are included. Strikingly this total 
cost to monitor a patient’s drug level on a single basis exceeds the drug cost for twice-
daily 1 gram intravenous dosing. The survey reported that the number of assays 
requested differed greatly from laboratory to laboratory by up to 5 to 7500 assays per 
year. Around 65% of all assays only received their results in one day. At that time, 
almost exclusively, 97% of the respondents were using the fluorescence polarisation 
immunoassay (FPIA) “FLx/TDx” from Abbott Diagnostics (Maidenhead, UK).  
 
Similar studies in Spain (Fernandez de Gatta et al. 1996; Portolés et al. 2006), in the 
U.S.A. (Paladino et al. 2007) and in France (Jelassi et al. 2011) led to comparable results 
as found by the NHS survey in 2002. They all support the case for the urgent 
development and complete reappraisal of therapeutic drug monitoring for vancomycin. 
 
Furthermore a recent study published by Touw et al. in “the European journal of 
hospital pharmacy science” (Touw et al. 2007) presented the results of cost-
effectiveness study of TDM. Their study published results on aminoglycoside and 
vancomycin treatments and showed statistically significant increased death rate (6.3%), 
length of stays in hospitals (12.3%), hearing loss (46.3%) and renal impairment (34.0%), 
and consequently higher total charges (6.3%) in hospitals that did not have pharmacist-
managed therapies, which included TDM combined with results interpretation by using 
mathematical derived pharmacokinetic models which then advised the physicians 
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correspondingly. Conclusively, they recommend that vancomycin therapy is guided by 
TDM, especially in patient populations at risk, such as intensive care unit (ICU) patients, 
oncology patients and patient receiving concomitant nephrotoxic medication, since 
vancomycin’s nephrotoxicity is usually associated to additional administration of 
nephrotoxic drugs (Paladino et al. 2007).  
4.3 Summary of Needs for Therapeutic Vancomycin Monitoring 
As laid out above, the following points highlight the unmet clinical need for therapeutic 
antibiotic monitoring. There are clear arguments for the implementation of TDM in 
general, as well as the application of TDM to antibiotic monitoring. Finally, there is a 
particular need for vancomycin monitoring, which cannot be met with the current gold 
standard techniques.  
 
i) TDM in general is assuring that the drug concentration stays within the drug’s 
therapeutic range. Hence, its main benefits are the improvement in efficacy, the 
attenuation of the toxic side effects, and the viability of personalised drug 
management according to the patient’s individual needs. Therefore, it results in 
a better health outcome, which is besides the improvement in healthcare also 
associated with lower costs. Furthermore, in terms of the continuous and real-
time monitoring at the PoC, it allows personalised drug management according 
to patient’s individual drug adsorption, distribution, metabolism, and excretion. 
Moreover, it detects accumulation or changes in the drug clearance rate and 
additionally may provide early detection of faults in the drug delivery system. 
Consequently, it will be a crucial step towards personalised medicine. 
 
ii) Aside from the previously mentioned general advantages of TDM, therapeutic 
antibiotic monitoring is a very valuable tool for antibiotic stewardship by 
ensuring that the antibiotic concentration stays above the MPC throughout the 
entire treatment period. This will promote prudent use of current antibiotics 
and reduce the development of resistance. 
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iii) In particular, the following list provides arguments for the need of a real-time, 
continuous and low cost PoC sensor for therapeutic vancomycin monitoring, 
which is currently an unmet clinical need: 
 
a. Vancomycin has a very narrow therapeutic window paired with a 
narrow therapeutic index and severe adverse side effects (Begg, Barclay, 
and Kirkpatrick 1999; Roberts and Lipman 2009). 
 
b. Vancomycin has to be kept effective as long as possible and therefore 
prudent use via antibiotic stewardship has to be promoted (Williams 
and Bardsley 1999).  
 
c. Vancomycin’s most reliable pharmacodynamics parameter requires 
several measurements for an accurate estimation, which is almost 
impossible with current gold standards. Consequently, it is normal for a 
single trough concentration measurement to be taken prior to the next 
dose (Tobin 2002). (Rybak et al. 2009b; Muppidi et al. 2012; Stein and 
Wells 2010; Avent et al. 2013; Dhand and Sakoulas 2012; Udy et al. 
2010; Roberts and Lipman 2009; Rybak 2006; Holmes, Johnson, and 
Howden 2012; Estes and Derendorf 2010; Gould 2011; Butterfield et al. 
2011; Thomson et al. 2009).  
 
d. Vancomycin pharmacokinetics differs hugely in different patient 
populations and may even be subject to change in the course of 
treatment due to different factors such as the disease state and its 
progression. Furthermore, the pharmacokinetics of certain patient 
groups, such as children, critically ill, renal impaired, immuno-
compromised, diabetic, dialysis patients and in those taking a 
combination of other drugs, where contraindications may arise, are 
usually neglected in general drug dosing models, which are derived from 
population averages (Roberts et al. 2011; Roberts and Lipman 2009; Udy 
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et al. 2010; Roberts, Kirkpatrick, and Lipman 2011). Therefore, 
continuous monitoring at the PoC, which puts immediate intervention 
into practice, is sought after.  
 
e. Vancomycin has a variable protein bound proportion, namely from 10 –
 82 % (Zeitlinger et al. 2011; Sun, Maderazo, and Krusell 1993; Kitzis and 
Goldstein 2006; Cantú, Yamanaka-Yuen, and Lietman 1994). Therefore 
the inter-patient variability and the disease state dependent protein 
levels are resulting in a challenging prediction for the ratio of 
bound/inactive and free/active antibiotic fractions (Estes and Derendorf 
2010). Furthermore, the current gold standard drug monitoring 
methods only measure the total antibiotic concentration (Butterfield et 
al. 2011).  
 
f. The MIC creep is leading to an inevitable increase in vancomycin dosing 
regimens, which renders the already narrow therapeutic window even 
narrower (Dhand and Sakoulas 2012). Consequently, the likelihood that 
the antibiotic concentration will fall below the lower limit or reach toxic 
concentrations by exceeding the upper limit is increasing. Hence, one 
could conclude that alongside the rise in vancomycin’s MIC, the desire 
for therapeutic vancomycin monitoring increases as well. 
 
g. Furthermore, the possible change from intermittent dosing to 
continuous vancomycin infusion regimens would support continuous 
monitoring very well (Roberts, Kirkpatrick, and Lipman 2011; Roberts, 
Lipman, et al. 2008; Rello et al. 2005; Jelassi et al. 2011). Since the 
therapeutic vancomycin monitoring sensor could be incorporated into 
the intravenous line (IV) of the vancomycin drip.  
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Hence, these arguments strongly demand a simple, rapid, reliable and regular 
measurement of the free vancomycin concentration. Therefore, the main objective of 
my PhD thesis is the development of sensors to monitor antibiotic levels in real-time at 
the PoC in collaboration with our industrial partner, Sphere Medical Ltd., Cambridge, UK. 
A profile of Sphere Medical Ltd. can be found in the following subsection (4.4). The focus 
of this thesis is the glycopeptide antibiotic vancomycin. It serves as a starting point for 
the mid-term aim to extend these sensors to other antibiotics. However, this lies beyond 
the scope of my thesis. Ultimately, the ideal and very ambitious long-term goal would be 
to expand the capability of these sensors towards other drugs, disease and health 
markers to make them indispensable multi-analyte sensors for future personalised 
healthcare. 
4.4 Industrial Partner – Sphere Medical Ltd., Cambridge, UK  
Sphere Medical Ltd. is a medical device company developing a range of monitoring and 
diagnostic products, which are designed to provide significant improvements in patient 
management in different hospital environments, such as critical care, operating theatre 
and emergency room. Their products are aiming to allow near real time measurement of 
blood gases, various electrolytes and drug levels with laboratory accuracy at the 
patient’s bedside (“Sphere Medical Ltd.’s Homepage: About Sphere Medical” 2014). 
Currently they have three products, the Pelorus propofol measurement system 
(figure 4.02 A), the Proxima system (figure 4.02 B) and the cardiopulmonary bypass 
monitor.  
 
The Pelorus system is directly relevant for this thesis and the Proxima system serves as 
future vision (see figure 1.01). Therefore, both systems are further presented below.  
 
- The Pelorus propofol measurement system is the world’s first commercial device that 
has the unique capability to rapidly quantify the concentration of the intravenous 
anaesthetic propofol in whole blood samples. Therefore it enables personalised 
sedation and intravenous anaesthesia management at the patient level in operating 
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room and ICU. It is a bench top device with a small footprint and its measuring time 
amounts to 5 minutes. (“Sphere Medical Ltd.’s Homepage: Pelorus Propofol 
Measurement System” 2014) 
 
- The Proxima system is a disposable multi-parameter micronanalyser, which measures 
the blood gases, haematocrit and electrolytes. It is a patient attached sensor for 
arterial blood, which is engineered to return all blood back into the patient after 
measurement. The first generation of Proxima achieved FDA 510(k) clearance in 
March 2011. Furthermore its second generation successfully completed a clinical trial 
in November 2011 and achieved European CE (“Conformité Européenne”) marking in 
December 2011 as a patient dedicated in-vitro arterial blood diagnostic analyser 
(“Sphere Medical Ltd.’s Homepage: About Sphere Medical” 2014). CE marking is a 
declaration by the manufacturer that their product meets the requirements of the 
applicable European Directives. (“Sphere Medical Ltd.’s Homepage: Proxima System” 
2014)  
CHAPTER 4: THERAPEUTIC DRUG AND VANCOMYCIN MONITORING  
  
 
 
70 
 
 
 
 
 
 
Figure 4.02: Point-of-care sensors developed by our Industrial Partner – Sphere Medical Ltd., 
Cambridge. A) Pelorus propofol measurement system. It measures rapidly the concentration of 
the intravenous anaesthetic propofol in whole blood samples and therefore enables an optimal 
therapy at the individual patient level. Image adopted from “Sphere Medical Ltd.’s Homepage: 
Pelorus Propofol Measurement System” 2014. B) Proxima system. It is a disposable multi-
parameter micronanalyser of arterial blood, which is patient attached and measures the blood 
gases, haematocrit and electrolytes on demand in real-time. Image adopted from “Sphere 
Medical Ltd.’s Homepage: Proxima System” 2014. 
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CHAPTER 5:  
Proof-of-Principle and Benchmarking 
of Colourimetric Detection 
5 Proof-of-Principle and Benchmarking of Colourimetric Detection  
The main objective of this PhD thesis is the development of a PoC sensor for therapeutic 
antibiotic monitoring, particularly for the glycopeptide antibiotic vancomycin, which 
improves current practise in TDM. As described in the first chapter (1.1), through the 
development of each detection technique for a PoC application in healthcare settings, 
the overall aim is to miniaturise a PoC device to allow simple, cost effective and real-
time monitoring of a specific analyte. In order for a sensor to be developed, it must 
meet the general requirements that were also established in chapter (1.1). 
 
The starting point for this miniaturisation process is the colourimetric detection of 
vancomycin by visible spectroscopy (see figure 1.01), which builds on Sphere Medical’s 
Pelorus bench top device that measures the anaesthetic propofol. The incorporation of 
colourimetric detection technique into a bench top device was the first objective and 
the main focus of this thesis. Hence, it is presented and discussed in three chapters (5, 6 
and 7).   
 
The objective of this chapter is to detail the development of the colourimetric assay with 
the initial proof-of-principle experiments followed by a set of benchmarking 
experiments against the existing Pelorus bench top device from Sphere Medical Ltd.  
 
This chapter is built up on four subsections: The first subsection (5.1) introduces 
spectroscopy, the Gibbs reagent, a concise history about general anaesthesia and a 
description of the anaesthetic propofol. The second part (5.2) lists materials and 
methods including the experimental set-up. The third subsection (5.3) presents the 
results including preliminary discussions and continues into the final subsection (5.4) 
with the overall discussion and conclusion.   
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5.1 Introduction 
This subsection introduces the theoretical background surrounding the development of 
a colourimetric or optical sensor for therapeutic antibiotic monitoring focusing on 
vancomycin. As described above this approach builds on Sphere’s Pelorus bench top 
instrument, in which the anaesthetic propofol is extracted from whole blood and 
subsequently labelled with Gibbs reagent to determine its concentration in blood 
samples. This coupling reaction with Gibbs reagent induces a detectable colour change, 
which can be measured via visible spectroscopy. 
 
Therefore this section contains an introduction to spectroscopy (5.1.1), with special 
emphasis on ultra-violet and visible spectroscopy, colourimetry and the Beer-Lambert-
Bouger law, the coupling reaction with the Gibbs reagent (5.1.2) and the anaesthetic 
propofol (5.1.3). A further and more detailed discussion on the coupling reaction 
involving Gibbs reagent can be found in chapter 7.   
5.1.1 Spectroscopy 
Spectroscopy is an analytical method based on the analysis of the interaction between 
specific radiative energy and matter. There are various different spectroscopic 
techniques that exist to analyse different aspects of atomic and molecular structure. 
Since the radiative energy is associated with certain transitions in atoms or molecules, 
spectroscopic techniques correspond to a particular part of the electromagnetic 
spectrum. The most frequently used methods in chemistry are nuclear magnetic 
resonance (NMR), infra-red (IR), ultra-violet (UV) and visible (vis) spectroscopy. This 
thesis will focus on the latter two techniques. 
 
Spectroscopy generally distinguishes between absorption and emission spectra. 
Absorption of electromagnetic radiation of the correct energy excites electrons of 
atoms, molecules or ions to make a particular transition from a ground to an excited 
state. The corresponding absorption spectrum records the energy and intensity of this 
specific radiation, which caused the particular excitation, against the entire initial range 
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of energies. The specific absorbance of a compound of interest can be either recorded 
as absorbance or transmittance and is dependent on several factors such as the 
probability of particular transitions occurring, the populations of the various energy 
states and the sample concentration. Contrariwise, emission spectra measure the 
radiation emitted by a compound of interest when it makes a transition from an excited 
to the ground state.  
 
Both absorption and emission always take place in discrete quanta. This quantisation of 
electromagnetic radiation was first proposed by the German theoretical physicist Max 
Karl Ernst Ludwig Planck (1858 – 1947; Nobel Prize in Physics 1918) in 1900 (Born 1948). 
The equation describing this is: 
            
   
 
 5.1 
where    is the difference between the ground and the excited state,   is Planck’s 
constant (                     ),   is the frequency of the absorbed radiation,   is the 
speed of light (                ) and   is the wavelength. This means that the 
energy of absorbed or emitted electromagnetic radiation must be a multiple of     . 
(Kellner et al. 2004; Vollhardt and Shore 2005) 
 
An important aspect of spectroscopy is the timescale. This is a fairly complex topic and 
will therefore not be discussed in great detail in this thesis. However, several points are 
particularly important and will need to be elaborated on. In particular, the spectroscopy 
methods that will be used to analyse compounds of interest will be discussed further. 
 
Molecules are not static systems and are constantly in rotational and translational 
motion defined as Brownian motion with roughly 1021 collision per second 
(Chandrasekhar 1943). The atoms within the molecules are also vibrating. These 
vibrations have typical frequencies of 1012 to 1014 Hz and can be of the following types: 
stretching, bending, rocking, wagging and twisting. Every molecular system has its 
characteristic energy profile consisting of discrete electronic, rotational and vibrational 
states.  
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Upon absorption of the appropriate type of electromagnetic radiation, transitions into 
excited states of the aforementioned molecule specific energy states can be induced. 
These excited states usually last for short (< 10 nanoseconds), variable periods, 
whereupon they decay to their original ground states. Therefore, it is important to 
consider that if the spectroscopic method is faster than these frequencies, then one 
analyses a “snapshot” of the event. On the other hand, if the method is slower, then the 
result is an average measurement of the molecule in motion.  
 
On this note, UV and visible spectroscopy are fast and so have the ability to give a 
snapshot of the current vibrational and rotational state of the molecule. NMR 
spectroscopy, on the other hand, is much slower resulting in an averaged view of the 
molecular motions within the sample. NMR spectroscopy is further presented in 
chapter 7, which describes the structural characterisation of the novel product. 
(Housecroft and Constable 2010; Vollhardt and Shore 2005; Kellner et al. 2004; Kalsi 
2004)  
5.1.1.1 Ultra-Violet and Visible Spectroscopy 
UV and vis spectroscopy use high energy radiation, normally between 160 and 
1250 kJ/mol. UV spectroscopy operates in the wavelength range of about 200 nm (which 
is the near ultra-violet part of the electromagnetic spectrum) to 400 nm while vis 
spectroscopy spans 400 nm to 800 nm reaching the beginning of the near infra-red 
region (see figure 5.01). This UV-vis range is especially important for the analysis of 
electronic structures of unsaturated molecules and the study of their conjugation width. 
Therefore UV/vis spectroscopy is often called electronic spectroscopy.  
 
In most molecules, the electrons, with the exception of lone electron pairs, are 
occupying bonding molecule orbitals, such as   and   molecular orbitals; hence the 
molecule is electronically in its ground state. Lone pairs are occupying non-bonding 
orbitals referred to as  -orbitals. During the absorbance of UV and visible radiation, 
valence electrons from occupied bonding and non-bonding molecular orbitals get 
excited and change to unoccupied anti-bonding molecular orbitals, such as  * and  * 
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molecular orbitals. As a result, the molecule is in its electronically excited state. This 
absorbed energy is released either in a chemical reaction, by emitting light (fluorescence 
or phosphorescence) or as thermal energy. The absorbed wavelength   is dependent on 
the energy difference between the occupied and the unoccupied molecular orbitals. 
Since the wavelength   is inversely proportional to the energy   and the frequency  , 
the higher the energy gap between the highest occupied molecular orbital (HOMO) and 
the lowest unoccupied molecular orbital (LUMO), also referred to as lowest anti-bonding 
molecular orbital, the smaller the wavelength that is needed.  
 
σ-bonds, i.e. carbon-carbon bonds and carbon-hydrogen-bonds, have a energy gap to 
the anti-bonding orbitals that is too high and hence cannot be excited and subsequently 
observed with UV/vis spectroscopy. On the other hand, lone pairs and π-bonds, which 
are, amongst other functions, bridging the σ-bond in multiple bonds, have a smaller 
energy gap to the LUMO. Therefore they can be studied in the spectral range from 
200 nm to 800 nm. Hence, as mentioned above, the UV/vis range is important in order 
to study unsaturated molecules and the extension of their conjugation. Conjugated 
molecules have a system of connected and overlapping p-orbitals (π-bonds) with 
delocalised electrons that stabilise the system and therefore lower both its overall 
energy and the energy gap between HOMO and LUMO. Consequently an electronic 
transition from a bonding or non-bonding to an anti-bonding molecular orbital can occur 
with lower energetic radiation, possibly via absorbance of light with a long wavelength 
in UV or even visible range. For conjugation, a continuous chain of atoms with 
overlapping p-orbitals and possibly additional overlapping lone pairs are needed. This 
can be achieved by alternating single and double bonds and in some types of ionic 
systems. Alternatively, in a more specific example, conjugation can occur by a five-
membered ring with two alternating double bonds and an oxygen with its lone pair at 
position 1 (known as furan).  
 
Besides their conjugation, aromatic compounds exhibit an additional stability due to the 
fulfilment of Hückel’s rule, which is named after the German physical chemist Erich 
Hückel (1896 – 1980). Hückel’s rule says a compound is aromatic (i) if it is planar,  
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(ii) every atom in its circle participates in the electron delocalisation by having p-orbital 
or a pair of unshared electrons, and (iii) if the number of its delocalised   electrons 
fulfils  
      5.2 
while      and an integer (Hückel 1931). Furthermore, additional examples for the 
extension of delocalisation beyond  -bonds to include lone pairs are aniline (also called 
phenylamine), phenol and benzaldehyde. The penultimate molecule will play an 
important role later on in this thesis.  
 
Conclusively, UV/vis spectroscopy is a measure of the degree of conjugation in a 
molecule and reveals important information about the excited states of molecules. In 
general, the more conjugated systems a molecule has, the higher the absorption 
wavelength   for the lowest energy gap and the lower the energy required for its 
excitations is needed.  
 
Besides this measure for the degree of conjugation, one also obtains an estimation of 
how many groups in a molecule absorb light in the studied range. Such groups are 
named chromophores. However, there are different definitions for chromophores in 
use. Some experts name a whole delocalised system one chromophore and others 
specify each individual part contributing to the system as chromophores. Within this 
thesis it has been decided that the whole delocalised system will be referred to as one 
chromophore based on the fact that the electrons are not distinguishable within the 
delocalised system and hence this whole system is causing the specific absorption.  
 
In a typical absorption spectrum, the wavelength of the peak with the maximal 
absorbance is called       and is characteristic for the absorbent species. The transition 
with the highest maximal wavelength usually corresponds to the one from the highest 
occupied molecular orbital to the lowest unoccupied of all the molecular orbitals.  
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Robert Burns Woodward (1917 - 1979) and Louis Fieser (1899 – 1977), both American 
organic chemists, empirically derived a set of rules that predict the       for a 
compound of interest in the UV/vis range. These rules are called Woodward’s rules or 
Woodward-Fieser rules and can be applied to conjugated dienes, polyenes and carbonyl 
compounds. They take into account the type of chromophores, the substituent and the 
solvent’s effects (Woodward 1941; Woodward and Clifford 1941; Woodward 1942a; 
Woodward 1942b; Fieser, Fieser, and Rajagopalan 1948; Slater 2002). These rules work 
well for conjugated systems with less than four double bonds.  
 
For conjugated polyenes with more than four double bonds, one can use the Fieser-
Kuhn rules, which gives an additional estimate of the maximum absorptivity      of the 
molecule of interest (Kalsi 2004). However, both rules are not applicable to aromatic 
compounds or fairly large systems and are therefore not further discussed in this thesis. 
(Kellner et al. 2004; Vollhardt and Shore 2005) 
 
As previously mentioned, besides the characteristic       , the absorbent species can be 
additionally characterised by its specific molar absorptivity or molar absorption 
coefficient   , which is completely independent of concentration and the cuvette size. 
How the absorptivity is defined and how it can be calculated is described in the 
following subsection (5.1.1.2), which presents the Beer-Lambert-Bouger law.  
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Figure 5.01: Electromagnetic spectrum including the visible spectrum. In this schematic the 
electromagnetic spectrum spans from γ-rays, X-rays, ultra-violet, through visible, infra red, 
microwave, to radio waves including frequency modulation (FM) and amplitude modulation 
(AM), and ends with long radio waves. It has to be highlighted that neither the borders between 
the different regions are exact and nor are the scales linear. Hence the schematic has to be seen 
as an approximation.  
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5.1.1.2 The Beer-Lambert-Bouguer Law 
The law is widely known as the Beer-Lambert law only, even though it was discovered by 
Pierre Bouguer (1698 – 1758), a French physicist, astronomer and geodesist, and first 
presented in his book “Essai d'optique sur la gradation de la lumière” in 1729 (Bouguer 
1729). He described the reduction of the radiation intensity according to the path length 
through an absorbent. In the year 1760 Johann Heinrich Lambert (1728 – 1777), a Swiss 
mathematician, logician, physicist, astronomer and philosopher, cited Bouguer’s book 
and even quoted from it (Lambert 1760). In the same publication he described the 
cosine emission law also named Lambert’s emission law, which will not be further 
discussed in this thesis. About a century later, in 1852, the German mathematician, 
chemist and physicist, August Beer (1825 – 1863) extended the Bouguer-Lambert law by 
adding the dependency of the transmitted light on the concentration of the absorbent 
(Beer 1852). (Perrin 1948)  
 
Transmittance ( ) is defined as the ratio of the final intensity of the emergent light (  ) 
and the intensity of the incident light (  ), hence it can be calculated as follows:  
    
  
  
 5.3 
Values of transmittance   lie between 0 and 1, but experimentally it is often expressed 
as a percentage, therefore:  
         
        
  
 5.4 
If light passes through a sample it can undergo absorption, reflection, interference and 
scattering, hence the intensity of the emergent light (  ) is reduced compared to the 
initial intensity (  ). In order to measure the amount of absorbed light only, an 
appropriate reference has to be measured either prior to or after the compound of 
interest in a single beam spectrometer. In a double beam spectrometer the beam is split 
in two, which allows simultaneous measurement of sample and reference. A suitable 
reference might be the solvent without the compound of interest present.  
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The principle of spectrometers is described in subsection 5.2.2.1 of the materials and 
methods chapter. Typically, a spectrometer can be operated in either transmittance or 
absorbance mode. Absorbance ( ) is calculated as the negative logarithm of the 
transmittance ( ): 
                   
 
 
       
  
  
  5.5 
As a result 100% transmittance corresponds to zero absorbance and vice versa. Since it 
is a logarithmic dependency, for a zero transmittance the absorbance continuously 
increases to infinite values. 1% transmittance corresponds to an absorbance of 2. 
Although absorbance is dimensionless, it is often reported in ‘absorbance units’ and 
abbreviated as AU. Usually UV/vis spectrometers operate up to 4 or 6 AU (Housecroft 
and Constable 2010).  
 
Historically, the Beer-Lambert-Bouguer law was derived separately and independently. 
Lambert’s law depended on Bouguer description and specified that the absorbance is 
proportional to the path length. Whilst Beer’s law defined that the absorbance is 
proportional to the concentration of the absorbent. The modern derivation correlates 
the absorbance to the path length and the concentration of the absorbent. In this way 
both laws are combined.  
 
This combined derivation derives the Beer-Lambert-Bouguer law as follows: The initial 
intensity reduces when light passes through a cuvette with a certain thickness 
containing a compound of interest in uniform concentration ( ), which absorbs light. It 
has been assumed that the cuvette consists of infinitesimal slices with thicknesses of 
(  ). The reduction of initial intensity (  ) is proportional to the thickness of the slice 
(  ), the concentration and the initial intensity ( ). Hence we can write that in term of 
the change in intensity (  ): 
                 5.6 
or 
                  5.7 
where   is the proportionality coefficient. Since there are fewer photons compared to 
the incident light and it is proportional in magnitude to the number of absorbed 
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photons,    is negative. To obtain the final intensity (  ), which emerges from the 
sample, when it has been illuminated with the initial intensity (  ), one has to sum all 
successive changes over the whole path length ( ) respectively whole sample thickness, 
which results in the following integrals: 
      
 
 
             
 
 
 5.8 
If the concentration ( ) is uniform then it is independent from variable   and the 
equation can be expressed as follows, which is the Beer-Lambert-Bouguer law; however 
in an unconventional notation: 
         
     5.9 
The intensity decreases exponentially with the sample thickness and the concentration, 
and the law is often expressed as: 
          
 ε   5.10 
or 
    
  
  
          5.11 
where   is the molar absorption coefficient or molar absorptivity of the absorbent 
species at a certain frequency, formerly called the extinction coefficient, and related to 
the proportionality coefficient ( ) by: 
 ε   
 
       
  
 
     
 5.12 
The molar absorption coefficient is dependent on the frequency of light absorbed by the 
molecular cross-section. As a result the coefficient is usually expressed as [M-1 cm-1]. The 
greater the cross-section of the molecule for the absorbance, the stronger it absorbs 
and the greater the attenuation of the incident beam of light. Typical molar 
absorptivities for the UV and vis region are in the range of 103 to 105 M-1 cm-1. 
Accordingly the absorbance ( ) (formerly known as optical density (OD)) of a chemical 
species is the defined as the following dimensionless product: 
        
  
  
  5.13 
 
which leads to the well known Beer-Lambert-Bouguer law: 
   ε     5.14 
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Since the absorbance is calculated as the negative logarithm of the transmittance, the 
transmittance or the transmission ( ) of a molecule can consequently be described as: 
    
  
  
     ε    5.15 
The Beer-Lambert-Bouguer law derivation assumes a linear relationship between   and 
the absorbent concentration  .  
 
However, it has to be emphasised that this is relationship is only true, if every absorbing 
particle can be contemplated independently and thus is not affected by other particles. 
That means that particles are not allowed to shadow each other, hence more than one 
particle along the same optical path will lead to deviations from the linear calibration 
curve. Consequently the Beer-Lambert-Bouguer law should only be used for dilute 
solutions where the absorbent concentration is equal or below 0.1 mol/l (      
   
 
  . 
For concentrations above this limit the actual concentration may be underestimated, 
which will lead to errors if the Beer-Lambert-Bouguer law is used. As a rule of thumb, 
absorbances in the range of 0.1 to 1 are less affected by this shadowing and therefore 
the law should be applicable. (Vollhardt and Shore 2005; Kellner et al. 2004; Housecroft 
and Constable 2010)  
 
Furthermore, it has to be highlighted that analyses of two or more component mixtures 
by UV/vis can be challenging. In optimal cases, the different species in the same sample 
are not interfering with each other. Consequently the light absorption by these species 
is additive. Even simpler would be if the present components have their respective 
maximal absorbances in different regions of the spectra and do not show absorbances in 
the maximal absorbance regions of the other components. However, this is not always 
the case and strong interferences can preclude simple simultaneous determinations of 
concentration. Especially if the different compounds present are absorbing in similar 
wavelength regions. (Sawyer, Heineman, and Beebe 1984)  
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5.1.1.3 Colourimetry 
Colourimetry is an analytical technique to determine the concentration of a coloured 
compound in solution. In a typical colourimeter, the light source emits only one specific 
wavelength according to the       of the compound of interest. Usually the objectives 
for colourimetric detection are to follow a reaction, to determine the stoichiometry of a 
reaction or to measure the concentration of a known compound as a one-off 
measurement. The latter relates to Sphere’s Pelorus device and will be the focus for our 
point-of-care sensor for therapeutic antibiotic monitoring.  
 
The difference between colourimetry and spectroscopy is that colourimetric detection is 
limited to the colour intensity of a known compound, which depends on its 
concentration in the solution. On the other hand, visible spectroscopy intends to analyse 
the colour of the compound based on the absorption wavelength  . 
 
If a molecule has its       above 400 nm, within in the visible range, then it appears 
colourful to the human eye. Generally, to predict the absorbed wavelength in relation to 
the observed colour by the human eye, one has to consult the visible spectrum of the 
electromagnetic radiation and find the wavelength of the complementary colour (see 
figure 5.02). To explain this principle, three examples will be discussed. The latter one 
will also serve the additional purpose of setting the stage for the following subsection 
(5.1.2) on Gibbs reagent labelling:  
 
i) The first example is β-carotene orange (figure 5.03 A i), which is a well known 
pigment from various plants and fruits such as carrots, pumpkins and sweet 
potatoes. It absorbs radiation throughout the UV region of the electromagnet 
spectrum and also very strongly between 400 and 500 nm as a result of its eleven 
conjugated carbon-carbon double bonds. The wavelength with the maximal 
absorbance (     ) is at about 451 nm with two shoulders at approximately 478 
and 430 nm, which is presented in figure 5.03 Aii (Khachik and Beecher 1987; 
Hornero-Méndez and Mínguez-Mosquera 2001; Khoo, Morsingh, and Liew 1979). 
This corresponds to the blue/cyan region of the visible light spectrum. However to 
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our eyes, it appears orange as this is the complementary colour of the transition 
between blue and cyan. The absorptivity of β-carotene at the          amounts to 
139500 M-1 cm-1 (=        ) (Zechmeister and Polgár 1943).  
 
ii)  Phenolphthalein (figure 5.03 B i) has been chosen as the second example in 
anticipation of the vancomycin Gibbs coupling reaction product, which will be 
discussed in more detail in chapter 6. Phenolphthalein is a halochromic chemical, 
which means that its absorbance, and therefore its colour, is pH dependent. In a 
pH range of 0 to 8.2, the three aromatic rings of phenolphthalein are bonded over 
a tetrahedrally coordinated and hence sp3-hybridised carbon atom, which is not 
contributing and also not extending the conjugation over the three aromatic rings 
within the molecule. Accordingly the molecule only absorbs in the UV region, 
which makes its appearance to humans colourless. However, as soon as the pH 
increases beyond 8.2 towards basic conditions, the central carbon atom loses a 
proton and becomes sp2-hybridised. This leaves a p-orbital that connects the 
delocalised electron systems of the three aromatic rings together to a large 
extended chromophore absorbing at 553 nm in the green range of the spectrum 
(see figure 5.03 Bii) (El-Nahhal, Zourab, and El-Ashgar 2001). This makes molecule 
appear magenta to the human eye. Phenolphthalein’s molar absorptivity at the 
maximal absorbance (       ) is usually given as 21000 M
-1 cm-1 (Barnes and 
LaMer 1942). Due to its halochromic characteristics, phenolphthalein is a 
component alongside methyl red, bromothymol blue and thymol blue in universal 
indicators for pH tests (Foster and Gruntfest 1937). 
 
iii) The last example is 2,6-dichlorophenolindophenol (see figure 5.03 Ci), which will 
be further abbreviated as DCPIP. It is a particularly relevant example for this 
thesis. DCPIP is the chlorine form product of the original Gibbs reagent reaction 
with phenol, which is further discussed in subsection 5.1.2. It has been used in 
proof-of-principle experiments for the colourimetric studies in order to initiate 
the development of the colourimetric antibiotic assay. DCPIP is a redox indicator 
or redox dye and so can quickly and reversibly change its colour depending on 
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whether it is predominantly in the oxidised or reduced form. The colour of its 
oxidised form is either blue in a basic environment or red in an acidic media. The 
latter can alternatively be more towards pink in more diluted solutions (Tillmans, 
Hirsch, and Reinshagen 1928; Kar, Mandal, and Palit 1969). The oxidised form has 
an extended conjugated system with a maximal absorption at 605 nm in basic 
media (see figure 5.03 Cii). The molar absorptivity is 21000 M-1 cm-1 at 605 nm 
(      ). This value was found experimentally (subsection 5.3.1) and fits exactly 
the manufacturer’s information provided by Sigma-Aldrich. The reduced form 
splits the extended chromophore at the secondary amine resulting in smaller 
conjugated systems with larger energy gaps, which require higher energies and 
shorter wavelengths in order to get excited. Consequently it appears colourless to 
the human eye. In general such redox indicators are divided into two groups, the 
pH independent and the pH dependent ones. As already mentioned, DCPIP 
belongs to the pH dependent group. Its specific electrode potential (  ), where it 
changes its redox form and consequently its colour, is pH dependent, namely 
+0.64 V at pH 0 and +0.22 V at pH 7 (Tillmans, Hirsch, and Reinshagen 1928). 
Therefore, besides being a redox dye, DCPIP can additionally be considered a 
halochromic chemical, comparable to phenolphthalein described in example 
two (ii). 
 
DCPIP’s acidic form is not stable and easily reducible. Therefore it is as an 
indicator for the presence and quantification of various chemicals such as thiols 
(Basford and Huennekens 1955) and ascorbic acid, commonly known as vitamin C 
(Owen and Iggo 1956; VanderJagt, Garry, and Hunt 1986). Vitamin C is a good 
reducing agent and turns the oxidised acidic form into the reduced colourless 
form. Therefore, if DCPIP is used for vitamin C quantification via titration, the 
endpoint is given by the appearance and persistence of the colour pink due to the 
accumulation of unreacted DCPIP in the acidic media. Since the reaction 
stoichiometry is one-to-one, the moles of DCPIP used to reach titration’s endpoint 
equals the moles of ascorbic acid (VanderJagt, Garry, and Hunt 1986; Owen and 
Iggo 1956).  
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With these three examples it can be concluded that the connection between the 
absorbance wavelength and the colour appearance to the human eye can be generally 
described as follows. By increasing the wavelength from 400 nm to 800 nm and with the 
condition that the concentration of the absorbent species in the solution is high enough, 
at the lower range of the visible spectra the appearance is yellow, then orange, red, 
violet and blue-green at the end (see table 5.01). However, it has to be emphasised that 
this is a general principle and in some cases where the molecule absorbs over a large 
range of wavelengths this principle may not be applicable. (Vollhardt and Shore 2005; 
Atkins and De Paula 2002; Kellner et al. 2004; Kalsi 2004)   
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Figure 5.02: Prediction of the absorbed wavelength according to observed colours by the use of 
the colour wheel. The colour wheel is an abstract illustration of the circular organisation of the 
colour hues. It is used for the ascertainment of the complementary colours, which lay in 
opposition to each other in the wheel. According to the oxford dictionary a complementary 
colour is “a colour that combined with a given colour makes white or black”. Complementary 
colours are the link between the observed colour and the prediction of absorbed wavelength for 
a coloured compound of interest. 
 
 
 
 colour apparent to 
human eye 
prediction of absorbed 
(complementary) colour 
in vis spectrum  
corresponding 
wavelength (λ) of 
absorption [nm] 
yellow 
 
violet 380 – 435 
blue 435 – 500 
orange cyan 500 – 520 
red green 520 – 565 
violet yellow 565 – 590 
blue orange 590 – 625 
blue-green red 625 - 740 
 
 
Table 5.01: Visible spectrum’s colour regions with approximate wavelengths. This table lists the 
main colour regions of the visible spectrum and the corresponding approximate wavelengths. It 
has to be highlighted that there are no clear cut-off points between the colours and that the 
wavelength values have to be seen as approximations. To see where the visible spectrum fits into 
the electromagnetic spectrum as a whole see figure 5.01. The following is an example for the 
absorbed wavelength prediction approach: If a compound in solution looks blue to the human 
eye, such as 2,6-dichlorophenolindophenol (DCPIP), one has to find the complementary colour to 
blue in the colour wheel (see figure 5.02), which is orange. According to the corresponding 
wavelength range in the table, one can predict that DCPIP’s maximal absorbance wavelength 
within the visible spectrum should lie between 590 to 625 nm. However, it should be emphasised 
that this is a general principle and may in some cases not be applicable.  
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Figure 5.03: Three compounds as examples for colourimetric studies. A) β-carotene. i) Lewis’ 
structure of β-carotene with the blue highlighted chromophore. ii) Typical UV/vis absorption 
spectra of various carotenoid pigments. Spectra adopted from Hornero-Méndez & Mínguez-
Mosquera, 2001. B) Phenolphthalein. i) Lewis’ structures of the colourless and mangenta form of 
phenolphthalein with highlighted chromophores. ii) UV/vis spectrum of phenolphthalein’s basic 
form in a water methanol mixture. Spectrum adopted from El-Nahhal et al., 2001. C) 2,6-
dichlorophenolindophenol. i) Lewis’ structures with chromophores of the halochromic redox dye 
DCPIP. ii) Spectrum of the oxidised form of DCPIP in basic conditions.   
      red/pink                   colourless 
      oxidation                  reduction         
C i) 
ii) 
A i) 
 
B i)                     ii) 
     colourl    angenta 
     pH =  .2        > 8.2         
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5.1.2  The Gibbs Reagent and its Reaction 
The first detection technique investigated in this thesis builds on the colourimetric 
detection of drugs. Vancomycin is of particular interest along with propofol in relation to 
the benchmarking experiments presented later in this chapter. Therefore, a detectable 
change in colour has to be introduced, which can subsequently be analysed and used for 
quantification of the compound of interest. In this thesis the colour change has been 
induced via the coupling of Gibbs reagent resulting in a brightly coloured product. 
 
However, it has to be emphasised that this coupling reaction is not specific to the 
aforementioned compounds of interest. The Gibbs reagent has the ability to bind to 
various different phenolic moieties (Gibbs 1927a; Gibbs 1927b; Dacre 1971; Josephy and 
Van Damme 1984; Pallagi and Dvortsák 1986; Pallagi, Toró, and Müller 1994; Pallagi, 
Toró, and Farkas 1994; Pallagi, Toró, and Horváth 1999), some esters (Kramer, Gamson, 
and Miller 1959; Gamson, Kramer, and Miller 1959), certain thiols and sulfhydryl groups 
(Kramer and Gamson 1959; Harfoush, Zagloul, and Abdel Halim 1982; Harfoush 1983), 
nitroxyl groups (Pallagi, Toró, and Horváth 1999) and some amines (De Boer et al. 2007; 
Kovar and Teutsch 1986; Kallmayer and Thierfelder 2003; Annapurna et al. 2010).  
 
Consequently for a specific labelling reaction, the use of vancomycin specific antibodies 
could be considered (Adamczyk et al. 2004; Adamczyk et al. 1999; Antoci et al. 2008; 
Cheng and Kim 2004; Fish et al. 2012; Hofmann, Anderson, and Marchant 2012; 
Rottman, Goldberg, and Hacking 2012; Varma, de Pedro, and Young 2007). Anti-
vancomycin antibodies are commonly used in the current gold standards of therapeutic 
vancomycin monitoring, which are described in subsection 4.1 and figure 4.01 (Pfaller et 
al. 1984; Trujillo et al. 1999; Wan and Le 1999; Fong et al. 1981). Nevertheless, the 
approach using Gibbs reagent has been investigated in this thesis due to various reasons 
including cost effectiveness, simplicity (especially in readout) and the existing expertise 
of Sphere Medical with this technique. Their Pelorus device, which uses Gibbs reagent 
for labelling the anaesthetic propofol, is already on the market (see chapter 4.4). As 
such, the development of a compatible assay will potentially reduce the time taken for a 
vancomycin-focussed device to reach the market.  
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The following two subchapters provide a concise introduction into the history of the 
Gibbs reagent (5.1.2.1) and describe its reaction mechanisms including examples of 
application (5.1.2.2).  
5.1.2.1 History of the Gibbs Reagent 
The Gibbs reagent is named after an American chemist named Harry Drake Gibbs (1872 -
 1934). Prior to the work with the compound carrying his name, H. D. Gibbs had been 
interested in arsenic occurrence in Californian wine (Gibbs and James 1905), and in 
phthalic anhydrides and quinones, specifically in anthraquinones (Gibbs 1923). In 1926 
and 1927, he published a series of four papers concerning “phenol tests”. Whereas the 
first paper extensively reviewed all available tests and classified them (Gibbs 1926a), the 
second paper focused on the “nitrous acid test” (Gibbs 1926b). The third and fourth 
paper described the “indophenol test” and the study of the formation of the 2,6-
dibromobenzenoneindophenol (figure 5.04 B) (Gibbs 1927a; Gibbs 1927b). Gibbs got 
this special indophenol by coupling 2,6-dibromoquinonechoroimide (figure 5.04 A) to 
the unsubstituted para-position of the hydroxyl group in a phenol. He suggested that the 
colour change upon completion of the reaction could be analysed via spectroscopic 
methods to determine the quantity of the phenolic compounds. Therefore, his work 
marked the beginning of the quantitative colourimetric assay for phenolic and 
hydoxypyridine derivates. 
 
Later due to the toxicity of 2,6-dibromoquinonechoroimide, the chlorine version, 2,6-
dichloroquinonechoroimide (figure 5.04 C), was adopted instead and has been further 
designated as the “Gibbs reagent”. The coupling reaction of Gibbs reagent to phenol 
yields the product 2,6-dichlorophenolindophenol (DCPIP), which was presented earlier 
as the third example for the prediction of the absorbed wavelength in relation to its 
apparent colour to the human eye in subchapter 5.1.1.3 and figure 5.03 C.   
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5.1.2.2 The Gibbs Reagent Reactions and their Applications 
Gibbs proposed that the para-position to the hydroxyl group in the phenol should be 
unsubstituted and that the pH of the reaction influences the rate of indophenol 
formation. For example at pH 10, a colour change was detected within two minutes. 
Comparable findings have been made by D. Svobodová and colleagues in 1977 and 1978 
(Svobodová et al. 1978; Svobodová et al. 1977). Furthermore, besides studying the 
influence of pH, different alcohols, mixing ratios of alcohol and buffer, and the ratio of 
the Gibb reagent to the phenol, they performed extensive investigations on stability and 
the yield of the reaction. For example, they found that maximum colour intensity for a 
reagent to phenol ratio is between 30 - 50 to 1, and the ideal pH lies between 7.5 and 
10. However, the decomposition of the Gibbs reagent to 2,6-dichloroquinoneimine, 
which is the reactive species and crucial for the initiation of the reaction, is fastest at a 
pH of 8.5.  
 
Despite their extensive studies on the optimal reaction conditions, they could not 
elucidate the detailed reaction mechanism (Svobodová et al. 1978; Svobodová et al. 
1977). Various groups showed that the Gibbs reaction also works on some para-
substituted phenols (Dacre 1971; Josephy and Van Damme 1984), and P. D. Josephy and 
A. Van Damme proposed the following reaction mechanism, which is presented in 
figure 5.04 D: 
 
First, the mechanism involves the solvolysis of the Gibbs reagent (1) to form 2,6-
dichloro-p-benzoquinone monoimine (2). This reactive species attacks the para-
position of the phenol (3). The resulting adduct (4) deprotonates to form the 
intermediate (5) which then loses a proton, H+, and the para-substituent, R-, to form 
2,6-dichloroindophenol (DCPIP) (6). 
 
However, this is only one example of a possible reaction mechanism and several other 
plausible alternatives have been proposed (Pallagi and Dvortsák 1986; Pallagi, Toró, and 
Müller 1994; Pallagi, Toró, and Farkas 1994; Pallagi, Toró, and Horváth 1999; Scudi 1941; 
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Rossi, Pierini, and Peñéñory 2003). Other alternative reaction mechanisms will not be 
discussed in this thesis for the sake of brevity.  
 
Moreover, it has to be highlighted that an indophenolic moiety is produced in the 
aforementioned reaction, which would strongly suggest a blue colour. However, the 
product colour apparent to the human eye can vary from magenta, purple over blue to 
greenish blue depending on the solvents, the pH, the form in which the reagent is 
added, the presence or absence of metallic catalysts, and the time allowed for reaction 
(Scudi 1941; Dacre 1971; Svobodová et al. 1977). Similar observations are described for 
the Gibbs reaction with amines, for which the coupling product is expected to be yellow 
absorbing between 380 to 480 nm (see figure 5.04 E). This absorbance range is 
comparable to the activated Gibbs form, the 2,6-dichloro-p-benzoquinone monoamine, 
which was previously described and is shown in figure 5.04 D (2). However, J. V. Scudi 
observed that Gibbs reaction with creatine, creatinine, and phenylhydrazine give the 
expected yellow colour, but with uric acid and carbon disulfide yield in a yellow to pink 
(Scudi 1941). These observations were support by extensive studies of for example W. R. 
Fearon and D. N. Kramer and colleagues (Fearon 1944; Gamson, Kramer, and Miller 
1959).  
 
Due to this inducible colour changes, the Gibbs reagent assay has been or is still used to 
study, detect and quantify different molecules, such as cresols (Gibbs 1927c; 
MacManus-Spencer and McNeill 2005), vitamins B6 (Scudi 1941) and K (Scudi and Buhs 
1941), uric acid (Fearon 1944), theophylline (also known as 1,3-dimethylxanthine) 
(Raybin 1945), methylthiouracil (McAllister 1950; Marsh and Hilty 1955), 
mercaptoimidazoles (McAllister 1951), porphyrilic acid of lichens (Wachtmeister 1954), 
anti-oxidants (Dacre 1971), catechols (Johnston and Renganathan 1987), opiates (Coop 
et al. 1995), whose presences also can get verified with a “Gibbs spray” on thin layer 
chromatography (TLC) plates (Baggi, Ram Rao, and Murty 1976), and drugs, such as the 
anaesthetic propofol (Adam et al. 1981; Pettigrew, Laitenberger, and Liu 2012; Liu et al. 
2012) and as well as some antibiotics (Daabees et al. 1998; Krishna 2010), which will be 
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further discussed in chapter 6 and 7. The use of Gibbs reagent for therapeutic propofol 
monitoring will be further discussed in the next subsection (5.1.3). 
 
Besides applications to study, detect and quantify molecules, the Gibbs reagent has also 
been utilised to measure enzymatic activity (Boyd and Eling 1984). Very recently 
C. S. Padidem and colleagues published a book chapter entitled “Sensor Enhancement 
Using Nanomaterials to Detect Pharmaceutical Residue: Nanointegration Using Phenol 
as Environmental Pollutant” in which they modified Gibbs reagent with gold 
nanoparticles for the detection of phenols (Padidem, Bashir, and Jingbo 2011).  
 
All aforementioned publications followed the Gibbs reaction and the resulting colour 
change mainly optically by eye or via colourimetric readout systems. However, 
R. Compton and colleagues presented the electroactive characteristics of indophenol, 
which they exploited for indirect electrochemical detection of cannabinoids (Compton 
and Banks 2006; Lowe, Banks, and Compton 2005). Another study suggests the 
construction of a phenol-based sensor derived from colloidal chemistry in which the 
Gibbs reagent acts as the “detecting element” for colorimetric and electrochemical 
detection (Bashir and Liu 2009).  
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Figure 5.04: The Gibbs reagent and its reactions. A) Lewis’ structure of 2,6-
dibromoquinonechoroimide, which was the reagent H. D. Gibbs used to label compounds with 
phenolic moieties. B) Lewis’ structure of 2,6-dibromobenzenoneindophenol, which is the 
product of 2,6-dibromoquinonechloroimide coupled to the para-position of a phenol. C) Lewis’ 
structure of 2,6-dichloroquinonechoroimide, which is used instead of 2,6-
dibromoquinonechloroimide and designated as the “Gibbs reagent”. D) One possible reaction 
mechanism of Gibbs reagent coupling to a compound containing a phenolic moiety. First, the 
mechanism involves the solvolysis of the Gibbs reagent (1) to form 2,6-dichloro-p-benzoquinone 
monoimine (2). This reactive species attacks the para-position of the phenol (3). The resulting 
adduct (4) deprotonates to form the intermediate (5) which then loses a proton, H+, and the 
para-substituent, R-, to form 2,6-dichloroindophenol (DCPIP) (6). Schematic adopted from 
Josephy & Van Damme, 1984. E) A reaction scheme of Gibbs reagent coupling to a compound 
containing amines. Schematic adopted from Fearon 1944.  
E 
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5.1.3 The Anaesthetic Propofol  
This subsection provides the literature review and background for anaesthetic propofol. 
Since propofol served as the precursor for the development of the colourimetric 
vancomycin assay in the benchmarking experiments, the information included in this 
section has been kept concise. The first part provides an insight into the history of 
general anaesthesia and anaesthetics followed by the second part, which is focused on 
the anaesthetic propofol.  
 
The anaesthetic state consists of three main neurophysiological changes, namely loss of 
consciousness, loss of response to painful stimuli also called analgesia and muscle 
relaxation. For major surgical operations, the induction of anaesthesia is rapidly 
achieved with an intravenous agent, such as propofol. During surgery, the anaesthesia is 
maintained with either intravenous or inhalation anaesthetics given in combination with 
muscle relaxants and analgesics. (Rang et al. 2007) 
5.1.3.1 Concise History of General Anaesthesia and Anaesthetics  
The term anaesthesia takes its origin from Greek language and means “without 
sensation”. General anaesthesia is by no means a modern medical technique as its use 
has been recorded throughout history. Records indicate that the Egyptians, Greeks, 
Romans, Indians, Chinese and Babylonians were using some form of anaesthesia. The 
first attempts at general anaesthesia were most likely with herbs such as opium poppies. 
(Miller and Pardo 2011) 
 
The origin of the anaesthesia known today can be dated back to 1772, when Joseph 
Priestly (1733 – 1804), an English scientist, discovered the nitrous oxide gas. About 
30 years later, Sir Humphry Davy (1778 – 1829), a British chemist and inventor, 
experimented with it on himself (Davy 1839). Based on the euphoria experienced upon 
inhalation of the gas, he dubbed nitrous oxide ‘laughing gas’. He also observed that it 
“appears capable of destroying physical pain, it may probably be used with advantage 
during surgical operations” (Davy 1800). However, the analgesic effect of nitrous oxide 
CHAPTER 5: PROOF-OF-PRINCIPLE & BENCHMARKING OF COLOURIMETRIC DETECTION 
  
 
 
96 
 
was ignored until Horace Wells (1815 – 1848), an American dentist, demonstrated its 
utility in dentistry in 1844. Since nitrous oxide anaesthesia showed inconsistency, the 
use of diethyl ether spread rapidly after William T. G. Morton (1819 – 1868), an 
American dentist and a former colleague of Horace Wells, demonstrated it successfully 
at a surgery in Boston in 1846. There have been several claims to the discovery of 
anaesthesia and it has been credited to many individuals including Crawford Long 
(1815 – 1878), an American surgeon and pharmacist, who performed a surgery in 1842 
under ether induced anaesthesia, but did not publish his findings until 1849. In 1847, 
James Y. Simpson (1811 – 1870), a Scottish Obstetrician, proposed chloroform as a 
viable alternative to Ether. (Miller and Pardo 2011) 
 
Less than 30 years later, intubation, for the purposes of anaesthesia administration, had 
been successfully performed for the first time. In 1902, the first barbiturate, barbitone 
(also known as barbital), was discovered by Emil Fischer (1852 – 1919), a German 
chemist and Nobel Prize winner, and Joseph von Mering (1849 – 1908), a German 
physician. It was commercially marketed under the names “Veronal” and “Medinal” by 
Bayer Pharmaceuticals, Germany. Significant advances have been seen in the mid-20th 
century due to halogenations and the subsequent introduction of non-flammable and 
safe vapours, which then gradually replaced chloroform and cyclopropane. Such 
halogenated hydrocarbons initially included halothane and later desflurane and 
sevoflurane. Furthermore, the first intravenous anaesthetic, sodium thiopental, was 
synthesised by Ernest H. Volwiler (1893 – 1992) and Donalee L. Tabern (1900 – 1974) at 
Abott Laboratories, Illinois, US, in 1934 and has been tested for the first time in the 
same year. (Miller and Pardo 2011) 
5.1.3.2 Propofol 
In 1980 J. B. Glen and colleagues reported for the first time the anaesthetic activity of 
ICI 35 868 in mice performed at the Biology Department of ICI (Imperial Chemical 
Industries), London, UK (Glen 1980; Adam, Glen, and Hoyle 1980). The active agent in 
ICI 35 868 was 2,6-diisopropylphenol, later called propofol, which was completely 
unrelated to the commonly used barbiturate or steroid agents. Due to its hydrophobic 
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characteristics, propofol has initially been dissolved in Cremophor EL®, which acted as a 
formulation vehicle to stabilise the compound in aqueous environment. Cremophor EL® 
is a registered trademark of the BASF Corporation (Badische Anilin- und Soda-Fabrik), 
Ludwigshafen, Germany. However, this additive led to adverse side effects and further 
research towards a new formulation was needed (Lambert 2008). The new formulation 
published in 1984 included soya bean oil, egg phosphatidate and glycerol and is highly 
comparable to the current formula of propofol (Glen and Hunter 1984). Two years later 
propofol was first introduced in Europe, then in 1989 it was approved by the US Food 
and Drug Administration (FDA) for induction and maintenance of anaesthesia. 
“Diprivan” is the market name for propofol and stems from the abbreviated version of 
diisopropyl intravenous anaesthetic. It is a small hydrophobic molecule and its structure 
can be described as a phenol with two isopropyl groups in ortho-position to the hydroxyl 
group of the phenol (figure 5.05 A) (Rang et al. 2007; Glass et al. 2010).  
 
Propofol has a very fast onset and is therefore widely used as a continuous infusion 
during surgeries. Furthermore, it is used in critical care for sedation of mechanically 
ventilated patients. The main unwanted side effects are cardiovascular and respiratory 
depression. However due to airway management techniques, such as intubation and 
close patient monitoring, these adverse events are very rare in current clinical practice 
(Rang et al. 2007). The human body is generally able to metabolise propofol very rapidly 
without cumulative effects, which assures a fast recovery from anaesthesia (Green 
2007). 
 
In-vivo, propofol is highly protein bound with reported fractions from 97 to 99% 
depending on its total concentration (Dawidowicz et al. 2006; Dawidowicz, Kobielski, 
and Pieniadz 2008b) and on certain diseases states such as diabetes, renal and hepatic 
insufficiency (Bohnert and Gan 2013; Dawidowicz and Kalitynski 2005; Glass et al. 2010). 
Approximately 80% of the administered propofol is bound to human serum albumin 
(HSA), which is the most abundant plasma protein in mammals (Bhattacharya, Curry, 
and Franks 2000; Zeitlinger et al. 2011). Studies by A. L. Dawidowicz and colleagues 
indicated that increases in temperature leads to increased propofol binding to HSA. 
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Variations in the hydration layer around the protein may play a major factor in changes 
in free drug fraction (Dawidowicz, Kobielski, and Pieniadz 2008a). Figure 5.05 B 
illustrates the crystallographic structure of the HSA protein containing two bound 
propofol molecules labelled with PR1 and PR2 (Bhattacharya, Curry, and Franks 2000). 
The binding site of PR1 is an especially well known binding site for various drugs and 
endogenous ligands (Curry 2011; Ghuman et al. 2005; Yamasaki et al. 2013). Due to the 
fact that propofol is not the main focus of this thesis, propofol’s general pharmacology 
including possible side effects is not further discussed.  
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Figure 5.05: Propofol and the crystallographic structure of its binding sites on human serum 
albumin (HSA). A) Lewis’ structure of 2,6-diisopropylphenol commonly known as propofol. 
B) The propofol binding sites on human serum albumin (HSA). i) Crystal structure of fatty acid 
free HSA containing two propofol molecules labelled with PR1 and PR2. ii) The propofol labelled 
with PR1 binds in sub-domain IIIA of HSA, which is an apolar pocket. The binding between the 
anaesthetic and the protein occurs mainly via two interactions. The first is a hydrogen bond 
(3.1 Å) between propofol’s phenolic hydroxyl group and HSA’s main-chain carbonyl oxygen of 
Leucine 430 (L430). The second is stacking of the propofol’s aromatic ring with the sides chains of 
Leucine 453 (L453) and Aspargine 391 (N391). If fatty acids are present, propofol would compete 
with them for ligand binding. iii) The second propofol labelled with PR2 binds in a cavity located 
in sub-domain IIIB, which is mainly lined by aromatic residues of 4 phenylalanines (F502, F507, 
F509 and F551). The hydroxyl group of Serine 579 (S579) forms a hydrogen bond (2.9 Å) with 
propofol’s hydroxyl group. In a similar way to the first binding pocket (ii), propofol binding could 
be prevented by ligands binding to fatty acid binding sites. Furthermore, it is believed that the 
binding site for propofol PR1 in the sub-domain IIIA has a higher binding affinity than the one for 
PR2 in IIIB (Bhattacharya, Curry, and Franks 2000). Moreover, later X-ray crystallography studies 
within the same group suggest that the binding site in sub-domain IIIA binds other endogenous 
ligands and drugs such as diazepam and ibuprofen (Curry 2011; Ghuman et al. 2005; Yamasaki et 
al. 2013). Schematic adopted from Bhattacharya et al., 2000.  
i             ii         iii 
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5.1.3.3 Therapeutic Propofol Monitoring using Gibbs reagent 
The clinically relevant concentrations for propofol range from about 1 to 10 μg/ml, 
which corresponds to 5.6 – 56.1 μM (Liu et al. 2012). Low concentrations in the range of 
1.3 – 2.8 μg/ml are used to achieve sedation (Casati et al. 1999). Higher concentrations 
from 3 to 5 μg/ml in conjunction with adjuvants such as nitrous oxide and opiates are 
administered during surgery (Stuart et al. 2000). If propofol is used as a sole agent then 
the required concentration range is 6.0 – 8.0 μg/ml (Liu et al. 2012; Glass et al. 2010). 
The drug dosage is determined by population-based pharmacokinetic data and adjusted 
to individual patient biometrics (Langmaier et al. 2011). Currently in clinics, propofol is 
not directly monitored in real-time; however, patient’s vital signs including ventilation, 
oxygen saturation, heart rate, blood pressure and level of consciousness are typically 
continuously monitored during administration of propofol to identify early signs of 
adverse events such as respiratory depression and hypotension (Rang et al. 2007; 
Sandiumenge Camps et al. 2000; Glass et al. 2010).  
 
The validated methods for determining propofol concentration from blood and other 
biological samples are laboratory-based assays such as high performance liquid 
chromatography (HPLC), which require considerable time for sample preparation and 
analysis (Liu et al. 2012; Cussonneau et al. 2007; Dawidowicz and Fornal 2000; 
Langmaier et al. 2011). Furthermore, due to the fact that propofol is highly protein 
bound (see chapter 5.1.3.2), an additional sample preparation step, in which the red 
blood cells are lysed prior to the analysis, is highly recommended before HPLC analysis 
(Dawidowicz and Fornal 2000). However, this additional step increases the time required 
to carry out this already lengthy process. Therefore several different techniques have 
been suggested for a continuous real-time propofol measurement. These include the 
monitoring of exhaled air during surgery studied by various groups (Hornuss et al. 2007; 
Miekisch et al. 2008; Harrison et al. 2003). However, these methods have not 
demonstrated consistent and reliable results regarding the correlation of exhaled breath 
to blood propofol concentration (Liu et al. 2012).  
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Sphere Medical’s Pelorus bench top device (see figure 5.06 A) has been designed for the 
rapid analysis of propofol directly from whole blood samples. A sample blood volume of 
0.7 ml can be injected into the device and the propofol concentration is calculated in 
approximately 5 minutes (Pettigrew, Laitenberger, and Liu 2012; Liu et al. 2012). The 
measurement technology implemented in Sphere’s device is based on a quantitative 
colourimetric principle via the coupling of Gibbs reagent where an intensely blue 
indophenolic compound is produced. As previously indicated in chapter 5.1.2, research 
by H. K. Adam and colleagues in 1981 established the viability of using Gibbs reagent for 
accurate estimation of the propofol concentration in blood. They described that 
propofol has a      of 275 nm and its molar absorptivity is insufficient to allow 
quantification at levels occurring in biological fluids after therapeutic dosing (Adam et al. 
1981). Just a year earlier, the same group were the first to report the anaesthetic 
activity of propofol (Glen 1980; Adam, Glen, and Hoyle 1980) (see chapter 5.1.3.2). As 
shown in figure 5.05 A, propofol is essentially a phenol with two isopropyl groups in the 
ortho-position to the hydroxyl group of the phenol. Therefore, it is likely to react with 
Gibbs reagent in a very comparable manner to phenol as described by Harry Drake Gibbs 
in 1927 (Gibbs 1927a; Gibbs 1927b) (see chapter 5.1.2.1 and figure 5.04). Adam et al. 
used HPLC separation followed by Gibbs coupling and subsequent quantification of 
propofol via UV/vis spectroscopy. They were able to detect and estimate the quantity of 
propofol at therapeutic levels and at concentrations as low as 25 ng/ml, which 
corresponds to 0.1 µM (Adam et al. 1981).  
 
Sphere Medical’s Pelorus device has implemented a solid phase extraction (SPE) method 
as opposed to HPLC, which was previously described by McGaughran and colleagues. 
They used SPE on a diluted whole blood sample followed by reaction with Gibbs reagent 
to produce the strongly coloured indophenolic product (McGaughran et al. 2006). The 
Pelorus device works after a similar principle in a fully automated manner without the 
requirement for sample preparation. After injection of a whole blood sample into the 
analyser, the sample gets diluted and the red blood cells are lysed. Propofol is then 
extracted via SPE and labelled with Gibbs reagent. Afterwards the instrument measures 
the concentration by absorption spectroscopy. The system is calibrated with two 
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calibration solutions containing low and high propofol concentrations respectively. 
Results from the Pelorus device were found to correlate linearly up to 12 μg/ml with a 
lower quantification limit of 0.75 μg/ml with an HPLC based method. Figure 5.06 B 
shows the correlation of the Pelorus 1000 to the reference HPLC method. It can be 
concluded that the Pelorus bench top device fulfils the requirements for monitoring 
propofol in whole blood samples with the required precision and accuracy in the 
clinically relevant range (Pettigrew, Laitenberger, and Liu 2012; Liu et al. 2012). 
Furthermore, in comparison to the currently validated methods for calculating the 
propofol concentration, the Pelours bench top device requires less space, staff, time, 
administration, shorter transportation distance and is consequently more cost effective 
(see figure 1.01).   
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Figure 5.06: Sphere Medical’s Pelorus bench top device and its correlation with a reference 
method. A) Photography of Sphere’s Pelorus device. It is one of the first commercially available 
bench top devices for the rapid measurement of propofol. There are two series. The 
Pelorus 1500, which has CE (Conformité Européenne) mark as an in-vitro diagnostic (IVD) device 
for Europe and the Pelorus 1000, which is for research use only outside Europe. Image adopted 
from “Sphere Medical Ltd.’s Homepage: Pelorus Propofol Measurement System” 2014. B) Scatter 
plot of the Pelorus 1000 versus the reference HPLC method. The comparison shows a linear 
relationship over the range of 0 – 12 μg/ml. The data values were analysed with the ‘Deming 
regression analysis’. It is a special ‘total least squares’ analysis which differs from the ‘simple 
linear regression’ in that it accounts for errors in both axes. The ‘Deming regression analysis’ 
results in a gradient of 1.001 with a 95% confidence interval of 0.992 – 1.010 and an offset of 
0.14 μg/ml with a 95% confidence interval of 0.09 – 0.19 μg/ml. Schematic adopted from Liu et 
al., 2012.  
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5.1.4 Objectives for Proof-of-Principle & Colourimetric Benchmarking 
The main objective of this thesis is the development of a PoC sensor for therapeutic 
antibiotic monitoring particularly for the glycopeptide antibiotic vancomycin. In order 
for a sensor to be developed, it must meet the general requirements that were 
established in the introduction in chapter 1.2. 
 
As previously described, along with developing each detection technique for therapeutic 
antibiotic monitoring at the point-of-care, the overarching aim is to evaluate the 
feasibility of miniaturising the different techniques for patient attached real-time 
monitoring devices. The starting point for miniaturisation is the colourimetric detection 
of vancomycin by visible spectroscopy as schematically illustrated in figure 5.07, which 
builds on Sphere Medical’s Pelorus bench top device that measures the anaesthetic 
propofol. This is the first out of two detection platforms studied in this body of work and 
it is also the technique on which my thesis was mainly focused on. Therefore, the 
colourimetric detection via visible spectroscopy is investigated and discussed in this 
chapter and in the following two chapters (6 and 7).  
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Figure 5.07: A schematic of the colourmetric detection of vancomycin via visible spectroscopy. 
The blue molecules depict vancomycin and the yellow spheres indicate Gibbs reagent. Upon 
coupling the colour changes and this can be detected via visible spectroscopy, thus quantifying 
the concentration of vancomycin. The colour change is indicated by the purple solution in the 
cuvette. The visible spectrometer is shown as a light bulb on the left and a prism and a detector 
on the right hand side. Even though this schematic is drawn with vancomycin molecules, it 
represents the general principle of colourimetric detection and could potentially work with many 
other drug molecules and different coupling reagents.  
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5.2 Materials and Methods 
This chapter provides the information of the used materials and methods for the proof-
of-principle (5.3.1) and benchmarking experiments for the colourimetric and optical 
detection assay (5.3.2). It is divided into three subchapters. The chemicals, including 
buffer solutions, solvents, phenolic compounds, and blood components, are described in 
the first subsection (5.2.1). The experimental set-up in the form of UV/vis spectrometer 
and the used cuvettes are presented in the second part (5.2.2). Lastly, the measurement 
procedure, data processing and analysis can be found in the third subsection (5.2.3).  
5.2.1  Chemicals  
All chemicals were purchased from Sigma-Aldrich (Dorset, UK), unless otherwise 
declared. They were handled, stored and disposed of in accordance with their safety 
guidelines stated in the corresponding ‘material safety data sheets’ (MSDS).  
5.2.1.1 Buffer Solutions and Solvents  
Borate buffer pH 10 solution was purchased from Fisher Scientific, which was initially 
used to either dissolve some phenolic compounds or was added to provide the required 
high pH for the Gibbs coupling. To dilute the hydrophobic propofol, a non-polar organic 
solvent is needed. According to Sphere’s procedure acetonitrile (IUPAC: acetonitrile) 
was used. To dissolve the Gibbs reagent, methanol was used, which additionally 
provided the necessary primary alcohol for the solvolysis of Gibbs reagent to initiate the 
reaction.  
5.2.1.2  Gibbs Reagent and Phenolic Compounds 
2,6-dichloroquinone-4-chloroimide (IUPAC: 2,6-dichloro-4-chloroiminocyclohexa-2,5-
dien-1-one) is referred to in this thesis as the Gibbs reagent (see figure 5.04). Although 
the original reagent H. D. Gibbs used for quantification of phenolic and hydoxypyridine 
derivates was 2,6-dibromoquinone-4-chloroimide, due to its toxicity it is not 
commercially available. Further information about the history of the Gibbs reagent can 
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be found in chapter 5.1.2. Two batches of Gibbs reagent were purchased with batch 
numbers 01705KJ and 02208KJ respectively. The first batch was used, unless otherwise 
declared. For the proof-of-principle experiments (5.3.1), the product of the original 
Gibbs reagent coupling reaction, sodium 2,6-dichloroindophenolate hydrate (IUPAC: 2,6-
Dichloro-N-(4-hydroxyphenyl)-1,4-benzoquinoneiminesodium salt) was purchased. It is 
hereafter designated as DCPIP. For the experiments, it has been dissolved in different 
concentrations in either pure borate buffer or in borate buffer with 600 µM bovine 
serum albumin (BSA), to imitate the complex background of blood serum. BSA is listed in 
the next subsection ‘5.2.1.3 Blood Components’. The second set of the experiments 
(5.3.2), for benchmarking the colourimetric detection assay at UCL against Sphere 
Medical’s system, used propofol. The anaesthetic propofol is marketed as ‘Diprivan’ 
(abbreviated version of diisopropyl intravenous anaesthetic), which is an opaque white 
emulsion with several ingredients such as oil and phospholipid and usually 1 % propofol 
(Rang et al. 2007). As a pure compound, propofol (IUPAC: 2,6-diisopropylphenol) is 
yellow in colour and liquid above 18 °C.    
5.2.1.3 Blood Components 
The experimental approach used to investigating the therapeutic monitoring of drugs 
needs to take into account the complex physiological background of whole human 
blood. It is possible that the constituent parts of human blood could interfere with the 
colourimetric detection of drugs using Gibbs reagent. For this reason, different blood 
components in increasing complexities have been studied. The starting point was fatty 
acid free bovine serum albumin (BSA). The albumin was dissolved in buffer in a 
concentration that mimics its concentration in normal blood serum. The amount of 
600 µM BSA is well established and commonly used in the scientific community to mimic 
serum (Bohnert and Gan 2013; Bhattacharya, Curry, and Franks 2000). In the interest of 
brevity, buffer (and in subsequent subsections water with 600 µM dissolved BSA or fatty 
acid free human serum albumin (HSA)) are designated as pseudo-serum. Serum 
albumins are the most abundant plasma proteins in mammals. They are believed to be 
the proteins to which drug molecules predominately bind to (see 3.3.3) (Zeitlinger et al. 
2011; Lin et al. 2013; Ndieyira et al. 2014). Wherever water or DI water is stated, 
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distilled and deionised water (usually abbreviated as ddH2O, herein as water or DI 
water) was used. The water was purified with an ELGA Purelab Ultra water purification 
system (ELGA, Buckinghamshire, UK). A more detailed discussion about the serum 
binding particularly of vancomycin can be found in chapter 3.3.3.  
5.2.2 Experimental Set-up  
5.2.2.1 UV/vis Spectrometer 
The used UV/vis spectrometer is an Agilent 8453 (Agilent Technologies, Santa Clara, 
California, US) in Dr. Daren Caruana’s laboratory in the Department of Chemistry at UCL. 
It is a one light path spectrometer with two light sources, a deuterium lamp for the UV 
and a tungsten lamp for the visible range. Therefore it is capable of measuring a 
spectrum from 190 to 1100 nm. Its maximal absorbance value is 4 absorbance units 
([AU]), which was experimentally established prior to the first experiments. The 
spectrometer’s software is “UV-Visible ChemStation” software from Agilent 
Technologies.  
5.2.2.2 Cuvettes  
For the proof-of-principle experiments with DCPIP (chapter 5.3.1), disposable poly-
methyl methacrylate (PMMA) cuvettes from Brand (BrandTech Scientific INC., Essex, 
Connecticut, US) have been used. However, due to the requirement of acetonitrile as 
solvent in the benchmarking experiments with propofol (chapter 5.3.2), the cuvettes 
had to be changed to the more stable disposable UV-cuvettes made of proprietary resin 
from Brand.  
5.2.3 Measurement Procedure, Data Capturing and Analysis 
The measurements were performed in a UV/vis spectrometer from Agilent Technologies 
with the “UV-Visible ChemStation” software. According to an empirical study performed 
prior to the first experiments, it was found that both light sources require a warm up 
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time. Therefore all experiments were performed after a 20 minute warm up period from 
when the bulbs were switched on. Since the Agilent 8453 spectrometer has only one 
light path, the reference or blank spectrum had to be captured first, which then was 
automatically subtracted from all further sample spectra. Different references had been 
studied, such as borate buffer, borate buffer with methanol, solely methanol, methanol 
and water mixtures and so on. The spectra data have been saved in comma-separated 
values (CSV) files by using the spectrometer’s software. The CSV-files have been 
imported, plotted and analysed with Origin Pro 8.6 software (Origin Lab Corporation, 
Northampton, Massachusetts, USA).  
 
Since these experiments served as the proof-of-principle and benchmarking 
experiments, the samples sizes were kept small and no statistical evaluation has been 
performed. The sample sizes for the proof-of-principle experiments (5.3.1) were two 
measurements of two independent samples (n = 2) and three measurements of one 
sample (n = 1). For the benchmarking experiments (5.3.2) three measurements of one 
sample were taken (n = 1). The included error bars indicate the corresponding standard 
deviation of the mean. 
5.3 Results and Discussions  
This chapter is separated into two parts. Firstly, chapter 5.3.1 demonstrates the proof-
of-principle that colourimetric detection via visible spectroscopy has the potential to be 
an integral part of a PoC sensor for therapeutic drug monitoring. It focuses on the 
colourimetric detection of a known indophenolic compound using the Beer-Lambert-
Bouguer law and showing a degree of sensitivity to clinically relevant drug 
concentrations. Secondly, chapter 5.3.2 presents the benchmarking experiments with 
propofol according to Sphere Medical’s procedure used in their Pelorus device as 
described in subsection  5.1.3.3 (Pettigrew, Laitenberger, and Liu 2012; Liu et al. 2012). 
Since the development described herein is a consecutive process, preliminary 
discussions are added directly within these subsections, whilst the conclusion can be 
found in section 5.4. 
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5.3.1 Proof-of-Principle Experiments 
The experiments with the commercially available end product of the Gibbs-phenol 
reaction, 2,6-dichlorophenolindophenol (DCPIP), served several purposes. Since the 
maximal absorbance wavelength (    ) and the molar absorption coefficient at this 
maximal absorbance wavelength (    ) are well known (see chapter 5.1.1.3 on page 
84), the concentration estimation via the Beer-Lambert-Bouguer law could be directly 
executed without any dependency on a successful chemical reaction. Hence, 
independently of a reaction with two compounds and an unknown yield, it could be 
tested what absorbance values can be expected and whether the spectroscopic 
detection of clinically relevant concentrations is possible. Moreover, it may be a simple, 
reliable and ‘coupling reagent free’ calibration method for example for Sphere Medical’s 
Pelorus device. Furthermore, it could be investigated whether detection in whole blood 
serum may be a possibility for the subsequent vancomycin colourimetric assay or 
whether the development of a specific extraction protocol cannot be circumvented, 
especially in relation to the non-specificity of the Gibbs coupling reaction. A direct 
detection assay without prior extraction would have several advantages, such as no loss 
of the compound of interest, increased rapidity, simpler instrumentation and 
consequently less associated costs, and no specificity concern according to the 
extraction process.  
 
A successful monitoring assay has to meet several requirements including high 
sensitivity to clinically relevant drug concentrations, high specificity for the drug of 
interest and low interference or cross-reactivity with other drugs or blood components. 
To test the sensitivity of the colourimetric detection, DCPIP in different concentrations 
has been diluted in either borate buffer or borate buffer with 600 µM BSA. 
Subsequently, the absorbance spectra of different DCPIP concentrations have been 
captured via UV/vis spectrometer. For a therapeutic drug monitoring device, the 
unambiguous assignment of a single drug concentration to a single readout signal within 
and beyond the boundaries of the therapeutic range is crucial. Consequently, the 
concentrations of DCPIP have been chosen to include the clinically relevant range of 
propofol, which ranges from 1 to 10 μg/ml and that is equivalent to 5.6 – 56.1 μM of 
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propofol. Therefore, the DCPIP concentrations were chosen to range from 2 to 90 μM, 
which is equivalent to 0.6 - 26 μg/ml DCPIP. 
 
Figures 5.08 A and B show overlays of the absorbance spectra of 2, 10, 30, 50 and 90 μM 
DCPIP in borate buffer and in pseudo-serum. Borate buffer and pseudo-serum without 
any DCPIP served as references. It should be highlighted that the small elevation at 
632 nm is instrumental and typical for the spectrometer used. In figure 5.08 A, all 
spectra show clear distinctive symmetrical and typical indophenolic peaks with maxima 
at wavelength 605 nm (    ). The spectra of the highest concentration (26 μg/ml) 
shows a small drift on the left hand side of the peak, which to date is unexplained. A 
possible explanation could be that at these high concentrations the molecules are 
shadowing each other. Hence they cannot be regarded as independent chromophores. 
As previously described on page 83, absorbances over 1 AU are an indication that a 
shadowing effect may occur. This effect could cause deviations from the linear 
calibration curve, which will lead to inaccuracies of the Beer-Lambert-Bouguer law. 
 
The spectra in pseudo-serum (figure 5.08 B) reveal that DCPIP’s      is bathochromic 
shifting approximately 30 nm towards red in the visible spectrum, from 605 to 632 nm. 
Furthermore, all maximal absorbances increased by values ranging from 0.04 to 0.06 AU. 
These values seem conserved over a fairly large concentration range of DCPIP spanning 
over more than a magnitude, which leads to the assumption that something constant 
within the sample must cause it. Consequently, it could not be increasing DCPIP and 
everything else such as proteins, which may denature and unfold in high pH, is 
subtracted by the reference. Therefore, this effect could not be explained and it was 
decided to not further investigate it. On the grounds of two reasons, (i) it is a conserved 
increase, which may result in higher sensitivity and (b) for which could be corrected for 
with a correction value.  
 
As already highlighted above, the      and      of DCPIP are well known and therefore 
its concentration estimations via Beer-Lambert-Bouguer law (see chapter 5.1.1.2) can be 
directly applied. According to the manufacturer, DCPIP’s absorption maximum can be 
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found at 605 nm (      ) and at this maximal wavelength it has a molar absorption 
coefficient of 21000 M-1 cm-1. To calculate the DCPIP concentrations via Beer-Lambert-
Bouguer law  
 
   ε     5.14 
 
the absorbance values at 605 nm, have been divided by the known molar absorption 
coefficient at the maximal absorbance (       = 21000 M
-1 cm-1) multiplied by the path 
length of the light (  = 1 cm), which results in concentrations ( ). These calculated 
concentrations have been plotted against the diluted concentrations. Figure 5.08 C 
presents this concentration comparison of DCPIP in borate buffer. The y-error bars 
correspond to the range from two measurements taken at different time points after 
preparation (5 and 15 minutes) of two independent sets of samples (n = 2). X-errors are 
not indicated. However, it has to be highlighted that dilution errors of two kinds can 
occur and may contribute to a potential x-error. The first kind is an instrumental error 
arising from the Gilson micro pipettes and the second kind is an experimental error 
introduced by the experimenter. Both types were minimised or kept similar by generally 
good laboratory practices and specifically by strict and constant dilution procedures.  
 
The same comparison of calculated to diluted concentrations is shown in figure 5.08 D 
for DCPIP in pseudo-serum. Additionally, a second set of concentrations according to the 
absorbance values at the shifted maximum wavelength, 632 nm, was calculated and 
plotted. Nonetheless, the molar absorption coefficient of 605 nm (       ) has been 
kept for these calculations. The y-error bars are standard deviations of the mean derived 
from three measurements taken at different time points after preparation (5, 10 and 
20 minutes) on one sample (n = 1), which are consequently very small and not 
significant. In both figures (5.08 C and D) it can be observed that generally low 
concentration calculations are in fairly good agreement with the corresponding 
calibrated concentrations. However, high concentrations, even taking errors into 
account, do not correlate very well. This may again be caused by the shadowing effect 
within these high concentrations mentioned earlier, which could lead to deviations from 
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the linear calibration curve and resulting in inaccuracy of the Beer-Lambert-Bouguer 
law. It seems that the concentrations calculated with the bathochromic shifted 
absorbance maximum in serum (             = 632 nm) (figure 5.08 D) fit slightly better 
the comparison with the concentration of the diluted solutions.  
 
In conclusion, even though the samples sizes were kept small and at high concentrations 
a deviation has been observed, the proof-of-principle experiments were considered 
successful. The objective was to prove the principle of colourimetric detection by visible 
spectroscopy and to consequently show its potential as an integral part of a PoC sensor 
for therapeutic drug monitoring. It could be demonstrated that by using the Beer-
Lambert-Bouguer law the concentrations can be estimated and the detection is sensitive 
in the clinically relevant concentration range. The observed deviation from the linear 
correlation for high concentrations are beyond the clinically relevant range and could, if 
required, be curbed by using an additional high calibration concentration. Furthermore, 
the experiments in serum showed promising results towards possible circumvention of a 
specific extraction protocol prior to the colourimetric detection. However, it has to be 
emphasised that this is just one aspect of direct detection in serum and interference, 
cross-contamination and Gibbs reagent’s non-specificity still have to be further 
investigated. Besides the proof of principle, the DCPIP assay seems reliable, can be 
performed rapidly and is stable over at least 20 minutes. Hence it provides many 
characteristics for a potential calibration system for Sphere Medical’s Pelorus device.  
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Figure 5.08: Proof-of-principle experiments with the commercially available product of the 
Gibbs-phenol reaction. A) Dilution series of 2,6-dicholorphenolindophenol (DCPIP) in borate 
buffer. Absorbance spectra of DCPIP in different concentrations in borate buffer. Reference is 
borate buffer. Vertical line at 605 nm corresponds to      of DCPIP. B) Dilution series of 2,6-
dicholorphenolindophenol (DCPIP) in pseudo-serum. Pseudo-serum corresponds to 600 µM BSA 
in borate buffer. Reference is pseudo-serum. Dashed line shows the bathochromic shifted 
     (632 nm) in serum. C) Beer-Lambert-Bouger law calculations of DCPIP’s concentrations in 
borate buffer. Error bars indicate the range obtained from 2 measurements of 2 independent 
samples (n = 2). D) Beer-Lambert law calculations of DCPIP’s concentrations in pseudo-serum. 
Error bars are standard deviations derived from 3 measurements of 1 sample (n = 1) and are 
therefore very small and not significant. 
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5.3.2 Benchmarking Experiments with Gibbs Reagent and Propofol  
The experiments to benchmark the colourimetric detection platform at UCL to Sphere 
Medical’s Pelorus device were performed based on Sphere’s experimental procedure, 
described in subsection 5.1.3.3 (Pettigrew, Laitenberger, and Liu 2012; Liu et al. 2012). A 
range of propofol concentrations were diluted in acetonitrile, which is the elution 
solvent for the solid phase extraction (SPE). Gibbs reagent was dissolved in methanol, 
which serves as the primary alcohol needed for the initial solvolysis required for the 
coupling reaction (see chapter 5.1.2.2). Gibbs reagent and borate buffer at pH 10, which 
provided the crucial alkaline pH, were added to the propofol/acetonitrile solution. 
Immediately after mixing, a colour change from a clear transparent to a striking blue 
colour was observed.  
 
Figure 5.09 A shows the absorbance spectra of 0.8 mM Gibbs in methanol reacted with 
propofol in different concentrations (2, 4, 8, 12 and 20 µg/ml) according to the 
described procedure. The concentrations have been chosen to include the clinically 
relevant propofol concentrations ranging from 1 to 10 µg/ml corresponding to 5.6 –
 56.1 µM. Sphere’s Pelorus device measures the absorbance at a wavelength of 595 nm, 
which is marked with a dotted black line. The reference used in this experiment was the 
same reaction mixture but in the absence of propofol. All absorbance spectra showed 
the distinctive indophenolic peak at 595 nm. However, the two low concentrations (2 
and 4 µg/ml) show large drift on the left hand side of the peak, which remains 
unexplained. However, since these experiments served as benchmarking experiments, 
repeats were not deemed necessary and no further investigations were performed. 
 
To quantify the concentration of propofol in the sample, Sphere Medical uses two 
known calibrations solutions, 2.5 and 7.5 µg/ml of propofol, which are measured prior 
to the experiments and analysed via linear regression fit. According to these calibration 
samples the unknown sample concentrations are calculated via the Beer-Lambert-
Bouguer law (see chapter 5.1.1.2),  
         5.14 
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Following Sphere’s procedure, the average of three spectra from three independent 
samples (n = 3) for 2 and 8 µg/ml of propofol were used to calculate the molar 
absorption coefficient of the coupling product at 595 nm (    ). Figure 5.09 shows 
these two absorbances including their y-errors, which are the standard deviations from 
the mean derived from the three independent samples (n = 3). The linear fit (depicted in 
red) through these values was forced to intercept zero and resulted in a slope of 
0.017 ± 0.002 and an adjusted R2 of 0.977. According to the Beer-Lambert-Bouguer law, 
the slope of a linear fit through data points arising from concentrations versus 
absorbances at a certain wavelength, presumably the maximal absorbance wavelength 
(    ) of the compound of interest, is a direct measure of the molar absorptivity at this 
wavelength  . However, this only applies if the utilised cuvette has a path length ( ) of 
1 cm. Therefore, the molar absorptivity (    ) of the coupling product, Gibbs-propofol, 
was found to be 17000 ± 2000 M-1 cm-1. This is comparable to the commercially available 
DCPIP, which has an         of 21000 M
-1 cm-1 (see previous subsection 5.3.1 and third 
example on page 84).  
 
After calculation of     , all concentrations (2, 4, 8, 12 and 20 µg/ml) were treated as 
‘unknown’ and the calculated         was used to estimate them via the Beer-Lambert-
Bouguer law. Figure 5.09 C shows these calculated concentrations versus the diluted 
concentrations. The diagonal line indicates the region of the most optimal case, which 
would be if the calculated concentrations match exactly the diluted concentrations. 
20 µg/ml is not shown due to the facts that it is double the upper end of the clinically 
relevant concentration range and showed a large deviation from the linear relationship. 
The latter observation however is in good agreement with the findings from the 
previous subsection (5.3.1) and the Pelorus device described in chapter 5.1.3.3, which 
report deviation from linearity above 12 µg/ml propofol (Pettigrew, Laitenberger, and 
Liu 2012; Liu et al. 2012). The calculated concentration, including accounted error bars, 
for the low concentration of 2 µg/ml correlates with the diluted concentration, but not 
the high concentration of 12 µg/ml propofol. The y-error bars correspond to the 
standard deviations of the mean derived from the three independent samples (n = 3). As 
discussed in the previous section (5.3.2), x-errors are not indicated.  
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However, despite these drifts and deviations, the experimental results were considered 
to be comparable to Sphere’s results. Furthermore, the calculated         for the Gibbs-
propofol molecule was in good agreement with DCPIP’s        . 
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Figure 5.09: Benchmarking 
experiments for the colourimetric 
detection of propofol via coupling 
reactions with Gibbs reagent.  
A) Dilution series of propofol 
labelled with Gibbs reagent. 
Absorbance spectra of 0.8 mM Gibbs 
in methanol reacting with different 
concentrations of propofol in 
acetonitrile. Borate buffer was 
added to the reaction mixture to 
provide the required high pH. The 
same mixture without propofol 
served as a reference. The dotted 
line at 595 nm marks the 
wavelength, which is used in Sphere 
Medical’s Pelorus bench top device 
to calculate the drug’s 
concentration. Elevation at 632 nm 
i  instrumental and characteristic for 
the spectrometer used. 
B) Estimation of the Gibbs-
propofol’s molar absorptivity. The 
differential absorbances of propofol 
reacted with Gibbs reagent are 
plotted against the corresponding 
concentrations. The indicated error 
bars are standard deviations of the 
mean derived from three 
independent samples (n = 3). 
According to the Beer-Lambert-
Bouguer, the slope of the linear fit 
gives an estimate of the Gibbs-
propofol’s molar absorptivity 
(ε      ). It was found to be 
17000 ± 2000 M-1 cm-1. The yellow 
box highlights propofol’s therapeutic 
window.  
C) Beer-Lambert-Bouguer law 
calculations of propofol’s 
concentrations. The calculated  
        was used to calculate the 
concentrations. These calculated 
concentrations were then plotted 
against the diluted concentrations.  
The error bars are standard 
deviations derived from three 
independent samples (n = 3). The 
yellow box highlights again 
propofol’s therapeutic window.  
 
 
 
 
 
 
 
 
 
 
fit: y = a + b*x 
a: 0 
b: 0.017 ± 0.002 
R2: 0.977 
CHAPTER 5: PROOF-OF-PRINCIPLE & BENCHMARKING OF COLOURIMETRIC DETECTION 
  
 
 
119 
 
5.4 Conclusion and Outlook 
The proof-of-principle experiments with DCPIP in subsection 5.3.1 demonstrated that by 
using the Beer-Lambert-Bouguer law clinically relevant concentrations can be 
spectroscopically quantified. The experiments in serum showed promising results that a 
specific extraction may not be required. Furthermore, the DCPIP assay seems reliable, 
can be performed rapidly and is stable over at least 20 minutes. Hence, it fulfils many 
requirements for a potential calibration system. Consequently, it was proposed to 
Sphere Medical for their Pelorus device, in which it is in use nowadays.   
 
The benchmarking experiments to the Pelorus device in subsection 5.3.2 were 
considered successful despite some drifts and deviations. Furthermore, the calculated 
        for the Gibbs-propofol molecule was comparable to DCPIP’s        .  
 
In conclusion, it was deemed appropriate to move onto the development of the 
colourmetric detection of vancomycin, which will be further discussed in the next 
chapter (6). 
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CHAPTER 6:  
Colourimetric Detection of Vancomycin 
6 Colourimetric Detection of Vancomycin 
The main objective of this PhD thesis is the development of a PoC sensor for therapeutic 
antibiotic monitoring, particularly for the glycopeptide antibiotic vancomycin. The 
starting point of this development is the colourimetric detection of vancomycin by 
visible spectroscopy built on the principle of Sphere Medical’s Pelorus bench top device.  
 
The previous chapter presented the proof-of-principle with DCPIP and the anaesthetic 
propofol and benchmarking experiments to Sphere Medical’s data. This chapter 
presents the first successful vancomycin-Gibbs colourimetric detection assay at clinically 
relevant concentration in whole blood within minutes. The work led to our patent 
submission “Analyte Extraction Apparatus and Method” (Kappeler et al. 2013).  
 
In order for a sensor to be developed, it must meet the general requirements that were 
established in chapter 1.2. The last point is of particular importance for the therapeutic 
monitoring of vancomycin, as it states that an additional benefit for a sensor would be 
the option to monitor free and active drug concentration.  
 
This chapter is divided into four subsections. The introduction in subsection 6.1 
summarises the hypothesis, the unmet clinical needs and the findings from the previous 
chapter. Subsection 6.2 lists the additional materials and methods used hereafter. 
Subsection 6.3 presents the results including preliminary discussions and is structured in 
major milestones of the development process. It continues into the final subsection (6.4) 
with the overall discussion and conclusion.  
 
In the following, chapter 7 will analysis the labelling reaction and the novel compound.  
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6.1 Introduction  
To specifically develop an optical quantitative detection assay for the antibiotic 
vancomycin during my PhD several objectives have been considered. The first and most 
important one is the compatibility with Sphere Medical’s existing Pelorus bench top 
device because of the associated market opportunities. Sphere Medical developed an 
assay to detect the anaesthetic propofol by labelling its phenolic moiety with Gibbs 
reagent (Adam et al. 1981; Pettigrew, Laitenberger, and Liu 2012; Liu et al. 2012). Gibbs 
reagent is named after Harry Drake Gibbs who used it 1927 to detect phenol and its 
derivates. Gibbs reagent induces a striking colour change by extending the conjugation 
in a molecule and the concentration of the newly produced light absorbing species can 
be accurately measured via visible spectroscopy (Gibbs 1926a; Gibbs 1926b; Gibbs 
1927a; Gibbs 1927b). An extended explanation and discussion of the history of the Gibbs 
reagent, the reaction mechanisms and their applications can be found in the preceding 
chapter in subsection 5.1.2.  
 
Vancomycin, as a heptapeptide, absorbs around 280 nm with values referenced 
between 280 – 282 nm (Nieto and Perkins 1971; Nagarajan 1994; “The Merck Index 
Online - Vancomycin” 2013) and has a molar absorptivity at 282 nm (      ) of  
5943 M-1 cm-1 in water (“The Merck Index Online - Vancomycin” 2013). Herein, the 
maximal absorbance wavelength of vancomycin (    ) has been taken as 281 nm as it is 
the median of the aforementioned values. In conclusion, vancomycin can just about be 
detected in quartz glass cuvettes with a typical UV/vis spectrometer that ranges from 
about 200 to 1100 nm.  
 
However, direct UV/vis detection of vancomycin in sample that additional contains 
proteins will be very complicated. Since due to their aromatic rings, which are paired 
with groups that are extending this delocalised system, the amino acid tyrosine (Tyr, Y) 
and especially tryptophan (Trp, W) absorb around 280 nm and consequently 282 nm as 
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well4. Tryptophan has a molar absorptivity at 282 nm (      ) of 5600 M
-1 cm-1 and 
tyrosine an        of 1200 M
-1 cm-1 both measured in guanidinium hydrochloride 
dissolved in phosphate buffer at pH 6.2 (Gill and von Hippel 1989; Sułkowska 2002). 
Further if two cystines (Cys, C) residues are linked by a disulfide bond, they absorb 
around 280 and 282 nm as well. However, their effect is small as their molar absorptivity 
is only 100 M-1 cm-1 (Gill and von Hippel 1989).  
 
Even though tyrosine and especially tryptophan are among the rarer amino acids in the 
average protein, they still influence the protein’s absorbance characteristic due to their 
fairly large molar absorptivity. Human serum albumin (HSA), which is the most abundant 
plasma protein in humans, has one tryptophan and 19 tyrosines. Its counterpart in 
bovines, bovine serum albumin (BSA) has two tryptophans and  17 tyrosines (Sułkowska 
2002; Zeitlinger et al. 2011). Since serum albumin’s concentration in serum is about 
600 µM, their absorbance will completely mask the absorbance of vancomycin in 
therapeutic concentrations of 4 to 28 µM (Bohnert and Gan 2013). Moreover, the Gibbs 
reagent may couple to tyrosines as it has a phenolic moiety. Even though the phenolic 
moiety is para-substiuted, as previously discussed, this may not prevent a successful 
Gibbs coupling (Dacre 1971; Josephy and Van Damme 1984) (see subsection 5.1.2).  
 
Furthermore besides serum albumin, there are other proteins present in serum such as 
globulins, as well as electrolytes, antibodies, antigens, hormones and exogenous 
substances, which may absorb in this wavelength region as well. Therefore an 
absorbance enhancement possibly paired with an extraction procedure seems inevitable 
for an optical therapeutic vancomycin monitoring (TVM) device.  
 
Moreover it has to be considered that solvents, including methanol, are absorbing in this 
wavelength region too and they may be required for the extraction of vancomycin from 
whole blood samples. The absorbances of solvents will be further discussed below in 
subsection 6.2.3 and figure 6.04.  
                                                            
4 Phenylalanine has only one aromatic ring without a functional group or heteroatom that 
provides further extension of the aromatic ring’s delocalised system and consequently has its 
maximal absorbance wavelength at around 260 nm (Ichikawa and Terada 1979).  
CHAPTER 6: COLOURIMETRIC DETECTION OF VANCOMYCIN 
  
 
 
123 
 
 
Since vancomycin has several aromatic groups, including some phenolic moieties, one 
hypothesis is that Gibbs reagent couples to one or several of these. The resulting 
indophenolic structures would allow quantification via visible spectroscopy and 
therefore enhance the absorbance. The schematic in figure 6.01 illustrates a possible 
coupling reaction of the Gibbs reagent to position 6 in the 7th residue of vancomycin via 
an electrophilic aromatic substitution (SEAr). Position 6 in the 7
th residue of vancomycin 
is the para-unsubstituted position of the hydroxyl group at position 3. The 7th residue is 
a dihydroxy benzene (IUPAC:  benzene-1,3-diol), which is colloquially know as resorcinol 
or resorcin.  
 
It has to be highlighted that the addition may occur to another position of the 
vancomycin molecule such as the position 2 in the same residue (7th), other aromatic 
moieties that may become phenolic or to amine groups, as it was previously presented 
in subsection 5.1.2.2 (De Boer et al. 2007; Kovar and Teutsch 1986; Kallmayer and 
Thierfelder 2003; Annapurna et al. 2010). Moreover, these alternative additions could 
result in multiple coupling reactions accompanied with maybe even fragmentation of 
the vancomycin molecule. These alternative reactions as well as the structural 
characterisation of the novel product will be further discussed in chapter 7. 
 
As indicated in the previous chapter in subsection 5.1.2.2, two references could be 
found describing Gibbs reagent reaction with antibiotics.  
 
i) The first paper is by H. G. Daabees et. al. and presents the use of Gibbs reagent for 
the colorimetric detection of some antibiotics, namely amoxicillin (a β-lactam 
antibiotic), mixtures of amoxicillin with nystatin (an antifungal drug) and dicloxacillin 
(a β-lactam antibiotic), cefadroxil and cefoperazone (both cephalosporin antibiotics) 
(Daabees et al. 1998).  
 
ii) The second reference is by P. S. N. H. R. Rao and colleagues and writes about the 
spectrophotometric detection of dobutamine (a symphathomimetic drug) and 
vancomycin with different chemicals including Gibbs reagent. However, the paper 
CHAPTER 6: COLOURIMETRIC DETECTION OF VANCOMYCIN 
  
 
 
124 
 
could not be obtained online, via the British library or via email from the authors or 
their respective university. Only its abstract has been found in the search by the 
patent office. The abstract mentions “acidic conditions” and a maximal absorbance 
wavelength of 460 nm. Additionally, the thesis by K. B. M. Krishna presents briefly 
this paper in a literature review. He wrote: “Rao et al [P. S. N. H. Ramachandra Rao, T. 
Siva Rao, U. Viplava Prasad and C. S. P. Sastry. Spectrophotometric methods for the 
determination of dobutamine and vancomycin in formulations. Indian pharmacist. 
2(9): 59-61(2003)] developed a spectrophotometric determination of dobutamine 
and vancomycin in pure samples and dosage forms based on the formation of yellow 
coloured (     at 400 nm) and condensation product with ethylacetoacetate in 
sulfuric acid medium.“ (Krishna 2010). Consequently, it remains unknown whether 
they successfully managed to couple the Gibbs reagent to vancomycin and to which 
part of the molecule the addition occurred. 
 
Moreover, Sphere Medical had previously tried to label vancomycin with Gibbs reagent. 
However, the obtained results were not conclusive. Conclusively, without a greater 
understanding of the reaction mechanism and a reduction in background interferences, 
this assay would not be viable as a commercial product.  
 
Therefore, the main objective of this part of the thesis is to develop a method to label 
vancomycin and consequently gain the ability to quantify its unknown concentration in a 
complex sample matrix – ultimately whole blood. Besides the just described objective, 
further objectives have been previously discussed (subsection 4.3). They in particular 
include the urgent need for free drug quantification and the benefits for the health 
economic case of therapeutic vancomycin monitoring.  
 
Hence the two main objectives for this section describing the colourimetric detection of 
vancomycin can be summarised as follows: 
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i) The first objective is to develop a method to label vancomycin for 
subsequent colourimetric quantification. This labelling reaction has to allow 
quantification in vancomycin’s therapeutic range. The starting point will be 
the Gibbs reagent.  
 
ii) The following objective is to demonstrate this method for a whole serum 
sample. If necessary, this may include the development of an extraction 
protocol prior to the labelling reaction. This extraction protocol will aim to 
reduce the complexity of the sample, remove interfering and cross-
contaminating species and may additionally increase the concentration of 
the compound of interest, thus improve the accuracy and sensitivity of 
subsequent quantification for TVM.  
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Figure 6.01: Hypothesis of Gibbs reagent coupling to vancomycin resulting in a novel vanGibbs 
molecule. Based on the theory of the Gibbs reaction, coupling to the para-unsubstituted position 
of the hydroxyl group at position 3 in 7th residues of vancomycin via an SEAr seems a likely 
scenario. The coupled Gibbs molecule is indicated in purple in the vanGibbs molecule. One 
isomeric structure of vanGibbs was chosen as an example for many possible isomers. It has to be 
highlighted that the addition may occur to another position of the vancomycin molecule such as 
the position 2 in the same residue (7th), other aromatic moieties that may become phenolic or 
addition to amine groups. This could result in multiple additions accompanied with maybe even 
fragmentation, which will be further discussed in chapter 7. Furthermore, the coupling reaction 
requires high pH. Therefore the charged groups of the vancomycin scaffold were adjusted to an 
assumed pH of around 8.9 to 9.5 resulting in an overall charge change from     to –   . The pKa 
values were taken from Takács-Novák, Noszál, Tókés-Kövesdi, & Szász, 1993.   
vancomycin 
 
 
 
 
 
 
 
     +  
 
Gibbs reagent 
 
 
                         
 
 
 
 
 
vanGibbs 
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6.2 Materials and Methods 
This subsection describes the materials and methods associated with the colourimetric 
detection of vancomycin. This materials and methods subsection is divided into three 
subchapters, namely chemicals (6.2.1), the experimental instrumentation (6.2.2) and 
measurement procedure, data processing and analysis including statistics (6.2.3).  
6.2.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich (Dorset, UK), unless otherwise 
declared. They were handled, stored and disposed of in accordance with their safety 
guidelines stated in the corresponding ‘material safety data sheets’ (MSDS).  
6.2.1.1 Buffer Solutions, Solvents and Antibiotic 
Borate buffer pH 10 solution was purchased from Fisher Scientific, which was initially 
used to dissolve the antibiotic vancomycin and to provide the required high pH for the 
Gibbs addition. Later in the development process, vancomycin was dissolved in distilled 
and deionised water (usually abbreviated as ddH2O, herein as water or DI water) and the 
necessary pH was achieved by adding 0.4 M sodium hydroxide (IUPAC: sodium 
hydroxide) in water. The water was purified with an ELGA Purelab Ultra water 
purification system (ELGA, Buckinghamshire, UK). Methanol was used in order to 
dissolve the Gibbs reagent. It also provided the required primary alcohol for the 
solvolysis of Gibbs reagent to initiate the reaction. The antibiotic vancomycin was 
purchased as vancomycin hydrochloride hydrate (IUPAC: (1S, 2R, 18R, 19R, 22S, 25R, 
28R, 40S)- 48- {[(2S, 3R, 4S, 5S, 6R)- 3- {[(2S, 4S, 5S, 6S)- 4 - amino- 5 - hydroxy- 4, 6- 
dimethyloxan- 2- yl]oxy}- 4, 5- dihydroxy- 6- (hydroxymethyl)oxan- 2- yl]oxy}- 22- 
(carbamoylmethyl)- 5, 15- dichloro- 2, 18, 32, 35, 37- pentahydroxy- 19- [(2R)- 4- methyl- 
2- (methylamino)pentanamido]- 20, 23, 26, 42, 44- pentaoxo- 7, 13- dioxa- 21, 24, 27, 
41, 43- pentaazaoctacyclo [26.20.2.23, 6.814, 17.18, 12.129, 33.010, 25.034, 39] 
pentaconta- 3, 5, 8(48), 9, 11, 14, 16, 29(45), 30, 32, 34, 36, 38, 46, 49 - pentadecaene- 
40 - carboxylic acid).  
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6.2.1.2 Blood Components 
The experimental approach used to investigating the therapeutic monitoring of drugs, 
such as vancomycin, needs to take into account the complex physiological background 
of whole human blood. It is possible that the constituent parts of human blood could 
interfere with the colourimetric detection of vancomycin using Gibbs reagent. For this 
reason, different blood components in increasing complexities have been studied. As 
described in the previous chapter (5.2.1.3), fatty acid free BSA marked the starting point 
for mimicking normal blood serum. Later in the development process, fatty acid free 
HSA was used. Serum albumins are believed to be the proteins to which drugs 
predominately bind to (Zeitlinger et al. 2011; Lin et al. 2013; Ndieyira et al. 2014). A 
more detailed discussion about the serum binding particularly of vancomycin can be 
found in chapter 3.3.3.  
 
After injection of a whole blood sample into Sphere’s Pelorus device analyser, the 
sample gets diluted and the red blood cells are lysed. Propofol is then extracted via solid 
phase extraction (SPE) (Liu et al. 2012; Pettigrew, Laitenberger, and Liu 2012). 
Therefore, experiments were performed with foetal bovine serum (FBS) and whole 
human serum (WHS), marking the last complexity step before one would consider 
testing with human blood samples. FBS from both European and American bovine 
specimens were used in this investigation. In the course of this investigation no 
significant difference between those two types were found. WHS was extracted from a 
male donor of US origin with an AB blood type. The serum was endotoxin tested and 
sterile-filtered by the supplier.   
6.2.1.3 Interferents 
In order to investigate the specificity of the developed extraction protocol, four 
interferents were chosen based on their possible presence in patient blood samples and 
the presence of phenolic motifs in their structure. In light of the previously proven 
ability for Gibbs reagent to couple to the anaesthetic propofol; propofol, tyrosine, 
dopamine and paracetamol were selected (see figure 6.02). Tyrosine (IUPAC: (S)-
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Tyrosine or L-2-Amino-3-(4-hydroxyphenyl)propanoic acid) was purchased as L-tyrosine, 
which is a crystalline white solid. Dopamine (IUPAC: 4-(2-aminoethyl)benzene-1,2-diol) 
was supplied as dopamine hydrochloride, which is a white powder. Paracetamol (IUPAC: 
N-(4-hydroxyphenyl)ethanamide or N-(4-hydroxyphenyl)acetamide) is alternatively 
named acetaminophen. It was bought as an over-the-counter preparation from the local 
pharmacist due to limited availability from Sigma-Aldrich (Dorset, UK). The active 
ingredient within one capsule was 500 mg paracetamol, which has been used as the 
basis for calculating the sample concentration. It has to be highlighted that this over-
the-counter preparation also contains additives including maize starch, sodium 
laurilsulfate and magnesium stearate (“Leaflet: Boots Paracetamol 500 mg Capsules 
from Boots Pharmaceuticals” 2011). The objectives were to determine whether these 
four interferents are eluted out together with vancomycin and if so, whether they react 
with the Gibbs reagent to form an indophenolic motif that would absorb in the same 
region as vancomycin labelled with Gibbs. It has to be emphasised that these four 
interferents do not form an exhaustive investigation into potential interferents and 
further studies concerning this matter will need to be performed. For example a possible 
interferent may be salicylic acid which is the active metabolite of aspirin (Sneader 2000). 
Furthermore, depending on the results of these studies, these interferents could 
become the compound of interest for monitoring purposes in their own right. Expanding 
this research beyond the scope of propofol and vancomycin, a multi-analyte therapeutic 
drug monitoring device might be a feasible proposition in the future.  
6.2.2 Experimental Instrumentation  
6.2.2.1 UV/vis Spectrometer 
As previously described in subsection 5.2.2.1, the used UV/vis spectrometer was a one 
light path spectrometer from Agilent (Agilent Technologies, Santa Clara, California, US) 
located in Dr. Daren Caruana’s laboratory in the Chemistry Department of UCL.  
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6.2.2.2 Cuvettes  
For the following vancomycin experiments, quartz glass cuvettes from Hellma (Hellma 
Analytics GmbH & Co. KG, Müllheim, Germany) were used instead of disposable 
cuvettes. This is due to the fact that absorbances below 300 nm wavelength were of 
interest as well. These could not be measured with the disposable cuvettes used since 
some plastics absorb below 300 nm. All cuvettes used had a path length (  ) of 1 cm. 
6.2.2.3 Solid Phase Extraction 
The extraction protocol established hereafter is a solid phase extraction (SPE) technique 
that utilises Strata-X 33u Polymeric Reversed Phase (30 mg/1 ml sample) cartridges from 
Phenomenex® (Phenomenex, Macclesfield, Cheshire, UK) (see figure 6.03). According to 
the manufacturer, the named Strata-X reversed phase sorbent retains analytes by 
hydrophobic interactions, such as conventional C18 or C8 reverse phase columns, but 
also by hydrogen- and π-π bonding resulting in stronger retention of aromatic and polar 
analytes. This enhanced retention allows washing with organic solvents without 
breaking the interaction between the analyte and the stationary phase. Therefore, it is 
suitable for polar and non-polar analytes. Every cartridge was conditioned with 1 ml 
methanol and equilibrated with two times 1 ml of DI water prior to usage. SPE cartridges 
can be operated in a parallel manner with a vacuum manifold. Beside the significant 
reduction in time, it also has the advantage of completely drying out the polymer. 
Nonetheless, as discussed further in the following results chapter (subsection 6.3.3), the 
majority of the experiments were performed with gravity flow. Further information 
including the reasoning behind this choice can be found in the same subsection (6.3.3) 
and in the conclusion and outlook chapter (6.3.8).  
6.2.2.4 Homogenous enzyme immunoassay  
The last set of experiments presented in this chapter (6.3.8) is the direct comparison of 
the developed colourimetric TVM assay with a gold standard technique routinely 
employed in clinics. The different gold standard assays are discussed in chapter 4.1.  
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The hereafter used gold standard technique is the competitive, homogenous enzyme 
immunoassay “VANC2” from COBAS®, Roche (Roche, Basel, CH). It belongs to the group 
of the enzyme multiplied immunoassay technique, which are commonly abbreviated as 
EMIT (see chapter 4.1). This assay is the technique of choice in the diagnostic 
laboratories of the Whittington Hospital NHS Trust and the University College London 
Hospital (UCLH). The latter is where the prepared samples were sent to and kindly 
measured by Dr. Anne Dawnay.  
 
The VANC2 assay has a lower detection limit of 1.7 µg/ml, which according to the 
technical support corresponds to 1.2 µM of vancomycin (conversion factor: 
µg/ml   0.690 = µM) (“Package Insert: VANC2 COBAS® from Roche Diagnostics” 2012). 
This limit represents the lowest measurable analyte level that can be distinguished from 
zero and is calculated as the value lying two standard deviations above the measured 
value for zero (1 + 2 StDev, n = 21). The measuring range of the VANC2 is stated as 1.7 –
 80.0 µg/ml of vancomycin, which corresponds to 1.2 – 55.2 µM. (Yeo, Traverse, and 
Horowitz 1989; “Package Insert: VANC2 COBAS® from Roche Diagnostics” 2012; Domke, 
Cremer, and Huchtemann 2000; Hermida, Zaera, and Tutor 2001; Domke 2002)  
6.2.3 Measurement Procedure, Data Capturing and Analysis 
6.2.3.1 Measurement Procedure and Data Capturing  
The measurements were performed in a UV/vis spectrometer from Agilent Technologies 
with the “UV-Visible ChemStation” software. The basic measurement procedure was 
described in the previous chapter 5.2.3. However, in contrast to the disposable cuvettes, 
the quartz cuvettes had to be cleaned and reused. Therefore (and for other reasons 
stated later), it was decided to unconventionally use the absorbance spectrum of the 
empty quartz cuvette as a reference and blank respectively. This spectrum was captured 
prior to every new sample measurement or specifically every time the cuvette was 
changed. This unconventional procedure served several purposes. Besides the usual 
benefits, which include subtraction of cuvette surface imperfections and ambient light 
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changes that can affect spectrometers without cover, three main benefits supported this 
procedure.  
 
1)  By observation of the blank spectrum, the cleanliness could be guaranteed. Hence it 
can be seen as a quality measure for the cleaning procedure, which typically included 
water and acetone washes. This was especially important after protein rich samples, 
which denatured during the cleaning process and then had the tendency to stick to 
the inside of the cuvette.  
 
2)  The characteristic in the spectra, which resulted from constant constituent such as 
buffer and solvents like water and methanol (see figure 6.04), could be used for 
evaporation control, and if required, for the respective adjustment. 
 
3)  Furthermore, these characteristics served as indicators if there was an error 
introduced by the experimenter. Hence it served again as a quality control measure.  
 
Besides these unconventional blank spectra from empty cuvettes, for each experimental 
series, spectra of appropriate references were also captured and subsequently 
subtracted as required during data analysis. These spectra included buffer solutions and 
solvents only, both inactivated and activated Gibbs reagent in various solutions, 
vancomycin in the corresponding solution mixture at neutral and high pH etc.   
Water and methanol mixtures are prone to separation, which may result in false 
absorbance values and difficulties of evaporation factor estimation. Consequently it was 
decided that after the first experiments presented in chapter 6.3.1, the reaction 
mixtures should be shaken in an Eppendorf tube prior to addition into the cuvette for 
subsequent spectroscopic analysis. Furthermore, two spectra were recorded for each 
sample in order to ensure a level of consistency. The obtained data were saved in 
comma-separated values (CSV) using the export function of the spectrometer software. 
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6.2.3.2 Data Processing, Analysis and Statistics 
The CSV-files were imported, plotted and analysed with Origin Pro 8.6 software (Origin 
Lab Corporation, Northampton, Massachusetts, USA). The solvent characteristics in the 
spectra could again be used as control indicating errors for instance in subtraction of the 
reference from the sample spectrum. 
 
Whenever the sample sizes were large enough a statistical evaluation was performed. 
This included a one-way analysis of variance (ANOVA) and when the results indicate 
significance a post hoc Fisher’s least significant difference (LSD) test followed. These 
tests were calculated using Microsoft Office Excel (Microsoft Corporation, Redmond, 
Washington, USA). Summaries of these calculations including formulae can be found in 
the appendix chapter A starting on page 347.  
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Figure 6.02: Chosen interferents with phenolic motifs, which may couple to Gibbs reagent and 
affect the vancomycin quantification. A) Propofol. The coupling of Gibbs reagent to the para-
unsubstituted position of propofol is well established and results in an indophenolic structure 
with a   at 595 nm (see chapter 5.3.2) (Pettigrew, Laitenberger, and Liu 2012; Liu et al. 2012; 
Adam et al. 1981). B) Tyrosine. Tyrosine (Tyr or Y) is a non-essential amino acid meaning it can be 
synthesised by the human body. Its phenolic moiety is para-substituted. C) Dopamine. Dopamine 
is a neurotransmitter and its structure consists of a dihydroxy phenol, where one para position to 
the hydroxyl group is occupied and one is free. D) Paracetamol. Paracetamol is also known as 
acetaminophen and is a widely used over-the-counter analgesic. In a similar way to tyrosine its 
structure consists of a para-substituted phenolic moiety. 
 
 
 
 
Figure 6.03: Solid phase extraction (SPE). The SPE 
cartridge was a Strata-X 33u Polymeric Reversed Phase 
(30 mg/1 ml sample) cartridge from Phenomenex® 
(Macclesfield, Cheshire, UK). According to the 
manufacturer, the named Strata-X reversed phase 
sorbent retains analytes by hydrophobic interactions, 
such as conventional C18 or C8 reverse phase columns, 
but also by hydrogen- and π-π bonding resulting in 
stronger retention of aromatic and polar analytes. This 
enhanced retention allows washing with organic 
solvents without breaking the interaction between the 
analyte and the stationary phase. Therefore it is 
suitable for polar and non-polar analytes. Every 
cartridge was conditioned with 1 ml methanol and 
equilibrated with two times 1 ml of water prior to 
usage. SPE cartridges can be operated in a parallel 
manner with a vacuum manifold. 
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Figure 6.04: UV/vis spectra of borate buffer and various solvents. All spectra show distinctive 
characteristics in the wavelength region from 850 to 1100 nm. It is clearly visible that the solvent 
mixtures depict characteristics of both constituents according to their corresponding ratio. 
Furthermore, it is evident that methanol, especially in a mix with water, is absorbing around 
281 nm and therefore is likely to mask absorbances of vancomycin. These specific characteristics 
of borate buffer and various solvents were used for quality measure during experiments and 
subsequent analysis including evaporation control and if necessary adjustment. The small 
elevations and drops at 486 and 656 nm are instrumental and specific for the used spectrometer.  
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6.3 Results and Discussion 
The results herein report the colourimetric detection of vancomycin by successful 
labelling of vancomycin with Gibbs reagent, which is a key result of this thesis. This 
chapter presents selected consecutive major milestones of the development process for 
the colourimetric TVM assay. Due to the fact that it is a consecutive process some 
discussion and sometimes hypotheses had to be included to lead to the subsequent 
step.  
 
This section is divided into eight parts. The first part (6.3.1) describes labelling of 
vancomycin at high concentrations. The second part (6.3.2) focuses on the detection in 
the therapeutic range and reports the first study in serum. The third part (6.3.3) 
presents the development of an extraction protocol for vancomycin from foetal bovine 
serum (FBS). The fourth part (6.3.4) contains the optimisation of the vancomycin to 
Gibbs reagent ratio. The fifth part (6.3.5) depicts the change from FBS to whole human 
serum (WHS). The sixth part (6.3.6) discusses the effect of serum protein binding on the 
vancomycin detection and studies the therapeutic monitoring of free and bound drug 
fraction. The seventh part (6.3.7) evaluates the selectivity of the assay with a subset of 
interferents. The eight and last part (6.3.8) presents the direct comparison of the 
developed vancomycin assay with a gold standard method that is routinely used in the 
microbiology laboratory of UCLH.5 
6.3.1 Labelling of Vancomycin at High Concentrations 
The starting point of the experimental procedure used herein is comparable to the one 
used for propofol described the precedent chapter in section 5.3.2. However, 
acetonitrile, as a polar aprotic solvent, could not be used for the dissolving of 
vancomycin. Therefore borate buffer, as a polar protic solvent, was chosen.  
The main reason for this choice was to not introduce another unknown solution to the 
                                                            
5 Some experiments in the fourth, fifth, sixth and seventh subsection were carried out in 
conjunction with Alexander Wright. He is a medical student, who did a six month project in our 
group.  
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reaction mixture, since borate buffer was used previously in the benchmarking 
experiment to achieve the required alkaline pH. Retrospectively, this turned out to be 
one of the crucial changes, which made the coupling reaction work successfully.  
 
Figure 6.05 A shows photographs of three quartz glass cuvettes. The first cuvette (i) 
contains 800 µM vancomycin in borate buffer, the second (ii) 800 µM Gibbs reagent 
dissolved in methanol mixed with borate buffer, and the third (iii) is a mixture of the first 
and the second showing the novel brightly purple coloured end product, which is 
hereafter called vanGibbs. The final concentrations in the mixture (iii) were 571 µM 
Gibbs reagent and 1710 µM vancomycin. The colour change occurs immediately after 
mixing the Gibbs and the vancomycin together.  
 
The corresponding UV/vis absorbance spectra are drawn in figures 6.05 B and C. It has to 
be highlighted that all absorbance spectra were measured from 200 to 1100 nm. This 
will not be necessary in the final bench top device, since the vanGibbs molecule has its 
maximal absorbance in the visible region. However, full spectra were captured for 
quality and evaporation control, which was previously described in the materials and 
methods subsection 6.2.3.1. Furthermore, full spectra allowed additional study of the 
vancomycin peak at 281 nm.  
 
The absorbance spectrum of vancomycin in borate buffer (i) appears transparent to the 
human eye. This observation agrees with the spectrum, which does not showing 
distinctive features above 350 nm that corresponds to the visible range. Additionally at 
the vancomycin maximal absorbance wavelength (      = 281 nm) an elevation is 
apparent but not a clear distinctive peak. Furthermore, it seems as if at around 300 nm 
an additional peak may occur. These observations may be due to the high pH paired 
with a very high vancomycin concentration which is likely to result in a shadowing effect 
(see chapter 5.1.1.2). A theoretical calculation according to the Beer-Lambert-Bouguer 
law results in an expected absorbance of about 4.75 AU, which is a too large absorbance 
value to be measured with the spectrometer and supports the previous assumptions. 
The absorbance characteristic of vancomycin and its molar absorptivity will be further 
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discussed later in this chapter. Between 900 and 1100 nm the characteristics peak of 
borate buffer and water respectively is visible as previously presented in figure 6.04.  
 
The spectrum of the Gibbs reagent (ii) shows high absorbances between 380 and 
500 nm with two shoulders at about 415 and 460 nm. They are followed by decreasing 
absorbance values that are saturating after 800 nm at about 0.2 absorbance unit [AU] 
until the characteristic peaks of methanol mixed with water or borate buffer starts just 
before 900 nm. This UV/vis spectrum corresponds with Gibbs’ yellow or brownish 
appearance. Its colour changes from initially faint yellow in neutral pH to yellow or 
brownish in alkaline pH. This colour change is associated with the formation of its 
reactive species, quinoneimine which is hereafter designated as ‘activated Gibbs’.  
 
Lastly, the spectrum of the brightly purple coloured product of Gibbs reagent coupled to 
vancomycin (iii) shows a distinctive bimodal peak from 500 to 620 nm with a maximum 
at around 589 nm, which is the yellow region of the visible spectra and therefore 
appears purple/violet to the human eye (see figure 5.03 and table 5.01). This observed 
wavelength of 589 nm is close to maximal absorbance wavelength (    ) of the product 
of the Gibbs reagent coupled to propofol, which absorbs the strongest at 595 nm. This 
wavelength is in the orange region and consequently appears blue to the human eye, 
which is very similar to DCPIP with a maximal absorbance wavelength (    ) of 605 nm 
(see chapter 5.3.1 and figure 5.09).  
 
This experiment provided the first direct evidence of a successful coupling of Gibbs 
reagent to vancomycin and the yield of a novel product – vanGibbs – with a        and 
corresponding colour that suggests an indophenolic motif as hypothetically proposed in 
figure 6.01. Additional experiments on the stability of this novel product showed a 
0.6 ± 0.1 % difference in absorbance at      after a period of 12 hours. The error 
corresponds to the standard deviation calculated from three independent experiments 
(n = 3). 
 
To further study the coupling reaction and to understand the fairly complicated UV/vis 
spectra, concentration series were measured and the reaction stoichiometry was 
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studied. 800 µM of vancomycin dissolved borate buffer was gradually added to 571 µM 
of Gibbs reagent dissolved in methanol. Corresponding absorbance spectra were 
captured. Figure 6.06 A shows some of these absorbance spectra and figure B is a zoom 
in on the characteristic peak of the novel vanGibbs molecule. It has to be highlighted 
that the final vancomycin concentration ranged from 114 to 1713 µM which is several 
orders of magnitude higher than the therapeutic range (4 - 28 µM).  
 
The spectrum with the highest absorbance at vanGibbs’        appeared to be the 
reaction of 571 µM Gibbs with 457 µM of vancomycin shown in violet in figure 6.06 A 
and B. These concentrations correspond to a molar equivalent of 0.8 vancomycin to 
1 equivalent of Gibbs reagent, which is good agreement with expectations based on the 
hypothesis of the Gibbs coupling to the position 6 of vancomycin’s 7th residue (see 
figure 6.01).  
 
To further investigate the stoichiometry of the coupling reaction, four wavelengths 
according to their distinctive features in the absorbance spectrum were chosen as 
illustrated in figure 6.06 A. These wavelengths are 281 nm (dark gray line), 452 nm (dark 
yellow line), 589 nm (purple line) and 475 nm (blue line). Figure 6.06 C plots the 
absorbances of these wavelengths against the concentration ratios of vancomycin over 
Gibbs reagent. All absorbances are adjusted to the changing Gibbs concentration due to 
the gradual addition of vancomycin and subsequently subtracted from the Gibbs reagent 
only absorbances.  
 
It is expected that the difference in absorbance values for the reaction product, 
vanGibbs (589 nm), is increasing simultaneously with the increase in starting material. 
This increase is expected until Gibbs reagent is depleted and then the absorbance values 
should saturate. Since a 1:1 reaction is expected this saturation should start at ratio 1. 
Additionally, a doubling of the value from 0.2 to 0.4 and from 0.4 to 0.8 is expected.  
 
On the other hand, two scenarios could be possible for the vancomycin      (281 nm). 
Firstly, it could show exactly the opposite behaviour to the vanGibbs wavelength. This 
would indicate that the Gibbs reagent is coupling to the chromophore responsible for 
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vancomycin’s absorbance at 281 nm and extending this chromophore so that it is 
absorbing at 589 nm. Or secondly, the absorbance values for 281 nm could increase in a 
linear manner irrespective of the vanGibbs concentration, which would support that the 
Gibbs reagent is coupling to another position at the vancomycin molecule. As evident in 
figure 6.06 C, the latter scenario is fulfilled.  
 
The absorbance around 452 nm was associated to the activated Gibbs reagents. 
Therefore, due to the adjustment these absorbances should stay around zero and not 
change upon different concentrations ratios. The same should be true for 975 nm, which 
is the characteristic peak of the solvent system, and therefore was influenced by the 
adjustment as well. The absorbance values in figure 6.06 C are in good agreement with 
all expectations.  
 
In conclusion, this data set shows that the peak at 589 nm corresponds to the formation 
of the new coupling product and that the reaction stoichiometry seems to be around 1:1 
vancomycin:Gibbs reagent. Furthermore, the results are suggesting that Gibbs reagent is 
not coupling to vancomycin’s chromophore responsible for the absorbance at 281 nm.  
 
Since the solvent system was changing constantly from sample to sample, no molar 
absorptivities were calculated so far. Due to the overlap of absorbances, the influence of 
Gibbs reagent absorbance upon the vanGibbs absorbance has to be studied firstly in 
order to be able to calculate the molar absorptivity of vanGibbs. It has to especially be 
evaluated whether these two absorbances at the vanGibbs   are additive, overlaying or 
even interfering with each other (see chapter 5.1.1.2). However, as the molar 
absorptivity is strongly influenced by the molecule’s environment including solvents and 
pH, the molar absorptivity will be calculated as soon as the optimal reaction conditions 
are established.  
 
The next objectives presented in the following subsection (6.3.2) are coupling and 
consequently detection in vancomycin’s clinical range (4 – 28 µM) and the test whether 
there may be a possibility to circumvent a specific extraction protocol. 
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 Figure 6.05: First vancomycin 
labelling with Gibbs reagent.  
A) Photographs of the quartz glass 
cuvettes with the two starting 
materials and the end product of the 
vancomycin Gibbs reaction. i) 800 µM 
vancomycin in borate buffer, 
ii) 800 µM Gibbs reagent dissolved in 
methanol mixed with borate buffer, 
and iii) 1713 µM vancomycin reacted 
with 571 µM Gibbs reagent in borate 
buffer.  
B) UV/vis absorbance spectra of the 
three cuvettes shown in image A. The 
absorbance spectrum of vancomycin 
in borate buffer (i) appears 
transparent to the human eye. This 
observation agrees with the spectrum, 
which does not showing distinctive 
features above 350 nm. Additionally 
at the vancomycin maximal 
absorbance wavelength (281 nm) an 
elevation is apparent but not a clear 
distinctive peak. This may be due to 
the basic pH and the large 
concentration of vancomycin in the 
sample. The spectrum of the Gibbs 
reagent (ii) shows high absorbances 
between 380 and 500 nm with two 
shoulders at about 415 and 460 nm. 
They are followed by decreasing 
absorbance values that are saturating 
after 800 nm at about 0.2 AU until the 
characteristic peaks of methanol 
mixed with water or borate buffer 
starts just before 900 nm. This UV/vis 
spectrum corresponds with Gibbs’ 
yellow or brownish appearance. 
Lastly, the magenta spectrum is the 
product Gibbs reagent (ii) coupled to 
vancomycin (ii) and is hereafter called 
vanGibbs (iii). 
C) Enlarged region from figure B. The 
vanGibbs spectrum shows a distinctive 
bimodal peak from 500 to 620 nm 
with a maximum at around 589 nm, 
which is indicated with a purple line. 
This maximal absorbance wavelength 
is in the yellow region of the visible 
spectra and therefore appears 
purple/violet to the human eye.  
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Figure 6.06: Vancomycin monitoring 
at high concentration and 
stoichiometric analysis. 
A) Absorbance spectra overlay of 
several high vancomycin 
concentrations after the labelling 
reaction with Gibbs reagent 
including vertical lines that indicate 
the four wavelengths chosen for 
subsequent stoichiometric analysis. 
The vertical dark grey line marks the 
wavelength 281 nm, which is 
expected to be the  max of 
vancomycin. The dark yellow line 
indicates 452 nm, which seems to be 
associated with the Gibbs reagent. 
The purple lines is at 589 nm the 
 max of the new coupling product 
vanGibbs. Lastly the blue line 
highlights the wavelength 975 nm, 
which is within the region of the 
solvent system characteristic peaks. 
B) Enlarged region from figure A. 
The spectrum with the highest 
absorbance at vanGibbs’    appeared 
to be the reaction of 571 µM Gibbs 
with 457 µM of vancomycin shown 
in violet, which corresponds to a 
vancomycin over Gibbs 
concentration ratio of 0.8. 
C) Stoichiometric analysis of the 
four chosen wavelengths against 
the concentration ratios of 
vancomycin to Gibbs reagent. All 
absorbances are adjusted to the 
changing Gibbs concentration due to 
the continuous addition of 
vancomycin and subsequently 
subtracted from the Gibbs reagent 
only absorbances, which were taken 
from the dark yellow spectrum in 
figure A and B. The x-axis 
corresponds to the vancomycin over 
Gibbs concentration ratios.  This 
data set proves that the peak at 
589 nm corresponds to the 
formation of the new coupling 
product and that the reaction 
stoichiometry seems to be around 
1:1 vancomycin:Gibbs reagent.  
 
```  `
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6.3.2 Detection in Clinical Range and Preliminary Serum Studies 
Building on the successful coupling of Gibbs reagent to vancomycin at high 
concentrations (114 – 1713 µM) in buffer, this chapter presents the first coupling and 
detection of vancomycin via Gibbs reagent in vancomycin’s clinical range (4 - 28 µM) 
followed by time dependent and preliminary serum studies. 
 
For this first set of experiments at vancomyin’s clinical range, the same experimental 
procedure as for the experiments with high concentrations was chosen. Hence a specific 
volume of vancomycin in borate buffer (571 µM) was gradually added to Gibbs reagent 
in methanol (571 µM). This stepwise addition resulted in increasing vancomycin and 
decreasing Gibbs concentrations, which can nicely be observed in figure 6.07 A. It 
presents an overlay of selected absolute absorbance spectra of the described 
experimental procedure including the two starting materials, Gibbs reagent (571 µM) 
shown in dark yellow and the vancomycin (571 µM) in dark grey. All absorbances were 
normalised to a constant volume. The vertical line depicts the      (589 nm) of the 
novel coupling product vanGibbs. The spectral region from 200 until 500 nm is 
comparable to figure 6.06 A and the vanGibbs peaks from about 525 until 625 nm are as 
expected much smaller. The decrease in Gibbs concentration resulting from the gradual 
addition of vancomycin can be observed. Concerning this matter, it is also evident that 
two spectra seem to behave slightly unexpected in comparison to the remaining spectra. 
The spectrum of ‘567 µM Gibbs + 6.8 µM van’ shown in dark red colour seems a bit too 
high in absorbance, whilst the magenta coloured spectrum of ‘570 µM Gibbs + 
2.3 µM van’ on the other hand seems a bit too low. This may be due to the fact that this 
experimental procedure hinders a complete mixing of the buffer with the methanol. This 
hindrance was the reason that the experimental procedure was changed for the 
following experiments. Furthermore, since this set of experiments was performed to 
only check the feasibility of vancomycin detection at clinical concentrations via the 
Gibbs reagent coupling, the sample size was kept to a minimum (n = 1).  
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Figure 6.07 B illustrates an enlarged section of figure A. Additionally the absorbances 
were adjusted to a constant Gibbs concentration. As evident, the characteristic vanGibbs 
peak is hardly visible below a vancomycin concentration of 11.3 µM and the spectra are 
hardly distinguishable from the reference spectrum with solely Gibbs reagent. 
Nevertheless a steady absorbance increase at the      of vanGibbs (589 nm) can be 
observed according to the increasing vancomycin concentrations. The graph 
figure 6.07 C plots the absolute absorbances at 589 nm in purple against the 
corresponding vancomycin concentrations. The blue box indicates the vancomycin’s 
therapeutic window spanning from 4 to 28 µM. The dependency of concentrations and 
absorbances seems almost linear with an approaching saturation at the top end of the 
therapeutic window. The magenta data points reflect the differential absorbances at 
589 nm derived by subtraction of the Gibbs only absorbance (shown on the left of the 
graph in dark yellow) from all vanGibbs absorbances. This subtraction is only legitimate 
if the absorbances of Gibbs and vanGibbs at 589 nm are additive, which at this point of 
the thesis was just an assumption and will further be evaluated and discussed.  
 
The next objective was to study the time dependency of the coupling reaction because 
so far all presented spectra were captured almost directly after addition of vancomycin. 
Therefore, the concentration of vancomycin was chosen slightly above the upper limit of 
the clinical range at 30 µM and the Gibbs reagent’s concentration was kept at 571 µM. 
Figure 6.08 A shows an overlay of several absorbance spectra from the two 
aforementioned compounds obtained at different time points after mixing. As usual, the 
vertical line marks the      of vanGibbs. The previously established procedure for 
obtaining presumably only the absorbance for the vanGibbs molecule via subtraction 
was used again. Figure 6.08 B illustrates this procedure. The purple spectrum labelled 
with an a) is the reaction of 571 µM Gibbs reagent in methanol with 30 µM vancomycin 
in borate buffer. The dark yellow spectrum labelled with a b) is from 571 µM Gibbs 
reagent in methanol mixed with borate buffer. Hence the only difference between a) 
and b) was that a) had 30 µM vancomycin in the borate buffer and b) not. The magenta 
spectrum is the differential spectrum obtained as the subtraction of spectrum b) from 
a). The enlarged image in the top right corner depicts the vanGibbs wavelength area of 
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the differential spectrum. It can be observed that the shape of the vanGibbs peak seems 
different and not bimodal as in previous experiments. This observation will be further 
investigated in this chapter. Figure 6.08 C plots the differential absorbances at 589 nm 
against various time points after sample preparation. The data points in magenta are 
take from spectra in which vancomycin was dissolved in borate buffer. The depicted 
error bars correspond to standard deviations calculated from three independent 
experiments (n = 3). Immediately after mixing, a significant increase in absorbance to 
about 0.155 AU could be observed. After approximately four minutes the system seems 
to stabilise.  
 
Comparable experiments have been performed in 10 % serum, which corresponds to 
10 % BSA added to borate buffer. The difference in absorbance of the spectra with 
vancomycin and without vancomycin at a wavelength of 589 nm plotted versus time can 
is shown in violet in figure 6.08 C. These data points are obtained by only one 
experiment (n = 1) and consequently no error could be calculated. It can be observed 
that the differential absorbance signal is dropping from around 0.155 AU to 0.045 AU. 
Additionally, the stabilisation seems to take insignificantly longer. According to 
literature, the proportion of vancomycin bound to serum proteins can vary significantly 
between 10 – 82 % with 55 % often quoted as the mean fraction bound (Sun, Maderazo, 
and Krusell 1993; Butterfield et al. 2011; Cantú et al. 1990; Ackerman et al. 1988; Zokufa 
et al. 1989; Rodvold et al. 1988; Kitzis and Goldstein 2006; Shin et al. 1992; Shin et al. 
1991; Zeitlinger et al. 2011). Although in this set of experiments only 10 % BSA was 
added to the borate buffer, the decrease in signal is about 70 %. Hence this absorbance 
decrease cannot be explained solely with binding of vancomycin to serum proteins and 
may arise due to further interference with the coupling reaction or with the optical read 
out method. 
 
Conclusively, the first aim of this colourimetric detection to monitor vancomycin by 
specific labelling with Gibbs reagent could be successfully demonstrated. The newly 
formed compound seems to have its maximal absorbance wavelength (      at 589 nm 
and a molar absorptivity (       ) of around 7200 ± 300 M
-1 cm-1 in a mixture of borate 
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buffer and methanol at a pH of approximately 10. Furthermore, this novel coupling 
reaction allows accurate detection at the upper limit of vancomycin’s therapeutic 
window within four minutes. However, the finding that only 10% BSA in buffer reduces 
the absorbance signal by 70 % is clear evidence that an extraction protocol cannot be 
circumvented. Therefore the following chapter (6.3.3) presents the development of an 
extraction protocol from foetal bovine serum.  
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Figure 6.07: Therapeutic 
vancomycin monitoring at clinical 
concentrations. 
A) Some absorbance spectra of 
vancomycin in clinical 
concentrations labelled with 
Gibbs reagent. Overlay of some 
spectra for which a certain volume 
of vancomycin in borate buffer 
(571 µM) was gradually added to 
Gibbs reagent in methanol 
(571 µM). These additions resulted 
in increasing vancomycin and 
decreasing Gibbs concentrations. 
All absorbances are normalised to 
have the same constant volume. 
The vertical line depicts the      
(589 nm) of the novel coupling 
product vanGibbs. The spectrum of 
‘567 µM Gibbs + 6.8 µM van’ 
shown in dark red seems a bit too 
high in absorbance, whilst the 
magenta coloured one of ‘570 µM 
Gibbs + 2.3 µM van’ on the other 
hand seems slightly low. 
B) Enlarged section of figure A. 
The absorbances are additionally 
adjusted to the gradual change in 
Gibbs reagent concentration. It can 
be observed that characteristic 
vanGibbs peak is hardly visible 
below a concentration of 11.3 µM 
vancomycin. 
C) Relationship between 
concentration and absorbance. 
The absolute (shown in purple) 
and differential (in magenta) 
absorbances are plotted against 
the corresponding vancomycin 
concentrations. The blue box 
indicates vancomycin’s therapeutic 
window (4 - 28 µM). The 
differences were obtained by 
subtracting the Gibbs value (in 
dark yellow) from the absolute 
absorbances. The dependency of 
concentrations and absorbances 
seems almost linear. The data 
points are obtained by one set of 
experiment (n = 1) and hence no 
error could be calculated.   
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Figure 6.08: Time dependency studies 
of the Gibbs reagent coupling 
reaction and first serum trials.  
A) Time dependency of this novel 
coupling reaction. Overlay of several 
absorbance spectra of Gibbs reagent 
(571 µM) reacted with vancomycin 
(30 µM) at different time points after 
preparation. Again the vertical purple 
line marks the      of vanGibbs. 
B) Absolute and differential spectra 
of Gibbs reagent with and without 
vancomycin 20 minutes after sample 
preparation. The purple spectrum (a) 
shows 571 µM of Gibbs reagent 
reacted with 30 µM of vancomycin. 
The dark yellow spectrum (b) is 
obtained from 571 µM Gibbs reagent 
in methanol mixed with borate buffer. 
Hence the Gibbs reagent is in exactly 
the same conditions as the reaction 
demands. Therefore the only 
difference between a) and b) is the 
presence and absence respectively of 
vancomycin. The enlarged image in 
the top right corner depicts the 
wavelength area of the new product 
vanGibbs. It can be observed that the 
shape of the vanGibbs peak seems not 
bimodal as in previous experiments. 
C) Time dependency of absorbance 
differences in borate buffer and 10 % 
pseudo-serum. Differential 
absorbances at 589 nm of 30 µM of 
vancomycin labelled with Gibbs 
reagent are plotted against various 
time points after sample preparation. 
The magenta data points are taken 
from spectra in which vancomycin was 
dissolved in borate buffer. Whilst the 
violet data points are from spectra in 
which vancomycin was dissolved in 
borate buffer with 10 % BSA, herein 
called 10 % pseudo serum. The error 
bars for the measurements in borate 
buffer indicate the standard deviation 
derived from three independent 
experiments (n = 3). One set only 
(n = 1) was performed in 10 % pseudo-
serum and consequently no error 
calculation could be performed.  
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6.3.3 Extraction Protocol Development from Foetal Bovine Serum 
The finding that only 10% BSA in buffer could reduce the absorbance signal by 70 %, 
highlighted the need for specific extraction protocol for whole blood. Although this 
necessitates an extra step, the extraction process also aims to reduce the complexity of 
the sample, by removing some or ideally all of the interfering species. The extraction 
process can also be designed to pre-concentrate the substance of interest thereby 
increasing the diagnostic window which may be beneficial for very low drug 
concentrations. It can therefore improve the specificity and sensitivity of drug 
quantification.  
 
For the purpose of the initial investigation, foetal bovine serum (FBS) was chosen as a 
biological matrix, and served as a useful development stepping stone to whole human 
serum (WHS). Historically, FBS has been widely used as a substitute for WHS in cell 
culture media (Tateishi et al. 2008; Freshney 2005; Gospodarowicz and Moran 1976). 
Additionally, Sphere Medical has used it during the development process of the Pelorus 
device. Therefore, it seemed a reasonable choice at the outset of this investigation.  
 
The starting point in relation to the extraction set-up was chosen in accordance with 
Sphere Medical’s existing bench top device for the anaesthetic propofol. By mimicking 
some aspects of Sphere’s current methodology implemented in their commercially 
available Pelours device, there was greater scope for reducing the required time for a 
vancomycin-focussed device to reach the market. The Pelorus device uses solid phase 
extraction (SPE) (Pettigrew, Laitenberger, and Liu 2012). Although it might not be the 
most optimal type for the extraction of vancomycin, this SPE cartridge will be the 
starting point. As described in more detail in chapter 6.2.2.3 and figure 6.03, reversed 
phase SPE separates analytes based upon their polarity. Its stationary phase retains 
analytes by hydrophobic interactions, hydrogen- and π-π bonding which results in 
stronger retention of aromatic and polar analytes in contrast to conventional reversed 
phases such as C8 and C18.   
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However being optimised for propofol extraction, the extraction protocol has to be 
significantly modified. Propofol, as a small hydrophobic molecule, has a greater capacity 
for extraction in organic solvents such as acetonitrile. On the contrary, vancomycin, due 
to its polarity, is almost insoluble in pure organic solvents including methanol, ethanol, 
acetone and acetonitrile.  
 
The procedure during the development process was as follows. The Gibbs labelling 
reaction mentioned previously (see chapter 6.3.1 and 6.3.2) has been used to detect the 
presence of vancomycin in the different washing and elution stages. Additionally, to 
account for possible unspecific coupling of the Gibbs reagent to numerous components 
present in serum, including proteins, hormones, antibodies, antigens, electrolytes and 
any exogenous substances, a reference preparation was treated the same way as serum 
spiked with vancomycin. Correspondingly, they were run in parallel through the SPE 
cartridge and labelled with Gibbs reagent. The UV/vis spectra of the reference 
preparations were subtracted from the sample spectra. It has to be emphasised that 
such a reference subtraction will not be possible in the actual bench top device. 
Therefore the procedure has to be optimised in such a manner that means subtraction is 
not required anymore.  
 
This chapter describes the development process of the extraction protocol with major 
milestones listed below.  
 
i) The first objective was to indentify a suitable solvent, an eluent, which disrupts the 
interaction between the compound of interest and the stationary phase of the SPE 
cartridge. Additionally this eluent must be different from the washing stages with 
which the unwanted components and interferents will be washed away prior to 
elution. Since it was previously found that borate buffer is not a requirement for the 
success of the coupling reaction and vancomycin can be dissolved in DI water while 
Gibbs is dissolved in methanol, various ratios of methanol to DI water were tested 
first. This approach was chosen on the grounds that no additional unknown 
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substance will be added to the system. As presented in figure 6.09, it was found that 
the most optimal mixing ratio is 1/3 water + 2/3 methanol.  
 
However, before moving to the next objective, it had to be demonstrated that this 
solvent mixture allows detection in the clinical range in a comparable matter as 
previously described in chapter 6.3.2 and figure 6.07. Figure 6.10 presents the results 
from one set of experiments showing that this new mixture allows detection slightly 
below and in the therapeutic window of vancomycin. Since these experiments were 
performed prior to finalising the elution protocol, the sample size was kept to a 
minimum (n = 1). Consequently neither error calculations nor statistical analysis 
could be conducted. The Gibbs concentration used at this stage was 13.3 mM whilst 
the addition of 0.4 M sodium hydroxide in DI water was used to reach the necessary 
high pH. These conditions gave the highest absorbances in previous experiments and 
will be further optimised after the ideal elution protocol has been established.  
 
Furthermore due to this concentration series, the molar absorptivity of vanGibbs 
could be roughly estimated again. This estimation would reveal changes according to 
the different Gibbs reagent ratio and the environmental alterations including slight 
adjustment in solvent mixture and pH as well as the omission of borate buffer. 
Figure 6.10 C depicts the differential absorbances obtained from the six different 
vancomycin concentrations. The linear fit through these data points forced to 
intercept zero resulted in a slope of 0.0073 ± 0.0003 and an adjusted R2 of 0.991. 
Therefore, the molar absorptivity of vanGibbs (       ) in a mixture of  
1/3 DI water + 2/3 methanol at a pH of approximately 13 seems to be around  
7300 ± 300 M-1 cm-1. This is in excellent agreement with the previously obtained 
        (6.3.2), which was 7200 ± 300 M
-1 cm-1 in a mix of borate buffer and MeOH at 
a pH of approximately 10.  
 
To assess whether a similar behaviour can also be observed if only vancomycin gets 
dissolved in this optimised eluent, comparable experiments were performed. If 
vancomycin would show an enhanced absorbance comparable to vanGibbs in these 
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conditions and if additionally the extraction protocol would be successful, then the 
use of a Gibbs coupling for absorbance ‘enhancement’ becomes futile. Figure 6.11 
presents that vancomycin dissolved in 1/3 DI water + 2/3 methanol shows a 
bathochromic shift of its maximal absorbance wavelength to 304 nm (    ). The 
molar absorptivity at this shifted wavelength (       ) does not change significantly 
and is with 5600 ± 100 M-1 cm-1 very comparable to vancomycin in water 
(        = 5943 M
-1 cm-1) (“The Merck Index Online - Vancomycin” 2013).  
 
Therefore, it can be concluded that molar absorptivity of vanGibbs 
(        = 7300 ± 300 M
-1 cm-1) remains also in the chosen eluent advantageous 
above vancomycin’s molar absorptivity (        = 5600 ± 100 M
-1 cm-1). Furthermore, 
due to the Gibbs reagent coupling the optical detection requires only a visible light 
source and will work in disposable plastic cuvettes. 
 
ii) The second objective was to develop a protocol that removes unwanted components 
and interferents from the serum. These could interfere with the quantification of 
vancomycin and lead to a masking or elevating effect on the detection signal. These 
components are endogenous, arising from the patient’s blood or are exogenous 
substances such as drugs and microorganisms, which may be present as well. The 
serum used herein lacks only the proteins involved in blood clotting and contains all 
usual electrolytes, antigens, antibodies, and hormones.  
 
Since the conditioning of the SPE stationary phase is performed with methanol followed 
by two DI water equilibration steps, DI water as a washing step was studied first. This 
starting point also considered the avoidance of a premature transition from DI water to 
methanol. This transition would inevitably lead to achieving the previously developed 
optimal elution solvent mixture within the stationary phase that consequently could 
result in partly or full loss of vancomycin. Another important aspect which had to be 
considered is that the same labelling reaction and the identical SPE cartridge are used 
for the anaesthetic propofol. Furthermore, both propofol and vancomycin are used in 
the critical care setting. Therefore, propofol contamination of a blood sample containing 
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vancomycin seems likely. Consequently at least one organic washing step had to be 
added to extraction protocol. However, as indicated above, this could have a significant 
effect on the protocol. Whilst changing from a watery washing step to an organic 
solvent, the previously developed elution condition for vancomycin will inevitably be 
achieved within the cartridge. This could lead to a potential loss of vancomycin. One way 
of circumventing this problem would be the application of a vacuum to the SPE 
cartridge, which will allow the stationary phase to dry out prior to the solvent change. 
Such a vacuum system will be integrated into a bench top device regardless, as a 
method for reducing the time the extraction protocol takes. However, such a system 
was not convenient in the laboratory environment. A lack of automation along with the 
need to have access to the SPE cartridges for application of solvent meant a continuous 
vacuum could not be maintained. Furthermore the sample loss from repeated venting 
and vacuum reapplication was too large. Therefore all experiments with gravity-assisted 
flow despite the increased time requirement. Several experiments with organic washing 
steps prior to the vancomycin elution were performed. For sample preparations with 
29 µM vancomycin, absorbances of 0.18 ± 0.03 AU were obtained. The stated error 
corresponds to the standard deviation of three independent experiments (n = 3). These 
absorbances were in excellent agreement with the results presented in figure 6.09 B, 
where absorbances of 0.19 ± 0.01 AU were found without any washing steps. 
Additionally, they were also in very good agreement with the, according to the         
(figure 6.10 C), calculated absorbance values of 0.21 ± 0.01 AU . Therefore, it was 
assumed that the level of loss due to gravity-assisted flow was negligible despite the 
unattainability of full dryness of the stationary phase. 
 
iii) The last objective was to increase the sensitivity of quantification via pre-
concentration of the analyte of interest in the eluate. This was achieved by reducing 
the volume of the eluent. It has been found that 0.5 ml of eluent with an initial 
sample volume of 1 ml is sufficient to wet the entire polymer within the cartridge and 
elute the vancomycin out without significant loss (figure 6.12).  
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In conclusion, the following extraction protocol was found to be ideal for eluting 29 µM 
vancomycin out of FBS (table 6.01):  
 
Table 6.01: 
Developed solid phase extraction protocol for the Strata-X 33 u 
Polymeric Reversed Phase SPE cartridges from Phenomenex®: 
A) Conditioning of the SPE cartridge 
 1 ml methanol 
B) Equilibration of the SPE cartridge 
 1 ml DI water 
 1 ml DI water 
 
C) Extraction 
#1 1 ml sample (spiked or reference/control) 
#2 1 ml DI water (washing stage) 
#3 1 ml DI water (washing stage) 
#4 1 m methanol (washing stage) 
#5 1 m methanol (washing stage) 
#6 0.5 ml 1/3 DI water + 2/3 methanol (eluent) 
 
 
 
 
Figure 6.13 presents this developed extraction protocol. The typical absorbance spectra 
of all Gibbs labelled stages from a reference preparation with only FBS (figure 6.13 A), a 
sample preparation additionally containing 29 µM vancomycin (figure 6.13 B) and the 
difference of the two aforementioned spectra (figure 6.13 C) are illustrated. The most 
distinctive feature of all differential spectra is the characteristic vanGibbs peak at 
589 nm of the elute (#6) shown in magenta in figure C. It indicates the presence of the 
highest quantity of vanGibbs, which therefore leads to the conclusion that this must be 
the stage in which vancomycin is mainly eluted out of the column. Figure D plots the 
mean absorbance values at 589 nm of all extraction stages including their standard 
deviations derived from three independent experiments (n = 3). The lack of overlap in 
error bars suggests that there is significant difference between stage #6 and the other 
stages (#1 - #5). This statement is supported by statistical analyses, which are discussed 
and presented in the appendix A.3. A one-way analysis of variance (ANOVA) and post 
hoc Fisher’s least significant difference (LSD) test were performed. The one-way ANOVA 
showed significance at the 5 % level. For the post hoc Fisher’s LSD test a pairwise 
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comparison for each stage of the SPE was performed aiming to determine which data 
groups are significantly different from each other. It was found that the peak 
absorbance signal from the eluent (#6) is significantly different from all other stages of 
the SPE. However, the second organic washing step (#5) showed significant difference 
from the sample (#1) and from the first DI water wash (#2). This may indicate that some 
vancomycin extraction is occurring in this wash as well. Nevertheless, it is not significant 
from any of the other stages. Moreover, it is has to be emphasised that only a small 
number of repeats (n = 3) have been performed and further experiments would lead to 
a strengthening of the statistical analysis. 
 
Furthermore, the recovery of vancomycin from the SPE cartridge could be roughly 
calculated using the established linear function and the corresponding molar 
absorptivity of vanGibbs (        = 7300 ± 300 M
-1 cm-1) in figure 6.10 C. This rough 
estimation results in vancomycin concentration of 12 ± 2 µM in the elute (#6). For the 
case of a total concentration of 29 µM vancomycin, this corresponds to a recovery from 
the SPE cartridge of 41 ± 10 %. The errors were derived from the standard deviation 
from three independent experiments (n = 3) and from the error of the linear fit. 
However, it has to be highlighted that this is only a rough estimation with only n = 1 
sample size on the linear function side and n = 3 on the SPE cartridge side and 
consequently the error is fairly large. More accurate recoveries will be calculated later 
on in the development process.   
 
The two photographs in figure 6.13 E show the reference (top) and the spiked (bottom) 
SPE stages after reaction with the Gibbs reagent. The characteristic magenta colour of 
the elute (#6) suggests the presence of vanGibbs. The yellow and orange colour of the 
wash stages (#2 - #4) indicates the presence of activated Gibbs reagent, more 
specifically the reactive quinoneimine intermediary. The darker orange for both samples 
(#1) lead to the assumption that Gibbs coupling (to unspecified components) is 
occurring within the collected sample of both the reference and the spiked preparation. 
This finding is strongly supported by the observed the peak around 600 nm in figures A 
and B. Since this peak is present in the reference and in the spiked FBS, it can be 
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assumed that it must be something within the serum and was not associated with 
vancomycin. However, since the subtraction of these peaks results in negative values 
resembling the shape of the peak (figure C), one may assume that the quantity of 
whatever it binds to is higher in the reference than in the sample preparation. Looking 
ahead, this is already a first indication of vancomycin’s protein binding and may lead to 
first presumption that SPE is not disrupting the drug-serum binding. Further studies of 
the effect of serum binding with special focus on free and bound drug monitoring will be 
discussed in subsection 6.3.6. These peaks at around 600 nm in figures A and B 
decreases drastically in the first DI water wash (#2) and almost vanishes in the second 
one (#3). This corresponds of course with the differential signal in figure C, where an 
increase is observed. This finding and the consequent assumption that Gibbs reagent 
may couple to the serum proteins was supported by two observations.  
 
i) The first observation was the decrease in viscosity observed during pipetting. During 
the initial transfer of the reference (pure serum) and sample (serum spiked with 
vancomycin) preparations into the SPE cartridges, it was observed that they were 
highly viscous. The subsequently collected sample (#1) and the first DI water wash 
(#2) were less and less viscous. And ultimately the viscosity of the second DI water 
wash resembled pure water. 
 
ii) The second observation was made after UV/vis measurements. If the cuvettes were 
initially cleaned with acetone, instead of water, aggregates, which stuck to the inside 
of the cuvettes and made them less transparent, were noticed. This effect decreased 
from the collected sample (#1), to the first wash (#2) and ultimately was not 
observable in the second DI water wash (#3). Hence, it was assumed that the serum 
proteins become denatured in the presence of acetone.   
 
It could not definitively be distinguished to what Gibbs binds to, but since proteins 
consist of phenolic-motif containing tyrosines, it was assumed that Gibbs may bind to 
them. This assumption was studied and it was found that Gibbs does indeed bind to 
serum proteins, specifically to serum albumins. Figure 6.14 presents one sets of 
experiments (n = 1) with various concentrations of two different types (BSA and HSA) of 
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serum albumins reacted with Gibbs reagent. Figure A and B depict BSA in concentrations 
of 75 µM, 150 µM, 300 µM and 600 µM dissolved in DI water reacting with 13.3 mM of 
Gibbs reagent. Figure C and D present exactly the same for HSA.  
 
Figure 6.14 E presents the relationships between the differential absorbances at 589 nm 
for both serum types and the serum albumin concentrations. As previously mentioned in 
subsection 6.1, BSA has 17 tyrosines, while its counterpart in humans, HSA, has 
19 tyrosines (Sułkowska 2002; Zeitlinger et al. 2011). It can be observed that for both 
serum protein types the spectra of 600 µM are almost indistinguishable from 300 µM, 
which supports the assumption that Gibbs reagent couples to the tyrosines. 17 and 
19 tyrosines for each albumin molecule in a concentration of 600 µM BSA and HSA 
respectively would in the most ideal case demand at least 10.2 and 11.4 mM Gibbs 
reagent. However, previous experiments have suggested that an excess of Gibbs reagent 
seems to be required for a complete coupling reaction. Additionally it can be observed 
that the absorbances for HSA are slightly higher than for BSA. This would again support 
the theory of coupling to tyrosines as HSA has two tyrosines more than its bovine 
counterpart. However, since the sample size is kept minimal (n = 1), these are only 
assumptions and the enlarged absorbances may be within errors. Hence further 
experiments would lead to a strengthening of these findings and would allow statistical 
analysis. However, at this point in the development process, this study was not deemed 
relevant for the colourimetric detection assay since serum proteins can be removed with 
the just described extraction protocol. Therefore, the ability of Gibb reagent to couple to 
serum albumin was not further investigated. Nevertheless, it may be something to 
consider for a future multi analyte therapeutic monitoring device as serum albumin 
levels are useful prognostic marker and indicator for nutritional status, inflammation 
and protein deficit especially in ICU patients (Don and Kaysen 2004; Seve et al. 2006; Lai 
et al. 2011; Pan et al. 2013). 
 
In conclusion, the proof that Gibbs is binding to serum albumin and absorbs at the same 
wavelength as vanGibbs adds another compelling argument for the necessity of an 
extraction protocol that removes serum proteins prior to the coupling reaction. 
CHAPTER 6: COLOURIMETRIC DETECTION OF VANCOMYCIN 
  
 
 
158 
 
Additionally it shows that two DI water washes seem sufficient to elute the majority of 
the proteins out of the SPE cartridge. Consequently, this will increase the sensitivity and 
specificity of the subsequent colourimetric quantification of vancomycin, which is crucial 
since in a bench top device no reference spectra can be obtained. The inter-patient 
serum levels may vary drastically, which would have lead to falsely elevated absorbance 
signals limiting the ability to accurately detect the vancomycin concentration within the 
patient’s blood.  
 
  
CHAPTER 6: COLOURIMETRIC DETECTION OF VANCOMYCIN 
  
 
 
159 
 
200 300 400 500 600 700 800 900 1000 1100
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
i)
 13300 M Gibbs with 
         29 M vancomycin (a)
 13300 M Gibbs (b)
 Differential (a - b)
A
b
s
o
lu
te
 a
n
d
 D
if
fe
re
n
ti
a
l 
A
b
s
o
rb
a
n
c
e
 [
A
U
]
Wavelength [nm]
A Sample and reference preparation collected after SPE
-0.05
0.00
0.05
0.10
0.15
0.20
s
a
m
p
le
 
D
if
fe
re
n
ti
a
l 
a
b
s
o
rb
a
n
c
e
 a
t 
5
8
9
 n
m
 [
A
U
]
 
ii)
-0.05
0.00
0.05
0.10
0.15
0.20
1
/3
 w
a
te
r 
+
2
/3
 M
e
O
H 
 
 
M
e
O
H
1
/2
 w
a
te
r 
+
1
/2
 M
e
O
H
2
/3
 w
a
te
r 
+
1
/3
 M
e
O
H
D
if
fe
re
n
ti
a
l 
a
b
s
o
rb
a
n
c
e
 a
t 
5
8
9
 n
m
 [
A
U
]
w
a
te
r
B Test of suitable solvent to elute vancomycin from SPE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.09: Test of a suitable solvent to elute vancomycin from the SPE cartridge. A) Sample 
and reference preparation collected after the passage through SPE cartridges. i) The dark yellow 
(a) and purple (b) curves represent 13300 µM Gibbs at high pH without and with 29 µM 
vancomycin respectively. The magenta spectrum (a – b) represents the difference of the two 
aforementioned spectra. The purple line highlights vanGibbs’     . ii) The column chart 
represents the average of the differential absorbances at 589 nm. The error bar corresponds to 
the range obtained by two independent experiments (n = 2). The negativity suggests that not 
only vancomycin is retained in the SPE cartridge but presumably also a serum constituent. This 
observation will be further studied later on in this thesis. B) After the sample and reference 
collection, several solvents were individually tested via the same procedure presented in the 
figures A. As the coupling reaction already consists of water and methanol, various mixtures of 
these solvents were tested first. Again the error bar corresponds to the range obtained by two 
independent experiments (n = 2). It is evident that the most vanGibbs is eluted from the SPE 
cartridge with a ratio of 1/3 water + 2/3 methanol.   
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Figure 6.10: Test of potential 
eluent for the ability to optically 
detect therapeutic vancomycin 
concentrations via Gibbs reagent 
coupling. 
A) Absorbance spectra of 
different vancomycin 
concentrations reacted with 
Gibbs in the solvent mixture 
chosen to be the eluent. Overlay 
of several absorbance spectra of 
Gibbs reagent (13.3 mM) reacted 
with therapeutic vancomycin 
concentration spanning from 1.2 
to 21.5 µM. As usual the Gibbs 
reference spectrum is shown in 
dark yellow and the vertical line 
highlights the      of vanGibbs. 
The enlarged image in the top 
right corner depicts the 
wavelength region where the 
vanGibbs peaks are occurring. 
B) Enlarged overlay of the 
differential spectra obtained by 
subtraction of the Gibbs 
reference spectrum from the 
various spectra presented in 
figure A. The vanGibbs peak is 
evident down to a concentration 
of 2.4 µM vancomycin. However, 
as previously seen in figure 6.08 B, 
the peaks do not show an explicit 
bimodal shape as observed in the 
initial experiments (see 6.3.1).     
C) Relationship between 
concentration and absorbance. 
The differential absorbances are 
plotted against their 
corresponding vancomycin 
concentrations. The blue box 
indicates vancomycin’s 
therapeutic window (4 – 28 µM). 
The slope of the linear fit gives an 
estimate for vanGibbs’         in 
this potential eluent. It equals to 
7300 ± 300 M-1 cm-1. Since this 
experiment was performed prior 
to finalising the elution protocol, 
the sample size was kept to a 
minimum (n = 1). 
s 
s 
 
 
 
x 
fit: y = a + b*x 
a: 0 
b: 0.0073 ± 0.0003 
R2: 0.991 
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Figure 6.11: Assessment of pure 
vancomycin absorbances in the 
solvent mixture planned to be 
the eluent for the SPE. 
A) Absorbance spectra of 
therapeutic vancomycin 
concentrations dissolved in the 
eluent. The absorbance spectrum 
of 29 µM vancomycin in borate 
buffer (bb) at neutral pH (n pH) 
has the      around 281 nm 
highlighted with a dark grey line. 
The other six therapeutic 
concentrations were dissolved in 
the eluent with an alkaline pH (a 
pH). The      in the eluent 
shifted to 304 nm marked with a 
grey line.  
B) Enlarged section of figure A. 
Besides the two peaks discussed 
above it can also be observed 
that the region between 220 to 
280 nm seems to be changing 
even though the ratios of 
methanol and water were kept 
constant. Hence it must be 
associated with vancomycin. This 
observation will not be further 
investigated in this thesis.   
C) Relationship between 
concentration and absorbance. 
The absorbances at 304 nm are 
plotted against their 
corresponding vancomycin 
concentrations. The blue box 
indicates van’s therapeutic 
window (4 – 28 µM). The slope of 
the linear fit gives an estimate for 
vancomycin’s        in this 
potential eluent. It equals to 
5600 ± 100 M-1 cm-1, which is in 
very good agreement with 
vancomycin in water at neutral 
pH (        =  
5943 M-1 cm-1) (“The Merck Index 
Online - Vancomycin” 2013). 
Since the objective of this 
experiment was just a brief 
assessment, the sample size was 
kept to a minimum (n = 1).  
 
s 
  
fit: y = a + b*x 
a: 0 
b: 0.0056 ± 0.0001 
R2: 0.998 
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Figure 6.12: Feasibility test for the reduction of the eluent volume aiming to increase the 
sensitivity. A) Previously used eluent volume: 1 ml of 1/3 water + 2/3 MeOH. i) As usual the 
dark yellow (a) and purple (b) curves represent 13300 µM Gibbs without and with 29 µM 
vancomycin, whilst the magenta spectrum (a – b) represents their difference. The dashed box 
highlights the image part, which is enlarged on the right hand side. ii) The column chart 
represents the average of the differential absorbances at vanGibbs’     . The error bar 
corresponds to the calculated standard deviation from three independent experiments (n = 3). It 
has to be highlighted that these absorbances are a bit lower than previous experiments. The grey 
dashed box including error bar indicates the expected differential absorbance if half of the eluent 
volume is used. B) Halved eluent volume: 0.5 ml. i) The figure presents the absorbance spectra 
obtained by elution with half of the previous eluent volume. The curves are displayed in a similar 
manner to figure A i. The expected increase in absorbance at 589 nm can be observed. ii) After 
the first elution with 0.5 ml, a second elution with the same volume was performed to check 
whether the first elution was sufficient to wet the entire polymer within the cartridge and to 
elute the vancomycin from it. It was found that the differential absorbance at 589 nm was almost 
zero. iii) The column chart designates the average differential absorbance at 589 nm for the first 
elution (part 1/2) shown in figure B i and the second one (part 2/2) shown in figure B ii. Again the 
error bars are the calculated standard deviations from three independent experiments (n = 3). It 
can be observed that the error bar of the expected absorbance, indicated in grey dashed lines, is 
overlapping the error bar of the absorbance of part 1/2. Furthermore, the error bar of the 
absorbance of part 2/2 intercepts zero. Therefore, it was concluded that 0.5 ml eluent is 
sufficient to elute vancomycin from the SPE cartridge without significant loss.  
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Figure 6.13: Developed extraction protocol 
of vancomycin from foetal bovine serum. 
A) Typical UV/vis absorbance spectra for 
solid phase extraction of the reference FBS 
without vancomycin. #1 sample refers to the 
first collected fraction from the SPE cartridge 
after adding the reference FBS into the 
cartridge. Four washes and the final elute 
were subsequently collected. 350 µl of each 
solution was transferred to an Eppendorf 
along with 50 µl of 13.3 mM Gibbs reagent in 
methanol followed by 40 µl of 0.4 M sodium 
hydroxide in water. 350 µl of the combined 
solution was then transferred to a cuvette for 
spectroscopic analysis. The purple line at 
589 nm denotes the      of vanGibbs. 
B) Typical UV/vis spectra for SPE of spiked 
FBS with vancomycin. The same procedure as 
described for graph A was applied to FBS 
spiked with 29 µM vancomycin. 
C) Differential UV/vis spectra. The 
corresponding absorbance values from spiked 
and reference FBS were subtracted from each 
other. D) Average differential absorbances at 
589 nm of all extraction stages and 
appropriate errors. The elute (#6) has the 
highest absorbance indicating the highest 
vanGibbs quantity. The errors are standard 
deviation of the averages (n = 3). The lack of 
overlap in error bars suggests that the elute is 
significantly different from the other stages, 
which is supported by statistical analysis 
presented in the appendix on page 350. 
E) Photography of the reference and the 
spiked SPE stages after reaction with the 
Gibbs reagent. The characteristic magenta 
colour of the elute proves the presence of 
vanGibbs. The darker orange for both 
samples may suggest Gibbs coupling to serum 
proteins. Yellow and orange corresponds to 
the presence of activated Gibbs reagent.  
#1 sample       #2 wash          #3 wash          #4 wash        #5 wash       #6 elute 
CHAPTER 6: COLOURIMETRIC DETECTION OF VANCOMYCIN 
  
 
 
164 
 
200 300 400 500 600 700 800 900 1000 1100
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
13.3 mM Gibbs
"    "     "  +  75 µM BSA
"    "     "  + 150 µM BSA
"    "     "  + 300 µM BSA
"    "     "  + 600 µM BSA
A
b
s
o
rb
a
n
c
e
 [
A
U
]
Wavelength [nm]
A BSA reacting with Gibbs reagent 
500 520 540 560 580 600 620 640
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
460 480 500 520 540 560 580 600 620 640 660 680 700
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
13.3 mM Gibbs  + 600 µM BSA
"       "      " + 300 µM BSA
"       "      " + 150 µM BSA
"       "      " +   75 µM BSA
D
if
fe
re
n
ti
a
l 
a
b
s
o
rb
a
n
c
e
 [
A
U
]
Wavelength [nm]
B BSA reacting with Gibbs reagent 
200 300 400 500 600 700 800 900 1000 1100
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
13.3 mM Gibbs
"    "    "  +   75 µM HSA
"    "    "  + 150 µM HSA
"    "    "  + 300 µM HSA
"    "    "  + 600 µM HSA
A
b
s
o
rb
a
n
c
e
 [
A
U
]
Wavelength [nm]
C HSA reacting with Gibbs reagent 
500 520 540 560 580 600 620 640
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
460 480 500 520 540 560 580 600 620 640 660 680 700
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
13.3 mM Gibbs + 600 µM HSA
"      "      " + 300 µM HSA
"      "      " + 150 µM HSA
"      "      " +   75 µM HSA
D
if
fe
re
n
ti
a
l 
a
b
s
o
rb
a
n
c
e
 [
A
U
]
Wavelength [nm]
D HSA reacting with Gibbs reagent 
0 100 200 300 400 500 600
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
 
 
 HSA
 BSA
D
if
fe
re
n
ti
a
l 
a
b
s
o
rb
a
n
c
e
 a
t 
5
8
9
 n
m
 [
A
U
]
Serum albumin concentration [M]
E Serum albumins reacting with Gibbs reagent 
s s  
s  s  
s  
Figure 6.14: Two types of serum albumins 
reacting with Gibbs reagent. A) Overlay of 
spectra from different BSA concentrations 
reacted with 13.3 mM Gibbs reagent. It can be 
observed that spectrum of 600 µM BSA with 
Gibbs is almost indistinguishable from 300 µM 
BSA with Gibbs, which supports the assumption 
that these high serum albumin concentrations 
are depleting the Gibbs reagent. This in turn 
may be caused due to binding to tyrosines, 
from which one BSA molecule contains 17. 
B) Differential spectra of the spectra in  
i 
figure A. The maximal absorbance wavelength of Gibbs-BSA is very similar to the vanGibbs, which 
is indicated with a purple line at 589 nm, whilst however the shape of the peak differs. C) Overlay 
of spectra from different HSA concentrations reacted with 13.3 mM Gibbs reagent. In general, 
the observations are very comparable to figure A. D) Differential spectra of the preceding 
spectra in figure C. Again the general observations are similar to figure A and B with the 
exception that the absorbances are slightly higher. These enlarged absorbances may be caused 
by the two additional tyrosines present in the HSA molecule. However, since the sample size is 
kept minimal (n = 1), these are only assumptions and the enlarged absorbances may be within 
errors. Hence further experiments would lead to a strengthening of these findings and would 
allow statistical analysis. E) Relationships between concentration and absorbance. All 
differential absorbances at 589 nm are plotted against the corresponding serum albumin 
concentrations. The previous made observation with saturation of the absorbance value can be 
observed. Furthermore, the slight enlarged absorbances of HSA can be seen as well.    
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6.3.4 Optimisation of the Gibbs Reagent Concentration 
Some studies suggested that an excess of 25 – 30 times Gibbs reagent versus phenolic 
compound leads to a high maximal absorbance of the coupling product (Svobodová et 
al. 1978; Svobodová et al. 1977), which was also supported by previous experiments 
discussed in the previous subsection (6.3.3). Furthermore, since rapidity is a key 
requirement for a sensor quantifying drug concentrations, a fast reaction is sought after. 
Consequently based on the fundamental principle of Le Châtelier (Atkins and De Paula 
2002), an excess of Gibbs reagent seems favourable.  
 
However, since Gibbs reagent coupled to vancomycin has to best of our knowledge 
never been done before, there are no existing studies that suggest a similar ratio would 
have the same effect with vancomycin coupling. Moreover, there has to be a balance 
between a sufficient reaction velocity and a high sensitivity via enlarging the absorbance 
intensity whilst keeping the background absorbance of un-reacted Gibbs as low as 
possible, so that it is not masking and falsely elevated the absorbance of vanGibbs. As 
visible in figures 6.06 and 6.08, high concentrations of activated Gibbs is absorbing 
between 350 and 500 nm with two distinctive shoulders at around 410 and 460 nm. 
Afterwards the absorbance decreases until it reaches zero at approximately 800 nm. 
Since the maximal absorbance of vanGibbs (     = 589 nm) lies within the decreasing 
slope, achieving the best balance of the arguments stated above is crucial. Furthermore, 
no subtraction of a reference spectrum for each individual sample is possible in a bench 
top device, which adds another compelling argument to a sensitive and accurate 
quantification of vancomycin.  
 
Therefore this subsection presents the optimisation of the Gibbs reagent concentration 
for two different vancomycin concentrations. The concentrations were chosen at the 
two extremes, namely below (1 µM) and beyond (36.5 µM) the therapeutic window of 
vancomycin (4 – 28 µM). The objective was to estimate whether an optimum can be 
found suitable for the whole therapeutic window. The concentration beyond was 
chosen a bit larger in anticipation that the administrated vancomycin concentration will 
follow its trend of constant increase observed in the past (Kitzis and Goldstein 2006; 
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Rybak et al. 2009a; Holmes, Johnson, and Howden 2012; Pumerantz et al. 2011; Estes 
and Derendorf 2010; Chen 2013; Calfee 2012; van Hal, Lodise, and Paterson 2012; 
Muppidi et al. 2012; Dhand and Sakoulas 2012).  
 
To not induce further potential for errors and for time efficiency reason, these 
experiments were performed in absence of a biological matrix in the elute mixture 
(1/3 DI water + 2/3 methanol). The optimisation was achieved via a several stages 
procedure, where in the Gibbs reagent concentrations systematically got narrowed to 
the most optimal concentration ratio range. The procedure was that the corresponding 
activated Gibbs reagent without vancomycin served as reference and was subtracted 
from the spectrum with vancomycin. 
 
Figures 6.15 A presents some selected spectra of the described optimisation procedure 
for 36.5 µM of vancomycin. The spectra are averages from the three spectra, which 
were taken per individual Gibbs reagent concentration with and without vancomycin 
respectively. Spectra with solely Gibbs reagent are drawn with open spheres, whilst 
spectra with vancomycin are drawn with solid spheres. The ‘av’ in brackets indicates 
that all drawn spectra are average spectra from three independent experiments (n = 3).  
 
It can be observed that especially the first shoulder of all Gibbs spectra around 400 nm 
decreases upon reaction with vancomycin. Hence this decrease could theoretically also 
be used to quantify the vancomycin concentration in the sample and seems to only 
depend on one compound namely the Gibbs reagent. However, since this decrease only 
ranged from -0.01 to -0.04 AU for a concentration slightly above vancomycin’s 
therapeutic window, this approach was deemed irrelevant for this thesis and 
consequently was not further studied. To investigate the contribution of the Gibbs 
reagent absorbance to the vanGibbs absorbance at 589 nm, the molar absorptivity of 
Gibbs reagent was calculated and was found to be 28 ± 1 M-1 cm-1 (      ). Therefore it 
can be concluded that its contribution to the vanGibbs absorbance is almost negligible. 
Nevertheless for exact quantification of vancomycin in a sample, the absorbance value 
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obtained after subtracting the absorbance of the used Gibbs reagent should be adjusted 
for the decrease in Gibbs reagent upon reaction with vancomycin.  
 
Figure 6.15 B plots the differential spectra of figure A. The absorbances at 589 nm from 
these differential spectra were plotted against the Gibbs reagent concentration. A bell 
shaped distribution of these data points was expected. On the left hand side of the bell 
shaped curve, where the Gibbs concentrations are low, the limiting factor of the 
reaction is the Gibbs concentration itself. Therefore, the concentration of the end 
product is correspondingly low resulting in a low absorbance at the vanGibbs maximal 
absorbance wavelength. Thus the predominant species is un-reacted vancomycin. Whilst 
increasing the Gibbs concentration, the reaction equilibrium shifts towards 
quantitatively more end product leading in increased absorbances at 589 nm. Heading 
over the maximum towards the right hand site of the bell shaped curve, where the 
Gibbs concentrations are high, the limiting factor are the quantities of vancomycin 
present in the sample. The resulting differential absorbances for the end product are 
low again, due to masking by the background absorbance of the activated Gibbs 
molecules. If no masking effect would occur, then a curve would be expected that 
saturates comparable in shape to figure 6.06 E. The saturation signal of this curve would 
correspond to approximately the initial vancomycin concentration.  
 
Figure 6.15 C shows the absorbances at 589 nm for the two different vancomycin 
concentrations, 1 and 36.5 µM, drawn against a common logarithmic (base 10) scale of 
the various Gibbs reagent concentrations. The expected bell curve is visible for 36.5 µM 
but not for 1 µM of vancomycin. Consequently, 1 µM of vancomycin was deemed as 
tentative detection limit. The associated error bars are the standard deviations derived 
from three independent experiments (n=3). Within the region with the largest 
absorbances, the error bars are overlapping, which suggests that these concentrations 
are not distinct from each other.  
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The large variation also makes it hard to fit a model to the data points. To get an 
estimate where the maximum lies regarding to its  -value, the weighted arithmetic 
mean was calculated using the following formula (Hackbusch, Schwarz, and Zeidler 
1996): 
 
     
       
 
   
    
 
   
  6.2 
 
  represents the individual values of absorbances in the figure 6.15 C. In the numerator, 
all   and  -values are multiplied and subsequently summed, and in the denominator 
only  -values are summed. Consequently, the calculated means of the maxima were 
6200 ± 900 µM Gibbs reagent for 36.5 µM vancomycin and 162 ± 1 µM Gibbs reagent for 
1 µM vancomycin. The errors correspond to the standard deviations derived from three 
independent sets of experiments. The maxima are indicated in the figure 6.15 C with a 
dotted line and a box for the high concentration of vancomycin and with a dotted line 
for the low concentration respectively. However, it has to be emphasised that these 
calculated maxima are strongly dependent on the chosen concentrations and should 
therefore only be considered as an estimation.   
 
Since the goal is to quantify unknown vancomycin concentrations in patient’s blood 
samples, it is important to initially find a Gibbs concentration range, which preferably 
would be ideal for the whole therapeutic range. Therefore, the Gibbs concentrations 
were divided by the corresponding concentrations of vancomycin (1 and 36.5 µM) 
resulting in a multiple of the Gibbs reagent excess in relation to the antibiotic 
concentration. It was found that range between 100 to 150 times excess of Gibbs 
reagent seems to be ideal for both extreme concentrations. Additionally the differential 
absorbances of both concentrations seem to stay constant within excesses of up to 
300 – 320 times and do not result in more than 13 % absorbances signal loss. This 
observation correlates with the calculated means of the maxima, which are 162 ± 1 µM 
for 1 µM and 170 ± 24 µM for 36.5 µM of vancomycin and consequently higher than 100 
to 150 times excess.  
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To summarise, it was found that the range between 100 and 150 times excess results in 
highest absorbances. In comparison to previous study quoted at the beginning of this 
subsection (Svobodová et al. 1978), this optimised excess is roughly five to six fold larger 
than that observed in the original Gibbs reagent reaction. This may be another 
indication that several Gibbs reagent molecules are coupling to one vancomycin 
equivalent. This will further be discussed in the next chapter 7. Moreover, it was found 
that from an excess of 100 to presumably 300 – 320 times the decrease in absorbance 
signal is not more than 13 %.  
 
Therefore, even though it cannot be unambiguously proven, it will be assumed for 
further experiments that in this optimised Gibbs region the Gibbs reagent and the 
vanGibbs absorbances are additive at vanGibbs’s       allowing subtraction of the Gibbs 
only absorbance from the total absorbance. However on the other hand, finding that 
such a large excess is the most optimal for the assay’s sensitivity is less ideal for a TDM 
device, which must detect the whole therapeutic window of vancomycin. Since for 
quantification of an unknown vancomycin concentration within 4 to 28 µM, the optimal 
Gibbs reagent concentration lays somewhere between about 400 to 4350 µM. This 
challenge will further be discussed in the conclusion and outlook chapter (6.4). 
 
To visualise the impact of this Gibbs reagent optimisation, figure 6.16 shows a 
comparison with the same vancomycin concentration. Graph A shows 29 µM of 
vancomycin reacted with the previously used Gibbs concentration, namely 13300 µM, 
which corresponds to an almost 460 times excess. Graph B shows the same antibiotic 
concentration reacted with a concentration within the optimal range according to the 
used vancomycin of 29 µM. The chosen concentration was 3625 µM of Gibbs reagent, 
which for 29 µM vancomycin correspond to an excess of 125 times. It can be observed, 
that the background absorbance of Gibbs reagent decreased significantly and 
consequently the characteristic bimodal shape of the vanGibbs peak in the raw as well 
as in the differential spectrum is more apparent and distinct. The absorbance at the 
vanGibbs wavelength (     = 589 nm) increased from 0.18 ± 0.02 AU for a Gibbs 
concentration of 13300 µM to 0.26 ± 0.01 AU for 3625 µM. The errors correspond to 
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standard deviations derived from three independent experiments (n = 3). Hence it can 
be concluded that this optimised Gibbs concentration corresponds to a 45 % increase, 
which should directly translate into the same increase of assay sensitivity.  
 
Therefore the next step was to test this expected sensitivity increase with a series in 
which therapeutic vancomycin concentrations (1.2 – 29 µM) in the eluent mixture were 
labelled with the novel optimised Gibbs reagent (3625 µM) in methanol. The 
experimental procedure was exactly the same as described in the previous 
chapter (6.3.3) for figure 6.10. The molar absorptivity (       ) there was found to be 
around 7300 ± 300 M-1 cm-1. Figure 6.17 A and B show the characteristic bimodal 
vanGibbs peak for all spectra except for the spectra with only 1.2 µM vancomycin. This 
suggests that this concentration may lie beyond the current detection limit. 
Furthermore, it can be observed that the vanGibbs’      has broadened with a slight 
hypsochromic shift. It seems to span from about 582 to 589 nm. This broadening will be 
kept under surveillance in the course of this thesis.  
 
Figure 6.17 C plots the differential absorbances against their corresponding vancomycin 
concentrations. The slope of the linear fit gives an estimate for the novel vanGibbs’ 
        with this optimised Gibbs reagent concentration, which was found to be 
9100 ± 200 M-1 cm-1. This is an increase of about 25 % in comparison to  
7300 ± 300 M-1 cm-1. It has to be highlighted that since this experiment was performed 
to only test the expected increase, the sample size was kept to a minimum (n = 1).  
 
Therefore with this enlarged molar absorptivity and consequently increased sensitivity 
all further experiments presented hereafter will be performed with a Gibbs reagent 
concentration of 3625 µM. Furthermore, all differential absorbances will be multiplied 
by a factor 1.00267 to account for the decrease in Gibbs reagent upon coupling to 
vancomycin. 
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Figure 6.15: Optimisation of the 
Gibbs reagent concentration in 
relation to two constant 
vancomycin concentrations.  
A) Selected spectra of different 
Gibbs concentrations only and 
the corresponding spectra where 
this Gibbs concentration had 
reacted with 36.5 µM 
vancomycin. The ‘av’ in brackets 
indicates that all spectra were 
average spectra obtained from 
three independent experiments 
(n = 3).  
B) Differential spectra of the 
preceding spectra in figure A. 
The inset on the right shows a 
zoom of the region framed with a 
dashed box. It can be observed 
that 3625 µM (~ 100 x excess) 
and 5075 µM (~ 140 x excess) of 
Gibbs seem to result in highest 
absorbances.  
C) Differential absorbances with 
errors at 589 nm of two 
vancomycin concentrations 
labelled with various different 
Gibbs concentrations versus this 
corresponding concentrations in 
logarithmic scale. The errors are 
standard deviations derived from 
three independent experiments. 
The expected bell curve is visible 
for 36.5 µM of vancomycin but 
not for 1 µM. This may be an 
indication that 1 µM is the 
detection limit, which will be 
further investigated hereafter. 
The dotted lines in the 
corresponding colours indicate 
the weighted arithmetic mean of 
the maxima of the 
concentrations, which are 
6219 ± 873 µM for 36.5 µM and 
162 ± 1 µM for 1 µM of 
vancomycin. The surrounding 
grey box of the maximum for 
36.5 µM of vancomycin 
corresponds to its error, which 
was again the standard deviation 
derived from three sets. 
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Figure 6.16: Comparison between the previously used Gibbs reagent concentration and the 
optimised concentration in reaction with 29 µM vancomycin. A) 29 µM vancomycin labelled 
with the previously used Gibbs reagent concentration of 13300 µM, which corresponds to 
almost 460 x excess. The dark yellow (labelled with an a) and purple (b) curves represent 
13300 µM Gibbs at high pH without and with vancomycin respectively. The magenta spectrum 
(a – b) represents the difference of the two aforementioned spectra. The dotted box indicates 
the section of the graph, which is enlarged in figure B. B) Enlarged section of figure A. The 
differential absorbance value at 589 nm was found to be 0.18 ± 0.02 AU. All errors correspond to 
standard deviations derived from three independent experiments (n = 3). As previously observed, 
the shape of the vanGibbs peak is not bimodal as in the initial experiments (see 6.3.1). B) 29 µM 
vancomycin labelled with a Gibbs reagent concentration within the optimal range for the 
corresponding vancomycin concentration, which was 3625 µM and that corresponds to an 
excess of 125 x. The colour coding is the same as in figures A and B. D) Enlarged section of 
figure C. The differential absorbance value at 589 nm was found to be 0.26 ± 0.01 AU, which is a 
45 % increase in comparison to the previously used Gibbs concentration. A similar increase is 
therefore expected for the colourimetric assay’s sensitivity (see figure 6.17). Furthermore, it can 
be observed that the shape of the vanGibbs peak is bimodal again as in the initial experiments in 
the first chapter. This leads to the assumption that large excess of Gibbs reagent may lead to a 
slightly different molecule or molecules than a smaller excess. This will be considered for the 
following experiments as well as the vanGibbs characterisation presented in chapter 7.  
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Figure 6.17: Test of expected 
sensitivity increase due to the 
optimised Gibbs reagent 
concentration.  
A) Absorbance spectra of different 
therapeutic vancomycin 
concentrations reacted with the 
optimised Gibbs concentration. 
Overlay of several absorbance 
spectra of 3625 µM Gibbs reagent 
reacted with vancomycin 
concentrations spanning from 1.2 
to 29 µM. The enlarged image in 
the top right corner depicts the 
region where the vanGibbs peak is 
occurring (     = 589 nm). 
B) Enlarged overlay of the 
differential spectra obtained by 
subtraction of the Gibbs reference 
spectrum from the various spectra 
presented in figure A. The 
characteristic bimodal vanGibbs 
peak is clearly visible in all spectra 
except in the spectrum of 1.2 µM. 
This suggests that this 
concentration lies beyond the 
current detection limit. Further, it 
seems that vanGibbs’      has 
broadened with a slight blueshift 
(hypsochromic). It ranges from 
about 582 to 589 nm, which will be 
kept under further surveillance. 
C) Relationship between 
concentration and absorbance. 
The differential absorbances are 
plotted against their 
corresponding vancomycin 
concentrations. The slope of the 
linear fit gives an estimate for 
vanGibbs’         with this 
optimised Gibbs reagent 
concentration. It equals to 
9100 ± 200 M-1 cm-1, which is an 
increase of about 25 % in 
comparison to 7300 ± 300 M-1 cm-1 
(figure 6.10 C). Since this 
experiment was performed to test 
the expected increase with the 
optimised Gibbs concentration, 
the sample size was kept to a 
minimum (n = 1).  
 
 
fit: y = a + b*x 
a: 0 
b: 0.0091 ± 0.0002 
R2: 0.998 
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6.3.5 Change from Foetal Bovine to Whole Human Serum  
After development of the extraction protocol (6.3.3) and optimisation of the Gibbs 
reagent ratio that lead in higher sensitivity (6.3.4dis), it was expected that changing from 
the foetal bovine serum (FBS) to whole human serum (WHS) is trivial and a matter of 
one set of experiments. But as evident in figure 6.18, this was not true and it seems that 
vancomycin partly change its elution condition according to serum type in which it is 
dissolved in.  
 
Figure 6.18 A shows an overlay of the differential UV/vis spectra for all SPE stages from 
FBS and subsequently labelling with the previously established optimised Gibbs reagent 
concentration of 3625 µM.  
 
Figure 6.18 B presents a comparable overlay but this time 29 µM vancomycin was 
dissolved in WHS as opposed to FBS. The differential spectra look fairly similar to 
figure A except of the first methanol wash (#4). The differential spectra of the first 
methanol wash (#4) shows also a vancomycin typical bimodal shaped peak slightly lower 
in absorbance than the peak from the elute (#6).  
 
Figure 6.18 C compares all average absorbances with the associated errors at the 
vanGibbs      (589 nm) for FBS and WHS. The stated errors correspond to standard 
deviations derived from three independent experiments (n = 3). The main difference 
between FBS and WHS is the extent of absorbance in the first methanol wash (#4), 
which is indicated with an arrow. This suggests vancomycin is additionally extracted 
from SPE carried out with WHS in the first methanol wash (#4).  
 
This suggestion is strongly supported by statistical tests, which can be found in the 
appendix A.4. The ANOVA and the post-hoc Fisher’s LSD tests of WHS showed that #4 
and #6 are significantly different from the all other SPE stages and therefore suggesting 
that vancomycin is mainly extracted at these two stages of SPE. However, the analysis 
for FBS was not statistically significant at the 95 % confidence level. This may be due the 
fairly high absorbance of the collected sample (#1).   
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For WHS, the average absorbance values at the vanGibbs maximal absorbance 
wavelength (     = 589 nm) are 0.178 ± 0.003 AU for #4 and 0.183 ± 0.015 AU for #6 
and consequently fairly similar. However, it has to be highlighted that the concentration 
of the compound of interest in both elutes (#6) is artificially doubled due to pre-
concentration achieved by halving the eluent volume (see subsection 6.3.3).  
 
Calculations with the previously estimated         = 9100 ± 200 M
-1 cm-1 (see 
subsection 6.3.4 and figure 6.17) gives a vancomycin content in the #6 for FBS of 
10 ± 2 µM, which corresponds to a recovery from the SPE cartridge of 34 ± 7 %. 
Furthermore, it seems as if #1 and #5 may also have a bit of vancomycin eluted out. 
However, it has to be highlighted that the associated errors are large. The corresponding 
concentrations are 6 ± 5 µM for #1 and 3 ± 2 µM for #5, which in total would give a 
concentration of 19 ± 9 µM vancomycin and a total recovery of 66 ± 31 %.  
 
On the other hand, concentration calculations for WHS yield in 20 ± 1 µM for #4 and 
10 ± 2 µM for #6, which added results in 30 ± 3 µM of total vancomycin concentration. 
This in turn gives a recovery of 102 ± 4 %, which cannot be true. Especially not in light of 
#3 and #5, which also show a slight vancomycin content of 3 ± 1 µM and 7 ± 2 µM 
respectively. An addition of all these vancomycin contents would render an even higher 
recovery of 138 ± 31 %. 
 
This finding suggests the hypothesis that one eluted species may be vancomycin bound 
to serum proteins and the other one free vancomycin. Therefore this falsely elevated 
recovery could be explained by the additional absorbance of the serum protein to which 
vancomycin is binding to. This is backed by previous findings (figure 6.14 in chapter 
6.3.3) showing that Gibbs reagent is binding to serum albumins and resulting UV/vis 
spectra show maximal absorbance at the vanGibbs     .  
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Moreover, this hypothesis is supported by the solvent difference between the two 
stages. The solvent for stage #4 is purely organic, whilst the solvent for #6 is an aqueous 
organic mixture, which demands a variation in the eluted species that changes this 
solvent preference.  
 
Nonetheless it can definitively be assumed that both eluted species are associated with 
vancomycin, since this is the only difference between the control and spiked serum 
samples. The investigation of this hypothesis of bound and free vancomycin will be 
discussed in the next subsection 6.3.6.  
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Figure 6.18: Comparison of 
elute compositions between 
FBS and WHS. Control and 
spiked with 29 µM vancomycin 
preparations of both serum 
types were used and 
subsequently subtracted. The 
vertical line denotes the      
(589 nm) of vanGibbs. 
A) Differential UV/vis spectra 
of all elute stages from FBS SPE 
and subsequently labelled with 
3625 µM Gibbs reagent. The 
strong absorbance at 589 nm of 
the elute (#6) indicates that the 
majority of vancomycin is 
present. This figure is 
comparable to figure 6.13 C 
which shows the same overlay 
with the previously used Gibbs 
concentration. B) Differential 
UV/vis spectra of all elute 
stages from WHS SPE and 
subsequent Gibbs coupling. 
Similarly bimodal shaped peaks 
are observed for the first 
methanol wash (#4) and the 
elute (#6). C) Average 
differential absorbances at 
589 nm of all extraction stages 
and appropriate errors. The 
main difference between FBS 
(purple) and WHS (magenta) is 
the extent of absorbance in the 
first methanol wash (#4) 
highlighted with an arrow. 
Statistical test showed that #4 
and #6 were each significantly 
different from the other stages 
(appendix A.4). Concentration 
calculations yielded in 
10 ± 2 μM vancomycin for #6 of 
FBS corresponding to a recovery 
of 34 ± 7 %. For WHS the 
concentrations were 20 ± 1 μM 
for #4 and 10 ± 2 μM for #6, 
which in addition results in a 
102 ± 4 % recovery. This large 
recovery lead to the hypothesis 
that either #4 or #6 may be 
protein bound vancomycin.  
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6.3.6 Effect of Serum Protein Binding on Vancomycin Detection 
As described in the prior subsection (6.3.5), whilst changing from FBS to WHS it became 
evident that vancomycin seems to change its elution conditions. In WHS it gets mainly 
eluted out in two stages, namely #4 and #6, as opposed to FBS in which its main fraction 
is detect in the eluent stage (#6). Furthermore, concentration and recovery calculations 
for WHS resulted in a more than 100 % recovery, which, amongst other indications, 
leads to the hypothesis that one eluted species may be vancomycin bound to serum 
proteins whilst the other one is free vancomycin. The bound vancomycin would 
therefore show an elevated absorbance value due to the additional absorbance of the 
protein, which may have been labelled with the Gibbs reagent as well.  
 
To test this hypothesis and to figure out which stage contains which species, a constant 
vancomycin concentration (29 µM) was dissolved in a series of different concentrations 
of serum albumins in DI water. The concentrations span from 0, 75, 150, 300 to 600 µM 
BSA and HSA respectively. Each concentration was run through a SPE cartridge. Both the 
first methanol wash (#4) and the final elute (1/3 water +2/3 methanol) (#6) were 
collected and labelled with Gibbs reagent. As usual for each concentration a control 
preparation without vancomycin was treated similarly to allow subsequent subtraction.  
 
Figure 6.19 summarises this one set experiment (n = 1) in four graphs. Graph A shows an 
overlay of the differential UV/vis spectra of the fourth SPE stage from five BSA 
concentrations plus FBS. Graph B presents the same as graph A but instead of BSA and 
FBS five HSA concentrations plus WHS are plotted. Graph C illustrates an overlay of the 
differential spectra of the final elute (#6) from five BSA concentrations and FBS, whilst 
the last graph (D) depicts the same as graph C but for five HSA concentrations and WHS. 
Generally, it can be noted that the graphs either show the characteristic bimodal 
vancomycin peak or basically no absorbance. Moreover, an either direct or a reverse 
dependency to the serum albumin concentrations can be observed.  
 
In figures 6.19 A and B the highest absorbance at 589 nm have the spectra coloured in 
blue, which are obtained by 29 µM vancomycin dissolved in water only. This is the first 
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evidence that the pure organic solvent of stage #4 disrupts the binding of free 
vancomycin to the stationary phase of the SPE cartridge resulting in its elution. Then 
with increasing amount of serum albumins, the absorbances are decreasing. This 
matches the expectation since the quantity of free vancomycin is decreasing with 
increasing amount of proteins to which the drug can bind to. Furthermore in figure B, it 
can be observed that WHS is behaving comparable to 600 µM HSA, which again is 
expected as this is the concentration of albumin present in whole serum. However, its 
counterpart, FBS in figure A does not show any absorbance, which allows the 
assumption that in FBS almost no free vancomycin is present.  
 
Then in the final elute (#6) graphs, C and D, the highest absorbance is measured for FBS 
and WHS respectively. Then the absorbances are decreasing from 600 µM, over 300 and 
150 µM, to 75 µM. Both samples in which vancomycin was dissolved in water only 
(coloured in blue) show no absorbance in graph D and a negligible one in graph C. It has 
to be highlighted that for both graphs, C and D, the absorbance and therefore also the 
concentration is artificially doubled due to final elution with half of the volume of the 
initial sample. Summarised all these findings are proof that the fourth stage (#4) 
includes the free vancomycin fraction and the sixth stage (#6) incorporates the bound 
fraction.  
 
Continuing from these findings, the next objective was to investigate whether and to 
which extent the serum proteins contribute to the absorbance at 589 nm of the bound 
fraction (#6). Firstly the vancomycin concentration in the free fraction could be directly 
calculated by execution of the Beer-Lambert-Bouguer law with the molar absorptivity 
        = 9100 ± 200 M
-1 cm-1 estimated in the penultimate subsection (6.3.4) and 
figure 6.17.  
 
Furthermore by calculating the vancomycin concentration from the two samples 
without protein (shown in blue in figures 6.19 A and B), the recovery of vancomycin 
from the SPE cartridge could be calculated. The recovery was found to be 95 ± 5 % 
(n = 2).   
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This was then taken into account for all further calculations with the assumption that 
the recovery is the same for the various samples as well as for the two extraction stages 
(#4 and #6). This assumption has not been tested.  
 
On the basis of these calculated free concentrations, the expected bound fraction could 
be estimated (see table 6.02). It was found that all absorbances from the samples with 
BSA and HSA including the two water samples measured in the final elute (#6) match 
this expectations. This suggests that neither BSA nor HSA are contributing significantly to 
the absorbance at 589 nm, which would have led to a larger absorbance than expected.  
 
For calculation of FBS and WHS, additionally data from the previous chapter (6.3.5 and 
figure 6.18) were taken with the aim to get a larger sample size (n = 4) and consequently 
more significant results. The measured absorbances for the bound fraction in FBS 
(graph C and figure 6.18 A shown in magenta labelled with ‘#6 elute’) did not meet the 
expected values. Since FBS has basically no measurable absorbance in the free fraction 
(graph A and figure 6.18 A shown in red denoted as ‘#4 wash’), a large absorbance 
matching a bound vancomycin concentration of about 28.5 µM was expected. Instead a 
similar absorbances to WHS (see graph C and figure 6.18 B) were measured.  
 
WHS, similar as observed in the previous chapter (6.3.5), shows a slightly higher 
absorbance than the expected value. The absorbances are about 9 ± 4 % too high, which 
corresponds to previous observations of more than 100 % recovery. It could be 
speculated that this enlarged absorbances may be due to binding to other proteins, such 
as for example alpha-1-acid glycoprotein which is also known to bind to vancomycin 
(Fournier, Medjoubi-N, and Porquet 2000; Zokufa et al. 1989; Dawidowicz, Kobielski, and 
Pieniadz 2008b; Sun, Maderazo, and Krusell 1993; Shin et al. 1991; Bohnert and Gan 
2013) or interaction to other serum constituents including antibodies, antigens and 
hormones.   
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Figure 6.20 graphically summarises all calculations made in this section and compares 
the percentages of the two fractions, free and bound. It has to be highlighted that these 
calculations were based on an initial recovery value obtained by only two independent 
experiments (n = 2). Hence further experiments would lead to a strengthening of this 
finding and statistical analysis could be performed.  
 
Nonetheless for further experiments and especially for the direct comparison with a 
gold standard TVM device presented in the last subsection (6.3.8) of these results and 
discussion section (6.3) the following findings will be used. The bound fraction in final 
elute obtained from a preparation with WHS should be corrected with factor of 
0.778 ± 0.004 to account for the enhanced absorbance presumably caused by protein 
absorbance. The general recovery from the SPE cartridge seems to be about 95 ± 5 %.  
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Figure 6.19: Effect of serum protein binding on vancomycin detection. 29 µM vancomycin was 
dissolved each individual serum albumin concentration plus FBS and HSA. A) Overlay of 
differential UV/vis spectra of the fourth SPE stage (#4) from five concentrations of BSA plus 
FBS. The different absorbances look reversely dependent on the protein concentration. The 
highest absorbance can be observed for the sample in which vancomycin was dissolved in water 
only. These two observations strongly suggest that the #4 stage includes the free vancomycin 
fraction. FBS seems to not incorporate much free vancomycin. B) Differential UV/vis spectra of 
the first methanol wash (#4) from five concentrations of HSA plus WHS. Generally, the 
observations are similar to figure A. Except that all absorbances are slightly higher suggesting 
more free vancomycin. Moreover, WHS absorbs between 600 and 300 µM. C) Differential UV/vis 
spectra of the final elute (#6) from five concentrations of BSA plus FBS. The differential 
absorbances show the opposite behaviour to figure A and B. They seem directly dependent on 
the serum protein concentrations. All these findings are clear evidence that the sixth stage 
includes the bound vancomycin fraction. The highest absorbance can be observed for FBS, whilst 
the lowest is for vancomycin in water. D) Differential UV/vis spectra of the final elute (#6) from 
five concentrations of HSA plus WHS. Again the observations are similar to figure C. Also the 
absorbance of WHS and FBS are highly comparable. It has to be highlighted that for both figures, 
C and D, the absorbance and therefore also the concentration is artificially doubled due to the 
final elution with half of the volume of the initial sample. Since these experiments had objective 
to test the hypothesis that one of these two stages contains the free and the other one the 
bound fraction, the samples size was kept to a minimum (n = 1). Continuing from these findings, 
table 6.02 and the following figure 6.20 are showing the percentages of the free and bound 
fractions. The objective is to investigate whether and to which extend serum proteins contribute 
to the absorbance at 589 nm of the final elute (#6).      
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        Table 6.02:  
29 µM 
vancomycin 
dissolved in... 
#4 stage 
[µM]*  
#4 stage 
[%]* 
#6 stage 
[%] 
expected*  
#6 stage 
[µM] 
expected* 
FBS 1 ± 1 2 ± 1 98 ± 1 29 ± 1 
600 µM BSA 10 ± 1 33 ± 2 67 ± 2 19 ± 1 
300 µM BSA 13± 1 43 ± 2 57 ± 2 16 ± 1 
150 µM BSA 14 ± 1 47 ± 2 53 ± 2 15 ± 1 
75 µM BSA 17 ± 1 60 ± 3  40 ± 3  12 ± 1 
0 µM BSA 29 (± 1) 100 (± 5) 0 (± 5) 0 (± 1) 
     
WHS 21 ± 1 71 ± 3 29 ± 3 8 ± 1 
600 µM HSA 16 ± 1 54 ± 3 46 ± 3 13 ± 1 
300 µM HSA 22 ± 1 76 ± 4 24 ± 4 7 ± 1 
150 µM HSA 23 ± 1 81 ± 4 19 ± 4 6 ± 1 
75 µM HSA 25 ± 1 85 ± 4  15 ± 4  4 ± 1 
0 µM HSA 29 (± 1) 100 (± 5) 0 (± 5) 0 (± 1) 
 
 
 
 
Figure 6.20: Detection of free and 
bound vancomycin in a single 
measurement. A) Percentages and 
the corresponding concentrations 
for the five concentrations of BSA 
plus FBS. The values for the final 
elute (#6) were initially calculated 
according to the measured free 
vancomycin. It was found that, 
except for FBS, all calculated values 
are matching the measured values. 
This allows the assumption that BSA 
is not significantly contributing to 
the absorbance of the sixth SPE 
stage. B) Percentages and the 
corresponding concentrations for 
the five concentrations of HSA plus 
WHS. The procedure was similar as 
described in figure A. It was found 
that, except for WHS, all calculated 
values are matching the measured 
values. This allows the assumption 
that also HSA is not significantly 
contributing to the absorbance. 
WHS in the sixth stage shows a 
larger absorbance than expected 
which may be due to presence of 
another protein or constituent of 
serum. For future experiments, a 
correction factor will be applied to 
account for this enlarged 
absorbance.  
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6.3.7 Selectivity Evaluation with a Subset of Interferents 
This subsection reports on the specificity studies with possible cross-contaminating 
agents such as propofol, tyrosine, dopamine and paracetamol. The objectives were to 
determine whether these interferents are eluted out together with the vancomycin, 
whether they will react with the Gibbs reagent and subsequently whether their coupling 
product with the indophenolic motif would absorb in the same region as vanGibbs. The 
aforementioned species were chosen based on their possible presence in patient’s 
blood and due to their chemical structure. As evident in figure 6.02 and 6.22, all of them 
have phenol moieties that render them potential candidates for a successful Gibbs 
coupling reaction. These four chosen species are most likely not all of the possible 
interfering species that can occur. Further specificity validation should be done. 
However, this lies beyond the scope of my thesis.  
 
High concentrations (600 µM) of interferents were dissolved in FBS and WHS and then 
run through SPE cartridges. The collected fractions were labelled with Gibbs reagent in 
an identical manner as before and analysed using UV/vis spectroscopy. High 
concentrations were used in order to not miss any coupling event. To match these high 
concentrations, the chosen Gibbs concentration for this study was 3625 µM, which is 
within the optimal range for high vancomycin concentrations. The amino acid, tyrosine, 
could not be dissolved in either FBS or WHS and consequently SPE could not be carried 
out. For all the other interferents, figure 6.21 shows the differential absorbance spectra 
of all collected fractions after Gibbs coupling reaction for FBS and WHS respectively. 
Results found for the two sera types were fairly consistent especially for propofol. It 
seems as if the first methanol wash (#4) is particularly effective at extracting the 
interferents from the stationary phase of the SPE cartridge.  
 
Figure 6.22 A and B summarises the absorbance values at 589 nm, which is the      of 
the vanGibbs, for each SPE fraction. Although this may not be the absorbance maximum 
of the interfering species, absorbance at this wavelength could result in false 
quantification of vancomycin. It becomes evident in the figure that the washing stages, 
especially the first methanol wash (#4), reduces the concentration of the studies 
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interfering species significantly. However as previously observed and discussed, the free 
fraction of vancomycin is present in the first methanol wash (#4) of extraction from 
WHS, which of course is the serum type of interest for a future bench top device.  
 
For the direct comparison with vancomycin, the absorbances of the interferents were 
adjusted according to their concentrations in patient’s blood. The concentrations were 
chosen to be at the higher end of the corresponding therapeutic range.  
 
 As mentioned in the preceding chapter (5.1.3.2), the clinically relevant 
concentrations for propofol are between 1 and 10 μg/ml, which corresponds to 5.6 –
 56.2 μM (Liu et al. 2012).  
 
 Circulating dopamine in humans occurs mainly as dopamine sulphate. The 
concentrations in plasma are highly depended on food intake. Typical dopamine 
sulphate concentrations before meals are in the region of 0.02 to 0.04 nM and raise 
after food intake up to 0.3 – 0.4 nM. However, after fasting overnight, they can 
increase up to 10 nM, which corresponds to 0.02 µg/ml of dopamine sulphate 
(Goldstein et al. 1999; Eisenhofer, Kopin, and Goldstein 2004). 
 
 The therapeutic level of paracetamol typically range from 10 to 20 µg/ml, which 
corresponds to 66 – 132 µM (Kost, Nguyen, and Tang 2000).  
 
Figures C and D show these adjusted absorbances according to corresponding 
concentrations occurring in patient’s blood. In both sera types the vancomycin shows 
clearly the highest absorbances in the eluent (6#) as well as in the first methanol wash 
(#4) for WHS. In the eluent (#6), no other interferents are absorbing significantly to 
interfere with the vancomycin quantification. In WHS, it seems that only propofol may 
pose a threat as possible interferents for the free vancomycin detection in the second 
wash (#4).  
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To conclude, for the monitoring of the bound fraction of vancomycin none of the tested 
interferents seems to pose a risk for significant interference of the antibiotic 
quantification. However for quantification of the free fraction, propofol is posing a 
possible threat of interference. Therefore, besides extended testing of other possible 
interferents, further optimisation of the extraction protocol is required. This is discussed 
further in the conclusion and outlook chapter (6.3.8), which emphasises the 
requirement for optimisation and presents some ideas about how this should be 
approached.  
 
Furthermore, as previously proposed in the materials and methods section (6.2.1.3), it 
has to be highlighted that these interferents could become the compound of interest in 
their own right (comparable to propofol and as opposed to vancomycin). This could lead 
to a foundation for the development of a multi-analyte therapeutic drug monitoring 
device.  
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Figure 6.21: SPE stages spectra of three possible interferents for selectivity evaluation. 
A) Differential spectra of all SPE stages for propofol extraction from FBS and WHS. The results 
for the two sera types are consistent. The propofol-Gibbs molecule is mainly appearing in the first 
methanol wash (#4) suggesting that the aqueous organic mixture (#6) is not ideal for propofol. 
B) Differential spectra for dopamine. The results vary between the two sera. FBS shows a fairly 
high absorbance in stage #4, whilst WHS shows absorbance in stage #1, #2 and #4. C) Differential 
spectra for paracetamol. In comparison to the other interferents, paracetamol has a relatively 
low absorbance across all stages. The second water wash (#3) produces a similar peak in both 
sera types. In the first stage of FBS paracetmol has a broad peak and on the contrary WHS shows 
a comparable peak but in the negative range. These observations may suggest that paracetamol 
interacts with a constituent of WHS and therefore retains in the stationary phase. On the other 
hand if it is dissolved in FBS, it seems to run through without interacting with the polymer.  
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Figure 6.22: Absorbances at 589 nm for each interferent and in direct comparison to 
vancomycin. A) All absorbances at 589 nm for all SPE stages of each interferent dissolved at 
high concentrations (600 µM) in FBS and WHS respectively. The lines between the data points 
were added to guide the eye. It can be observed the washing stages especially the first methanol 
wash (#4) reduces the interferent concentrations significantly. B) Absorbances adjustments are 
calculated to the top end of the therapeutic range of each interferent for direct comparison 
with vancomycin in FBS and WHS respectively. Generally, it can be observed that in both sera 
types vancomycin shows clearly the highest absorbances in the eluent (#6) in FBS and WHS, as 
well as in the first methanol wash (#4) in WHS. In the eluent (#6) of both serum types, no other 
interferent is absorbing significantly to interfere with the vancomycin quantification. In WHS, it 
seems that only propofol may pose a threat as possible interferents for the free vancomycin 
detection in the second wash (#4).   
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6.3.8 Direct Comparison with a Gold Standard Technique 
The very last experiment presented in this chapter is the direct comparison with a gold 
standard technique. The chosen gold standard technique is the homogenous enzyme 
immunoassay “VANC2” from COBAS®, Roche (Basel, CH) located at the diagnostic 
laboratories of the University College London Hospital (UCLH). Its mode of action is 
described in the material and methods section (6.2.2.4). The VANC2 assay has a lower 
detection limit of 1.7 μg/ml, which according to the technical support corresponds to 1.2 
μM of vancomycin (conversion factor: µg/ml   0.690 = µM) (“Technical Support: VANC2 
COBAS® from Roche Diagnostics,” 2012). The measuring range of the VANC2 is stated as 
1.7 – 80.0 μg/ml of vancomycin, which corresponds to 1.2 – 55.2 μM. (I. Domke, Cremer, 
& Huchtemann, 2000; Ingrid Domke, 2002; Hermida, Zaera, & Tutor, 2001; “Technical 
Support: VANC2 COBAS® from Roche Diagnostics,” 2012; Yeo, Traverse, & Horowitz, 
1989)  
 
The direct comparison experiments were conducted as follows. A stock solution of 
29 µM vancomycin in WHS was used to dilute down into concentrations of 14.8, 4.7 and 
1.2 µM vancomycin in WHS. Each concentration was prepared six times, so that three 
individual samples sets with three samples per concentration could be measured with 
the VANC2 and the other three sets via the herein developed colourimetric vancomycin 
detection. Additionally for each technique, a reference set of three samples without any 
vancomycin was measured as well.  
 
Figure 6.23 and table 6.03 present the results of the VANC2 measurements. The 
concentrations were measured in μg/ml and the conversion factor provided by the 
technical support was used (µg/ml   0.690 = µM) (“Package Insert: VANC2 COBAS® from 
Roche Diagnostics” 2012). The data points and the corresponding linear fit are shown in 
red. The linear fit has a R2 of 0.998. The error bars highlighted in dark red correspond to 
the standard deviation of the three samples (n = 3). In the table 6.03, the abbreviation 
‘n. d.’ denotes for ‘not detectable’, whilst ‘n/a’ denotes ‘not applicable’. A general 
observation is that all errors are very small. However, it seems that the higher the 
concentration gets, the larger is the deviation from the diluted concentration, which is 
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indicated with a dotted diagonal line. Due to the dilution procedure from a stock 
solution in each sample preparation, errors introduced by the experimenter would 
either presents themselves as a constant value off the dotted line or as a propagation 
from higher to lower concentration and consequently be much larger for the lower 
concentrations. Therefore, it is believed that this deviation may be instrumental.   
 
To initiate the herein developed colourimetric detection assay for TVM, calibration 
measurements had to be done. Furthermore, it has to be highlighted that for this last 
set of experiments a newly order batch of Gibbs reagent (see chapter 5.2.1.2) was used. 
Therefore the calibration was done slightly more extensively and a novel estimation of 
vanGibbs molar absorptivity (       ) was performed. The procedure was exactly the 
same as in previous estimation described in section 6.3.4 figure 6.17. It was found that 
with this new Gibbs reagent the         increased from 9100 ± 200 to  
12200 ± 300 M-1 cm-1 with an adjusted R2 of 0.998.  
 
The measurements of the five concentrations in the three sets were performed as usual 
with the developed extraction protocol (see subchapter 6.3.3). The first methanol (#4) 
and the final elute (#6) were collected for subsequent quantification via Gibbs labelling 
of the free and bound fraction respectively. As usual the reference spectra were 
subtracted. The resulting differential absorbances were adjusted to account for the 
decrease in Gibbs reagent (see subsection 6.3.4), for the recovery and for the enlarged 
absorbance in the bound fraction (see subsection 6.3.6). Table 6.04 presents all results 
and calculations including the standard deviation for the three individual sets in which 
each sets has five different concentrations (n = 3). 
 
The total vancomycin concentration was calculated by addition of the free and bound 
concentrations. For direct comparison with the gold standard these total vancomycin 
concentrations including their standard deviation were added to figure 6.23. They are 
shown in blue with navy coloured error bars. The corresponding linear fit has a R2 of 
0.992. It can be observed that the errors are significantly larger than for the Roche 
COBAS®’ VANC2.  
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It has to be highlighted again that all these experiments were performed with gravity 
flow and manually droplet by droplet were captured from the SPE cartridge, which 
despite very strict experimental procedure induces errors and discrepancies. Therefore 
in the ultimate automated bench top device these errors should be significantly smaller. 
Besides these findings, the measured total vancomycin concentration with the herein 
developed colourimetric assay is comparable to the gold standard. Furthermore, it has 
the great advantage to monitor the free and bound vancomycin fraction in a single step 
within minutes. This will ultimately be achieved directly from whole blood in a bench top 
device at the PoC without any previous sample preparations.  
 
Figure 6.24 depicts all free, bound and total concentrations per triplet including error 
bars and linear fits. It can be observed that the errors for the bound fractions are slightly 
smaller than for the free. Generally, it can be observed that the amount of free 
vancomycin increases more with increasing of total concentration than the amount of 
bound. Hence the slope for the free fraction is steeper than the slope for the bound 
fraction. The corresponding percentages of the two fractions in each triplet can be 
found in the table 6.04.  
 
Furthermore the measurements of the control samples, which did not incorporate any 
vancomycin, allow a preliminary estimation of the detection limit. The procedure was 
the same as presented in the technical support from the Roche COBAS®’ VANC2 
(“Package Insert: VANC2 COBAS® from Roche Diagnostics” 2012). The VANC2 has a 
detection limit of 1.2 µM, which has been calculated as the value lying two standard 
deviations above the measured value for zero (1 + 2 StDev, n = 21). First calculations for 
the colourimetric assay resulted in a 1.1 µM detection limit. However, it has to be 
highlighted that the used sample size was only n = 3. Furthermore in light of the 
previous measured concentrations for 1.2 µM vancomycin that resulted in a far too 
large concentration, it has to be concluded that further experiments are required as well 
as statistical analysis.   
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Figure 6.23: Direct comparison of the herein developed colourimetric assay with the gold 
standard VANC2 from Roche COBAS®. The diagonal dotted line illustrates the linear region 
where data points would be if the diluted and measured concentration would be exactly the 
same. The red points (see table 6.03) present the measured concentrations with the VANC2. The 
blue data points (see table 6.04 on the next page) depict the total vancomycin concentrations 
measured with the herein developed colourimetric assay. The errors are derived standard 
deviations from three independent measurements (n = 3) and are significantly larger for the 
colourimetric assay than for the VANC2. Furthermore, the colourimetric measured concentration 
for the diluted 1.2 µM of vancomycin is far too high. Besides these findings, the results of the two 
techniques seem comparable, as well as the calculated R2 of the linear fits.   
 
 
 
 
Table 6.03: 
 
concentration 
diluted 
series A:  
measured conc. 
series B: 
measured conc. 
series C: 
measured conc. 
average st. deviation 
(n = 3) 
[µg/ml] [µM] [µg/ml] [µM] [µg/ml] [µM] [µg/ml] [µM] [µg/ml] [µM] [µg/ml] [µM] 
0 0 n. d. n. d. n. d. n. d. n. d. n. d. n/a n/a n/a n/a 
1.74 1.2 1.99 1.37 1.75 1.21 1.75 1.21 1.83 1.26 0.14 0.10 
6.81 4.7 5.62 3.88 5.38 3.71 5.92 4.08 5.64 3.89 0.27 0.19 
21.45 14.8 20.2 13.94 19.2 13.25 20.2 13.94 19.87 13.71 0.58 0.40 
42.03 29 38.8 26.77 37.6 25.94 39 26.91 38.47 26.54 0.76 0.52 
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Figure 6.24: Colourimetric assay for therapeutic monitoring of free and bound vancomycin 
concentration. As in the previous figure (6.23), the blue values are again the total vancomycin 
concentrations calculated by addition of the bound and free concentrations. The cyan data 
points depict the bound concentrations measured from the final elute (#6), whilst the green 
points illustrate the free concentrations obtained by labelling the first methanol wash (#4). The 
errors are derived standard deviations from three independent measurements (n = 3) and it can 
be observed that the errors for the free concentrations are larger. The linear fits and their 
corresponding R2 values seem comparable with each other. The percentages for the free and 
bound vancomycin concentrations can be found in the table (6.04) below.  
 
Table 6.04: 
 
expla-
nation  
concentration 
diluted 
series A:  
measured c. 
series B: 
measured c. 
series C: 
measured c. 
average percen-
tages 
st. deviation 
(n = 3) 
 [µg/ml] [µM] [µg/ml] [µM] [µg/ml] [µM] [µg/ml] [µM] [µg/ml] [µM] [%] [µg/ml] [µM] 
free n. k. n. k. -0.55 -0.38 0.55 0.38 0.47 0.32 0.16 0.11 92 0.61 0.42 
bound n. k. n. k. 0.15 0.10 -0.15 -0.10 0.05 0.03 0.02 0.01 8 0.15 0.11 
total 0 0 -0.4 -0.28 0.4 0.28 0.52 0.35 0.18 0.12 100 0.76 0.53 
free n. k. n. k. 2.76 1.91 6.18 4.27 0.89 0.62 3.28 2.26 52 2.69 1.86 
bound n. k. n. k. 3.11 2.15 2.21 1.53 3.90 2.70 3.07 2.12 48 0.84 0.58 
total 1.74 1.2 5.87 4.06 8.4 5.80 4.79 3.32 6.35 4.38 100 3.53 2.44 
free n. k. n. k. 3.99 2.75 6.78 4.68 2.73 1.89 4.50 3.11 56 2.07 1.43 
bound n. k. n. k. 3.49 2.41 4.41 3.04 2.91 2.01 3.60 2.48 44 0.75 0.52 
total 6.81 4.7 7.48 5.16 11.19 7.72 5.64 3.9 8.1 5.59 100 2.82 1.95 
free n. k. n. k. 9.59 9.59 14.89 10.28 13.16 9.08 13.98 9.65 65 0.87 0.60 
bound n. k. n. k. 6.90 4.76 6.76 5.29 8.64 5.96 7.69 5.30 35 0.94 0.65 
total 21.45 14.8 16.49 14.35 21.65 15.57 21.8 15.04 21.67 14.95 100 1.81 1.25 
free n. k. n. k. 30.64 20.00 34.61 23.88 28.21 19.48 30.61 21.12 70 3.48 2.40 
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6.4 Discussion and Conclusion 
The objective of this chapter was to develop a colourimetric detection assay for 
vancomycin on the basis of the existing Pelorus device for therapeutic propofol 
monitoring. For the sake of brevity the major milestones and corresponding findings of 
this development process are listed in bullet points below. Furthermore the key 
characteristics of this novel colourimetric detection for TVM are stated in table 6.05 at 
the end.  
 
i) It could be demonstrated that Gibbs reagent is binding to vancomycin. Its 
coupling product is detectable by visible spectroscopy with a maximal wavelength 
of 589 nm (       ) and a molar absorptivity of 12200 ± 300 M
-1 cm-1 (       ). 
The coupling reaction is fast within minutes and an immediate colour change from 
transparent with a hint of yellow from the Gibbs reagent to bright purple can be 
observed. It has to be highlighted that mixing is crucial as separation of the 
aqueous and organic is likely to occur. 
 
ii) An excess of Gibbs reagent of about 100 to 150 times results in the largest 
absorbances and consequently leads to the highest sensitivity. However, the 
range from 100 to 320 times does not result in an absorbance loss of more than 
13 %. The reaction product or maybe products will be analysed in the next 
chapter (7).   
 
iii) Detection of therapeutic vancomycin concentrations could be demonstrated. 
Preliminary estimations suggested a detection limit of about 1.1 µM. However, 
due to time limitations further experiments could not be performed. As they 
would lead to a strengthening of this finding and allow the crucial statistical 
analysis, they should be considered for future work.  
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Additionally in light of the required Gibbs excess, one may consider the use of two 
different Gibbs concentrations for the lower and the higher part of the 
therapeutic vancomycin to achieve best possible sensitivity.   
 
iv) The Gibbs reagent coupling is not specific to vancomycin and it was shown that it 
for example in addition to propofol also couples to serum albumin. Therefore and 
for several other reasons, an extraction protocol seemed inevitable. Consequently 
an extraction protocol was developed based on the same SPE cartridge as used in 
the Pelorus device. Therefore it is direct compatible and only the solvents and the 
procedure have to be adjusted. This fulfils one another objective, which was the 
ability to reduce the required time for a vancomycin-focussed device to reach the 
market.  
 
The extraction protocol was developed for WHS and should based on Sphere 
Medical’s prior knowledge be directly transformable to whole blood samples. 
Furthermore, it was found that from one sample free and the bound vancomycin 
fraction could be eluted out in different stages of the extraction protocol, which 
therefore allows separate quantification. The free and bound concentrations can 
then be added to obtain the total concentration. These total concentrations were 
directly compared to a gold standard method and found to be comparable.   
 
v) A small study with a subset of possible interferents was performed to evaluate the 
selectivity of the developed colourimetric assay for TVM. It was found that neither 
dopamine, nor paracetamol, nor propofol are interfering with the quantification 
of the bound vancomycin concentration, which is eluted out in the final elute. 
Again neither dopamine nor paracetamol were possible interferents for the 
quantification of the free vancomycin, which is included in the fourth SPE stage. 
However, propofol was identified as possible interfering substance.  
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In order to avoid potential interference of propofol, the following measures may 
be considered. Since propofol does not naturally occur in patients, vancomycin 
may be monitored when the patient is not under the influence of propofol. 
Alternatively, the propofol concentration may be determined independently and 
subsequently subtracted. The propofol could be quantified either via the Pelorus 
device or within a multi-analyte monitoring device that measures besides 
vancomycin also propofol and maybe serum albumin etc. Moreover, since the 
propofol-Gibbs reaction product is blue and consequently has a      of 595 nm 
(see chapter 5.3.2), measuring the UV/vis spectrum over an appropriate spectral 
range instead of at a fixed wavelength may allow for the extraction of the 
propofol contribution from the overall determined concentration.  
 
It has to be highlighted that these three interferents are most likely not all of the 
possible interfering species that can occur. Therefore further specificity validation 
should be done in the future.  
 
 
To conclude the ability to monitor free and bound concentrations and consequently 
calculate the total concentration of vancomycin in a single step from ultimately whole 
blood samples without the requirement of any prior sample preparations within 
minutes paired with integrability into a bench top device for PoC has to the best of our 
knowledge never been described before. Therefore we patented this invention including 
the labelling reaction of vancomycin with the Gibbs reagent (Kappeler et al. 2013). The 
patent just entered ‘Patent Cooperation Treaty’ (PCT) phase on the 18th February 2014.   
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Table 6.05:  
 
Sensing Technique Colourimetric 
Investigated Core  
Detection Technology 
Visible Spectroscopy 
Sensor Attributes or Requirements and their Feasibility and Fulfilment 
Specificity without cross-
contamination 
Developed extraction protocol is fairly specific for 
the bound fraction eluted in stage #6 and until now 
propofol could be identified as possible interferents 
for the free fraction present in stage #4. 
Sensitivity according to 
therapeutic window/clinical 
range: vancomycin’s clinical 
range: 4 – 28 µM 
Detection limit: preliminary estimation yielded in 
about 1.1 µM of vancomycin, which according to 
conversion from the VANC2 assay corresponds to 
about  1.7 µg/ml (“Package Insert: VANC2 COBAS® 
from Roche Diagnostics” 2012) 
Simplicity and requirement for 
specially trained staff 
Very simple and no specially trained staff required. 
Required sample preparation As a final product none. Currently, SPE followed by 
Gibbs labelling reaction.  
Stability in application 
environment/robustness 
Assumed to last long depending on material 
abrasion including tubes and fittings within the 
device. 
Shelf-life/robustness Similar to above depending on material abrasion 
plus chemicals and buffer shelf life time. 
Miniaturisation Light source and light paths are the limiting factor. 
Intravenous flow through 
application/patient attached 
Not possible due to addition of chemicals and 
miniaturisation issue. 
Safety in case of malfunction Not tested.  
Expected costs Overall low. Single investment for the device and 
very low per test, which only requires a novel SPE 
cartridge (assumed < £ 1). 
Measuring speed/rapidity Labelling reaction & vis spectroscopic measurement: 
about 4 minutes. Overall assay including blood 
injection & SPE: less than 10 minutes.   
Distinguish free vs. bound 
antibiotic fraction  
Yes, both. In WHS, elute (#6) clearly carries the 
bound and wash (#4) the free fraction.  
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CHAPTER 7:  
Structural Characterisation of the Novel Product – 
VanGibbs 
7 Study of Labelling Reaction and Coloured Product  
This chapter is the last of the three chapters outlining the colourimetric detection of 
vancomycin. Following on the successful development of the Gibbs reagent labelling 
reaction for vancomycin and the specific extraction protocol discussed in the previous 
chapter 6, the objective of this chapter is the analysis of this reaction and its coloured 
product, which is herein called ‘vanGibbs’. This objective serves the purposes of 
validating the filed patent via structural characterisation of the vanGibbs molecule, 
which to the best of our knowledge is a novel molecule never described before, and to 
acquire a better understanding of the almost 90 year old reaction mechanism, which 
despite its age and many publications is not fully understood (Dacre 1971; Svobodová et 
al. 1977; Svobodová et al. 1978; Adam et al. 1981; Josephy and Van Damme 1984; 
Pallagi and Dvortsák 1986; Pallagi, Toró, and Müller 1994; Pallagi, Toró, and Farkas 1994; 
Pallagi, Toró, and Horváth 1999). The structural analysis and study of the labelling 
reaction, described hereafter, were performed by mass spectrometry (MS) technique 
and nuclear magnetic resonance (NMR) experiments.  
 
Similar to previous chapters, this chapter is divided into four subsections: The first 
subsection (7.1) introduces the Gibbs reagent literature again and summarises the 
relevant findings from the preceding chapters 5 and 6. The second part (7.2) lists the 
used materials and methods. The third subsection (7.3) presents the results including 
preliminary discussions and continues into the final subsection (7.4) with the overall 
discussion, conclusion and outlook towards future work.  
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7.1 Introduction 
The Gibbs reagent, including its history, different reaction mechanisms and applications 
was introduced in chapter 5.1.2. In the original Gibbs reaction, as described by Harry D. 
Gibbs in 1926 and 1927, the Gibbs reagent is adding to para-unsubstituted position of 
the hydroxyl group in a phenol resulting in blue coloured indophenols (Gibbs 1926a; 
Gibbs 1926b; Gibbs 1927a; Gibbs 1927b). However later on, several research groups 
showed that Gibbs reagent has the ability to add to the para-substitued position of 
phenolic compounds (Dacre 1971; Josephy and Van Damme 1984; Pallagi, Toró, and 
Müller 1994; Pallagi, Toró, and Farkas 1994), as well as to some esters (Kramer, Gamson, 
and Miller 1959; Gamson, Kramer, and Miller 1959), certain thiols and sulfhydryl groups 
(Kramer and Gamson 1959; Harfoush, Zagloul, and Abdel Halim 1982; Harfoush 1983), 
nitroxyl groups (Pallagi, Toró, and Horváth 1999) and some amines (De Boer et al. 2007; 
Kovar and Teutsch 1986; Kallmayer and Thierfelder 2003; Annapurna et al. 2010).  
 
As described in the preceding chapter (6.1) vancomycin has several aromatic groups, 
including some phenolic moieties. Therefore one hypothesis is that Gibbs reagent 
couples to one or several of these. The schematic in figure 7.01 illustrates a possible SEAr 
reaction of the Gibbs reagent to position 6 in the 7th residue of vancomycin, which is the 
para-unsubstituted position. However, the addition may occur to another position of the 
vancomycin molecule such as the position 2 in the same residue (7th), other aromatic 
moieties that may become phenolic or to amine groups (De Boer et al. 2007; Kovar and 
Teutsch 1986; Kallmayer and Thierfelder 2003; Annapurna et al. 2010). Moreover, these 
alternative additions could result in multiple coupling reactions accompanied with 
possibility of fragmentation of the vancomycin molecule. These alternative reactions as 
well as the structural characterisation of the novel product ‘vanGibbs’ will be studied 
and discussed in this chapter.  
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Figure 7.01: Hypothesis of Gibbs reagent coupling to vancomycin resulting in a novel vanGibbs 
molecule. Based on the theory of the Gibbs reaction, coupling to the para-unsubstituted position 
of the hydroxyl group at position 3 in 7th residues of vancomycin via a SEAr seems a likely 
scenario. The coupled Gibbs molecule is indicated in purple in the vanGibbs molecule. One 
isomeric structure of vanGibbs was chosen as an example for many possible isomers. It has to be 
highlighted that the addition may occur to another position of the vancomycin molecule such as 
the position 2 in the same residue (7th), other aromatic moieties that may become phenolic or 
addition to amine groups. This could result in multiple additions accompanied with maybe even 
fragmentation, which will be further discussed in chapter 7. Furthermore, the coupling reaction 
requires high pH. Therefore the charged groups of the vancomycin scaffold were adjusted to an 
assumed pH of around 8.9 to 9.5 resulting in an overall charge change from     to –   . The pKa 
values were taken from Takács-Novák, Noszál, Tókés-Kövesdi, & Szász, 1993.  
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7.2 Materials and Methods 
This chapter provides the information of the materials used and methods for the study 
of the labelling reaction and the resulting novel product vanGibbs. It is divided into three 
subchapters. The chemicals, including coupling reagent, the antibiotic and the solvents 
are described in the first subsection (7.2.1). The analytical instrumentation is presented 
in the second part (7.2.2). The procedure and data analysis is described in the third and 
last part (7.2.3).  
7.2.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich (Dorset, UK), unless otherwise 
declared. They were handled, stored and disposed of in accordance with their safety 
guidelines stated in the corresponding ‘material safety data sheets’ (MSDS).  
7.2.1.1 Coupling Reagent and Antibiotic 
The Gibbs reagent and the vancomycin, which were used in the hereafter presented 
experiments, were previously described in chapter 5.2.1.2 and 6.2.1.1.   
7.2.1.2 Solvents  
For the mass spectrometry experiments the same solvents were used as described in the 
previous chapter 5.2.1.1 and 6.2.1.1. For the NMR experiments, the deuterated solvents 
of the aforementioned solvents were used accordingly.  
7.2.2 Instrumentation  
7.2.2.1 Mass Spectrometer  
The mass spectra presented herein were taken by Reach Separations (Nottingham, UK). 
The used mass spectrometer was an Agilent 1100 series G1946D with an electrospray 
ionisation (ESI) probe from Agilent (Santa Clara, California, U.S.A.). The different 
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ionisation techniques in mass spectrometry can be separated in hard and soft ionisation 
techniques. ESI is the archetypal hard ionisation technique. Since in hard techniques a 
larger amount of energy is transferred to the analyte ion, subsequent unimolecular 
dissociation reactions can be expected resulting in more fragmentations than soft 
ionisation techniques, which include for example matrix-assisted laser 
desorption/ionisation (MALDI) (Kellner et al. 2004). Additionally several experiments 
were performed with a MALDI time-of-flight (MALDI-TOF) mass spectrometer, namely 
an AXIMA CFR from Shimadzu (Kyoto, Japan) located at UCL’s Cancer Institute and 
operated by Dr. Carolyn Hyde. However, as comparable results were obtained, they are 
not presented herein for the sake of brevity.  
7.2.2.2 NMR instrumentation 
The used NMR instruments were Avance III 600 Cryo and Avance 500 both from Bruker 
(Billerica, Massachusetts, U.S.A.). The instruments are located in the Chemistry 
Department of UCL and operated by Dr. Abil Aliev. For the calibration of the chemical 
shift (parts per million (ppm)) the characteristic water peak was used. 
7.2.3 Measurement Procedure, Data Capturing and Analysis 
This chapter presents the analytical study of the reaction of vancomycin with Gibbs 
reagent and the structural characterisation of its product. However, it was found that 
the vanGibbs molecule is not stable for more than about 12 hours in various conditions 
including different aggregate states (liquid and solid obtained via freeze drying), pHs, 
temperature and molar ratios of the starting materials. Moreover, it was not stable in 
the purified form with an equimolar ratio of vancomycin and Gibbs reagent, which in 
theory should not allow further coupling reactions.6  
 
In conclusion, this instability prevented a fully successful purification as well as 
consecutive scaling up experiments required for a complete characterisation of the 
                                                            
6 Most purification attempts were performed in conjunction with Dr. Antonio Ruiz-Sanchez. The 
several hours stability experiments via NMR were conducted by the aforementioned. Reach 
Separations performed some purification attempts via HPLC and analytical studies via MS. 
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molecule such as elemental analysis or, besides the hereafter presented 1H-NMR 
studies, additional 13C-NMR studies.  
 
Therefore the herein presented analytical techniques are techniques in which the crude 
reaction mixture could be used. These techniques include mass spectrometry (7.3.1) and 
one and two-dimensional 1H-NMR (7.3.2). 
 
According to the measurement procedure, the studies with both techniques were 
initiated with the starting materials followed by the reaction with different molar ratios 
of the aforementioned. Further, the procedure for capturing mass spectra and one-
dimensional 1H-NMR data were as usual in analytical chemistry and will not be further 
described in this thesis. Regarding the two-dimensional NMRs, the typical procedure is 
to start with COSY (COrrelated SpectroscopY) analysis, followed by TOCSY (TOtal 
Correlation SpectroscopY) spectra and then NOESY (Nuclear Overhauser Effect 
SpectroscopY) and if required ROESY (Rotating frame nuclear Overhauser Effect 
SpectroscopY) studies.  
 
However in this thesis, no COSY (COrrelated SpectroscopY) study was performed 
because of two reasons. Firstly, the almost all protons of vanGibbs could be assigned 
with one-dimensional 1H-NMRs (see subsection 7.3.2); Secondly, the NOESY spectrum of 
the product, vanGibbs, could be directly compared with the NOESY spectrum of the 
starting material, vancomycin. In addition, due to the fact that the Gibbs group is 
believed to couple to vancomycin via the heteroatom nitrogen, it has a separate spin 
system. This spin system separation renders results from a TOCSY not very helpful for 
the distinguishing of the exact coupling position in the 7th residue of vancomycin. 
However, an analysis via NOESY spectra was performed as it was expected to give 
further structural information of the vanGibbs molecule and may show where the Gibb 
reagent is exactly coupling to. Since the NOE (Nuclear Overhauser Effect) interaction is 
not through bonds but rather through space, it is a useful technique for the local 
assignment of different spins systems relative to each other and consequently the three-
dimensional structure of molecules.  
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A transient NOE effect can occur via dipolar coupling of homonuclei such as H-H 
coupling. Each nucleus gets individually irradiated to detect whether and to which other 
nucleus a NOE effect occurs. The irradiated nucleus acts as source spin (S) and the 
nucleus which either does or does not interact upon this source spin is called interesting 
spin (I). The NOE range is restricted to about 3 to 6 Å, which is about 3 to 6 times the 
length of a carbon-hydrogen bond (~1.1 Å). However, it has to be highlighted that a 
proximity of 6 Å gives a fairly weak NOE signal. The NOE interactions are also influenced 
by the strength of the NMR magnet and the spin velocity of the molecules which gives 
rise to either positively or negatively signed cross peaks. Positive signals are usually 
obtained from fast tumbling smaller molecules, which are typically less than 1000 
Daltons. Negative signals on the other hand are from slow tumbling larger molecules 
such as proteins. Negative signs also have diagonal peaks which can be seen as the 
peaks from the corresponding one-dimensional NMR plotted diagonally. Even though by 
convention the diagonal should be plotted negative, it is often plotted positive which 
inverts the signs. Therefore, small molecules are negative and large molecules positive. 
In a NOESY spectrum two colours indicate positive and negative signs.  
 
Very importantly for the interpretation of NOESY spectra is that the presence of an NOE 
cross peak is evidence that two nuclei are in spatial proximity to each other. However, 
the absence of an NOE peak does not necessarily mean that they are not in close 
proximity to each other. This arises from the nature of the interactions which are 
anisotropic, hence they are asymmetric. NOESY spectra contain additional axial peaks, 
which typically do not provide extra information and can be eliminated. Furthermore, 
NOESY spectra are prone to artefacts, therefore other techniques or direct comparisons 
are crucial for the verification of the nuclei connections and structural interpretation. 
(Noggle and Schirmer 1971; Kellner et al. 2004)  
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7.3 Results and Discussion 
This chapter presents the results of the analytical study of the reaction of vancomycin 
with Gibbs reagent and the structural characterisation of the novel product vanGibbs. 
The first section (7.3.1) describes mass spectrometry and the second (7.3.2) describes 
1H-NMR studies.  
7.3.1 Mass Spectrometry Studies  
To initiate the mass spectrometry study, a spectrum of pure vancomycin hydrochloride 
was taken. Vancomycin has the chemical formula C66H75Cl2N9O24, an exact mass 
(monoisotopic nominal mass) of 1447.4 g/mol and a molecular weight, which equals to 
the average mass, of 1449.3 g/mol. Figure 7.02 A shows the theoretical prediction of the 
isotopic pattern of vancomycin, which has a characteristic shape mainly due to presence 
of the two chlorine atoms. Figure 7.02 B shows the corresponding experimental 
spectrum obtained by ESI mass spectrometry. The main peaks around 1447 m/z 
corresponding to the ionised mass of vancomycin [M]+ and are in very good agreement 
with the predicted pattern. Both sets of peaks around 1469 m/z and 1485 m/z with 
comparable isotopic shapes correspond to vancomycin’s mass plus a sodium [M+Na]+ 
and a potassium cation [M+K]+ respectively. 
 
After successful initiation of the mass spectrometry studies, characterisation of the 
novel product vanGibbs was performed. According to the hypothesis presented above 
(see section 7.1) and in the previous chapter 6.1, a stoichiometric one to one reaction is 
expected to result in a molecule with the chemical formula C72H76Cl4N10O25, a 
corresponding exact mass of 1620.4 g/mol and a molecular weight of 1623.2 g/mol. 
Figure 7.03 A shows the theoretical isotopic pattern of such a molecule. Figure 7.03 B 
presents the experimentally measured spectrum of two molar equivalents of Gibbs 
reagent reacted to one equivalent of vancomycin under alkaline condition. The main 
peaks around 1620 m/z represent the vanGibbs molecule in its cationic form [M]+ and 
display a comparable pattern to the predicted isotopic shape. Similar to pure 
vancomycin in figure 7.02, the comparable shaped peak patterns around 1644 m/z and 
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1663 m/z correspond to vanGibbs’ mass plus a sodium [M+Na]+ and a potassium cation 
[M+K]+ respectively. The peaks at lower masses are fragmentations of the vanGibbs 
molecule displaying similar isotopic pattern, which suggests that the four chlorine atoms 
are still attached to these main fragments. The peaks around 1579 m/z could be due to 
the loss of a carboxylic acid group, which equals to a loss of about 45 m/z (Kellner et al. 
2004). The peaks around 1480 m/z may be due to the loss of one sugar moiety resulting 
in a mass loss of about 144 m/z. Furthermore, no peaks can be observed around 
1447 m/z, which are displaying a vancomycin typical pattern.   
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Figure 7.02: Theoretical and experimental mass spectra of pure vancomycin.  
A) Theoretical isotopic pattern of vancomycin. Vancomycin has a chemical formula of 
C66H75Cl2N9O24, a monoisotopic nominal mass of 1447.4 g/mol and a molecular weight of 
1449.3 g/mol. The characteristics in the isotopic pattern are mainly due to the presence of the 
two chlorine atoms. B) Experimentally measured mass spectrum of vancomycin with an ESI 
mass spectrometer. The main peaks around 1447 m/z correspond to the cationised mass of 
vancomycin [M]+ and are in very good agreement with the predicted pattern. The both sets of 
peaks around 1469 m/z and 1485 m/z with comparable isotopic shapes correspond to 
vancomycin’s mass plus a sodium [M+Na]+ and a potassium cation [M+K]+ respectively. 
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Figure 7.03: Theoretical and experimental mass spectra of the novel reaction product vanGibbs. 
A) Theoretical isotopic pattern of vanGibbs. The vanGibbs molecule in a one to one stochimetric 
reaction has an expected chemical of C72H76Cl4N10O25, an exact mass of 1620.4 g/mol and a 
molecular weight of 1623.2 g/mol. B) Experimentally measured mass spectrum of 2 equivalents 
of Gibbs reagent with one equivalent of vancomycin under alkaline conditions. The main peaks 
around 1620 m/z represent the vanGibbs molecule in its cationic form [M]+ and display a 
comparable pattern to the predicted isotopic shape. The comparable shaped peak patterns 
around 1644 m/z and 1663 m/z correspond to vanGibbs’ mass plus a sodium [M+Na]+ and a 
potassium cation [M+K]+ respectively. The peaks at lower masses are fragmentations of the 
vanGibbs molecule displaying similar isotopic pattern, which suggests that the four chlorine 
atoms are still attached to these main fragments. The peaks around 1579 m/z could be due to the 
loss of a carboxylic group, which equals to a loss of about 45 m/z (Kellner et al. 2004). The peaks 
around 1480 m/z may be due to the loss of one sugar moiety resulting in a mass loss of about 
144 m/z. Furthermore, no peaks can be observed around 1447 m/z, which are displaying a 
vancomycin typical pattern.   
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7.3.2 1H-NMR Analysis 
Since to the best of our knowledge Gibbs reagent has never been successfully coupled to 
vancomycin molecule before, the structure of this new product is unknown. As 
previously hypothesised in the above section 7.1 and in chapter 6.1, the Gibbs is 
expected to couple to the position 6 in the resorcinol, which is the 7th residue of 
vancomycin. However, it has been previously highlighted that the addition may occur at 
another position of the vancomycin molecule, for instance in position 2 of the same 
residue (7th), which would be the ortho-position to both hydroxyl groups, other aromatic 
moieties that become phenolic or amine groups. This may result in multiple additions 
accompanied with possible fragmentation.  
 
To initiate the 1H-NMR study7, spectra of the starting material, vancomycin, in 
deuterated dimethyl sulfoxide (DMSO-d6) were captured and compared to a spectrum 
taken by Clive M. Pearce and Dudley H. Williams in 1995 (Pearcea and Williams 1995). 
Figure 7.04 presents these two spectra and figure 7.05 in addition with table 7.01 
compares their full proton assignments. The last row in table 7.01 represents the 
difference of the two assignments. Since both spectra are very similar and the proton 
shifts are highly comparable, this initial study was considered successful.  
 
The study of the novel coupling product was proven difficult due to the required 
reaction conditions such as high pH and mixture of aqueous and organic solvents, as 
well as the stability of the produced molecule in both liquid and solid form. Therefore, 
structural characterisation of the product was performed by studying NMRs of the crude 
reaction mixture. For this reason, firstly the chemical shifts of the starting material 
vancomycin and their changes in the deuterated solvent mixture with increasing pD was 
analysed. Afterwards the novel molecule was studied and compared to this analysis of 
vancomycin in reaction conditions for characterisations of the structure of the novel 
product vanGibbs.  
                                                            
7 Most NMR experiments and analysis were performed in conjunction with Dr. Antonio Ruiz-
Sanchez. Additionally, their results were discussed with Dr. Stephen Hilton and Dr. Abil Aliev. 
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Figure 7.06 presents some 1H-NMR spectra of vancomycin in deuterated water (D2O) 
and deuterated methanol (MeOD) with increasing pD achieved by addition of 40% 
deuterated sodium hydroxide (NaOD) in D2O. The first spectrum from the top is 
vancomycin in pure D2O, the second one is in a mixture of 1/3 D2O and 2/3 MeOD and 
then the subsequent four spectra have increasing amounts of NaOD. The last spectrum 
at the bottom shown in red has the exact reaction conditions needed for a successful 
Gibbs coupling as established in the previous chapter (6). These reaction conditions are 
hereafter called alkaline conditions and abbreviated with ‘ac’ in brackets. It has to be 
highlighted that the resolution for vancomycin in a mixture of 1/3 D2O and 2/3 MeOD is 
not as good as in the other spectra. This may be due to the addition of organic solvent, 
which could have resulted in an aggregation of the vancomycin molecules according to 
the poor solubility of vancomycin in organic solvents. However, this observation and 
hypothesis was not further studied. In general, it can be observed that protons are 
shifting towards lower chemical shifts the higher the pD gets.  
 
Figure 7.07 in addition with table 7.02 compares the full assignment of the very last 
spectrum shown in red with an assignment found in literature from A. S. Antipas and 
colleagues (Antipas et al. 2000). They have studied the 1H-NMR of vancomycin in D2O 
with increasing pDs. The first row of table 7.02 lists the code of the protons according to 
figure 7.07, the second row is the assignment copied from Antipas et al. 2000 and the 
third row presents the assignment of the last spectrum shown in red. In general, the 
vancomycin spectrum with the exact reaction conditions can be roughly divided in the 
following five parts: 
 
- From 7.6 to 6.5 ppm are the aromatic protons of the 2nd, 5th and 6th residues 
coded with d, e, g, f, i, j, k, m and l.  
 
- From 6.5 to 5.75 ppm are the two doublets of the aromatic protons of interest 
from the 7th residue – o and p.  
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- 5.75 to 5.2 ppm include the last two aromatic protons of the 4th residue – s1 and 
s2, the protons from the two carboxylic acids – u and t, as well as the protons 
neighbouring many deshielding groups such as amines, carboxylic acids and 
hydroxyls or oxygen atoms - r4 and A1. 
 
- From 5.2 to 2.3 ppm are the peaks of aliphatic protons that directly neighbours 
one deshielding group such as an amine, a carboxylic acid, a carbonyl or a 
hydroxyl or an oxygen atom as it is the case in the disaccharide moiety. Typically 
in peptide chemistry, the protons which are attached to the carbon before the 
carbonyl carbon are called ‘alpha protons’ (H ) and the corresponding protons 
are the ‘alpha carbons’ (C ).  
 
- Below 2.3 ppm are the peaks from aliphatic protons which have mainly aliphatic 
neighbouring protons. In light of the above described H , some of these protons 
are ‘beta protons’ (Hβ) or even ‘gamma protons’ (Hγ) if they are attached to a 
‘beta carbon’ (Cβ) or a ‘gamma carbon’ (Cγ) respectively. A Cβ is the second 
carbon to the carbonyl group whilst a Cγ is the third.     
 
The last row in table 7.02 represents the difference in chemical shifts of the two 
precedent assignments. It can be observed that all differences, except of two zeros, are 
positive in the range between 0.01 and 0.52 ppm. Consequently, it seems that the pD of 
the reaction mixture is higher than 9.0. Furthermore, it can be observed that the two 
protons of the 7th residue (proton coded as o and p in figure 7.07) are one peak in 
Antipas et al. (Antipas et al. 2000). This observation is similar to the experimentally 
obtained spectra with 1 and 3 µl NaOD, which supports previous finding suggesting that 
the pD of the exact reaction conditions with 10 µl NaOD (ac) is higher than 9.0. Overall, 
it can be concluded that almost all peaks can be assigned to the protons of vancomycin 
and the experimentally obtained spectra are in good agreement with the literature.  
 
Therefore, the next step was to study the 1H-NMR spectra of the novel molecule – 
vanGibbs – in comparison to vancomycin in reactions conditions (ac). Figure 7.08 
presents a spectra overlay of the two starting materials, Gibbs reagent and vancomycin, 
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and the product vanGibbs obtained with different molar ratios of the starting materials. 
The shown ratios of vancomycin and Gibbs reagent are equimolar (1:1), 1:2, 1:3, 1:4, 1:5 
and 1:65. One of the most predominant changes is highlighted with a dotted box 
marking the two doublets resulting from the two protons from the 7th residue. 
According to the previous described hypothesis, these are the positions to which the 
Gibbs reagent coupling may occur resulting in an indophenolic moiety (see 
subsection 7.1 and figure 7.01). 
 
It can be observed that the doublets decrease to about half of their original size from 
the spectrum of pure vancomycin (shown in red) to the equimolar ratio spectrum 
(shown in black) and finally completely disappear in the 1:2 ratio spectrum (shown in 
blue). This observation leads to the assumption that despite an equimolar amount of 
Gibbs reagent, some vancomycin starting material remains unreacted. However, with 
two molar equivalents of Gibbs reagent in contrast to one mol of vancomycin, no 
starting material could be detected via 1H-NMR. The spectra with higher molar 
equivalents of Gibbs reagent do not show these two peaks.  
 
Moreover, the resolution of spectra is decreasing the larger the excess of the Gibbs 
reagent. It was found that the peaks in the spectra of an excess above 5 equivalents of 
Gibbs reagent are wider and consequently the spectra is losing resolution. This finding 
could be an indication of multiple additions or even fragmentation of the molecule. 
However, the spectra of the ratios 1:2 to 1:5 show highly similar positions, shapes and 
integrals of peaks below 4.1 ppm to pure vancomycin. These are strong evidences that 
the main vancomycin structure is conserved and that this vancomycin derivative 
represents the majority compound in the reaction mixture. This is further supported 
with figure 7.09 and table 7.03 which are comparing the spectra of pure vancomycin in 
the second row and vanGibbs obtained by a ratio of 1:2 in the third row shaded in 
magenta. The fourth and last row lists the difference of the two preceding assignments. 
Only the chemical shifts of the protons coded as follows have changed: r1, r2, r3, o, p, k 
and d. According to figure 7.09, all these changes are in proximity to the aromatic ring of 
the 7th residue or in case of o and p concerning directly the two protons of the resorcinol 
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itself. These findings are supporting evidence that the Gibbs reagent coupling occurs to 
this part of the antibiotic molecule and results in a change of electronic properties that 
changes the corresponding chemical shifts of these protons. Moreover, a new peak 
appears at a chemical shift of 7.02 ppm which is associated with the two protons of the 
Gibbs reagent.  
 
Figure 7.10 shows a detailed comparison of the three 1H-NMR spectra, pure vancomycin 
and vanGibbs obtained with an equimolar and a 1:2 ratio of vancomycin:Gibbs in the 
region from 8.0 to 4.2 ppm. The doublet with a chemical shift of 6.51 ppm is present and 
constant in all three spectra (indicated with a dark grey box). This doublet comes from 
the proton coded with l and has therefore an integral of 1. This integral serves as 
reference for the calculations of the other integrals in the spectra.  
 
Similar to figure 7.08, the dotted box marks the two doublets of residue 7. Their 
integrals are about 1 each in pure vancomycin (shown in red). They decrease to a total 
of about 0.85 in middle spectra (shown in black), which is a bit less than half of their 
original size. Finally, they completely disappear in the spectrum obtain with a molar 
ratio of 1:2 vancomycin:Gibbs (shown in blue). As previously indicated, this observation 
leads to the assumption that with an equimolar ratio of Gibbs reagent a bit more than 
half of the vancomycin molecules in the sample have reacted. Then with 2 equivalents 
Gibbs reagent, all vancomycin molecules seems to have reacted into the novel product 
vanGibbs.  
 
Upon reaction with the Gibbs reagent, it is expected that the peak of the proton at the 
position where the coupling occurs vanishes due to substitution with the Gibbs reagent, 
whilst the other proton shifts due to the change in the electronic environment. The 
additional substitution of the aromatic ring with a moderately activating group increases 
the electron density in the conjugated π system. This increase leads in a shielding effect 
and consequently an upfield shift to lower ppm values of the neighbouring proton. 
Moreover, the peak has to change its multiplicity from a doublet to a singlet. The two 
arrows below the peaks depict this shift of one of the two protons into the existing 
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multiplet of s2, t, A1, u and s1 to a chemical shift of about 5.43 ppm (indicated with a red 
box). Since the shifted peak is in the middle of the existing multiplet, a superposition of 
various peaks is occurring which complicates the integration. Therefore, the integral 
differences are with about 0.73 for the difference of vancomycin and equimolar 
vanGibbs and with 1.54 for the difference of equimolar and 1:2 vanGibbs too large. 
 
On the other hand, the new arising peak at 7.02 ppm (illustrated with a yellow box) has 
an integral of 0.88 in the equimolarly obtained vanGibbs, which is in good agreement 
with the expectation that this peak is associated with two similarly shifted protons of 
the newly attached Gibbs reagent group. The same applies for the 1:2 ratio vanGibbs in 
which all vancomycin molecules have reacted to vanGibbs and therefore the integral is 
with a value of 1.94 close to 2. 
 
The next step was to find the exact position in the resorcinol to which the Gibbs reagent 
is coupling to. Therefore, a two-dimensional NMR study was performed. As described in 
subsection 7.2.3 neither COSY nor TOCSY spectra were captured. It was directly started 
with the NOESY analysis.  
 
Figure 7.11 shows two NOESY spectra. The first one (A) is vancomycin in reaction 
conditions and the second one (B) is vanGibbs obtained with a molar ratio of 1:2 
between vancomycin and Gibbs reagent. The blue colour indicates interactions with a 
negative sign whilst yellow depicts the positive interactions. As previously described in 
subsection 7.2.3, since vancomycin and vanGibbs are both large molecules, the NOE 
interactions shown as cross peaks have the same sign and consequently colour as the 
diagonal peaks. The axial peaks with a positive sign are arising from the water molecules 
present in both samples. The quantity of water seems slightly higher in spectrum B than 
A. In general, it can be observed that both spectra look very similar, which is expected 
and strongly supports previous findings.  
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The lines were added to the spectra to guide the eye. All horizontal lines illustrate the 
regions in the spectrum where cross peaks will occur if the irradiated nucleus at this 
chemical shift has detectable NOE interactions with nuclei in its close proximity. Hence, 
the nucleus of interest acts as a source spin which is further abbreviated as S. All vertical 
lines indicate the regions of the spectrum where peaks would occur if the nucleus of 
interest would interact with a nearby irradiated nucleus and upon this interaction shows 
as detectable NOE interaction. Hence, it would be then the interesting spin which is 
further abbreviated as I.  
 
In figure 7.11 A the green lines indicates the interaction regions of the proton o and the 
grey lines of proton p. The cyan arrow highlights a very weak NOE interaction between 
the protons r2 and p, where r2 is S and p is I. For improved visibility, the grey line is 
interrupted. This dipolar coupling has also be seen by C. M. Pearce and D. H. Williams 
(Pearcea and Williams 1995). Besides this interaction, neither nucleus o nor p are 
showing any NOE interaction peaks, except of interactions as S with the water peak 
around 4.8 ppm. The orange lines depict the chemical shift of 5.43 ppm, which is part of 
the multiplet arising from the protons s2, t, A1, u and s1. As previously described (see 
figure 7.10), this is the ppm value where one of the protons o and p will shift to in the 
vanGibbs molecule. Therefore, it is highlighted for simpler direct comparison with the 
red lines in the vanGibbs 1H-NMR NOESY spectrum in figure 7.11 B.  
 
In figure 7.11 B, it can be observed that all cross peaks are very similar to figure 7.11 A 
and no new interaction peaks can be found. In the region where the shifted nucleus act 
as S (highlighted by the horizontal red line), the peaks between 8 and 7.5 ppm have 
shifted slightly downfield and the peak at 6.75 ppm slightly upfield. All these shifts were 
previously observed in the one-dimensional 1H-NMR spectra. Furthermore, some peaks 
seem to vanish, but as previously indicated in subsection 6.2.3 this does not necessarily 
mean that there is no interaction. Comparable observations can be made for the region 
where the shifted peak acts as I spin (illustrated with the vertical red line). Furthermore, 
the cyan arrow indicates again where the NOE interaction may appear if the p proton is 
the one which is shifting. However, this region is already occupied by NOE interaction 
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peaks from the multiplet as indicated in figure 7.11 A. The dark yellow lines in figure B 
indicate the NOE interaction regions of the new arising peak from the two protons of 
the attached Gibbs group. Both horizontal and vertical regions are not showing any cross 
peaks.  
 
The yellow peaks with the opposite sign close to the diagonal peaks in the area 8 to 
7.5 ppm indicate that a molecule is present in the sample with a molecular weight below 
1000 Da. As visible in figure 7.08, the chemical shifts of the protons of the Gibbs reagent 
in the reaction conditions are in this region. Hence, these peaks are arising from the free 
Gibbs molecules which have not coupled to vancomycin.    
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Figure 7.04: 1H-NMR analysis of vancomycin in DMSO and comparison with literature.  
A) 1H-NMR analysis of vancomycin in DMSO by Clive M. Pearce and Dudley H. Williams. 
Illustration adopted from Pearcea & Williams, 1995. B) 1H-NMR of vancomycin in DMSO. The full 
assignment of both spectra and the direct comparison can be found on the next page in 
figure 7.05 and table 7.01.   
A 
 
 
 
 
 
 
 
 
 
 
B 
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Table 7.01: 
 
Figure 7.05: Labelled structure of 
vancomycin for 1H-NMR 
assignments and comparison with 
literature. Proton coded structure 
for the full assignments of the two 
NMRs from figure 7.04. Schematic 
taken from Pearcea & Williams, 
1995. 
 
Table 7.01: Comparison of 
experimental full assignment with 
literature. The first and grey shaded 
assignment is taken from literature 
and belongs to figure 7.04 A 
(Pearcea and Williams 1995). The 
second assignment is experimentally 
obtained presented in figure 7.04 B. 
The last row presents the difference 
between the preceding assignments.   
 
Multiplicity abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, non = nonet, 
m = multiplet, o = obscured, br = broad, and v br = very broad. 
Proton δH [ppm] (multiplicity) ∆δH Proton δH [ppm] (multiplicity) ∆δH 
1d 0.86 (d)  0.81 (d) 0.05 4f 5.21 (d) 5.19 (d) 0.02 
1c 0.91 (d) 0.89 (d) 0.02 V1 5.24 (d) 5.22 (d) 0.02 
V6 1.07 (d) 1.02 (d) 0.05 G1 5.27 (d) 5.25 (d) 0.02 
V7 1.32 (s) 1.29 (s) 0.03 G3-OH 5.38 (d) 5.40 (d) -0.02 
 a’ 1.47 (quin) 1.42 (quin) 0.05 V4-OH 5.43 (br s) 5.43 (br s) 0 
1a 1.51 (quin) 1.51 (quin) 0 4b 5.55 (br s) 5.50 (br s) 0.05 
1b 1.72 (non) 1.70 (non) 0.02 X4 5.75 (d) 5.75 (d) 0 
V2eq 1.75 (br d) 1.72 (br d) 0.03 Z2-OH 5.82 (br s) 5.89 (v br s) -0.07 
V2ax 1.90 (br d) 1.89 (br d) 0.01 Z6-OH 5.96 (d) 5.96 (d) 0 
3a’ 2.14 (dd) 2.12 (dd) 0.02 7f 6.26 (d) 6.21 (d) 0.04 
1e 2.37 (s) 2.34 (s) 0.03 7d 6.42 (d) 6.39 (d) 0.03 
3a 2.42 (o) 2.38 (o) 0.04 W3 6.62 (v br s) 6.60 (v br s) 0.02 
V4 3.23 (br s) 3.18 (br s) 0.05 W6 6.67 (d) 6.65 (d) 0.02 
X1 3.31 (o)  3.31 (o)  0 5e 6.72 (d) 6.70 (d) 0.02 
G4 3.31 (o) ~3.31 (o) ~0 5f 6.77 (dd) 6.73 (dd) 0.04 
G5 3.31 (o) ~3.31 (o) ~0 CONH2 6.92 (br s) 6.92 (br s) 0 
G3 3.50 (t)  3.50 (t)  0 5b 7.18 (br s) 7.16 (br s) 0.02 
G6a’ 3.57 (dd) 3.57 (dd) 0 2e 7.26 (d) 7.24 (d) 0.02 
G2 3.59 (t) 3.59 (t) 0 6e 7.34 (d) 7.31 (d) 0.03 
G6a 3.68 (dd) 3.68 (dd) 0 CONH2 7.37 (o) 7.34 (o) 0.03 
G6a-OH 4.05 (t) 4.08 (t) -0.03 2b 7.39 (br s) 7.36 (br s) 0.03 
X6 4.19 (d) 4.19 (d) 0 6f 7.47 (dd) 7.44 (dd) 0.03 
X3 4.35 (br q) 4.37 (br q) -0.02 2f 7.52 (d)  7.50 (d)  0.02 
X7 4.42 (d) 4.40 (d) 0.02 6b 7.86 (s) 7.83 (s) 0.03 
X5 4.43 (d) 4.41 (d) 0.02 W2 7.93 (v br s) 7.89 (v br s) 0.04 
V5 4.68 (q) 4.64 (q) 0.04 W4 8.25 (v br s) ~8.21 (o) ~0.04 
X2 4.88 (br m) 4.85 (br m) 0.03 W7 8.48 (br d) 8.45 (br d) 0.03 
G4-OH 5.11 (br s)  5.09 (br s)  0.02 W5 8.64 (br d) 8.63 (br d) 0.01 
Z6 5.13 (br s) 5.10 (br s) 0.03 OH 9.12 (v br s) 9.14 (v br s) 0 
Z2 5.16 (br s) 5.14 (br s) 0.02 OH 9.44 (br s) 9.45 (br s) -0.01 
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Figure 7.06: 1H-NMR study of vancomycin in reaction conditions and comparison with 
literature. The full assignment of the last spectrum (red) is in the correct alkaline reaction 
condition required for the successful coupling of the Gibbs reagent. Its direct comparison with a 
full assignment found in literature is listed on the next page in figure 7.07 and table 7.02.  
CHAPTER 7: STRUCTURAL CHARACTERISATION OF THE NOVEL PRODUCT - VANGIBBS 
  
 
 
220 
 
 
Figure 7.07: Proton coded vancomycin structure for the 1H-NMR assignments and comparison 
with literature. Schematic taken from Antipas, Vander Velde, Jois, Siahaan, & Stella, 2000. 
 
Table 7.02: 
Proton δH [ppm] ∆δH [ppm] Proton δH [ppm] ∆δH [ppm] 
c' 0.90 0.82 0.08 r2 4.50 4.41 0.09 
c 0.90 0.82 0.08 r3 4.59 4.45 0.14 
F 1.19 1.12 0.07 C 4.85 4.66 0.19 
E 1.13 1.02 0.11 v 5.10 4.90 0.2 
a 1.50 1.50 0 B 5.24 5.18 0.06 
b 1.63 1.55 0.08 s2 5.46 5.30-5.45 0.16-0.01 
a’ 1.50 1.50 0 t 5.44 5.30-5.45 0.29-0.01 
D, D’ 1.80 1.70 0.1 A1 - 5.30-5.45 - 
z’ 2.60 2.45 0.15 u 5.51 5.30-5.45 0.21-0.06 
z 2.70 2.45 0.25 s1 5.64 5.30-5.45 0.34-0.19 
y 2.35 2.20 0.15 r4 5.87 5.61 0.26 
G 3.20 3.00 0.2 o, p 6.40 5.97, 5.88   0.43, 0.52 
A4 3.56 3.15 0.41 l 6.90 6.51 0.39 
A2 3.60 3.30 0.3 m 7.00 6.70 0.3 
A3 3.73 3.57 0.16 k 7.05 6.80 0.25 
A6 3.73 3.70 0.03 i, j 7.36 7.14 0.22 
A5 3.82 3.70 0.12 f 7.52 7.34 0.18 
x 3.31 3.27 0.04 e, g 7.64 7.41 0.23 
r1 4.27 4.14 0.13 d 7.70 7.56 0.14 
w 4.76 4.64 0.12 
 
Table 7.02: Comparison of experimental full assignment with literature at high pD. The first 
grey shaded assignment was taken from literature and belongs to a vancomycin in deuterated 
water with a pD of 9.0 (Antipas et al. 2000). The chemical shifts in the third row are 
experimentally obtained and taken from the 1H-NMR spectrum at the bottom (red) in 
figure 7.06. The last row represents the differences of the two precedent assignments. Since the 
differences are all either zero or positive, the pD of the experimental spectrum is expected to be 
higher than 9.0.      
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Figure 7.08: Overlay 1H-NMR spectra of the starting materials and the novel product vanGibbs 
obtained with different molar ratios of the two starting materials. The dotted box highlights the 
two doublets that belong to the two protons in the resorcinol of the 7th residue of vancomycin – 
o and p. The abbreviation ‘ac’ in brackets indicates that all spectra were taken in the same 
alkaline conditions required for the successful coupling of Gibbs reagent to vancomycin.    
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Figure 7.9: Proton coded vancomycin structure for the 1H-NMR assignments of vancomycin 
and vanGibbs. Schematic taken from Antipas, Vander Velde, Jois, Siahaan, & Stella, 2000. 
 
Table 7.03: 
Proton δH [ppm] ∆δH [ppm] Proton δH [ppm] ∆δH [ppm] 
c' 0.82 0.82 0 r2 4.41 4.37 0.04 
c 0.82 0.82 0 r3 4.45 4.46 -0.01 
F 1.12 1.12 0 C 4.66 4.66 0 
E 1.02 1.02 0 v 4.90 4.90 0 
a 1.50 1.50 0 B 5.18 5.18 0 
b 1.55 1.55 0 s2 5.30-5.45 5.30-5.45 0 
a’ 1.50 1.50 0 t 5.30-5.45 5.30-5.45 0 
D, D’ 1.70 1.70 0 A1 5.30-5.45 5.30-5.45 0 
z’ 2.45 2.45 0 u 5.30-5.45 5.30-5.45 0 
z 2.45 2.45 0 s1 5.30-5.45 5.30-5.45 0 
y 2.20 2.20 0 r4 5.61 5.61 0 
G 3.00 3.00 0 o, p 5.97, 5.88 x↔~5.43 x↔~0.54 
A4 3.15 3.15 0 l 6.51 6.51 0 
A2 3.30 3.30 0 m 6.70 6.70 0 
A3 3.57 3.57 0 k 6.80 6.81 -0.01 
A6 3.70 3.70 0 i, j 7.14 7.14 0 
A5 3.70 3.70 0 f 7.34 7.34 0 
x 3.27 3.27 0 e, g 7.41 7.41 0 
r1 4.14 4.24 -0.1 d 7.56 7.65 -0.09 
w 4.64 4.64 0 Gibbs  not existing  7.02 - 
 
Table 7.03: Comparison of the full assignments of vancomycin and the novel product both in 
reaction conditions. The second row lists the chemical shifts of vancomycin as it was previously 
established (see table 7.02). The assignment in the third row shaded in magenta is from the new 
product vanGibbs obtained by a reaction of 2 equivalents Gibbs with 1 equivalent vancomycin, 
which corresponds to the fourth spectrum from the top in figure 7.08 shown in blue. The 
symbol ‘↔’ for the protons o and p indicates that it was not certain to which position the 
coupling occurs. The fourth row lists the differences between the two preceding assignments.  
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F 
Figure 7.10: Detailed 1H-NMR comparison of vancomycin and the novel product obtained with 
two different molar ratios in the region of 8.0 – 4.2 ppm. The doublet with integral 1 at 
6.51 ppm, indicated with a grey box, is from proton l. It is constant in the three spectra and was 
taken as reference for the other integral calculations. The dotted box marks the two doublets 
from the 7th residue. The arrows indicate that one of the two protons is shifting towards lower 
chemical shifts into the multiplet of 5.30 to 5.45 ppm, whilst the other one is disappearing due to 
the addition of the Gibbs reagent. This shifted peak is indicated with a red box at 5.43 ppm. The 
novel arising peak at 7.02 ppm highlighted with a yellow box has integrals of 0.88 and 1.94. It is 
associated with the two protons of the added Gibbs reagent group.   
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Figure 7.11: 1H-NMR NOESY analysis of vancomycin and vanGibbs. All horizontal lines illustrate 
the regions where peaks can occur if the nucleus at this chemical shift is irradiated (S). All vertical 
lines indicate the regions where peaks would occur if the nucleus of interest would interact with 
a nearby S and would act as I. A) Vancomycin. The green and grey lines indicate interaction 
regions of the protons o and p respectively. The cyan arrow highlights a NOE interaction of p with 
r2. For improved visibility, the grey line is interrupted. The orange lines depict 5.43 ppm as part of 
the multiplet to which one proton will shift after coupling (see B). B) VanGibbs with a 1:2 molar 
ratio. The dark yellow lines illustrate the new peak arising from the attached Gibbs protons. The 
red lines highlight the shifted peak. The cyan arrow is copied for comparison with A).  
 
 
A Vancomycin (ac) 
 
 
 
 
 
 
 
 
 
 
 
 
B Vancomycin:Gibbs 1:2 (ac) 
 
 
 
 
 
 
 
 
B 
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7.4 Conclusion and Outlook 
The results presented herein provide very strong evidence that the Gibbs reagent is 
coupling to vancomycin under these reaction conditions in a one to one stoichiometry. 
However, two molar equivalents of Gibbs reagent are required so that vancomycin, as 
one of the two starting materials, is not detectable anymore via 1H-NMR. The majority 
product of the aforementioned reaction has a molecular weight of 1623.2 g/mol and its 
isotope pattern supports the chemical formula of C72H76Cl4N10O2. These observations are 
in an excellent agreement with the theoretically predicted values. Furthermore, the 1H-
NMR results show that the Gibbs reagent coupling takes place on the resorcinol ring of 
the 7th residue of vancomycin. However, the presented results do not show clear 
evidence for a coupling in either position 6 or 2 of the 7th residue. Therefore for the 
patent, the reaction schematic was formulated as presented in figure 7.12 (Kappeler et 
al. 2013). This allows leeway and assures a wide patent protection.  
 
Nevertheless, the following arguments support a coupling to position 2 of the resorcinol 
ring which is the ortho-position to both hydroxyl groups.  
 
i) If the fairly large Gibbs group with two nuclei would add to position 6, one would 
expect a NOE interaction with proton r2. However, as previously indicated, no NOE 
interaction cross peaks in the NOESY spectra do not necessarily mean that there 
are no interactions. 
 
ii) Position 2 is more nucleophilic than position 6 of the 7th residue. This increased 
nucleophilicity which was used by several groups for modifications of vancomycin 
and other glycopeptide antibiotics. For example A. Y. Pavlov and colleagues 
modified eremomycin with various primary and secondary amines via Mannich 
reactions. As illustrated in figure 7.13 A the reaction was exclusively directing to 
position 2 or as it is in the paper called position 7d which is the same labelling as 
previously proposed by C. M. Pearce and D. H. Williams (Pearcea and Williams 
1995) (see figure 7.04, 7.05 and table 7.01). They also tested the antibacterial 
activity of their various aminomethylated eremomycin derivatives and found that 
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the 7d-decylaminmethyl derivative (addition of NHC10H21) was the most active one 
(Pavlov, Lazhok, and Preobrazhenskaya 1997).  
Another very prominent example for a Mannich reaction to position 2 is the 
synthesis of telavancin (Leadbetter et al. 2004; Benito-Garagorry 2013; Higgins et 
al. 2005; Hegde et al. 2004). Telavancin was the first semi-synthetic derivative of 
vancomycin to receive FDA approval in September 2009 (Corey et al. 2009). 
Telavancin’s trade name is ‘Vibativ’ and it is manufactured by Theravance Inc. (San 
Francisco, California, U.S.A.) and Astellas Pharma Inc. (Tokyo, Japan) (Corey et al. 
2009; Kresse, Belsey, and Rovini 2007). It was first approved for complicated skin 
and skin structure infections (cSSSI) which are usually caused by S. aureus. Since 
June 2013, it can additionally be used for hospital-acquired and ventilator-
associated bacterial pneumonia (HABP/VABP) also caused by S. aureus, but only if 
alternative treatments are not suitable (Yao 2013). Figure 7.13 B depicts 
telavancin’s structure which is comparable to our vanGibbs molecule if we assume 
the Gibbs reagent is coupling to position 2 (figure 7.13 C).   
 
However, despite these arguments supporting a coupling at position 2 in a one to one 
stoichiometric reaction, it has to be emphasised that with a larger excess of Gibbs it may 
be possible that a different molecule or various fractions with several Gibbs couplings 
are produced. Especially in light of the unexpected high absorbance in the UV/vis 
spectra with more than 100 times excess of Gibbs reagent (see chapter 6). This and the 
ultimate proof for the structure are still unsolved questions and should be considered 
together with purification and scaling-up as objectives for future work.  
 
Furthermore, this novel vanGibbs molecule may be a new antibiotic which definitively 
should be tested for its antibacterial activity. As mentioned above, its structure is 
comparable to telavancin which may be promising for its antibacterial activity. 
Moreover, the Gibbs coupling reaction could be expanded to other members of the 
glycopeptide antibiotic family and could further serve as scaffold for various 
modifications resulting in novel semi-synthetic glycopeptide antibiotics.   
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Figure 7.12: Proposed reaction scheme of the vancomycin Gibbs reaction under alkaline 
conditions as it is presented in our patent (Kappeler et al. 2013). It has to be highlighted that 
this reaction scheme is proposed for a one to one stoichiometric reaction only. It may be possible 
that larger excess of Gibbs results in a different molecule or that various fractions of the molecule 
are produced with multiple Gibbs additions.  
  
alkaline conditions 
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Figure 7.13: Structural comparison of different glycopeptide antibiotic derivatives obtained by 
Mannich reactions with our vanGibbs molecule. A) General structure of aminomethylated 
derivatives of eremomycin. Schematic adopted from Pavlov, Lazhok, and Preobrazhenskaya 
1997. B) Structure of telavancin. Schematic adopted from Corey et al. 2009. C) Structure of 
vanGibbs if assumed that Gibbs couples to position 2 of the 7th residue of vancomycin. 
  B 
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CHAPTER 8:  
Nanomechanical Detection of Vancomycin 
8 Nanomechanical Detection of Vancomycin 
The main objective of this PhD thesis is the development of a PoC sensor for therapeutic 
antibiotic monitoring, in particular for the antibiotic vancomycin. As described in the 
first chapter in section 1.1, the ultimate aim is to develop a patient attached real-time 
monitoring device by exploring the miniaturisation potentials of the different detection 
techniques. The starting point for this miniaturisation attempt was the colourimetric 
detection as a bench top device, which was previously presented in the chapters 5, 6 
and 7. The technique in this chapter serves as the subsequent step in this 
miniaturisation development process and represents the transition from a bench top 
device to a future patient attached sensor (figure 1.01). In simple terms, the aim is to 
incorporate the sensor into the patient’s the existing IV line. This platform typifies the 
change from intermittent measures of the drug concentration and its associated 
drawbacks of higher levels of staff involvement and invasiveness due to the need for 
repeated blood taking, to fully automated continuous and real-time monitoring, which 
could even feedback and regulate drug admission via automatic adjustment of drip flow 
rate.  
 
The technique discussed in this chapter is cantilever array sensors. For 20 years, 
cantilever sensors have been used in different research fields as fast, real-time, and 
label-free detectors of various interactions taking place in solution, air, gas and vacuum. 
Due to their small size, they have the ability of being integrated into microfluidic 
systems and offering possibilities for various applications in lab-on-chip technology. 
Furthermore, multiple cantilevers, so-called cantilever arrays, provide a direct internal 
reference during the measuring process and enable the parallel measurement of several 
different analytes, making them an ideal platform for a patient attached multi-analyte 
sensor chip.  
 
This approach builds on previous work by Rachel McKendry’s group, which have shown 
that cantilever array sensors offer a unique tool to study surface-active drugs and the 
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nanomechanical consequences of drug-target binding interactions. Furthermore, it is 
speculated that these nanomechanical consequences are mimicking the antibiotic mode 
of action in real bacteria, where drug-target binding events introduce defects and act 
collectively to disrupt the cell wall leading to death of the bacteria (Watari et al. 2007; 
Ndieyira et al. 2008; Ndieyira et al. 2014; Watari, Ndieyira, and McKendry 2010; 
McKendry 2012; Kappeler 2010; Vögtli 2011; Watari 2007; Barrera 2008). Therefore 
cantilever array sensors paired with specific surface chemistry for antibiotic capturing 
create an optimal basis for a nanomechanical sensor for therapeutic vancomycin 
monitoring.  
 
In this thesis, the approach using cantilever array sensors is placed in the gap between a 
bench top device and a patient attached sensor (see figure 1.01). Options for 
miniaturisation are limited, because it builds on an optical readout system. The same 
applies for directly monitoring analytes in blood, which is not feasible with an optical 
readout system. But various groups have shown that other readout systems are 
possible, which would allow miniaturisation and detection in opaque liquids such as 
whole blood (see chapter 8.1.2). Therefore, the objective of this chapter is exploring the 
feasibility of nanomechanical detection of antibiotics, in particular vancomycin, via 
cantilever array sensors. The hope is that it can be conclusively shown that with a 
different readout system, cantilever array sensors could become the next generation of 
PoC sensors for therapeutic antibiotic monitoring. In order for a sensor to be developed, 
it must meet the general requirements that were established in the introduction in 
chapter 1.2. 
 
This chapter is divided into four subsections: The first subsection (8.1) describes the 
history of cantilever sensors, their application, modes of operation as well as discussions 
regarding surface stress and binding events. The second part (8.2) lists materials and 
methods. The third subsection (8.3) presents the results including preliminary 
discussions and continues into the final subsection (8.4) with the overall discussion and 
conclusion. 
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8.1 Introduction 
This subsection introduces the nanomechanical detection via cantilever array sensors 
and starts with the history of cantilevers and cantilever array sensors (8.1.1), presents 
the modes of operation (8.1.2), reviews their applications (8.1.3), which leads to 
discussions on surface stress with beam deflection readouts including Stoney’s equation 
(8.1.4) and nanomechanical detection of drug-target binding investigated via Langmuir 
adsorption isotherm (8.1.5 and 8.1.6), and ends in percolation model (8.1.7) followed by 
objectives (8.1.8).  
8.1.1 History of Cantilever and Cantilever Array Sensors 
The term “cantilever”, as a description for a microscale beam, accompanied the 
development of the atomic force microscope (AFM) in the late 1980s (Binnig, Quate, and 
Gerber 1986; Albrecht et al. 1990). The inventors were Gerd Binnig, a German physicist, 
Calvin F. Quate, an American engineer, and Christoph Gerber, a Swiss physicist, at 
Standford University and IBM Research Laboratory, San Jose, both in California, USA. 
Gerd Binnig and Christoph Gerber were at that time on leave from the IBM Research 
Laboratory in Zürich, Switzerland. The principle of an AFM, sometimes called scanning 
force microscopy (SFM), is comparable to a gramophone in which interactions between 
a sharp tip at the end of a cantilever and underlying surface are monitored in order to 
obtain information from the topography. The change in topography results in a 
deflection of the cantilever, which can be precisely measured with a readout system 
such as the one described in subsections 8.1.4 and 8.2.3.1.  
 
The deflection in the very first AFM (figure 8.01 B) has been measured with a scanning 
tunnelling microscope (STM) mounted on top of the AFM. The STM (figure 8.01 A) had 
been described just a couple of years earlier in 1983 by Heinrich Rohrer (1933 - 2013), a 
Swiss physicist, Gerd Binnig, Christoph Gerber and Edmund Weibel at the IBM Research 
Laboratory, Zürich, Switzerland (Binnig and Rohrer 1983; Binnig et al. 1982). In 1986, 
Gerd Binnig and Heinrich Rohrer received the Nobel Prize in physics for this invention. 
STM’s mode of operation is based on the quantum tunnelling effect. If a conducting tip 
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is brought in very close proximity to a conducting or semi-conducting surface, electrons 
can tunnel through the vacuum between both of them. Tunnelling is induced due to an 
applied bias, which is a difference in voltage between tip and surface. By keeping either 
the height or the tunnelling current constant via a so-called feedback loop, the 
topography can be imaged down to atomic levels. By the year 2000, typical STM 
resolutions were reported in the range of 0.1 nm lateral and 0.01 nm vertical (Bai 2000). 
These days, low-temperature STMs even allow sub-surface imaging of different charge 
states induced by doping (Studer et al. 2012; Sinthiptharakoon et al. 2013) or adsorbed 
molecules (Dr. Cyrus Hirjibehedin, personal communication). One could argue that both 
STM and AFM laid foundations for the field of nanoscience and nanotechnology. 
Nowadays, both microscopes are key tools in nanoscale research and are used across all 
different nanoscientific disciplines from molecular biology to quantum physics.  
 
If cantilevers are used as sensors by themselves, than there is no need for the tip at the 
end as in the AFM instrumentation, since the whole lever becomes the sensing part. 
Two papers published almost simultaneously at the end of 1993 marked the starting 
point for the use of cantilever sensors in research. Both of them were using probes 
developed for AFM experiments. The first paper to be published was authored by James 
K. Gimzewski, a Scottish physicist, and colleagues at the IBM in Zürich and the University 
in Basel both in Switzerland. It described a new form of calorimetric sensor usable in gas 
and vacuum environments. The proposed calorimeter is a silicon micromechanical lever 
coated with aluminium and platinum, which measures the heat flux of the catalytic 
conversion of hydrogen and oxygen to water with high sensitivity. Moreover, they 
advocated that with micromechanical technology the fabrication of an array of 
cantilevers is possible and could be used to construct a multi-analyte sensor similar to 
the human olfactory system, which they called “nose”. Furthermore, besides the photo 
illumination used by the group, which resulted in a temperature rise of the lever, they 
suggested alternative readout systems such as capacitative position sensing, changes in 
piezoresistance, piezoelectricity or the historically used electron tunnelling sensing 
technique (Gimzewski et al. 1994). The second paper, which was published only four 
months later by Thomas Thundat and colleagues at Oak Ridge National Laboratory in 
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Tennessee, USA, reported cantilever deflections upon temperature variation and 
adsorption of mercury and water vapours. Similar to Gimzewski et al., they observed 
that the optical readout results in a heating of the lever which in turn leads to cantilever 
deflections and continuous drift. Furthermore, they measured in static and dynamic 
mode, which are the two modes of operation for cantilevers also used for AFM work. 
Static mode refers to measurements of deflection on an idle cantilever. On the other 
hand, dynamic mode relates to observations of the resonance frequency of a vibrating 
cantilever (Thundat et al. 1994). Further information about static and dynamic mode can 
be found in subsection 8.1.2 
 
Despite the proof that cantilevers possess additional sensor applicability beyond their 
use in AFMs as tip leverage for the amplification of topographical features, cantilever 
sensors did not attract large interest until 2000. In this year, Jürgen Fritz and colleagues 
published in the journal “Science“ that cantilevers offer a tool to measure the direct 
nanomechanical response of DNA hybridisation and receptor-ligand binding (Fritz et al. 
2000). In the same year, A. M. Moulin and colleagues from University of Cambridge, UK, 
and Singapore showed that conformation changes of proteins over time and in response 
to adsorption of a molecule leads to surface stress that is measurable with a 
microcantilever-based biosensor (Moulin, O’Shea, and Welland 2000). Both papers have 
been denoted to be part of the breakthrough of the cantilever sensor research field 
(Tenje et al. 2012).  
 
As evident in the histogram in figure 8.02, after several years of few publications 
incorporating cantilever sensors, the field seemed to gain momentum until its peak in 
2009. The histogram visualises in blue the number of publications per year incorporating 
the terms “MEMS” (abbreviation of micro-electro-mechanical system), “cantilever” and 
“sensor” in title, keywords or abstract of publications. If the publication additionally had 
the term “array” in the above sections, then it is shown in yellow. Interestingly, the 
publication of papers pertaining to cantilever arrays seems to not have peaked yet. 
Moreover, their numbers appear to be fairly constant over the last five years despite the 
decrease in the overall publications with the terms “MEMS”, “cantilever” and “sensor”. 
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All publication numbers were taken from the Scopus® webpage. Scopus® is a registered 
trademark of Elsevier B.V. (Reed Elsevier PLC/N.V., Amsterdam, Netherlands) and offers 
a tool to search through various scientific journals. It has to be considered that the 
searches resulting in the illustrated publication numbers are not exhaustive and only 
serve the purpose of visualising general trends.  
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Figure 8.01: Photographs of STM and AFM replicas. A) The replica of the very first scanning 
tunnelling microscope (STM). It was built 1981 by Heinrich Rohrer, Gerd Binnig, Christoph Gerber 
and Edmund Weibel at the IBM Research Laboratory in Zürich, Switzerland. B) The replica of the 
very first atomic force microscope (AFM). Built by Gerd Binnig, Calvin F. Quate and Christoph 
Gerber at Standford University and IBM Research Laboratory, San Jose, California, USA in 1986. 
Both objects are in possession of the IBM Research Laboratory, Zürich, Switzerland.  
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Figure 8.02: Publications per year incorporating specified search terms related to cantilever 
sensors. The histogram visualises in blue the number of publications per year incorporating the 
terms “MEMS” (abbreviation of micro-electro-mechanical system), “cantilever” and “sensor” in 
the title, keywords or abstract. If the publication additionally had the term “array” in at least one 
of these sections, then it is shown in yellow. The numbers for the search terms in blue did 
increase after a low in 2000 and peaked in 2009. However, the publication numbers of cantilever 
array seem to not have peaked yet. Moreover, their numbers appear to be fairly constant over 
the last five years despite the decrease in the overall publications. All publication numbers were 
taken from the Scopus® webpage. Scopus® is a registered trademark of Elsevier B.V. (Reed 
Elsevier PLC/N.V., Amsterdam, Netherlands) and is offering a tool to search through various 
scientific journals.   
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8.1.2 The Core and Mode of Operations for Cantilever Array Sensors  
The core elements of a cantilever array sensor are the cantilevers, which are usually 
attached to a chip body. In this work a microfabricated silicon chip consisting of a chip 
body with eight thin rectangular silicon beams at the front was used (figure 8.03 A). Each 
of these cantilevers is 500 µm long, 100 µm wide and about 0.9 µm thick. More 
information about the fabrication of this silicon based cantilever array can be found in 
the materials and methods chapter on page 262.  
 
However, the quantity of the cantilevers is variable as well as their shape and base 
material. For example, other groups (Zhang et al. 2007) have used a multiwell sensors 
with 16 cantilevers or paddle shaped cantilevers (Ilic et al. 2004; Yue et al. 2004; 
Stachowiak et al. 2006). Anja Boisen’s group at the Technical University of Denmark 
(DTU) are using cantilevers made out of SU-8, which is a viscous polymer commonly 
used as a negative photoresist (Keller, Haefliger, and Boisen 2010; Nordström et al. 
2008). Generally, due to their microscopic dimensions, the cantilevers are very flexible 
and have, in our case, a nominal spring constant of about 0.02 N/m. This flexibility and 
the corresponding sensitivity are the crucial and fundamental properties that govern 
how the sensors function. The advantage of multiple cantilever arrays is that each 
cantilever can be coated differently and is therefore able to sense various analytes 
simultaneously. Furthermore, single cantilevers are prone to artefacts such as thermal 
drifts, refraction index change and unspecific adsorption on the non-functionalised 
underside of the cantilever. This may cause a baseline drift during the static mode 
measurement. To account for these interferences, passivated, in-situ reference 
cantilevers are used and subsequently subtracted from the sensing cantilevers in order 
to obtain the veritable differential deflection signal (Watari, Ndieyira, and McKendry 
2010; Shu et al. 2005). However, the entire drift causality is still subject of scientific 
debate. Further information about reference cantilevers can be found in subsection 
8.2.1.2 in the ‘Materials and Methods’ chapter on page 267 including the corresponding 
figure 8.10 B.  
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Cantilever array sensors can be operated in static or dynamic mode. Static mode 
measures the bending of static cantilevers upon changes to the in-plane surface stress 
or due to mechanical expansion or contractions on one side of the lever. Dynamic mode 
detects the resonance frequency shift of oscillating cantilever beams after adsorption of 
additional mass, which is equivalent for mass sensing. The working principles for 
cantilever sensors can be divided into (i) temperature, (ii) mass change, and (iii) surface 
stress (figure 8.03 B) (Tenje et al. 2012): 
 
i) The first principle typically involves mechanical expansion or contraction due to 
variations in temperature on the cantilever itself or in close proximity to it.  For 
example an evaporated gold layer, on top of the silicon cantilever, has different 
thermal expansion coefficients than the underlying silicon. In this thesis this was 
analysed during a “heat test”, which served a quality control measure for the gold 
layer on the upper sides of the cantilevers and the optical readout alignment. Further 
information referring to the heat test can be found in the subsection 8.2.4 starting on 
page 267, which includes figure 8.10 A.  
 
ii) The second working principle is the change in resonance frequency of a dynamically 
operated cantilever due to added mass. However, the change in resonance frequency 
can also be triggered due to coating stiffness or changes in density or viscosity of the 
surrounding medium. In order to clearly distinguish between cantilever 
characteristics, changes in the surrounding environment and added mass, in-situ 
reference cantilevers besides the sensing cantilevers are of vital importance. 
 
iii) The last principle is the change of surface stress on one side of the cantilever. This 
change can be generated during adsorption of a molecular layer, by surface charge as 
a result electrostatic repulsion, from conformational changes of the immobilised 
molecules, or by molecular recognition and binding events such as drug-target 
interactions. Stress can be caused by steric competition, structural changes, 
hydration, charge effects, mechanical expansion, swelling or a combination of all of 
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these factors. However, the stress causality is still the subject of scientific debate and 
is further discussed in subsection 8.1.4.  
 
As previously mentioned, various different readout systems can be used to detect the 
bending of the cantilevers. The following list provides a concise summary of some of 
these techniques in chronological sequence and discusses their associated advantages 
and disadvantages:   
 
 Original optical readout: The optical readout originated from the AFM 
instrumentation (Binnig, Quate, and Gerber 1986) and has been applied 
successfully to the cantilever sensors (Gimzewski et al. 1994; Thundat et al. 1994). A 
laser beam is focused at the apex of the cantilever and reflected to a position 
sensitive detector (PSD). By registering the deflection of this reflected laser light, 
the bending of each cantilever can be read out. This technique was used in the 
nanomechanical detection experiments and is therefore further described in the 
subsection ‘8.1.4 Surface Stress and Optical Beam Deflection Readout’. One of the 
advantages of the optical readout is its sensitivity. On the other hand, its size and 
stability is disadvantageous and renders miniaturisation towards a hand-held device 
almost impossible. Furthermore, the laser light has to travel through the sample, 
which means that opaque liquids, such as blood, cannot be measured.  
 
 Piezoresistive readout: Piezoresistive materials change their resistivity when they 
are mechanically strained. For many years various groups have embedded such 
materials into cantilevers in order to detect the deflection by electrical property 
changes (Tortonese, Barrett, and Quate 1993; Mukhopadhyay, Lorentzen, et al. 
2005; Wee et al. 2005; Rowe et al. 2008; Yoshikawa et al. 2009; Mukhopadhyay, 
Sumbayev, et al. 2005; Lang et al. 2009). The advantage of this kind of readout 
system is that the detector is embedded in the cantilever, which is ideal for 
miniaturisation and also allows analysis of opaque liquids. As such, this in theory 
would sound promising for a patient attached PoC sensor. However, its main 
disadvantage so far is a low detection sensitivity.  
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 Capacitive readout: In the capacitive readout, the cantilever is acting as one 
electrode of a capacitor and is therefore placed in parallel to a counter electrode. If 
the cantilever is deflecting, the distance between the two “electrodes” changes 
along with the capacitance, giving a measure for the extent of the cantilever’s 
deflection (Blanc et al. 1996; Amírola et al. 2005). The sensitivity of this technique is 
very high in the range of 10 picomolar. However, its application is limited to 
gaseous environments.  
 
 Interferometric readout: The interferometric readout is another optical technique 
in which a light beam is split into a measuring and reference beam. Whilst the 
measuring beam is reflected on the cantilever’s surface, the reference beam stays 
intact. The subsequent combination of the beams leads to an interference patter 
due to phase shifts. This interferogram not only allows for the calculation of the 
deflection at the cantilever’s free end, but also gives a measure for its bending 
profile (Wehrmeister et al. 2007; Helm et al. 2005; Kelling et al. 2009). This 
technique is very sensitive and produces readouts for small cantilevers. However, 
similar to the original optical readout, the required optics renders miniaturisation 
almost impossible. 
 
 Diffraction readout: The diffraction readout interprets the change in diffraction 
pattern generated by the deflection of the cantilevers. The pattern is obtained via 
entire illumination of the cantilevers (Hermans, Bailey, and Aeppli 2013; Aeppli and 
Dueck 2008). Therefore, as in the technique previously described, this readout 
system needs optics, which renders the miniaturisation almost impossible.  
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 Optical waveguide readout: This readout scheme is based on single-mode 
waveguides, which are integrated into the cantilevers. The deflection is determined 
by detecting intensity changes of the light transmitted through the cantilever 
(Nordstr m et al. 2007). The advantages of this technique are the possibility of 
miniaturisation and the applicability in air and opaque liquid. However, so far, it is 
only applicable for SU-8 cantilevers, which have the disadvantage of already being 
bent after the fabrication process (Keller, Haefliger, and Boisen 2010).   
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Figure 8.03: Core of a cantilever array sensor and its mode of operations. A) Scanning electron 
microscope image of a cantilever array fabricated by IBM Zürich, Switzerland. This silicon 
cantilever array consists of eight cantilevers with the dimensions of 500 µm length, 100 µm width 
and 0.9 µm thickness. The distance between the levers is 250 µm. Image courtesy of Dr. Hans 
Peter Lang and Professor Christoph Gerber. B) The working principles of cantilever sensors. 
Firstly (i) temperature, then (ii) mass change and lastly (iii) surface stress, on which this thesis will 
focus. Schematic adopted from Tenje et al., 2012.   
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8.1.3 Applications of Cantilever (Array) Sensors 
Cantilever sensors and cantilever array sensors, similar to AFMs and STMs, are 
applicable to all the various disciplines important to nanosciece. Due to their small size, 
cantilevers can be integrated into microfluidic systems offering possibilities for the 
development of ‘lab-on-chip’ technologies. This is an area of immense interest for 
biomedicine, quality control applications as well as for proteomics and genomics 
research. They can be used as sensors for chemical analysis as well as biosensors for the 
detection of biomolecules (Raiteri, Grattarola, and Berger 2002) and cells (Antonik, 
D’Costa, and Hoh 1997).  
 
The advantages of cantilever arrays are that they enable the parallel measurement of 
several analytes and provide direct internal references whilst measuring. Reference 
cantilevers are essential for subtracting all the unspecific interactions and artefacts that 
arise during the experimental procedure, such as temperature changes, refractive index 
changes and unspecific adsorption. Cantilever sensors have been successfully applied for 
monitoring temperature and pH-changes (Fritz 2008; Zhang et al. 2012) and for sensitive 
gas detection as a so-called “nose” (Lang et al. 2007; Lang et al. 1999; Yoshikawa et al. 
2009; Baller et al. 2000; Lang et al. 2009). Furthermore, they can be used for 
characterisation of self-assembled monolayers (Backmann et al. 2010; Watari, Ndieyira, 
and McKendry 2010), in which they combine the two fundamental nanotechnology 
approaches. They integrate “top-down” miniaturisation of micro and nano-electro-
mechanical systems (MEMS and NEMS) with a “bottom-up” self-assembled monolayer 
sensing coatings (Sushko et al. 2008; Lang, Hegner, and Gerber 2005).  
 
The applicability of cantilever array sensor detection has also been demonstrated for 
various interactions such as antibody-antigen complex formation (Backmann et al. 2005; 
Raiteri et al. 2001), protein-ligand (Braun et al. 2009) including protein-protein (Raiteri 
et al. 2001) and drug-target interactions (Ndieyira et al. 2008; McKendry 2012; Ndieyira 
et al. 2014). Moreover they are used for the study of DNA and RNA hybridisation 
(McKendry et al. 2002; Shu et al. 2005; Hagan, Majumdar, and Chakraborty 2002; Zhang 
et al. 2006; Huber et al. 2006; Tietze, Bell, and Chandrasekhar 2003; Zhang et al. 2012; 
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Alvarez et al. 2004) as well as the adsorption of microorganisms. This adsorption of 
microorganisms includes fungi (Nugaeva et al. 2005), bacteria (Detzel, Campbell, and 
Mutharasan 2006; Longo et al. 2013; McKendry and Kappeler 2013; Gfeller, Nugaeva, 
and Hegner 2005a; Gfeller, Nugaeva, and Hegner 2005b; Ilic et al. 2000; Ramos et al. 
2008), and different fungal (Nugaeva et al. 2007) and bacterial spores (Dhayal et al. 
2006). 
 
In summary, mechanical microcantilever-based sensors and arrays with multiple 
cantilevers in particular have the following advantages:  
 
• label-free detection in real time 
• high sensitivity i.e, attomolar (Meyer, Hug, and Bennewitz 2004), atto-joule 
(Raiteri, Grattarola, and Berger 2002), sub-attogramm (Ilic et al. 2004) and sub-
parts-per-million (sub-ppm) (Yoshikawa et al. 2009; Mertens et al. 2004; Lang et 
al. 2009) 
• high specificity with in-situ reference cantilevers 
• low cost silicon microfabrication  
• miniaturised µm and nm dimensions  
• scalable technology i.e. for point-of-care applications  
• stress, mass, stiffness & viscosity measurements in solution, air, gas and 
vacuum 
• availability of application specific readout systems 
8.1.4 Surface Stress and Optical Beam Deflection Readout   
The principle governing the use of a rectangular or beam shaped object as a sensor for 
surface stress has a long history. It can be dated back more than one century when G. 
Gerald Stoney reported on the measurements of surface stress in 1909 (Stoney 1909). 
He used a several centimetre long steel ruler and measured its millimetre-ranged 
deformation upon the deposition of metallic thin films. The unit of surface stress is force 
per unit length (N/m). The surface stress difference between the upper and the lower 
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surface of the ruler has been in the range of kN/m. The sensitivity achieved with 
cantilever sensors nowadays is in the mN/m range, which is a million times smaller than 
with Stoney’s steel ruler. Nevertheless, the “cantilever bending method”, which is used 
to calculate surface stress as a function of cantilever deflections, is still based on 
Stoney’s equation. The method can be described as follows (Haiss 2001): Before any 
adsorption takes places, the surface stresses on both sides    and    of a cantilever are 
equal  
         8.1 
thus no bending occurs (figure 8.04 A). If chemisorption takes places exclusively on one 
side of the cantilever, the difference (  ) in surface stress between the upper and lower 
surface  
         –    8.2 
can induce a bending of the cantilever (figure 8.04 B). Generally it is deemed that if a 
force acts only on one side of a cantilever and if it is large enough, then it can cause a 
change in the curvature of the lever. If the force is repulsive, the corresponding side of 
the cantilever expands, generating a compressive surface stress. On the other hand, if 
the force is attractive, the cantilever surface contracts and generates a tensile surface 
stress, which causes the beam to bend upwards (Watari et al. 2007; Ibach 1994). To 
simplify the analysis of the cantilever curvatures, some assumptions have to be made 
(Haiss 2001; Kappeler 2010; Vögtli 2011):  
 
 The length of the cantilever has to be large in comparison to its width, which 
itself is large compared to the thickness.  
 The adsorbate layer is of the order of several atomic layers and therefore 
negligible in comparison with the cantilever thickness.  
 The bending of the cantilever is very small compared to its dimensions so that 
the coordinates can be maintained during the deformation process.  
 It is assumed that the cantilever holders do not exert any forces on the 
cantilevers. 
 The only components of stress which act in the   direction determine the 
bending in the  -  plane.  
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The bending curvatures of the cantilever in the  -  plane can be characterised as a 
section of a circle with radius   (figure 8.04 B), since the bending induced by the surface 
stress is constant along the x-axis. Therefore the induced substrate strain        can be 
described as:  
        
    
 
 8.3 
   is the distance of the unstrained plane within the cantilever from the lower surface 
  . To achieve the bulk stress in the   direction (       ) the Young's modulus (   ) and 
the Poisson number (   ) of the cantilever material have to taken in account:  
        
 
    
         8.4 
After integration of the bulk stress from   to  , substitution of equation 8.4 into 8.5, and 
application of the condition that in equilibrium the bending moment inside the 
cantilever has to be zero, Stoney's equation (Stoney 1909) can be derived as described 
by W. Haiss (Haiss 2001): 
    –      
   
       
 8.5 
By considering the cantilever curvature (    
 
 
), the equation (8.6) can be expressed:  
     
    
      
  8.6 
The absolute bending was measured using a time multiplexed optical laser readout 
method with a position sensitive detector (PSD). For typical cantilever deflection much 
smaller than the length of the cantilever, the change in cantilever curvature (    ) is 
linearly proportional to the change in deflection (    ) at the free end of the cantilever. 
Furthermore, it is also linearly proportional to changes of the angle of laser beam 
reflection (    ) at the effective length (      ) of the cantilever. The effective length is 
the distance from the hinge to the centre of the laser spot, which is in proximity to the 
apex of the cantilever. Therefore the change in curvature (    ) can be defined as: 
    
   
    
     
  
      
 8.7 
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The change in angle of reflection (    ) is linearly related to the position change of the 
laser spot (    ) on the PSD detector located at distance (  ) from the reflection point 
on the cantilever apex. After substituting    into the equation 8.9, the result is:  
             
    
    
 8.8 
Due to the physical distance (  ) between the cantilevers and the PSD, the cantilever 
deflection (    ) is amplified and can be read out by the detector.  
 
The absolute bending signal (    ) can be converted into surface stress (    ) between 
the upper and lower sides of the cantilever using the combination of Stoney's equation 
(8.8) and the curvature change (8.9):  
    
 
 
 
 
    
 
 
 
 
   
   8.9 
  is the cantilever thickness (herein 0.9 µM),      the effective length of the cantilever 
(herein 490 nm, since the size of the laser spot has been taken into account) and 
 
   
           is the ratio between the Youngs's modulus (   ) and the Poisson ratio 
(   ) of Si(100) (Brantley 1973). (Kappeler 2010; Vögtli 2011)  
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Figure 8.04: Schematic of the set-up to measure adsorbate induced surface stress with the 
bending cantilever method. A) Schematic before any adsorption takes place. The letter   in the 
schematic represents the surface stress. In the main this is named  .   stands for the surface 
area and   is the strain acting on the surface. B) Bending of the cantilever due to chemisorptions 
onto the upper surface. The superscript   indicates that nothing has been absorbed on this side; 
whereas the superscript   designates that chemisorption of any kind took place on this side. 
Schematic adopted from Haiss, 2001.  
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8.1.5 Principle of Nanomechanical Detection of Drug-Target Binding 
The objective to nanomechanically detect antibiotics builds on the effect of steric 
competition and electrostatic repulsion upon introduction of disorders in a self 
assembled monolayer (SAM), which then results in an in-plane surface stress. In the case 
of glycopeptide antibiotics, this reflects very well the in-vivo drug-target mechanisms, 
where the antibiotic molecules bind to the precursor of the bacteria’s peptidoglycan, 
hindering cross-linking and thus introducing defects into the bacterial cell wall.  
 
Therefore cantilever arrays seem an optimal tool for measuring the nanomechanics of 
the ‘antibiotics to bacterial cell wall’ interactions, which are responsible for the clinical 
efficacy of the glycopeptide antibiotics (Watari et al. 2007; Ndieyira et al. 2008; Watari, 
Ndieyira, and McKendry 2010; McKendry 2012; Ndieyira et al. 2014). Herein the sensing 
cantilevers are functionalised with peptides that mimic cell wall precursors found in 
vancomycin-sensitive and vancomycin-resistant bacteria. These peptides are hereafter 
also designated as mucopeptides, which is the umbrella term for the polypeptides 
forming the crystal lattice structure of the bacterial cell wall.  
 
To enable asymmetric adsorption of the peptides, the upper side of the cantilevers can 
be coated with gold. This allows semi-covalent attachment of thiol group-terminated 
molecules on the upper cantilever side only. Moreover, the gold layer enhances the 
reflectivity of cantilever surface, which is favourable for the optical readout method 
(Lang et al. 1998) and can be used as quality control measures. The thiolated peptides 
self assemble in a monolayer, whose density is concentration dependent. The formation 
and characteristics of these SAMs have been thoroughly investigated in Rachel 
McKendry’s group as well as their influence on the generation of surface stress 
(Kappeler 2010; Vögtli 2011; Watari 2007; Barrera 2008). Therefore, in the scope of this 
thesis, empirical values have been used according to previously obtained findings and no 
secondary quality control measures and characterisations have been performed.  
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If binding between the bound peptides and antibiotic molecules in solution occurs, the 
peptides on the cantilever surface become crowded, which results in a surface stress 
due to electrostatic repulsion and steric hindrance. This stress leads to a downward 
bending of the cantilevers, which is illustrated in figure 8.05. A downward bending of a 
cantilever is referred to as a compressive surface stress and an upward bending as a 
tensile surface stress (Watari et al. 2007). The origin of the binding induced surface 
stress is still the subject of scientific debate and will be further discussed in the following 
subsection (8.1.6). 
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Figure 8.05: Nanomechanical detection of drug-target interactions via cantilever array sensors. 
This schematic shows nanomechanical sensing of drug-target interactions. The drug molecules, 
herein vancomycin molecules (turquoise), bind only to the cantilevers, which are coated with the 
specific targets or receptors and induce a downward bending momentum upon increased surface 
stress. No binding occurs towards the reference cantilevers, which are therefore not deflecting, 
and can be used to subtract for non-specific interactions and artefacts. The laser beam (red) is 
reflected on the apex of the cantilever and detected by position sensitive detector (PSD), which is 
not shown in the illustration.  
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8.1.6 Binding Investigation via Langmuir Adsorption Isotherm 
For the characterisation of the drug-target binding interactions on the cantilever 
surface, the Langmuir adsorption isotherm model was used. This model has been 
developed by Irving Langmuir (1881 – 1957), an American chemist and physicist, in 
1918. It describes the concentration dependent adsorption of gas molecules on a solid 
surface (Langmuir 1918). The original Langmuir's model is based on the following 
assumptions:  
 
 The surface, containing the binding sites, is a flat plane.  
 The substance adsorbs into an immobile state onto this plane.  
 Each binding site can hold only one adsorbed molecule, and  
 no interactions occur between the adsorbed molecules or between adsorbed 
molecules and empty sites.  
 
This model has been adapted to describe the adsorption of antibiotic molecules in 
solution to immobilised mucopeptide analogues onto the cantilever surface. It has been 
found to model very well the experimental drug-target binding curves and therefore has 
been used to derive an antibiotic surface equilibrium dissociation constant     
(McKendry et al. 2002; Vögtli 2011; Kappeler 2010).  
 
The adapted Langmuir adsorption isotherm model can be derived as follows:  
The adsorption of antibiotic molecules to mucopeptide analogues immobilised on 
cantilevers can be described with the following chemical equation: 
                              8.10 
where [ ] is the concentration of antibiotic molecules in solution, [ ] is the 
concentration of the free binding sites, [  ] is the concentration of antibiotic molecules 
bound to the binding sites on the surface, and     and      are adsorption (or 
association) and dissociation constants respectively. The corresponding association rate 
     and dissociation rate      are:  
                  8.11 
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                  8.12 
In equilibrium state, these rates are equal,           , and thus: 
                        8.13 
which also can be written with the equilibrium dissociation constant (   ): 
 
      
    
   
    
   
      8.14 
By defining the total number of available binding sites [  ] and in assumption of no 
depletion, [ ] can be written as            –      and this can be substituted in the 
equation above: 
     
               
    
 8.15 
and rearranged  
          
      
   
 8.16 
By introducing the surface coverage [  ] which is the ratio of the number of bound 
molecules [AS] to the total number of available binding sites [  ]          
    
    
 ) and 
combine it with the equation above, it yields the Langmuir adsorption isotherm:  
        
   
       
  8.17 
If we assume that the cantilever bending and surface stress are proportional to the 
surface coverage, and by introducing a factor   that describes the maximum surface 
stress value when all binding available site are occupied, the equation can be rewritten 
as: 
        
           
           
 8.18 
     is the equilibrium signal of the cantilever surface stress, [     ] is the antibiotic 
concentration in solution and   is the surface equilibrium dissociation constant on the 
cantilever (Ndieyira et al. 2008; McKendry et al. 2002; Kappeler 2010; Vögtli 2011). 
However, to be suitable for modelling the drug-target interactions the two following 
conditions should be fulfilled (McKendry et al. 2002): 
 
 The drug-target binding events have to be independent, and  
 they have to be unaffected by surface coverage. 
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In practice, this seems to be applicable only very locally and therefore a percolation 
model has been proposed, which will be described in the next section 8.1.7 (Ndieyira et 
al. 2008).  
8.1.7 The Percolation Model on Cantilevers and Bacteria 
The percolation model describes the surface stress in terms of chemical and geometric 
factors. The chemical factors describe the local drug-target binding via the Langmuir 
adsorption isotherm, and the geometric factors represent the large scale connectivity 
and mechanical consequences of the formation of a strained network. It is speculated 
that nanomechanical percolation plays an important role not only in the deflection of 
the sensor, but also in the in-vivo antibiotic mode of action in real bacteria, in particular 
for surface active antibiotics, such as glycopeptide antibiotics. Glycopeptide antibiotics 
are known to hinder cross-linking of peptidoglycan precursors, but the large scale 
mechanical consequences and the cooperative binding may put additional constraints 
on the bacteria. Specifically, drug-target binding events may act collectively to disrupt 
the bacterial cell wall leading to bacterial cell death. (Ndieyira et al. 2008) 
 
The model was developed to fit mechanical stress response data from cantilevers with 
mixed monolayers of susceptible peptides to which binding occurs and reference 
peptides to which no binding occurs. Experiments with fixed antibiotic concentrations 
showed that above a certain surface coverage fraction of susceptible peptides, a steady 
increase in nanomechanical signal was measured. This suggests that the surface stress 
transduction is a “collective” phenomenon that requires connectivity of the occupied 
binding sites, which have to overcome a specific threshold (see figure 8.06 A). This, in 
turn, is dependent on a certain surface coverage and proximity of the binding targets. 
Based upon the assumption that the local chemical events are separable from the 
geometric effects responsible for the large scale connectivity, the percolation model for 
cantilever surface can be described as follows:  
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 8.19 
 
for        and       if       . The first term of the equation represents the Langmuir 
adsorption isotherm (8.18) derived and discussed in the previous subsection (8.1.6), and 
the second term describes the percolation resulting in the formation of a strained 
network of interactions (Stauffer and Aharony 1991).   defines the surface coverage 
fraction,    the critical percolation threshold and the exponent of the power   accounts 
for elastic interactions between the binding sites upon antibiotic binding. For short-
range interactions, including neighbouring repulsion upon steric hindrance, there will be 
a finite percolations threshold    above which a connected network will be formed that 
results in cantilever deflection. The experiments performed by Dr. Joseph Ndieyira led to 
a power   value of 1.3 and a percolation threshold    of 0.075, which is schematically 
illustrated in figure 8.06 B (Ndieyira et al. 2008). In this,   was defined as the surface 
coverage for the susceptible peptides with       for a pure layer of susceptible 
peptides and       for a pure coverage of reference peptides. This percolative 
triggered surface stress differs significantly from the previous studies of the Young’s 
modulus, which is described in the previous subsection 8.1.4. (Vögtli 2011; Ndieyira et 
al. 2008)  
 
As previously mentioned, the origin of the binding induced surface stress on cantilevers 
is still the subject of scientific debate, and several other models have been described 
(Wu et al. 2001; Hagan, Majumdar, and Chakraborty 2002; Zhang and Shan 2008). 
However, since the Langmuir adsorption isotherm paired with the percolation model has 
been successfully applied in Rachel McKendry’s group for many years, it will also be used 
in the scope of this thesis. 
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A 
 
 
B 
 
Figure 8.06: Nanomechanical drug-target percolation model on cantilever arrays and bacteria. 
A) Illustration of the percolation on cantilevers. The turquoise objects represent the antibiotic 
molecules either binding to the target peptides on the cantilever or floating freely in the solution. 
The red line symbolises the percolation effect and the connectivity of the drug-target binding 
sites. Illustration adopted from Vögtli 2011. B) Schematic showing the percolation model on 
cantilever array (a) and bacteria (b). a) If      surface stress can be detected, and if      the 
cantilevers are not deflecting, showing that there is no detectable surface stress. Schematic 
adopted from Ndieyira et al. 2008.  
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8.1.8 Objectives for Nanomechanical Detection of Vancomycin  
The objective of this chapter is to explore the feasibility of nanomechanical detection of 
vancomycin via cantilever array sensors. The hope is that it can be conclusively shown 
that with a different readout system, cantilever array sensors would become the next 
generation of PoC sensors for therapeutic antibiotic monitoring. In order for a sensor to 
be developed, it must meet the general requirements that were established in the 
introduction in chapter 1.2 and preferably include the additional option for vancomycin 
listed last. 
 
The focus of the feasibility study has been mainly laid on sensitivity and specificity whilst 
investigating the possibility of detecting the free and active drug fraction as opposed to 
the bound drug fraction. The approach of this second sensor technique builds on 
previous work by Rachel McKendry’s group. Therefore, the first part consists of 
benchmarking experiments followed by requirements study for a nanomechanical 
therapeutic antibiotic monitoring sensor. 
8.2 Materials and Methods 
This subsection describes the materials and methods associated with the 
nanomechanical sensing technology with its core cantilever array sensors. This materials 
and methods subsection is divided in four subchapters, namely chemicals (8.2.1), 
cantilever arrays (8.2.2), the experimental set-ups (8.2.3) and measurement procedure, 
data processing and analysis (8.2.4). The corresponding results can be found in the 
successive subchapter (8.3) starting on page 271.  
8.2.1 Chemicals  
All chemicals were purchased from Sigma-Aldrich (Dorset, UK), unless otherwise 
declared. They were handled, stored and disposed of in accordance with their safety 
guidelines stated in the corresponding ‘material safety data sheets’ (MSDS). 
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8.2.1.1 Buffer Solution and Antibiotic 
Phosphate buffer was used as buffer solution. It is a commonly used water-based salt 
solution abbreviated to PBS, which is the abbreviation for phosphate buffer saline. Its 
ion and osmotic concentration resembles human blood and it can contain different salt 
types as a basis for the phosphate, such as sodium phosphate or potassium phosphate. 
Additionally it usually contains either sodium chloride or potassium chloride. However, 
previous experiments performed in Rachel McKendry’s group suggest that for cantilever 
array measurements additional sodium chloride may lead to interference, therefore 
mono- and di-basic sodium phosphate were dissolved in water (0.1 M) and mixed 
together to achieve a buffer solution of pH 7.4. The used distilled (DI) water was purified 
with an ELGA Purelab Ultra water purification system (ELGA, Buckinghamshire, UK).  
 
To block the non-specific binding to the cantilevers, 0.005% bovine serum albumin (BSA) 
was additionally dissolved in the phosphate buffer solution. This buffer solution was 
filtered by syringe filters with a 0.2 µm pore size purchased from Triple Red, Long 
Crendon, UK and consecutively degassed by ultra-sonication for 30 minutes before every 
use. This phosphate buffer solution with added BSA will be denoted as phosphate 
buffer, buffer or PBS in this thesis. To mimic normal blood serum, additionally 600 µM 
BSA or human serum albumin (HSA) was also added to the phosphate buffer described 
above, which is further designated as pseudo-serum and specified with HSA or BSA 
accordingly. The amount of 600 µM BSA is well established and commonly used in the 
scientific community to mimic serum (Bohnert and Gan 2013; Bhattacharya, Curry, and 
Franks 2000). Serum albumins are the most abundant plasma proteins in mammals. 
They are believed to be the protein where drug molecules predominately bind to 
(Zeitlinger et al. 2011; Lin et al. 2013; Ndieyira et al. 2014). A more detailed discussion 
about the serum binding particularly of vancomycin can be found in chapter 3.3.3.  
 
For all antibiotic solutions, the phosphate buffer or pseudo-serum as described above 
were used. The vancomycin solutions were prepared by dissolving various 
concentrations of vancomycin hydrochloride in phosphate buffer or pseudo-serum. 
Vancomycin hydrochloride hydrate has been described previously in chapter 6.2.1.1. 
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8.2.1.2 Mucopeptides Analogues, Internal Reference and SAM 
The analogues of the mucopeptides used within this thesis, which are produced by 
vancomycin-susceptible Enterococci (VSE) and vancomycin-resistant Enterococci (VRE), 
as precursors for their peptidogylcan cell wall, were (figure 8.07 A):  
 
 HS(CH2)11(OCH2CH2)3O(CH2)(CO)NH(CH2)5(CO)-L-Lysine-(ε-Ac)-DAlanyl-DAlanine 
in VSE abbreviated as DAla; and 
 
 HS(CH2)11(OCH2CH2)3O(CH2)(CO)NH(CH2)5(CO)-L-Lysine-(ε-Ac)-DAlanyl-DLactate  
in VRE abbreviated in this thesis as DLac.  
 
Both peptides were synthesised by Targanta Therapeutics (Cambridge, Massachusetts, 
USA) (Cho, Entress, and Williams 1997). For the functionalization of the cantilevers, 
1 µM ethanolic solutions of these analogues were used.  
 
The reference cantilevers that are generally used in Rachel McKendry’s group (Ndieyira 
et al. 2008; Watari, Ndieyira, and McKendry 2010; Vögtli 2011; Watari 2007; Kappeler 
2010) are passivated with a 2 mM ethanolic solution of thiol terminating tri-ethylene 
glycol, HS(CH2)11(OCH2CH2)3OH, hereafter called PEG, which is the abbreviation for 
polyethylene glycol (figure 8.07 A). PEG is commercially available from Sigma-Aldrich.   
 
The peptide concentrations used for cantilever functionalization were empirically 
studied in previous experiments and were considered optimal for the formation of a 
SAM of peptidoglycan precursors for nanomechanical detection of drug-target 
interactions (Ndieyira et al. 2008; Vögtli 2011; Watari 2007; Kappeler 2010; Watari, 
Ndieyira, and McKendry 2010). For many years the adsorption of alkanethiols on gold, 
silver, copper, palladium, platinum and mercury surfaces has been extensively studied 
by various groups (Love et al. 2005; Ulman 1996; Schreiber 2000; Biebuyck, Bain, and 
Whitesides 1994; Bain, Biebuyck, and Whitesides 1989; Bain et al. 1989; Nuzzo and 
Allara 1983).  
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The bonding energy that anchors the adsorbed molecules of the SAM to the gold surface 
was first studied in 1987 by L. H. Dubois and colleagues. The strength of the heterolytic 
Au-S bond is believed to be in the same order as the S-S homolytic bond, which is 
approximately 62 kcal/mol and 259 kJ/mol respectively (Nuzzo, Zegarski, and Dubois 
1987). In case of full coverage of a gold lattice with structure 111, which corresponds to 
the highest possible packing density, the binding of the alkanethiols is generally 
accepted to be based on a               structure (figure 8.07 Bi.) (Love et al. 2005). 
The arrangement          indicates that the distance between two sulphur atoms is 
    , where   is the distance between two gold atoms corresponding to a molecule-
molecule spacing of 5 Å and an area per molecule of 22 Å2. The   in the              
structure represents rotation and means that the thiol axis is tilted by 30  to normal of 
the surface). Generally it is deemed that formation of SAMs is an interplay between the 
bond energies, the surface free energy and the lateral interactions among the adsorbed 
molecule to achieve the energetically most favourable confirmation (Love et al. 2005; 
Schreiber 2000).  
 
Previous characterisations by Manuel V gtli in Rachel McKendry’s group suggested that 
from functionalization concentration of DAla of 1 µM, the majority of the thiols must be 
in upright position, which allows the antibiotic molecules to bind and causes a 
compressive surface stress on the surface of the cantilever (Vögtli 2011). This is 
schematically illustrated in figure 8.07 Bii. However, it has to be highlighted that the 
concentrations, where the transition from ‘lying down’ to ‘standing up’ occur, are not 
generalizable, but rather are peptide specific. For example, preliminary data suggests 
that DLac, with only the alteration from amide to ester, shows transition around a 
functionalization concentration of 0.1 µM (Kappeler 2010). 
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A  
 
 
 
 
 
 
 
B 
 
Figure 8.07: Mucopeptides analogues, internal reference and self-assembled monolayer. 
A) Lewis’s structures of the mucopeptide analogues (DAla and DLac) and the typical reference 
thiol (PEG) used to functionalise the cantilevers. The only difference between the susceptible 
(DAla) and the resistant (DLac) cell wall precursors is the alteration of an amide into an ester 
within the binding site. PEG was typically used as internal reference. B) Alkanethiol SAMs on a 
gold surface. a) The typical               arrangement of alkanethiols on Au(111) if maximal 
coverage is attained. The S atoms (dark grey circles) are positioned in the 3-fold hollows of the 
gold lattice (white circles,   = 2.88 Å). The light grey circles surrounded with dashed lines indicate 
the approximate projected surface area occupied by each alkane chain; the dark triangles 
indicate the projection of the C-C-C plane of the alkane chain on the surface. This alternating 
orientation of the alkane chains defines a          superlattice structure (marked with long 
dashed lines), which is an unconventional notation. The more conventional notation is 
rectangular           unit cell (marked with short dashed lines). The alkane chains tilt in the 
direction of their next nearest neighbours. Schematic adopted from Love et al., 2005. b) A ‘lying 
down phase’ is proposed for concentrations below 1 μM. It has to be highlighted that molecules 
are not drawn as highly packed as they would be in reality. c) A fully ordered monolayer is 
formed for DAla concentrations of around 50 μM. Schematics b) and c) courtesy of Dr. Manuel 
Vögtli.    
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8.2.2 Cantilever Arrays 
Silicon microfabricated cantilever arrays with eight rectangular cantilevers were used. 
Each cantilever is 500 µm long, 100 µm wide and 0.9 µm thick. The pitch between the 
cantilevers is 250 µm. The arrays were fabricated via deep reactive ion etching of silicon-
on-insulator (SOI) wafers at IBM Zürich Research Laboratory (Rüschlikon, Switzerland) 
and purchased from Concentris (Basel, Switzerland) (Kappeler 2010).  
8.2.2.1  Metal Coating  
The cantilever arrays were first cleaned with piranha solution (hydrogen peroxide 
(H2O2): sulphuric acid (H2SO4) at a ratio of 1:1) for 20 minutes. After six rinsing steps with 
DI water and three with ethanol, they were dried on a hotplate at 70°C. If the chip was 
been previously used and therefore coated with titanium and gold, it has been put in 
aqua regia (hydrochloride acid (HCl): nitric acid (HNO3) at a ratio of 3:1) for 5 minutes in 
advance and afterwards cleaned with piranha solution.  
 
After successful cleaning procedure, the upper surface of the array was coated with 
2 nm titanium (Ti) followed by 20 nm thin gold (Au) layer at evaporation rates of 
0.03 nm/s for Ti and 0.07 nm/s for Au from a base pressure of approximately  
5 x 10-7 mbar. The depositions of the metal layers were performed in an electron beam 
(e-beam) evaporator (Edwards EB Evaporator Auto 500 – FL, Crawley, UK). This metal 
deposition was performed to provide a reflective surface and an interface for attaching 
probe molecules (Kappeler 2010). 
8.2.2.2  Functionalization 
Directly after the metal deposition, the cantilevers were functionalised with thiolated 
peptides. The functionalization was performed by immersion in a liquid-filled array of 
micro-capillaries. Thus, every cantilever was individually coated with a functional layer. 
The capillaries were arranged matching the pitch of the cantilever array. Therefore, glass 
capillaries with an outer diameter of 240 µm and an inner diameter of 150 µm (King 
Precision Glass, Claremont, CA, USA) were utilised. Figure 8.08 shows two pictures of the 
CHAPTER 8: NANOMECHANICAL DETECTION OF VANCOMYCIN 
  
 
 
263 
 
cantilever functionalization ‘stage’. The cantilevers were incubated within the capillaries 
for 20 minutes and afterwards washed three times with ethanol. During the incubation 
it was ensured that no crossover was occurring between any of the different 
functionalization liquids. As previously mentioned, this timings were also empirically 
studied in previous experiments and were considered optimal for the SAM formation 
(Ndieyira et al. 2008; Vögtli 2011; Watari 2007; Kappeler 2010; Watari, Ndieyira, and 
McKendry 2010). In a typical deflection experiments with vancomycin, the eight 
cantilevers were functionalised as follows: 2 cantilevers with PEG, 4 with DAla and 2 
with DLac. They were randomly localised over all eight cantilever, thus alignment 
dependencies could be excluded.  
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Figure 8.08: Cantilever array functionalization ‘stage’. The functionalization ‘stage’ holds an 
array of eight micro-capillaries in which the cantilever array is immersed. The capillaries are filled 
with coloured liquids for visualisation purposes. The inset in the right corner of the picture 
illustrates how the each individual cantilever is inserted in an individual capillary. This 
functionalization ‘stage’ was purposely built by the University of Basel (Basel, Switzerland). 
Schematic adapted from H.-P. Lang, Hegner, and Gerber 2005. 
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8.2.3 Experimental Set-ups 
Two cantilever array sensor set-ups, the Veeco Scentris and the “Basel Nose”, for 
nanomechanical investigation of the drug-target binding interactions are in house at the 
London Centre for Nanotechnology (LCN). However, all binding measurements were 
performed with the “Basel Nose” and therefore only this experimental set-up is 
presented in the following subsection. 
8.2.3.1  The “Basel Nose” System  
The so-called “Basel Nose” is a home-built device from the University of Basel (Basel, 
Switzerland). A schematic of the measurement set-up is shown in figure 8.09 A and 
pictures in figure 8.09 B and C. The cantilever array is placed into a liquid chamber made 
out of polyetheretherketone (PEEK) with a volume of about 8 µl featuring an inlet and 
an outlet port. The liquid is pumped through the measurement chamber by a syringe 
pump (Kent Scientific Corporation, Torrington, CT, USA) and a ten-way-valve (Vici AG 
International, Schenkon, Switzerland).  
 
As described previously, the deflection of each cantilever is read out separately via an 
array of eight vertical cavity surface emitting lasers (VCSELs), which are arranged at a 
linear pitch of 250 µm to exactly match the cantilevers pitch. They emit at a wavelength 
of 760 nm and are switched on and off sequentially by a time-multiplexing procedure. 
The laser-light is reflected off the cantilever surface and detected by a PSD. The resulting 
absolute deflection signals are digitised and recorded together with time information on 
a computer. The temperature control, the sample injection and the data acquisition 
hardware are all controlled by LabView software. LabView is the abbreviation for 
“Laboratory Virtual Instrument Engineering Workbench”, which has been developed by 
National Instruments (Austin, Texas, USA). The whole measurement set-up, except the 
syringe pump, the controller and the computer, is placed in a temperature-controlled 
box (Lang, Hegner, and Gerber 2005; Kappeler 2010).  
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A  
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.09: Schematic and picture of the “Basel Nose” instrumental set-up. A) Schematic 
drawing of the set-up. The device can be divided into four main parts: 1) the measurement cell 
with a mounted cantilever array shown in grey, 2) optical readout system (VCSELs and PSD), 
3) data processing and acquisition and 4) valve selector connected to liquid samples. The grey 
box illustrates the temperature controlled chamber. The syringe pump assures a steady flow rate. 
Image courtesy of Dr. Hans Peter Lang. B) Overview picture of the “Basel Nose” device. 
C) Zoomed picture of the device core. The red lines indicate the laser beams emitted by the laser 
arrays, reflected at the apexes of the cantilevers and the mirror, and detected by the PSD. 
Pictures B and C courtesy of Dr. Manuel Vögtli.   
B 
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8.2.4  Measurement Procedure, Data Processing and Analysis 
After functionalization, the chips were inserted into the liquid chamber of the “Basel 
Nose” and the eight lasers were optically aligned at the apex of the cantilevers using a 
camera system. Then the laser positions were precisely optimised by tracking the sum of 
the signals and the deflections on the PSD monitored via the LabView software on the 
computer. To check if the alignment was successful a “heat test” was performed 
(figure 8.10 A). Therefore the liquid cell, which is mounted on a peltier-element, was 
heated by 1°C within 10 minutes and allowed to cool down for another 10 minutes. Due 
to the bi-metallic effect, the gold layer expands more with increased temperature than 
the underlying titanium and silicon, which results in a downward deflection of all 
cantilevers. This is due the fact that the thermal expansion coefficient for gold is larger 
than the ones for silicon and titanium. This property only slightly depends on the 
cantilever functionalization and therefore the heat test can be considered reliable as a 
quality control measure of the mechanics of the cantilever, the metal coating and the 
laser alignment. If a bending of around 200 nm was reached and the deviation of the 
bending signals of all eight cantilevers was less than 10%, then the heating test was 
considered a success and subsequent the antibiotic experiments could be started 
(Kappeler 2010).  
 
The experimental procedure for the antibiotic experiments typically consisted of the 
following steps, which are additionally exemplified in figure 8.10 B:  
 
I)  injection of buffer solution to establish a baseline;  
II)  injection of antibiotic solution, which causes compressive stress in binding events 
that results in downward bending;  
III)  buffer injection, which is optional, to study the off-rate due to dissociation of the 
drug-target complex;  
IV)  injection of 10 mM hydrochloric acid (HCl) or rarely 10 mM sodium hydroxide 
(NaOH) to remove the bound antibiotic molecules and thereby regenerate the 
peptide surface; and  
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V)  buffer injection to restore the baseline signal and to set a baseline for a new 
antibiotic injection  
 
The surface regeneration (IV) via an acid injection is commonly used in surface plasmon 
resonance (SPR) experiments, and has been previously described, for example by Dudley 
Williams’s group in Cambridge, UK, for different glycopeptide antibiotics binding to 
peptides (Cooper et al. 2000). Acidity dissociates the antibiotic molecule from the 
peptide by disrupting the hydrogen bond, but leaves the peptides and their semi-
covalent binding to the gold intact. This regeneration step can be performed up to 10 
times per chip until new functionalization is required. The regeneration and its 
reproducibility have been extensively studied by Rachel McKendry’s group (Ndieyira et 
al. 2008; McKendry et al. 2002; Sushko et al. 2008; Shu et al. 2005; Houk et al. 2003; 
Zhang et al. 2006; Watari et al. 2007; McKendry 2012; Kappeler 2010; Vögtli 2011; 
Watari 2007; Barrera 2008; Watari, Ndieyira, and McKendry 2010). The same applies for 
the respective injection times, which were empirically studied during previous 
experiments. Typically, antibiotic solutions were injected for 30 minutes, and 10 minutes 
less for more concentrated antibiotic solutions on the grounds that saturation signals for 
high antibiotic concentrations were reached after a shorter time period. 10 mM HCl was 
injected for 40 minutes and followed by a 60 minutes buffer injection. Otherwise, if 
NaOH was used, 10 mM NaOH solution was injected for 5 minutes and followed by a 
60 minutes buffer wash.  
 
Furthermore, “single cycle” experiments with increasing antibiotic concentration 
injections were performed (figure 8.10 C). In these experiments the uncertainty, if the 
surface regeneration step (IV) was completely successful, did not play a role anymore 
and led to a gain in experimental time. Thus instead of buffer (III) or HCl/NaOH wash (IV) 
after each antibiotic injection (II), the next higher antibiotic concentration was injected 
consecutively. Experiments with vancomycin showed that the “single cycle” experiments 
led to results that were very comparable to the conventional experiments illustrated in 
figure 8.10 B. Moreover, it could be concluded that the regeneration step (IV) is 
sufficient to remove the bound vancomycin molecules. 
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The absolute deflection data of the cantilevers was recorded continuously during the 
experiment period via LabView software. The raw data was processed and fitted using 
OriginPro 8.8 software (Origin Lab Corporation, Northampton, MA, USA). The average 
absolute bending signals of the reference cantilevers were subtracted from the average 
absolute bending signals of the drug-sensitive cantilevers to get the effective differential 
bending upon drug-target integration. Reference cantilevers are essential to distinguish 
between the real drug-target binding signal and the following artefacts: temperature 
drift, sudden temperature changes due to solution transitions, changes in refractive 
index of the different solutions and non-specific binding on both or one side of the 
cantilever. This is especially evident in figure 8.10 B, in which both the reference and 
sensing cantilever are drifting. By subtracting the reference from the sensing cantilever, 
one can obtain the real drug-target binding with almost no drift. The estimated errors 
are the standard deviation of each single bending signal of DAla coated cantilevers from 
the average value. Due to the small number of experiments carried out, no statistical 
evaluation has been performed.  
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Figure 8.10: Cantilever Arrays as 
Nanomechanical Sensors.  
A) Example of a heat test for one 
cantilever array. The peltier element on 
which the cell is mounted was heated by 
1°C for 10 minutes and allowed to cool 
down for another 10 minutes. The heat 
test was considered a success, if at least 
200 nm ± <10% deflections were 
reached. The surface stress was 
calculated using Stoney’s equation (see 
page 244). Hence wherever deflection is 
written it can be directly converted to 
surface stress by dividing a factor 4.94.  
 
B) Typical experimental procedure of an 
antibiotic binding experiment. After the 
injection of buffer or pseudo-serum (I), 
the antibiotic solution (II) is injected into 
the cell followed by an optional buffer 
wash (III). To remove the bound 
antibiotic molecules and to regenerate 
the sensing surface, the cell is purged in 
this case with a 10 mM HCl solution (IV). 
Afterwards buffer solution (V) is injected 
again to restore the baseline signal in 
preparation for a new antibiotic 
injection (I). The observed drift in both 
sensing (shown in red labelled DAla) and 
reference (shown in black labelled PEG) 
cantilevers may be caused due to 
change in temperature and/or non-
specific binding on both or one side of 
the cantilever. However, the entire drift 
causality is still subject of scientific 
debate. The purple data represent the 
differential deflection of the sensing 
minus the reference cantilever. 
 
C) “Single cycle” experiment with 
increasing antibiotic concentration 
injections. The absolute bending signal 
of one PEG and one DAla coated 
cantilever to phosphate buffer (B) and to 
increasing concentrations of 
vancomycin, (1) 0.1 µM, (2) 1 µM, (3) 
10 µM, (4) 20 µM, (5) 30 µM, (6) 50 µM, 
(7) 100 µM and (8) 250 µM vancomycin, 
are shown. Figure adopted from 
Kappeler, 2010.  
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8.3 Result and Discussions 
This chapter presents and discusses the results of the second detection technique 
studied in this thesis. As previously mentioned, the objective of this chapter is to 
demonstrate that nanomechanical detection of antibiotics, particularly vancomycin, is 
feasible via the use of cantilever array sensors. In order for sensor development to be a 
viable prospect, the general requirements established in chapter 1.2 need to be fulfilled.  
 
The approach of nanomechanical detection of vancomycin builds on previous work by 
Rachel McKendry’s group, which showed that cantilever array sensors allow the label-
free detection of antibiotic binding to bacterial cell wall precursor analogues 
(mucopeptides) found in vancomycin-susceptible Enteroccoci (VSE) (designated as DAla). 
Cantilevers have been proven to be highly sensitive to changes in in-plane forces caused 
by drug-target binding events and to have the specificity to detect the deletion of a 
single hydrogen bond from the antibiotic binding pocket, which is associated with the 
drug resistance. Additionally, they have the specificity to detect the difference in binding 
of different glycopeptide antibiotics (Watari et al. 2007; Ndieyira et al. 2008; Watari, 
Ndieyira, and McKendry 2010; McKendry 2012; Kappeler 2010; Vögtli 2011; Watari 
2007; Barrera 2008; Ndieyira et al. 2014).  
 
However, none of the previous work had investigated the use of cantilever array sensor 
for TDM. Therefore, the objective of this feasibility study was the investigation of 
cantilever array’s potential to be the next generation PoC therapeutic antibiotic 
monitoring sensor. Hence, the focus laid on high sensitivity to clinically relevant drug 
concentrations, high specificity for the required drug, low interference or cross-
reactivity and the possibility of detecting the free and active drug fraction rather than 
the total concentration, which is measured in the current gold standards. The other 
sensor requirements will be addressed at a later stage in the development process, 
especially during the adaptation of such a device for the commercial market. 
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Furthermore, it has to be highlighted that due to small number of experiments no 
statistical analysis was performed. 
 
Accordingly, this results chapter is divided into benchmarking experiments (8.3.1), which 
including specificity and sensitivity experiments, and in requirement studies for 
nanomechanical detection of vancomycin for a therapeutic antibiotic monitoring sensor 
(8.3.2). The latter includes discussions regarding specificity, sensitivity studies in pseudo-
serum and monitoring of total versus free drug fraction. Furthermore, it has to be 
highlighted that, similar to the previous results chapters, initial discussion is 
incorporated in this chapter, whereas the overall discussion, conclusion and outlook can 
be found in the next chapter (8.4).  
8.3.1 Benchmarking Experiment  
The results presented in this subsection are benchmarking experiments, which provide 
preliminary data to help guide the feasibility studies discussed in chapter 8.3.2. These 
initial experiments were focused on the specific detection of vancomycin in buffer 
(8.3.1.1) and extended to detection in the complex background of pseudo-serum 
according to previous work (8.3.1.2). 
8.3.1.1 Benchmarking Specificity  
The first set of benchmarking experiments were performed with high concentrations of 
vancomycin with the objective of detecting specific binding to the mucopeptides 
mimicking the cell wall precursor of the vancomycin-susceptible Enteroccoci (VSE) 
terminating in DAla. By functionalizing other cantilevers in the same array with 
mucopeptides terminating in DLac, the objective was to test the detection specificity of 
the deletion of one single hydrogen bond from the antibiotic binding pocket, which 
prevents the antibiotic from specific binding. To account for artefacts such as 
temperature drift and refractive index change, at least two cantilevers in each array 
were passivated with PEG. The description of the experimental procedure can be found 
in chapter 8.2.4.  
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Figure 8.11 A shows an example of the differential data of such a binding experiment. 
The three DAla coated cantilevers in the array reached a deflection average of  
-169 ± 12 nm while the three DLac cantilevers reached an average of  
-15 ± 9 nm, which corresponds to a surface stress of -34.2 ± 2.4 mN/m and  
-3.0 ± 1.8 mN/m respectively. It has to be emphasised that the errors are large due to 
the relative small sample sizes of only three (n = 3). Nevertheless, these deflections are 
in good agreement with previous results in Rachel McKendry’s group. For example the 
‘Nature Nanotechnology’ paper of 2008 reports a nanomechanical surface stress signal 
for 250 µM vancomycin in one array of -34.6 ± 0.9 mN/m for DAla and -4.2 ± 0.5 mN/m 
for DLac, which corresponds to cantilever deflections of -171 ± 4 nm and -21 ± 2 nm 
respectively (Ndieyira et al. 2008).  
8.3.1.2 Benchmarking Sensitivity and Detection in Pseudo-Serum 
Cantilever array sensors have been proven to be highly sensitive with a detection limit of 
10 nM for binding to DAla in buffer (Ndieyira et al. 2008). In comparison, similar 
experiments with SPR showed detection limits of 300 nM (Rao et al. 1999) and 310 nM 
only (Cooper et al. 2000). For a patient attached PoC sensor, the cantilever array sensor 
would have to be able to detect vancomycin in the complex environment of blood. 
However, as previously mentioned, the current optical laser readout makes it impossible 
to detect the cantilever’s deflection in opaque liquids. Therefore, to imitate the complex 
environment of blood, 600 µM HSA has been added to the PBS buffer, which is widely 
accepted to closely mimic the albumin concentration of normal blood serum (Bohnert 
and Gan 2013). It will hereafter be called pseudo-serum.  
 
The objective is to benchmark against previous work done in the group, which has 
shown that cantilever array sensors are sensitive enough to detect the vancomycin in 
the complex environment of blood serum, which in this case has been 90% foetal calf 
serum mixed with 10% PBS buffer (Ndieyira et al. 2008). Moreover, these experiments 
should demonstrate the investigated detection technique’s ability to distinguish 
between free and bound antibiotic fraction. Additionally, they should also show that 
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neither serum proteins nor the antibiotic-serum-complex bind to the ersatz bacterial cell 
wall precursors and, more specifically, do not result in detectable surface stress.  
 
Therefore, experiments to compare vancomycin in buffer and pseudo-serum have been 
performed. Figure 8.11 B i and ii present the absolute bending signal of the same DAla 
coated cantilevers from upon injection of 100 μM vancomycin in buffer (i) and in 
pseudo-serum (ii). The vancomycin-DAla deflection signals were found to be around  
-175 and -100 nm, which correspond to -35 and -20 mN/m surface stress respectively. 
This is a decrease of about 57% in comparison to the bending signal in phosphate buffer 
alone. According to the literature, the proportion of vancomycin bound to serum can 
vary from 10 to 82% with 55% often quoted as the mean fraction bound (Sun, 
Maderazo, and Krusell 1993; Butterfield et al. 2011; Cantú et al. 1990; Ackerman et al. 
1988; Zokufa et al. 1989; Rodvold et al. 1988; Kitzis and Goldstein 2006; Shin et al. 1992; 
Shin et al. 1991; Zeitlinger et al. 2011) (see chapter 3.3.3). Furthermore, this decrease 
supports the assumption that neither serum proteins nor antibiotic-serum-complex, 
herein HSA proteins and HSA-vancomycin-complex, are binding to the immobilised 
peptides. More specifically, they do not result in a detectable surface stress as indicated 
in figure 8.11 B iv.  
 
In conclusion, these benchmarking experiments proved that cantilever arrays have the 
specificity and sensitivity required to detect the free antibiotic fraction in the complex 
environment of pseudo-serum. Therefore the benchmarking experiments were 
considered successful.  
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Figure 8.11: Benchmarking experiments. A) Specificity example of vancomycin detection. 
Differential deflection and surface stress of a DAla coated cantilever (shown in red) and a DLac 
coated cantilever (in blue) to buffer and 250 μM vancomycin dissolved in buffer. Almost no 
binding occurs to the cell wall analogues of the resistant bacteria (DLac). Resistance is caused by 
the deletion of one hydrogen bond from the binding pocket as illustrated in the schematics on 
the right. B) Comparison of vancomycin detection in buffer and pseudo-serum. i) Absolute 
deflection of a DAla cantilever and reference cantilever upon injection of 100 μM vancomycin 
dissolved in buffer, and ii) in pseudo-serum. iii) Binding schematic of antibiotic molecules in 
buffer, and iv) in pseudo-serum. The serum proteins are competing for the antibiotic molecules, 
resulting in two fractions, free and bound. The decrease in deflection signal results from the 
reduced quantity in free drug molecules and supports the theory that neither serum proteins nor 
antibiotic-serum-complexes are causing any surface stress.    
DLac 
DAla 
  i)                                                                                                                      ii) 
 
      iii)                                                                                                   iv) 
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8.3.2 Requirements Study for Nanomechanical Antibiotic Monitoring 
Continuing on from the successful benchmarking experiments, this section describes the 
follow up experiments. The objective was to study whether cantilever array sensors are 
able to fulfil important prerequisites in order to be the next generation of PoC 
therapeutic antibiotic monitoring sensors. These requirements include high sensitivity to 
clinically relevant drug concentrations, high specificity for the required drug, low 
interference or cross-reactivity with other drugs or blood components and the ability to 
detect the free drug concentration, which is associated with the antibacterial active 
fraction.  
8.3.2.1 Specificity and Discussion of Reference  
Since the binding of vancomycin to DAla terminating mucopeptides is a highly specific 
drug-target interaction and already the loss of one of the five hydrogen bonds results in 
almost no binding at low vancomycin concentrations, the specificity has not been 
further studied in the scope of this thesis. However, it has been contemplated whether 
DLac would make a better in-situ reference than PEG due to the high structural similarity 
to DAla. Nevertheless, the following three arguments support PEG as an optimal 
reference coating:  
 
i) Previous work (see chapter 8.2.1.2 on page 259) shows that despite their structural 
similarities, the SAMs of DAla and DLac have different formation behaviour, 
determined on the basis of maximal stress at different functionalisation 
concentrations (Vögtli 2011; Kappeler 2010).  
 
ii) DLac has to be tailor synthesised against the commercially available PEG, which is 
less cost effective for a sensor, and therefore a drawback for commercialisation.  
 
iii) PEG has been studied extensively by Rachel McKendry’s group for passivation of 
reference cantilevers and so is better known for this kind of application. Therefore, 
for the subsequent experiments PEG was used as an internal reference.  
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8.3.2.2 Sensitivity in Vancomycin’s Clinical Range  
Sensitivity in the range of clinically relevant drug concentrations is one of the most 
crucial aspects of a TDM sensor. Cantilever array sensors have been proven to be highly 
sensitive with a detection limit of 10 nM for binding to DAla in buffer (Ndieyira et al. 
2008). However, for a therapeutic antibiotic monitoring device, the unambiguous 
assignment of a single drug concentration to a single readout signal within and beyond 
the boundaries of the therapeutic range is also a crucial property. Thus, the function 
describing the function of concentration (x-axis) versus readout signal (y-axis), denoted 
as the cantilever deflection or surface stress, must be a strictly increasing monotonic 
function. As a result, the function must fulfil the following two requirements:  
 
i) Its derivative has to be positive         at every single point, which is equal to a 
positive slope; and  
 
ii) the slope must not be constrained to such a degree so that the noise or uncertainty 
of the measurement do not make the results ambiguous.  
 
Preferably, every single point should fulfil         . The simplest way to achieve this is 
if the dependence of drug concentration to cantilever deflection and surface stress is 
linear, which also means that the small changes in drug concentration have large effects 
on the implicit deflection and surface stress respectively.  
 
Moreover, sensors have to be calibrated prior to the first use and additionally at regular 
time intervals. For vancomycin monitoring devices in clinics, this is generally done with 
three different known concentrations spanning the whole clinical range (Dr. Michael 
Kelsey, personal communication). Therefore, linear relation would render this 
calibration process easier and should therefore be sought after.  
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As previously mentioned, the used functionalization concentration for the mucopeptides 
has been empirically studied and optimised from previous experiments in the group. 
This could mean that the optimised functionalisation concentration may not be optimal 
for therapeutic antibiotic monitoring and should therefore be tested.  
 
To experimentally test linearity and to investigate the sensitivity in vancomycin’s clinical 
range, injection series of different vancomycin concentrations in buffer and pseudo-
serum were performed. As an example the injection series with different antibiotic 
concentrations in buffer of one cantilever array is presented in figure 8.12 A. Five 
different arrays with three cantilevers per array (n = 15) were exposed to such injection 
series in buffer. Their deflection values and the corresponding errors were subsequently 
fitted with the Langmuir adsorption isotherm model, which is shown in black over the 
red deflection values in figure 8.12 B. The thermodynamic equilibrium dissociation 
constant    was found to be 1.0 ± 0.3 μM. The   value, which corresponds to the 
saturation signal when all available sites are occupied, was 170 ± 7 nm. These findings 
confirm previous work done in the group, which describes exactly the same    of 
1.0 ± 0.3 μM and   value of 29.7 ± 1.0 mN/m that corresponds to 148 ± 5 nm (Ndieyira 
et al. 2008). The turquoise box in figure indicates the therapeutic window of 
vancomycin, which is 4 – 28 µM and corresponds to 6 – 42 µg/ml (see chapter 3.3.1).  
 
Comparable injections series were performed with different concentrations of 
vancomycin in pseudo-serum. However, due to time constraints only one array with 
three different cantilevers has been studied (n = 3). The corresponding Langmuir 
adsorption isotherm model fit is shown in black over the orange data points including 
errors in figure 8.12 B. The thermodynamic equilibrium dissociation constant    was 
found to be 6.0 ± 2.6 μM and the   value was 110 ± 8 nm. In this context, the larger     
value is caused by addition of another competing ligand to the system, in the form of 
serum proteins (see figure 8.11 B iv). These ligands and their effects upon addition are 
further discussed in our paper (Ndieyira et al. 2014).   
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As evident in figure 8.11 B, the linear region of both Langmuir fits for buffer and pseudo-
serum are not within vancomycin’s therapeutic range. However, the fit for pseudo-
serum, which is the fit of interest based on the aims of this thesis, is still least following 
the previously defined requirements of a strictly increasing monotonic function and 
          within the clinical range. Nevertheless, these findings lead to the conclusion 
that the current underlying DAla SAM is not optimal for therapeutic antibiotic 
monitoring and has to be further fine-tuned and optimised. This however lies beyond 
the scope of my thesis and is consequently discussed in the next chapter ‘8.4 Conclusion 
and Outlook’.  
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Table 8.01: 
Vancomycin in 
buffer 
n = 15 
   [µM] 1.0 ± 0.3 
  value [nm] 170 ± 7 
    0.96 
 
Table 8.02: 
Vancomycin in 
pseudo-serum 
n = 3 
   [µM] 6.0 ± 2.6 
  value [nm] 110 ± 8 
    0.90 
 
 
Figure 8.12: Requirements study for a nanomechanical therapeutic vancomycin monitoring 
sensor. A) Example of injections series of different concentrations performed to establish 
sensitivity in vancomycin’s clinical range. The diagram shows differential deflections and 
surfaces stress of DAla coated cantilevers to buffer and different concentrations of vancomycin 
dissolved in buffer. B) Langmuir analysis of differential cantilever deflections in buffer and in 
pseudo-serum with reference to the clinical range. Deflection averages of DAla coated 
cantilevers upon different antibiotic concentration injections with error bars according to 5 
different arrays with 3 cantilevers (n = 15) for buffer (black dot filled with red) and 3 cantilevers 
on 1 array (n = 3) for pseudo-serum (ochre square filled with red). The grey lines show the 
Langmuir adsorption isotherms fitted using Origin software, whereas the blue box indicates 
vancomycin’s therapeutic range from 4 – 28 µM.  
Table 8.01: Fitted values relating to the Langmuir fit for vancomycin injection series of different 
concentrations in buffer. Details about the Langmuir adsorption isotherm model can be found in 
chapter 8.1.6. 
Table 8.02: Fitted values relating to the Langmuir fit for vancomycin injection series of different 
concentrations in pseudo-serum.    
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8.4 Conclusion and Outlook 
In the introduction to this chapter (8), it has been stated that cantilever array sensors 
serve as the subsequent step in the miniaturisation development process required in the 
transition from a bench top device to a patient attached sensor. Cantilever array sensors 
have been placed at the transition stage because the current device in Rachel 
McKendry’s group at the London Centre for Nanotechnology has an optical readout with 
an array of eight lasers. In its current state, the sensor is not directly implantable in a 
patient’s IV line and can also not monitor the antibiotic concentration in whole blood. 
However, it is able to serve as a functional bench top device. Furthermore, various 
groups have shown that alternative readout systems are possible, which would allow 
miniaturisation and detection in opaque liquids, such as whole blood (see chapter 8.1.2).  
 
Keeping that in mind, the objective of this chapter was proving the feasibility and 
investigating the potential for nanomechanical detection of antibiotics, particularly 
vancomycin, via cantilever array sensors. The focus of the feasibility study was laid on 
specificity, sensitivity and the possibility of detecting the free and active drug fraction. 
The following two bullet points present the key findings, which are also listed in 
table 8.03 together with other general sensor requirements that were not extensively 
studied in this thesis.   
 
i) Firstly the results of the benchmarking experiments (8.3.1) were in very good 
agreement and confirmed previous work in Rachel McKendry’s group. Therefore, 
they set an optimal starting point for the further requirement study for the 
nanomechanical antibiotic monitoring. 
 
ii) The results of this requirement study (8.3.2) confirmed the specificity of 
vancomycin detection and the ability to sensitively detect vancomycin binding to 
the bacterial cell wall analogues in the clinically relevant concentrations (4 – 28 µM) 
and in the complex background of pseudo-serum. However, it was observed that 
the clinically relevant region is not in the linear region of the Langmuir fit, which 
indicates that the underlying SAM film is not optimal.   
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This requires further optimisation and fine-tuning. Theoretically, according to Langmuir’s 
model, increasing the number of drug targets would reduce the surface stress and 
consequently the cantilever deflection upon injection of the same amount of drug 
molecules. Therefore the saturation stage would be reached later, which would enlarge 
the dynamic range wherein linearity and the constraint of the strictly increasing 
monotonic function would be fulfilled. However this, in turn, would lead to a loss in 
sensitivity. As a result there is a trade-off, which will have to be carefully investigated 
further.  
 
Furthermore, it should be noted that, as discussed in chapter 8.1.7, in practice the 
Langmuir model is applicable only very locally. Therefore, the large scale mechanical 
consequence of the formation of a strained network, referred to as the percolation 
model, has to be taken into account as well.  
 
This became evident in previous studies of the influence of the underlying film on 
surface stress by Dr. Manuel Vögtli (Vögtli 2011) for DAla SAMs and my previous work 
on DLac SAMs (Kappeler 2010). It was found that the generally used functionalization 
concentration of 1 µM for DAla lies below the peak of maximal surface stress and seems 
to be the point where the transition from ‘lying down’ to ‘standing up’ occurs (see 
figures 8.13 below; and figures 8.07 Bb and 8.07 Bc in chapter 8.2.1.2). As evident in 
figure 8.13, the ideal functionalization concentration for a therapeutic antibiotic 
monitoring sensor seems to lie beyond the peak occurring at 50 µM and presumably 
above 100 µM.  
 
After optimising the underlying film, the cantilever array sensors could potentially be 
used as a bench top device similar to the previously discussed colourimetric assay. 
Furthermore with a different readout system, cantilever array sensors could become the 
next generation of patient attached sensor for therapeutic antibiotic monitoring since 
they have the specificity, the sensitivity and even the ability to fulfil the additional 
perquisite of monitoring the free and active drug fraction.   
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Figure 8.13: Influence of the underlying DAla self-assembled monolayer (SAM) film on surface 
stress and equilibrium dissociation constant (  ). This graph shows the average deflection of 
250 µM vancomycin solution from five different cantilever arrays (in red) and equilibrium 
dissociation constant (  ) (in blue). The yellow box indicates the area, where it is believed that 
the transition from the ‘lying down’ to the ‘standing up’ phase is occurring. The equilibrium 
dissociation constants (   ’s) were calculated from deflection measurements with different 
vancomycin concentrations at the respective DAla concentrations.    values of 1 µM were found 
for DAla concentrations between 10-3 and 1 mM, which is consistent with previously measured 
binding affinities (Cooper et al. 2000; Ndieyira et al. 2008). However,    values for DAla 
concentrations above and below this range were about 1 to 2 orders of magnitude larger. Figure 
adopted from Vögtli 2011. 
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Table 8.03:  
 
Sensing Technique Nanomechanical 
Investigated Core  
Detection Technology 
Cantilever Array Sensor 
Sensor Attributes or Requirements and their Feasibility and Fulfilment 
Specificity without cross-
contamination 
Highly specific, even to deletion of single hydrogen 
bonds from the binding pocket and for different 
glycopeptide antibiotics. Therefore, no further 
interferents tested. 
Sensitivity according to 
therapeutic window/clinical 
range: vancomycin’s clinical 
range: 4 – 28 µM 
Detection limits: 10 nM in buffer, 7 µM in serum*  
(* = 90% foetal calf serum and 10% buffer) (Ndieyira et 
al. 2008; Ndieyira et al. 2014), and about 1 µM in 
pseudo-serum (see figure 8.12 B). 
Simplicity and requirement 
for specially trained staff 
Currently the readout is fairly complicated, including 
reaching a stable baseline, and therefore requires highly 
trained staff. 
Required sample 
preparation 
Measurements possible in pseudo-serum and serum 
(see above), but not whole blood due to the optical 
readout. Hence, currently requires sample preparation, 
but e.g. with piezoresistive readout none. 
Stability in application 
environment/robustness 
Coating stability and drift, which depend on the coating 
stability, may be issues. Further, sensitive temperature 
and vibrations. 
Shelf-life/robustness Stability depends on the coating. 
Miniaturisation Optical read-out is the limiting factor. However, other 
readouts are possible (e.g. piezoresistive etc.). 
Intravenous flow through 
application/patient attached 
Possible with a different readout system and if the 
coating is not detachable. 
Safety in case of malfunction Not tested.  
Expected costs Currently medium-high. Device approximately 
£ 100,000 & price per array £ 50. More efforts are 
needed to determine manufacturability of chips & if 
functionalization can be done in parallel. 
Measuring speed/rapidity After reaching a stable baseline (which may take up to 2 
hours), measurement takes between 10 to 15 minutes. 
Distinguish free vs. bound 
antibiotic fraction  
Yes, only the free vancomycin fraction can be 
measured. 
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CHAPTER 9:  
Conclusion and Future Work 
9 Conclusion and Outlook 
The objective of this PhD thesis was the development of PoC sensors for therapeutic 
antibiotic monitoring in collaboration with industry partner, Sphere Medical Ltd. These 
sensors will not only allow more prudent use of our existing antibiotics whilst ensuring 
that their concentrations stay above the mutant prevention concentration, but also lead 
to better health outcomes and are associated with lower healthcare costs. Such a sensor 
will be a key tool for antibiotic stewardship and for personalised medicine. It will reduce 
the therapeutic decision time and enable the drug dose to be titrated to the desired 
active target concentration according to the patient’s individual drug adsorption, 
distribution, metabolism and excretion characteristics. Furthermore, it will detect 
accumulation or changes in the drug clearance rate and provide early detection of faults 
in the drug delivery system.  
 
In order to achieve this challenging goal, this thesis focused on the investigation of two 
different techniques: I) colourimetric (chapters 5, 6 and 7) and II) nanomechanical 
(chapter 8) detection. Along with developing each technique for TVM at the PoC, the 
overarching aim was to evaluate the feasibility of miniaturising the different detection 
techniques for patient attached real-time monitoring devices (figure 1.01). Furthermore, 
these technologies can be either seen as two independent approaches or one could 
envisage as the project matures, that a combination of detecting technologies may be 
an essential step towards PoC sensor for TDM.  
 
This chapter consists of three subsections. The first subsection (9.1) gives an overall 
conclusion of each sensing technique and compares them in table 9.01. The second 
subsection presents the future work (9.2). The third and last subsection closes this thesis 
with closing remarks (9.3).    
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9.1 Conclusion 
This subsection summarises the main conclusions in this thesis and is separated 
according to the two individual techniques: colourimetric detection (9.1.1) and 
nanomechanical detection (9.1.2). A detailed comparison of attributes and requirements 
of the different detection techniques including their feasibility and fulfilment are listed 
in table 9.01 starting at the end of this section.  
9.1.1 Colourimetric Detection  
The objective for the colourimetric detection (chapters 5, 6 and 7) was to label 
vancomycin with Gibbs reagent to induce a detectable colour change, which can be used 
to accurately quantify the antibiotic’s concentration via UV/vis spectroscopy. The 
labelling reaction with Gibbs reagent builds on Sphere Medical’s Pelorus bench top 
device that monitors the anaesthetic propofol.  
 
Prior to the vancomycin detection (chapter 5), propofol assays were performed to 
benchmark UCL’s set up to Sphere Medical’s system. Furthermore experiments with the 
commercially available end product of the Gibbs to propofol coupling, the indophenol, 
were conducted to study the Beer-Lambert-Bouguer law’s practical applications. Besides 
successful benchmarking and studying the Beer-Lambert-Bouguer law for drug 
monitoring applications, the experiments with indophenol showed a fast, stable, and 
very reliable calibration system for the therapeutic propofol monitoring device. It is now 
used for calibration in the commercial device.  
 
Both, the indophenol and the propofol, experiments served further purposes, such as 
identification and minimisation of errors in the experimental procedure, which were 
highly beneficial for the following development of therapeutic vancomycin detection 
assay in chapter 6. 
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Starting from chapter 6.3.1, it was found that Gibbs reagent is binding to vancomycin 
and that the resulting coupling product is detectable by visible spectroscopy. The 
developed extraction protocol via SPE reduced the sample complexity, eliminated some 
possible interfering species, especially free serum proteins, and pre-concentrated the 
analyte of interest. Furthermore, it enables the separate elution of free and bound 
vancomycin fraction from the same sample. This is of particular importance for TVM 
device as it is generally accepted that only the free drug fraction is pharmacologically 
active. However, measurements of free antibiotic concentrations are not routinely 
performed in health care facilities as they require several preparation steps and 
consequently are very time consuming and expensive (Berthoin et al. 2009). Therefore, 
routine drug monitoring currently only measures the total antibiotic concentration, even 
though protein binding can vary dramatically and studies have suggested that the 
correlation between free and total fraction is poor (chapter 3.3.3) (Zeitlinger et al. 2011; 
Estes and Derendorf 2010; Butterfield et al. 2011). 
 
However, it has to be emphasised that is not clear yet how the free and bound 
vancomycin gets separated in the SPE cartridge and whether the extraction alters the 
serum binding. Furthermore, experiments suggested that the serum protein to which 
the vancomycin binds either stays in the sorbent material of the SPE cartridge or is not 
coupling to Gibbs reagent and consequently not contributing to the absorbance. 
However, on the other hand, the origin of the enhanced absorbance in WHS in contrast 
to HSA remains unclear and can only be assumed to arise from another serum protein to 
which vancomycin is binding to, such as alpha-1-acid glycoprotein (Fournier, Medjoubi-
N, and Porquet 2000; Zokufa et al. 1989; Dawidowicz, Kobielski, and Pieniadz 2008b; 
Sun, Maderazo, and Krusell 1993; Shin et al. 1991; Bohnert and Gan 2013) or interaction 
to other serum constituents including antibodies, antigens and hormones.  
 
The experimental results suggested that 48 to 30 % of vancomycin is serum bound for 
clinical concentrations ranging from 1.2 to 29 µM vancomycin in WHS (see 
subsection 6.3.8). These percentages fall broadly into the literature range, which 
extends from 10 to 82 %, however are lower than the typical mean fraction of 55 %. 
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Future work should include direct comparison with current methods measuring the free 
and bound vancomycin fraction, such as described by K. Berthoin and colleagues 
(Berthoin et al. 2009), who were using extensive sample preparation followed by HPLC 
analysis.   
 
The experiments with 600 µM HSA and 29 µM vancomcyin, on the other hand, can be 
compared to the findings of the nanomechanical vancomycin detection described in 
chapter 8.3.1.2. Via cantilever array sensors, it was found that approximately 57 % of the 
total vancomycin is bound to the HSA. In contrast via the colourimetric assay 
(chapter 6.3.6), it was found that 46 ± 3 % was bound to HSA. Hence, both values are in 
the same range. However, more experements are needed to confirm the staticstical 
significance of these differences and to test different batches of serum proteins and 
WHS. 
 
By colourimetric quantification of free and bound concentration, facilitated via prior 
Gibbs labelling, the total concentration can additionally be determined by simple 
addition of the two aforementioned. These total concentrations were compared directly 
with a gold standard technique, the Roche COBAS® VANC2 assay based at the UCLH 
laboratory. The colourimetrically measured vancomycin concentrations were found to 
be in excellent agreement to the concentrations obtained by the gold standard 
technique. The preliminary calculation of the detection limit (1.1 µM) was found to be in 
good agreement with the VANC2 system (1.2 µM).  
 
In a small study of a subset of possible interferents, it was found that neither dopamine 
nor paracetamol are interfering with the vancomycin detection. However, propofol is a 
possible interferent for the free vancomycin quantification, which can be avoided or 
overcome with various different approaches described in chapter 6.4. Furthermore, this 
propofol interference could also be an opportunity for a multi-analyte drug monitoring 
device, which will be further discussed in subsection (9.2.1). This small interferents study 
most likely did not cover all the possible interfering species and further specificity 
validation should be performed. 
 
CHAPTER 9: CONCLUSION AND FUTURE WORK 
  
 
 
289 
 
 
To conclude the herein developed assay has the ability to monitor free and bound 
vancomycin concentrations, and the total concentration in a single step, within minutes 
and ultimately from whole blood samples. The method does not require any prior 
sample preparation s and can be integrated into a bench top device for PoC. To the best 
of our knowledge this demonstration is the first of its kind and has never been described 
before. Therefore, this invention together with the labelling reaction of vancomycin with 
the Gibbs reagent was patented (Kappeler et al. 2013). The patent just entered PCT on 
the 18th February 2014.  
 
The novel product of the coupling reaction vanGibbs was structurally characterised and 
the reaction mechanism studied (chapter 7). Strong evidence was found that Gibbs and 
vancomycin couple in a one to one stoichiometric ratio. The 1H-NMR study showed that 
the SEAr reaction takes place on the resorcinol ring of the 7
th residue of vancomycin. 
However, coupling to position 6 or 2 of the 7th residue could not be distinguished. 
Nevertheless, two strong arguments, which are further described in subsection 7.4, 
supported the coupling to position 2 of the resorcinol ring. Furthermore, since the 1H-
NMRs were losing their resolution at higher Gibbs excesses and due to difficulties in 
purification and scaling-up, it is plausible that a different molecule is produced or 
fragmentation of the vanGibbs molecule due to a large Gibbs excess. Thus, purification 
and scaling-up studies as well as solving the definitive structure of the vanGibbs 
molecule are objectives for the future. 
 
Future work should also involve integration of this patented assay into a bench top 
device in which adjustment to automation and whole blood samples have to be 
performed. However, since the extraction protocol could be developed based on the 
same SPE cartridge as used in the Pelorus device, the required adjustment time could 
therefore be successfully reduced. Further the vancomycin-focused bench top device 
also requires clinical evaluation for whole blood samples, more extensive interferents 
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study as well as the development of the most optimal calibration procedure. After 
successful completion of all these steps, commercialisation follows.8  
9.1.2 Nanomechanical Detection  
The objective for the nanomechanical sensing technique (chapter 8) was to demonstrate 
the feasibility of therapeutic antibiotic monitoring via cantilever array sensors. The focus 
was laid on specificity, sensitivity and the possibility of detecting the free and active 
vancomycin fraction in serum samples. 
 
Prior to the therapeutic vancomycin detection, benchmarking experiments were 
performed (subsection 8.3.1). They were found to be in very good agreement and 
confirmed previous work in Rachel McKendry’s group. Therefore subsequent 
requirements studies focusing on specificity and sensitivity for the nanomechanical 
antibiotic monitoring were conducted (subsection 8.3.2). These results confirmed the 
specificity of vancomycin detection and the ability to sensitively detect vancomycin 
binding to the bacterial cell wall analogues in the clinically relevant concentrations (4 -
 28 µM) and in the complex background of pseudo-serum (600 µM of serum albumin 
proteins). However, the clinically relevant region was not in the linear region of the 
Langmuir fit, which indicated that the underlying SAM film is not optimal. This requires 
further optimisation and fine-tuning as described in subsection 8.4, which should be 
considered for future work.  
  
                                                            
8 On a personal note, I would like to take this opportunity to propose two names for the 
future PoC bench top device for therapeutic vancomycin monitoring. The first 
suggestion is “Vanolorus” in the style of Pelorus. In the case that this is too similar to the 
four ships of the Royal Navy, named “HMS Valorous” (Lyon and Winfield 2004), then I 
would like to suggest “Vancolorus”, which in a brief search through the internet did not 
come up with any hits.  
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In the overarching miniaturisation development process cantilever array sensors were 
placed as the transition step from a bench top device to a patient attached sensor. This 
is due to the fact that the current device has an optical readout system, which renders 
monitoring in whole blood impossible. Therefore in its current state, the sensor is not 
directly implantable in a patient’s IV line. Nonetheless, it is able to serve as a sensor in a 
bench top device, which pre-treats the whole blood sample to serum similarly to Sphere 
Medical’s Pelorus device. Various groups have shown that alternative cantilever readout 
systems that allow detection in opaque liquids are possible, e.g. piezoresistive readout 
(subsection 8.1.2). This would then allow miniaturisation and should be considered for 
future work.  
 
Conclusively, it can be said, that cantilever array sensors are meeting many of the 
requirements for a PoC sensor for TVM, which are listed in table 9.01 at the end of this 
chapter. However, further optimisation according to the readout system, coating 
stability and usability are needed and should be considered for future work.  
 
The herein described experiments combined with findings from a different setup and in 
association with an established surface-solution equilibrium theory were recently 
published in a Nature Nanotechnology paper (Ndieyira et al. 2014). The nanomechanical 
detection of active free antibiotic concentration combined with the equilibrium theory 
led to better understanding of the biophysical mode of action of antibiotics, which will 
improve future drug discovery and development as well as treatment and dosage.  
 
Moreover, general interest on new cantilever array methods for studying antibiotic 
resistance and stewardship led to a Nature Nanotechnology ‘News & Views’ article 
(McKendry and Kappeler 2013) and in an enquiry for a review article on “Cantilevers for 
Biological Monitoring” in Contemporary Physics. Furthermore, an image could be 
designed for the ‘News & Views’ article, which was written for our paper by F. Huber,  
H. P. Lang and Ch. Gerber in Nature Nanotechnology (Huber, Lang, and Gerber 2014). 
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Table 9.01: 
Sensing 
Technique 
Colourimetric Nanomechanical 
Investigated 
Core 
Detection 
Technology 
Visible Spectroscopy Cantilever Array Sensor 
Specificity 
without cross-
contamination 
Developed extraction protocol is 
fairly specific for the bound 
fraction eluted in stage #6 and 
until now propofol could be 
identified as possible interferents 
for the free fraction present in 
stage #4. 
Highly specific, even to deletion of 
single hydrogen bonds from the 
binding pocket and for different 
glycopeptide antibiotics. Therefore, 
no further interferents tested. 
Sensitivity 
according to 
therapeutic 
window/ 
clinical range: 
vancomycin’s 
clinical range:  
4 – 28 µM 
Detection limit: preliminary 
estimation yielded in about 
1.1 µM of vancomycin, which 
according to conversion from the 
VANC2 assay corresponds to 
about  1.7 µg/ml (“Package 
Insert: VANC2 COBAS® from 
Roche Diagnostics” 2012) 
Detection limits: 10 nM in buffer, 
7 µM in serum*  
(* = 90% foetal calf serum and 10% 
buffer) (Ndieyira et al. 2008; 
Ndieyira et al. 2014), and about 
1 µM in pseudo-serum (see 
figure 8.11B). 
Simplicity and 
requirement 
for specially 
trained staff 
 
 
Very simple and no specially 
trained staff required. 
Currently the readout is fairly 
complicated, including reaching a 
stable baseline, and therefore 
requires highly trained staff. 
Required 
sample 
preparation 
As a final product none. 
Currently, SPE followed by Gibbs 
labelling reaction.  
Measurements possible in pseudo-
serum and serum (see above), but 
not whole blood due to the optical 
readout. Hence, currently requires 
sample preparation, but e.g. with 
piezoresistive readout none. 
Stability in 
application 
environment/
robustness 
Assumed to last long depending 
on material abrasion including 
tubes and fittings within the 
device. 
Coating stability and drift, which 
depend on the coating stability, 
may be issues. Further, sensitive 
temperature and vibrations. 
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Shelf-life/ 
robustness 
Similar to above depending on 
material abrasion plus chemicals 
and buffer shelf life time. 
Stability depends on the coating. 
Miniaturi-
sation 
Light source and light paths are 
the limiting factor. 
Optical read-out is the limiting 
factor. However, other readouts 
are possible (e.g. piezoresistive 
etc.). 
Intravenous 
flow through 
application/ 
patient 
attached 
Not possible due to addition of 
chemicals and miniaturisation 
issue. 
Possible with a different readout 
system and if the coating is not 
detachable. 
Safe in case of 
malfunction 
Not tested.  Not tested.  
Expected 
costs 
Overall low. Single investment for 
the device and very low per test, 
which only requires a novel SPE 
cartridge (assumed < £ 1). 
Currently medium-high. Device 
approximately £ 100,000 & price 
per array £ 50. More efforts are 
needed to determine 
manufacturability of chips & if 
functionalization can be done in 
parallel. 
Measuring 
speed/ 
rapidness/ 
rapidity 
Labelling reaction & vis 
spectroscopic measurement: 
about 4 minutes. Overall assay 
including blood injection & SPE: 
less than 10 minutes.   
After reaching a stable baseline 
(which may take up to 2 hours), 
measurement takes between 10 to 
15 minutes. 
Distinguish 
free vs. bound 
antibiotic 
fraction 
Yes, both. In WHS, elute (#6) 
clearly carries the bound and 
wash (#4) the free fraction.  
Yes, only the free vancomycin 
fraction can be measured. 
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9.2 Future Work  
Besides the previously indentified objectives for future work, this section presents some 
further visions. It is divided into three subsections. The first subsection describes a multi-
analyte sensor for therapeutic drug monitoring (9.2.1), the second (9.2.2) a hand-held 
device and the third and last subsection (9.2.3) goes into a different direction, namely 
antibiotic drug discovery on the basis of vanGibbs.  
9.2.1 Multi-analyte Sensor for Therapeutic Drug Monitoring   
A multi-analyte sensor that monitors serum albumin, propofol and free and bound 
vancomycin concentrations seems to be obvious according to previous findings. One 
could therefore consider collecting the fractions #1 – #3 for the serum albumin 
monitoring, #4 for the propofol and free vancomycin, and #6 for the bound vancomycin. 
 
Furthermore, beyond the aforementioned analytes, an extension towards other 
antibiotics should be considered, especially in light of the recent treatment approaches 
with combinatorial antibiotic therapy (Ndieyira et al. 2014; Tamma et al. 2013; Rodrigo 
et al. 2013; Edgeworth et al. 2014). Combination antibiotic therapies have shown better 
efficacy against many multi-resistant bacteria as well Gram-negative bacteraemia than 
single antibiotic therapy. However, most of the antibiotics are not fully tested in 
combination with other antibiotics and therefore such therapies have a high risk of 
unwanted and toxic side effects. Hence, a multi-antibiotic therapeutic monitoring sensor 
would be a useful device for antibiotic stewardship whilst maximising efficacy and 
minimising side effects and can additionally be used as early detection system for 
accumulations or changes in drug clearance rate.  
 
Furthermore, as previously emphasised in the thesis, such a multi-analyte sensor may 
possibly also be approached by combination of the two investigated sensor techniques.   
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9.2.2 Hand-held Device 
In light of the overarching objective of miniaturisation, further miniaturisation of the 
colourimetric drug monitoring assay into a handheld device may be investigated. The 
extraction may be further optimised so that for instance the manual injection of blood 
with a syringe is sufficient to elute out the compound of interest. The readout may be 
done either optically by eye, with a smart phone camera or with Google glasses, as it 
was proposed for lateral flow PoC tests (Feng et al. 2014).  
 
Figure 9.02 illustrates a photograph of four different therapeutic vancomycin 
concentrations and a control preparation treated according to the herein developed 
colourimetric assay. It is evident that especially the two high concentrations, 14.8 and 
29 µM vancomycin, are optically clearly distinguishable from each other as well as from 
the other concentrations including the control preparation. Hence this illustrates that 
with further optimisation an optical detection without the use of an UV/vis 
spectrometer may be possible. Besides general TDM, such a handheld device may have 
further specific applications in antibiotic stewardship to test whether patients are 
compliant in their prescribed course of medication or in food safety for rapid 
determination of drug levels, which improves the ease with which food standards may 
be controlled. 
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Figure 9.01: Therapeutic vancomycin concentrations for a future handheld device. Photograph 
of four different therapeutic vancomycin concentrations and a control preparation treated 
according to the herein developed colourimetric assay. Especially the two high concentrations, 
14.8 and 29 µM of vancomycin, show strong colouration and are clearly distinguishable from 
each other as well as from the other concentrations including the control preparation. This 
observation illustrates that with further optimisation an optical detection without the use of an 
UV/vis spectrometer may be possible. The readout could for example be done either optically by 
eye, with a smart phone camera or with Google glasses. If the extraction could be further 
optimised so that for instance the manual injection of blood with a syringe is sufficient to elute 
out the compound of interest, then this colourimetric assay may be integrated into a handheld 
device. Besides general TDM, such a handheld device may have further specific applications in 
antibiotic stewardship to test whether patients are completing their prescribed course of 
medication or in food safety for rapid determination of drug levels, which improves the ease with 
which food standards may be controlled. 
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9.2.3 Antibiotic Drug Discovery on the Basis of the novel VanGibbs 
As previously mentioned in chapter 7.4, the vanGibbs molecule is to the best of our 
knowledge a novel molecule never been described before. Furthermore, it is a derivative 
of vancomycin and has structural similarities to telavancin. Consequently, it is plausible 
that the vanGibbs molecule may be a novel antibiotic belonging to the class of semi-
synthetic vancomycin derivative. Therefore, testing vanGibbs’ antibacterial activity 
should also be considered for future work. Moreover, the Gibbs coupling reaction could 
be expanded to other antibiotics from the same or different families and could further 
serve as a scaffold for various modifications that may resulting in novel antibiotics.  
9.3 Closing Remarks  
My thesis is an excellent example of interdisciplinary research spanning various different 
scientific fields. Furthermore, due to the collaboration with industry and the objective to 
develop a medical assay for improvement in healthcare and antibiotic stewardship, my 
project led to exciting work at the interface of industry, clinic and academia and 
therefore included meeting clinicians, scientists and researchers from various different 
backgrounds. In my opinion all these aspects were perfect to me and made me enjoy my 
thesis very much.  
 
Therefore, I would like to round off with reference to the quotation from Sir Gareth G. 
Roberts quoted at the very beginning of the thesis, and conclude, besides the 
measurable outcomes of my doctoral study, the development of myself was very 
important and will carry on in my hopefully successful academic career.  
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A. Statistical Analysis 
This chapter presents the statistical analysis and is divided into four subsections. The 
first two subsections present the two tests used in this thesis, a one-way analysis of 
variance (ANOVA) (subsection A.1) and a post hoc Fisher’s least significant difference 
(LSD) (subsection A.2). These are followed by two subsections presenting the analysis of 
the absorbances of the six extraction protocol stages (#1 - #6) of chapter 6.3.3 
(subsection A.3) and chapter 6.3.5 (subsection A.4). 
 
To initiate the statistical analysis of the absorbances a one-way ANOVA was used. The 
one-way ANOVA test compares the means of several groups with each other in a single 
test. It was chosen on the basis that the data is quantitative so demands a parametric 
test, has more than two unpaired data sets without direct relationship, and has one 
independent variable - the antibiotic concentration - that influences the depended 
variable - the absorbance. The null hypothesis    states that none of the absorbances of 
any extraction stage is significantly different from any other stage. If this null hypothesis 
   could be rejected, a post hoc Fisher’s LSD was performed subsequently to decide 
which stages are significantly different from each other (Ashcroft and Pereira 2003).  
 
A.1. One-way ANOVA 
The theory behind the ANOVA test is the rejection of the null hypothesis    on the basis 
that the variability between the mean values of the samples is greater than can be 
accounted for by the intrinsic variability of the data within the samples. Therefore, the 
variabilities between and within the samples have to be estimated. This estimation is 
typically done as a mean square deviation of the general form: the sum of squares 
divided by the degrees of freedom. If the null hypothesis   is correct, which means that 
the samples are drawn from a normal distribution with equal means and variances, the 
two estimations of the within- and the between-samples variability are the same. These 
two estimates are compared via the  -test that tests whether their ratio is close enough 
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to 1 allowing the conclusion that the null hypothesis   is true at a certain level of 
significance (Ashcroft and Pereira 2003).  
 
The formulae used for the one-way ANOVA test are the listed below, wherein     depicts 
the value of the observation   in the sample  ,   is the number of samples or the 
population and     is the number of observation in sample   (Ashcroft and Pereira 2003). 
 
The between-samples sum of squares (   ) is defined as: 
          
 
                
  I.I 
wherein    is the mean of the samples   and   is the overall mean of all observation.  
And the within-samples sum of squares (   ) is defined as: 
                    
   
   
 
    I.II 
And the addition of equations I.I and I.II results in the total sum of squares (    : 
               I.III 
 
The between-samples degrees of freedom (   ) and the within-samples degrees of 
freedom (   ) are defined as:  
           I.IV 
and: 
         
 
        I.V 
The between-samples mean square (   ) and the within-samples mean square (   ), 
which are the estimates of the variabilities, are defined as the sums of the squares (I.I 
and I.II) over the corresponding degrees of freedom (I.IV and I.V): 
      
   
   
 I.VI 
and:  
      
   
   
 I.VII 
These estimates are then compared via the  -test using the  -ratio ( ) with the 
formula:  
    
   
   
 I.VIII 
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To compare the calculated  , the corresponding predefined critical value for  -
distribution has to be found in literature such as in Ashcroft & Pereira, 2003. This critical 
  value is dependent on the level of significance and the two degrees of freedom for 
between- and within-samples. If the calculated   exceeds the critical   then it can be 
concluded that there is significant difference between at least two of the mean values of 
the data set, hence the null hypothesis    can be rejected at the chosen significance 
level (Ashcroft and Pereira 2003). 
A.2. Fisher’s LSD test 
2 Fisher’s LSD test 
When the results of an ANOVA analysis indicates that at least one mean is significantly 
different from another mean in the analysis, a multiple comparison has to be performed 
to indentify which mean or means are different. These comparisons are called post hoc 
tests and many different tests exist. The Fisher’s Least Significant Difference (LSD) test 
was chosen as it is one of the commonly used tests following an ANOVA. The Fisher’s 
LSD is a pair-wise comparison of all the means and calculates a modified  -statistic based 
on the within samples mean squares. It is also known as Protected  -test. 
The three important formulae for the Fisher’s LSD test are the following. 
The number of comparisons    for   samples:  
      
      
 
 I.IX 
The t-test: 
    
               
     
 
  
  
 
  
  
 I.X 
where     is the within-samples mean square from the ANOVA test (see chapter A.1 
and         and        are the mean value for the two pairs, which are compared with    and 
   values respectively.  
Lastly, the calculated t-value of equation I.X has to be compared to the corresponding 
critical  -value, which can be found in literature such as in Ashcroft & Pereira, 2003. If 
the calculated  -value is greater than the critical  -value, it can be concluded that the 
corresponding pair, which was been compared, is significantly different at the chosen 
level of significance. To find the corresponding critical  -value the total degrees of 
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freedom (   ) has to be calculated by the formula, which was previously described for 
     (I.V): 
        
 
       I.XI 
wherein   samples are subtracted from    
 
   , which is the total number of 
observations (Ashcroft and Pereira 2003).  
 
 Statistical Analysis of 6.3.3 Extraction Protocol Development from Foetal Bovine Serum 
A.3. Statistical Analysis of Subsection 6.3.3 Extraction Protocol Development 
from Foetal Bovine Serum 
 
This subsection presents the statistical analysis of chapter 6.3.3 in particular the data 
presented in figure 6.11 D, which is shown below. As described above, firstly a one-way 
ANOVA analysis was performed. If the ANOVA indicated that at least one mean is 
significantly different from another mean, a post hoc Fisher’s LSD was performed. For 
the sake of brevity, the interpretation of the statistical analysis results were not included 
in the appendix and can be found in the main part of the thesis in the corresponding 
chapter.  
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Table I: 
one-way ANOVA SS DF MS  F-ratio 
between-samples (b) 0.135 5 0.027 
12.668 
within-samples (w)  0.026 12 0.002 
  
critical F-value at 1% significance level 5.06 
 
 
 
 
 
 
 
 
 
 
Table II: 
 
Fisher's LSD   t-value 
  critical t-value at 1% significance level for 12 df 3.055 
            
Nc = 15 sample pair for comparison  t-value Significant? 
1 #1 sample vs. #2 wash 1.857 no 
2 #1 sample vs. #3 wash 0.798 no 
3 #1 sample vs. #4 wash 0.939 no 
4 #1 sample vs. #5 wash 2.349 no 
5 #1 sample vs. #6 elute 5.605 yes 
6 #2 wash vs. #3 wash 2.655 no 
7 #2 wash vs. #4 wash 2.796 no 
8 #2 wash vs. #5 wash 4.206 yes 
9 #2 wash vs. #6 elute 7.462 yes 
10 #3 wash vs. #4 wash 0.141 no 
11 #3 wash vs. #5 wash 1.550 no 
12 #3 wash vs. #6 elute 4.807 yes 
13 #4 wash vs. #5 wash 1.409 no 
14 #4 wash vs. #6 elute 4.666 yes 
15 #5 wash vs. #6 elute 3.256 yes 
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A.4. Statistical Analysis of Subsection 6.3.5 Change from Foetal Bovine to 
Whole Human Serum 
 
This subsection presents the statistical analysis of chapter 6.3.3 in particular the data 
presented in figure 6.16 C, which is again shown below. The procedure was similar as 
described in the previous subsection A.3. Again for the sake of brevity, the 
interpretation of the statistical analysis results were not included in the appendix and 
can be found in the main part of the thesis in the corresponding chapter. The tables III 
and IV present the analyses for FBS and the tables V and VI the analyses for WHS. 
 
 
3 Statistical Analysis of 6.3.5 Change from Foetal Bovine to Whole Human Serum 
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Table III: FBS 
 
one-way ANOVA  SS DF MS  F-ratio 
between-samples (b) 0.089 5 0.018 
31.411 
within-samples (w)  0.007 12 0.001 
  
critical F-value at 1% significance level 5.06 
 
 
 
 
 
 
 
 
Table IV: FBS 
 
Fisher's LSD   t-value 
  critical t-value at 1% significance level for 12 df 3.055 
            
Nc = 15 sample pair for comparison  t-value Significant? 
1 #1 sample vs. #2 wash 3.549 yes 
2 #1 sample vs. #3 wash 2.337 no 
3 #1 sample vs. #4 wash 2.666 no 
4 #1 sample vs. #5 wash 1.254 no 
5 #1 sample vs. #6 elute 6.913 yes 
6 #2 wash vs. #3 wash 1.212 no 
7 #2 wash vs. #4 wash 0.883 no 
8 #2 wash vs. #5 wash 2.294 no 
9 #2 wash vs. #6 elute 10.462 yes 
10 #3 wash vs. #4 wash 0.329 no 
11 #3 wash vs. #5 wash 1.083 no 
12 #3 wash vs. #6 elute 9.250 yes 
13 #4 wash vs. #5 wash 1.412 no 
14 #4 wash vs. #6 elute 9.579 yes 
15 #5 wash vs. #6 elute 8.168 yes 
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Table V: WHS 
one-way ANOVA  SS DF MS  F-ratio 
between-samples (b) 0.162 5 0.032 
48.308 
within-samples (w)  0.008 12 0.001 
  
critical F-value at 1% significance level 5.06 
 
 
 
 
 
 
 
 
Table VI: WHS 
 
Fisher's LSD   t-value 
  critical t-value at 1% significance level for 12 df 3.055 
            
Nc = 15 sample pair for comparison  t-value Significant? 
1 #1 sample vs. #2 wash 2.617 no 
2 #1 sample vs. #3 wash 2.042 no 
3 #1 sample vs. #4 wash 9.252 yes 
4 #1 sample vs. #5 wash 3.842 yes 
5 #1 sample vs. #6 elute 9.495 yes 
6 #2 wash vs. #3 wash 4.660 yes 
7 #2 wash vs. #4 wash 11.870 yes 
8 #2 wash vs. #5 wash 6.459 yes 
9 #2 wash vs. #6 elute 12.112 yes 
10 #3 wash vs. #4 wash 7.210 yes 
11 #3 wash vs. #5 wash 1.800 no 
12 #3 wash vs. #6 elute 7.453 yes 
13 #4 wash vs. #5 wash 5.410 yes 
14 #4 wash vs. #6 elute 0.243 no 
15 #5 wash vs. #6 elute 5.653 yes 
 
 
